0000919956-18-000050.txt : 20181101 0000919956-18-000050.hdr.sgml : 20181101 20181101160518 ACCESSION NUMBER: 0000919956-18-000050 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181101 DATE AS OF CHANGE: 20181101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 181153692 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20180930x10q.htm 10-Q 2018 Q3 Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: September 30, 2018
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨(do not check if a smaller reporting company)
Smaller reporting company
 
ý
 
 
 
Emerging growth company
 
¨
       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 
¨


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,518,013
(Outstanding shares of the issuer’s common stock as of October 29, 2018)
 



Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
September 30,
2018
 
December 31,
2017
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
3,293

 
$
3,524

Receivables, less allowance for doubtful accounts of $14,235 at December 31, 2017
65,927

 
64,929

Other receivables
1,551

 
375

Prepaid expenses and other current assets
3,829

 
3,248

Income tax refundable
862

 
537

Current assets of discontinued operations
20

 
45

Total current assets
75,482

 
72,658

PROPERTY AND EQUIPMENT, at cost
137,430

 
147,549

Less accumulated depreciation and amortization
(83,956
)
 
(78,345
)
Property and equipment, net
53,474

 
69,204

OTHER ASSETS:
 
 
 
Deferred income taxes, net
15,891

 
15,154

Deferred lease and other costs, net
279

 
137

Acquired leasehold interest, net
6,403

 
6,691

Assets held for sale
13,299

 
—

Other noncurrent assets
7,503

 
3,725

Total other assets
43,375

 
25,707

 
$
172,331

 
$
167,569

The accompanying notes are an integral part of these interim consolidated financial statements.

2


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(continued)
 
 
September 30,
2018
 
December 31,
2017
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and capitalized lease obligations, net
$
12,576

 
$
13,065

Trade accounts payable
14,146

 
14,080

Current liabilities of discontinued operations
461

 
461

Accrued expenses:
 
 
 
Payroll and employee benefits
20,131

 
20,013

Self-insurance reserves, current portion
13,051

 
8,792

Other current liabilities
8,361

 
7,856

Total current liabilities
68,726

 
64,267

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net
77,308

 
74,603

Self-insurance reserves, less current portion
16,301

 
13,458

Accrued litigation contingency
6,400

 
—

Other noncurrent liabilities
5,134

 
8,779

Total noncurrent liabilities
105,143

 
96,840

COMMITMENTS AND CONTINGENCIES

 

SHAREHOLDERS’ EQUITY (DEFICIT):
 
 
 
Common stock, authorized 20,000 shares, $.01 par value, 6,749 and 6,687 shares issued, and 6,517 and 6,455 shares outstanding, respectively
68

 
67

Treasury stock at cost, 232 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
23,267

 
22,720

Accumulated deficit
(23,432
)
 
(14,534
)
Accumulated other comprehensive income
1,059

 
709

Total shareholders’ equity (deficit)
(1,538
)

6,462

 
$
172,331

 
$
167,569

The accompanying notes are an integral part of these interim consolidated financial statements.

3


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended September 30,
 
2018
 
2017
PATIENT REVENUES, net
$
141,431

 
$
146,377

EXPENSES:
 
 
 
Operating
113,799

 
118,104

Lease and rent expense
13,764

 
13,791

Professional liability
2,933

 
2,617

Litigation contingency expense (Note 6)
6,400

 
—

General and administrative
7,537

 
8,083

Depreciation and amortization
2,964

 
2,988

Lease termination receipts
—

 
(180
)
Total expenses
147,397

 
145,403

OPERATING INCOME (LOSS)
(5,966
)
 
974

OTHER INCOME (EXPENSE):
 
 
 
Other income
36

 
—

Interest expense, net
(1,666
)
 
(1,668
)
Hurricane costs
—

 
(232
)
Total other expense
(1,630
)
 
(1,900
)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(7,596
)
 
(926
)
BENEFIT FOR INCOME TAXES
207

 
345

LOSS FROM CONTINUING OPERATIONS
(7,389
)
 
(581
)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
 
 
 
Operating income (loss), net of tax expense of $0 and $1, respectively
(8
)
 
1

NET LOSS
$
(7,397
)
 
$
(580
)
NET LOSS PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
(1.15
)
 
$
(0.09
)
Discontinued operations
—

 
—

 
$
(1.15
)
 
$
(0.09
)
Per common share – diluted
 
 
 
Continuing operations
$
(1.15
)
 
$
(0.09
)
Discontinued operations
—

 
—

 
$
(1.15
)
 
$
(0.09
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.055

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,400

 
6,294

Diluted
6,400

 
6,294

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

4


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands and unaudited)
 
 
Three Months Ended September 30,
 
2018
 
2017
NET LOSS
$
(7,397
)
 
$
(580
)
OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
46

 
203

Less: reclassification adjustment for amounts recognized in net income
—

 
(115
)
Total other comprehensive income
46

 
88

COMPREHENSIVE LOSS
$
(7,351
)
 
$
(492
)

The accompanying notes are an integral part of these interim consolidated financial statements.

5


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Nine Months Ended September 30,
 
2018
 
2017
PATIENT REVENUES, net
$
423,798

 
$
430,427

EXPENSES:
 
 
 
Operating
337,517

 
341,937

Lease and rent expense
41,202

 
41,297

Professional liability
8,890

 
8,011

Litigation contingency expense (Note 6)
6,400

 
—

General and administrative
24,971

 
25,277

Depreciation and amortization
8,692

 
8,095

Lease termination receipts
—

 
(180
)
Total expenses
427,672

 
424,437

OPERATING INCOME (LOSS)
(3,874
)
 
5,990

OTHER INCOME (EXPENSE):
 
 
 
Gain on sale of investment in unconsolidated affiliate
308

 
733

Other income
115

 
—

Interest expense, net
(4,996
)
 
(4,692
)
Hurricane costs
—

 
(232
)
Total other expense
(4,573
)
 
(4,191
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(8,447
)
 
1,799

BENEFIT (PROVISION) FOR INCOME TAXES
670

 
(651
)
INCOME (LOSS) FROM CONTINUING OPERATIONS
(7,777
)
 
1,148

LOSS FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax benefit of $11 and $25, respectively
(34
)
 
(42
)
NET INCOME (LOSS)
$
(7,811
)
 
$
1,106

NET INCOME (LOSS) PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
(1.22
)
 
$
0.18

Discontinued operations
(0.01
)
 
(0.01
)
 
$
(1.23
)
 
$
0.17

Per common share – diluted
 
 
 
Continuing operations
$
(1.22
)
 
$
0.18

Discontinued operations
(0.01
)
 
(0.01
)
 
$
(1.23
)
 
$
0.17

COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.165

 
$
0.165

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,362

 
6,274

Diluted
6,362

 
6,465

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

6


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Nine Months Ended September 30,
 
2018
 
2017
NET INCOME (LOSS)
$
(7,811
)
 
$
1,106

OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
501

 
603

Less: reclassification adjustment for amounts recognized in net income
(151
)
 
(348
)
Total other comprehensive income
350

 
255

COMPREHENSIVE INCOME (LOSS)
$
(7,461
)
 
$
1,361


The accompanying notes are an integral part of these interim consolidated financial statements.

7


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Nine Months Ended September 30,
 
2018
 
2017
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income (loss)
$
(7,811
)
 
$
1,106

Discontinued operations
(34
)
 
(42
)
Income (loss) from continuing operations
(7,777
)
 
1,148

Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
 
 
 
Depreciation and amortization
8,692

 
8,095

Provision for doubtful accounts
—

 
6,407

Deferred income tax provision (benefit)
(829
)
 
52

Provision for self-insured professional liability, net of cash payments
2,224

 
(168
)
Litigation contingency expense
6,400

 
—

Stock-based compensation
947

 
766

Gain on sale of unconsolidated affiliate
(308
)
 
(733
)
Provision for leases in excess of cash payments
(1,363
)
 
(517
)
Deferred bonus
—

 
700

Other
250

 
388

Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
(2,134
)
 
(8,387
)
Prepaid expenses and other assets
(2,379
)
 
459

Trade accounts payable and accrued expenses
2,391

 
1,977

Net cash provided by continuing operations
6,114

 
10,187

Discontinued operations
(645
)
 
(241
)
Net cash provided by operating activities
5,469

 
9,946

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(5,964
)
 
(8,638
)
Property acquisitions
—

 
(8,750
)
Proceeds from sale of unconsolidated affiliate
308

 
1,100

Net cash used in continuing operations
(5,656
)
 
(16,288
)
Discontinued operations
—

 
—

Net cash used in investing activities
(5,656
)
 
(16,288
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt obligations
(15,330
)
 
(24,381
)
Proceeds from issuance of debt
17,203

 
31,574

Financing costs
(137
)
 
(195
)
Issuance and redemption of employee equity awards
(219
)
 
(94
)
Payment of common stock dividends
(1,053
)
 
(1,038
)
Payment for preferred stock restructuring
(508
)
 
(492
)
Net cash (used in) provided by financing activities
(44
)
 
5,374

Discontinued operations
—

 
—

Net cash (used in) provided by financing activities
$
(44
)
 
$
5,374

The accompanying notes are an integral part of these interim consolidated financial statements.

8


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Nine Months Ended September 30,
 
2018
 
2017
NET DECREASE IN CASH AND CASH EQUIVALENTS
$
(231
)
 
$
(968
)
CASH AND CASH EQUIVALENTS, beginning of period
3,524

 
4,263

CASH AND CASH EQUIVALENTS, end of period
$
3,293

 
$
3,295

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest
$
4,511

 
$
3,989

Cash payments of income taxes
$
474

 
$
667

SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:

 
 
 
Acquisition of equipment through capital lease
$
203

 
$
507

The accompanying notes are an integral part of these interim consolidated financial statements.

9


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2018 AND 2017
(Dollars and shares in thousands, except per share data)
(Unaudited)

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted and residential living beds.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the nine-month periods ended September, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership. All amounts subject to the liquidation of remaining assets affiliated with the partnership have been settled.
The interim consolidated financial statements for the three and nine month periods ended September 30, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2018, and the results of operations for the three and nine month periods ended September 30, 2018 and 2017, and cash flows for the nine month periods ended September 30, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended September 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

3.
RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects

10


of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make an accounting election by asset class not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company intends to use the optional expedient to reflect adoption in the period of adoption (which is January 1, 2019 for us) rather than the earliest period presented. For periods presented under Topic 842, extensive quantitative and qualitative disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company anticipates this standard will have a material impact on the consolidated financial position, primarily from nursing center operating leases. The Company has organized an implementation group of cross-functional departmental management to ensure the completeness of the lease information (specifically for new contracts entered into after the adoption date), analyze the appropriate classification of leases under the new standard, and develop new processes to execute, approve and classify new leases on an ongoing basis. The Company has also implemented software tools and processes to maintain lease information critical to applying the standard. The Company is in the process of cataloging its existing lease contracts and implementing changes to the systems, related processes and controls. The Company is planning to elect the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The Company is continuing to evaluate the extent of this anticipated impact on the consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be

11


collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.

4. REVENUE RECOGNITION
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.

12


The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Financial Statement Impact of Adopting ASC 606

The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:

 
Three Months Ended September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,431
 
3,903
(a)
$145,065
 
(269)
(b)
 
3,634
 
Operating Expenses
$113,799
 
3,903
(a)
$117,702
Total Expenses
$147,397
 
3,903
(a)
$151,300

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
Nine Months Ended September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$423,798
 
11,155
(a)
$434,066
 
(887)
(b)
 
10,268
 
Operating Expenses
$337,517
 
11,155
(a)
$348,672
Total Expenses
$427,672
 
11,155
(a)
$438,827

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.


13


 
As of September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Accounts Receivable
$65,927
 
(887)
(a)

$81,275
 
16,235
(b)
 
15,348
 
Accumulated Deficit
$(23,432)
 
887
(a)

$(22,829)
 
(284)
(c)
 
603
 

(a) Adjusts for the implementation of ASC 606.
(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.
(c) Reflects the tax impact for the ASC 606 adjustment of $887.

Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended September 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
68,929

48.7
%
 
$
78,200

53.9
%
 
$
77,027

52.6
%
Medicare
26,997

19.1
%
 
34,933

24.1
%
 
36,449

24.9
%
Managed Care
12,404

8.8
%
 
10,874

7.5
%
 
10,992

7.5
%
Private Pay and other
33,101

23.4
%
 
21,058

14.5
%
 
21,909

15.0
%
Total
$
141,431

100.0
%
 
$
145,065

100.0
%
 
$
146,377

100.0
%
 
Nine Months Ended September 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
198,418

46.8
%
 
$
226,631

52.2
%
 
$
223,410

51.9
%
Medicare
84,611

20.0
%
 
109,150

25.1
%
 
113,360

26.3
%
Managed Care
39,919

9.4
%
 
34,854

8.0
%
 
31,756

7.4
%
Private Pay and other
100,850

23.8
%
 
63,431

14.7
%
 
61,901

14.4
%
Total
$
423,798

100.0
%
 
$
434,066

100.0
%
 
$
430,427

100.0
%

(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.

5.
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.

14


Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $72,150 as of September 30, 2018, consisting of $63,150 on the term loan facility with an interest rate of 6.00% and $9,000 on the acquisition loan facility with an interest rate of 6.8%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.
Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of September 30, 2018, the Company had $18,500 borrowings outstanding under the Amended Revolver compared to $16,000 outstanding as of December 31, 2017. The interest rate related to the Amended Revolver was 6.00% as of September 30, 2018. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Also, borrowings on the revolver relate to the timing of cash flows and our operating activities. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,714 outstanding as of September 30, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $37,710 the balance available for borrowing under the Amended Revolver was $5,496 at September 30, 2018.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at September 30, 2018.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $27,915 as of September 30, 2018. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at September 30, 2018, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $661 at September 30, 2018. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at September 30, 2018 is $403 net of the income tax provision of $258. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.

15



6.    COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $500 per medical incident with a sublimit per center of $1,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $27,070 as of September 30, 2018. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of September 30, 2018, the Company is engaged in 83 professional liability lawsuits. Twenty lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $4,452 and $6,077 for the nine months ended September 30, 2018 and 2017, respectively.
The Company follows the FASB ASU No. 2010-24, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of September 30, 2018 there are estimated insurance recovery receivables of $5,425.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.

16


Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
The Company is engaged in preliminary discussions with the DOJ regarding settlement of this investigation. The Company denies any wrong doing and is prepared to vigorously defend its actions. However, based upon preliminary settlement discussions, the Company believes that it is probable a loss will result from this contingency and has accrued $6,400 as a contingent liability in connection with this matter during the three months ended September 30, 2018. The Company cannot predict whether a settlement can be achieved, the outcome of the litigation if there is no settlement or the length of time necessary to conclude. Accordingly, the contingent liability has been classified as a noncurrent liability in the accompanying interim consolidated balance sheets.  The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ, the Company’s assessment of the risks of litigating this case and the effect of protracted litigation or settlement terms on the Company’s business plans.  Because the outcome of this investigation and related settlement discussions remain uncertain, there is a reasonable possibility that the amount ultimately incurred in connection with the resolution of this matter could differ materially from the current accrual, as the Company cannot, at this time, estimate the possible range of loss that may result from either a settlement or litigation of this matter.  The ultimate outcome of this litigation could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to the practices of some of its employees with respect to PAEs and PASRRs, and the Company provided documents responsive to this subpoena and coordinated examinations of certain employees of the Company.  The Company understands that this criminal investigation has been closed, subject to re-opening at the discretion of the government.

Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July 1, 2008 through September 30, 2018, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $620 at September 30, 2018. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,074 as of September 30, 2018. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of September 30, 2018, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,662 at September 30, 2018. The differences between actual settlements and reserves are included in expense in the period finalized.


17


7.
STOCK-BASED COMPENSATION

Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.
Equity Grants and Valuations
During the nine months ended September 30, 2018 and 2017, the Compensation Committee of the Board of Directors approved grants totaling approximately 90 and 88 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Generally, unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. In addition, during the nine months ended September 30, 2018, the Company granted stock options to purchase a total of 30 shares of common stock at an exercise price equal to the market price of the Company’s common stock on the date of grant to two new directors. These stock options vest one third on the date of grant and one third on the first and second anniversary of the date of grant.
Prior to 2017, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
211

 
$
6.64

Granted
30

 
8.14

Exercised
(100
)
 
5.79

Expired or cancelled
(17
)
 
9.76

Outstanding, September 30, 2018
124

 
$
7.24

 
 
 
 
Exercisable, September 30, 2018
104

 
$
7.06



18


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
4

 
6.95

Vested
(131
)
 
9.71

Cancelled
(7
)
 
9.62

Outstanding, September 30, 2018
120

 
$
8.77


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
6.89

Vested
(17
)
 
8.91

Outstanding, September 30, 2018
44

 
$
9.25


The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.80
 
$
9.32

 
60

 
$
—

 
40

 
$
—

$2.37 to $5.86
 
$
5.28

 
64

 
$
75

 
64

 
$
75

 
 
 
 
124

 
 
 
104

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $947 and $766 in the nine month periods ended September 30, 2018 and 2017, respectively. The stock-based compensation expense balance for the nine month period ended September 30, 2018 is inclusive of $259 related to the vesting of executive equity awards.


19


8.
EARNINGS PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net loss
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(7,389
)
 
$
(581
)
 
$
(7,777
)
 
$
1,148

Income (loss) from discontinued operations, net of income taxes
(8
)
 
1

 
(34
)
 
(42
)
Net loss
$
(7,397
)
 
$
(580
)
 
$
(7,811
)
 
$
1,106

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(1.15
)
 
$
(0.09
)
 
$
(1.22
)
 
$
0.18

Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – basic
$
(1.15
)
 
$
(0.09
)
 
$
(1.23
)
 
$
0.17

Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(1.15
)
 
$
(0.09
)
 
$
(1.22
)
 
$
0.18

Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – diluted
$
(1.15
)
 
$
(0.09
)
 
$
(1.23
)
 
$
0.17

Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,400

 
6,294

 
6,362

 
6,274

Diluted
6,400

 
6,294

 
6,362

 
6,465

The effects of 124 and 46 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the nine months ended September 30, 2018 and 2017, respectively, because these securities would have been anti-dilutive.


20


9.
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $140 of acquisition costs and a $925 recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The final allocation of the purchase price to the net assets acquired is as follows:
 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675


2018 Assets Held for Sale
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The carrying value of these centers' assets are $13,299. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets. Refer to Note 10 for further discussion.
2017 Lease Termination
On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December 31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the nine-month periods ended September 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.



21


10.
SUBSEQUENT EVENTS

On July 8, 2018, the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to transfer all of the issued and outstanding membership units of Ontario Pointe, a stand-alone 50 bed assisted living facility. The termination of this lease was effective on October 1, 2018.

On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two 10 year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.

On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, Diversicare of Clinton and Diversicare of Glasgow (the "Properties"). The purchase price of the Properties is $18,700 and the sale is expected to be completed in the fourth quarter of 2018.



22


ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted living and residential beds.
Key Performance Metrics
Skilled Mix. Skilled mix represents the number of days our Medicare or Managed Care patients are receiving services at the skilled nursing facilities divided by the total number of days (less days from assisted living patients).
Average rate per day. Average rate per day is the revenue by primary payor source for a period at the skilled nursing facility divided by actual patient days for the revenue source for a given period.
Average daily skilled nursing census. Average daily skilled nursing census is the average number of patients who are receiving skilled nursing care.
Strategic Operating Initiatives
We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving our facilities' quality metrics, improving skilled mix in our nursing centers, improving our average Medicare rate, implementing and maintaining Electronic Medical Records (“EMR”) to improve Medicaid capture, and completing strategic acquisitions and divestitures. We have experienced success in some of these initiatives and expect to continue to build on these improvements. In light of challenges facing the industry and the Company specifically, including the unresolved governmental investigation, we believe that now is not the time to attempt to engage in a company-wide strategic transaction.
Improving skilled mix and average Medicare rate:
Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the three months ended September 30, 2018 and 2017 was 14.0% and 14.5%, respectively. The graph below illustrates our average Medicare rate per day period over period:
medicarerateperday.jpg

23


Utilizing Electronic Medical Records to improve Medicaid acuity capture:
As another part of our strategic operating initiatives, we successfully completed a full implementation of EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. We completed the implementation on time and under budget, and since implementation, have increased our average Medicaid rate per day despite rate cuts in certain acuity based states by accurate and timely capture of care delivery. The graph below illustrates our success with increasing our average Medicaid rate per day since implementation:
medicaidrateperday.jpg
Completing strategic acquisitions and dispositions:
Our strategic operating initiatives include a renewed focus on completing strategic acquisitions and dispositions. We continue to pursue and investigate opportunities to acquire, lease or develop new centers, focusing primarily on opportunities within our existing geographic areas of operation. We expect to announce additional development projects in the near future.
Effective July 1, 2017, we acquired a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8.8 million, pursuant to an Asset Purchase Agreement with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC. This transaction is further discussed in Note 9 "Business Development and Other Significant Transactions" to the interim consolidated financial statements.
As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions was in line with the short-term and long-term strategy of the business. As a result, we ceased operations at our Carthage, Mississippi, facility in September 2017 thus terminating our lease agreements with the lessor. This transaction was not reported as discontinued operations as described in Note 9 to the interim consolidated financial statements.
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $13.3 million as of September 30, 2018. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheet.
On July 8, 2018, the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to transfer all of the issued and outstanding membership units of Ontario Pointe, a stand-alone 50 bed assisted living facility. The termination of this lease was effective on October 1, 2018.
On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two 10 year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.
On October 29, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, Diversicare of Clinton and Diversicare of Glasgow (the "Properties"). The purchase price of the Properties is $18.7 million and the sale is expected to be completed in the fourth quarter of 2018.

24


Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2017 Annual Report on Form 10-K.


25


Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other payors are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The following table sets forth net patient and resident revenues related to our continuing operations by primary payor source for the periods presented (dollar amounts in thousands). The difference between 2018 revenue reported below and in the accompanying statements of operations is due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.
 
Three Months Ended September 30,
 
2018
 
2018
 
2017
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
68,929

48.7
%
 
$
78,200

53.9
%
 
$
77,027

52.6
%
Medicare
26,997

19.1
%
 
34,933

24.1
%
 
36,449

24.9
%
Managed Care
12,404

8.8
%
 
10,874

7.5
%
 
10,992

7.5
%
Private Pay and other
33,101

23.4
%
 
21,058

14.5
%
 
21,909

15.0
%
Total
$
141,431

100.0
%
 
$
145,065

100.0
%
 
$
146,377

100.0
%
 
Nine Months Ended September 30,
 
2018
 
2018
 
2017
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
198,418

46.8
%
 
$
226,631

52.2
%
 
$
223,410

51.9
%
Medicare
84,611

20.0
%
 
109,150

25.1
%
 
113,360

26.3
%
Managed Care
39,919

9.4
%
 
34,854

8.0
%
 
31,756

7.4
%
Private Pay and other
100,850

23.8
%
 
63,431

14.7
%
 
61,901

14.4
%
Total
$
423,798

100.0
%
 
$
434,066

100.0
%
 
$
430,427

100.0
%

The following table sets forth average daily skilled nursing census by primary payor source for our continuing operations for the periods presented: 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
2017
 
2018
2017
Medicaid
4,692

 
70.0
%
 
4,734

 
69.1
%
 
4,642

 
68.9
%
 
4,672

 
68.8
%
Medicare
686

 
10.2

 
724

 
10.6

 
728

 
10.8

 
775

 
11.4

Managed Care
254

 
3.8

 
270

 
3.9

 
279

 
4.1

 
262

 
3.9

Private Pay and other
1,071

 
16.0

 
1,126

 
16.4

 
1,086

 
16.2

 
1,082

 
15.9

Total
6,703

 
100.0
%
 
6,854

 
100.0
%
 
6,735

 
100.0
%
 
6,791

 
100.0
%
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry
The health care industry is subject to regulation by numerous federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of patient care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care

26


providers of a number of statutes and regulations, including those regulating fraud and abuse, false claims, patient privacy and quality of care issues. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. The Company is involved in regulatory actions of this type from time to time.
In recent years, the U.S. Congress and some state legislatures have considered and enacted significant legislation concerning health care and health insurance. The most prominent of these efforts, the Affordable Care Act, affects how health care services are covered, delivered and reimbursed. As currently structured, the Affordable Care Act expands coverage through a combination of public program expansion and private sector reforms, provides for reduced growth in Medicare program spending, and promotes initiatives that tie reimbursement to quality and care coordination. Some of the provisions, such as the requirement that large employers provide health insurance benefits to full-time employees, have increased our operating expenses. The Affordable Care Act expands the role of home-based and community services, which may place downward pressure on our sustaining population of Medicaid patients. Reforms that we believe may have a material impact on the long-term care industry and on our business include, among others, possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. However, there is considerable uncertainty regarding the future of the Affordable Care Act. The Presidential administration and certain members of Congress have made and expressed their intent to repeal or make additional significant changes to the law, its implementation or its interpretation. For example, in 2017, Congress eliminated the financial penalty associated with the individual mandate, effective January 1, 2019.
Skilled nursing centers are required to bill Medicare on a consolidated basis for certain items and services that they furnish to patients, regardless of the cost to deliver these services. This consolidated billing requirement essentially makes the skilled nursing center responsible for billing Medicare for all care services delivered to the patient during the length of stay. CMS has instituted a number of test programs designed to extend the reimbursement and financial responsibilities under consolidating billing beyond the traditional discharge date to include a broader set of bundled services. Such examples may include, but are not exclusive to, home health, durable medical equipment, home and community based services, and the cost of re-hospitalizations during a specified bundled period. Currently, these test programs for bundled reimbursement are confined to a small set of clinical conditions, but CMS has indicated that it is developing additional bundled payment models. This bundled form of reimbursement could be extended to a broader range of diagnosis related conditions in the future. The potential impact on skilled nursing center utilization and reimbursement is currently unknown. The process for defining bundled services has not been fully determined by CMS and therefore is subject to change during the rule making process.
On July 31, 2018, CMS issued a final rule outlining Medicare payment rates for skilled nursing facilities that became effective October 1, 2018. In addition, CMS updated the SNF market basket percentage to 2.4%, as required by the Bipartisan Budget Act of 2018. CMS finalized a payment system called the Patient-Driven Payment Model ("PDPM") to replace the Resource Utilization Group ("RUG-IV") model. The PDPM is an updated version of the 2017 Advanced Notice of Proposed Rulemaking Resident Classification System Version 1 ("RCS-1"). CMS notes RCS-1 was revised based on stakeholder input. The implementation date for the final system is October 1, 2019. CMS will use a budget neutrality factor to satisfy the requirement that PDPM be budget neutral relative to RUG-IV. CMS stated that it intends for the new model not to change the aggregate amount of Medicare payments to SNFs, but to more accurately reflect resource utilization without incentivizing inappropriate care delivery.


27


Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of September 30, 2018, summarized by the period in which payment is due, as follows (dollar amounts in thousands):
Contractual Obligations
Total
 
Less than
1  year
 
1 to 3
Years
 
3 to 5
Years
 
After
5 Years
Long-term debt obligations (1)
$
103,274

 
$
17,723

 
$
85,526

 
$
25

 
$
—

Settlement obligations (2)
876

 
876

 
—

 
—

 
—

Operating leases (3)
1,032,207

 
59,120

 
121,294

 
125,221

 
726,572

Required capital expenditures under operating leases (4)
10,486

 
1,160

 
2,320

 
2,320

 
4,686

Total
$
1,146,843

 
$
78,879

 
$
209,140

 
$
127,566

 
$
731,258

 
(1)
Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our capital lease obligations. Our long-term debt obligations decreased $0.2 million between December 31, 2017 and September 30, 2018. See Note 5, "Long-Term Debt and Interest Rate Swap," to the interim consolidated financial statements included in this report for additional information.
(2)
Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.
(3)
Represents lease payments under our operating lease agreements. Assumes all renewal periods are enacted. Our operating lease obligations decreased $33.4 million between December 31, 2017 and September 30, 2018.
(4)
Includes annual expenditure requirements under operating leases. Our required capital expenditures decreased $1.4 million between December 31, 2017 and September 30, 2018.
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1.7 million as of September 30, 2018. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee.


28


Results of Operations
The following tables present the unaudited interim consolidated statements of operations and related data for the three and nine month periods ended September 30, 2018 and 2017:
 
(in thousands)
Three Months Ended September 30,
 
2018
 
2017
 
Change
 
%
PATIENT REVENUES, net
$
141,431

 
$
146,377

 
$
(4,946
)
 
(3.4
)%
EXPENSES:
 
 
 
 
 
 
 
Operating
113,799

 
118,104

 
(4,305
)
 
(3.6
)%
Lease and rent expense
13,764

 
13,791

 
(27
)
 
(0.2
)%
Professional liability
2,933

 
2,617

 
316

 
12.1
 %
Litigation contingency expense
6,400

 
—

 
6,400

 
—
 %
General and administrative
7,537

 
8,083

 
(546
)
 
(6.8
)%
Depreciation and amortization
2,964

 
2,988

 
(24
)
 
(0.8
)%
Lease termination receipts
—

 
(180
)
 
180

 
100.0
 %
Total expenses
147,397

 
145,403

 
1,994

 
1.4
 %
OPERATING INCOME (LOSS)
(5,966
)
 
974

 
(6,940
)
 
(712.5
)%
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Other income
36

 
—

 
36

 
100.0
 %
Interest expense, net
(1,666
)
 
(1,668
)
 
2

 
0.1
 %
Hurricane costs
—

 
(232
)
 
232

 
100.0
 %
 
(1,630
)
 
(1,900
)
 
270

 
14.2
 %
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(7,596
)
 
(926
)
 
(6,670
)
 
(720.3
)%
BENEFIT FOR INCOME TAXES
207

 
345

 
(138
)
 
(40.0
)%
LOSS FROM CONTINUING OPERATIONS
$
(7,389
)
 
$
(581
)
 
$
(6,808
)
 
(1,171.8
)%


29


(in thousands)
Nine Months Ended September 30,
 
2018
 
2017
 
Change
 
%
PATIENT REVENUES, net
$
423,798

 
$
430,427

 
$
(6,629
)
 
(1.5
)%
EXPENSES:
 
 
 
 
 
 
 
Operating
337,517

 
341,937

 
(4,420
)
 
(1.3
)%
Lease and rent expense
41,202

 
41,297

 
(95
)
 
(0.2
)%
Professional liability
8,890

 
8,011

 
879

 
11.0
 %
Litigation contingency expense
6,400

 
—

 
6,400

 
—
 %
General and administrative
24,971

 
25,277

 
(306
)
 
(1.2
)%
Depreciation and amortization
8,692

 
8,095

 
597

 
7.4
 %
Lease termination receipts
—

 
(180
)
 
180

 
100.0
 %
Total expenses
427,672

 
424,437

 
3,055

 
0.8
 %
OPERATING INCOME (LOSS)
(3,874
)
 
5,990

 
(9,684
)
 
(164.7
)%
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Gain on sale of investment in unconsolidated affiliate

308

 
733

 
(425
)
 
(100.0
)%
Other income
115

 
—

 
115

 
100.0
 %
Interest expense, net
(4,996
)
 
(4,692
)
 
(304
)
 
(6.5
)%
Hurricane costs
—

 
(232
)
 
232

 
100.0
 %
 
(4,573
)
 
(4,191
)
 
(382
)
 
(9.1
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(8,447
)
 
1,799

 
(10,066
)
 
(569.5
)%
BENEFIT (PROVISION) FOR INCOME TAXES
670

 
(651
)
 
1,321

 
202.9
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
(7,777
)
 
$
1,148

 
$
(8,745
)
 
(777.4
)%

Percentage of Net Revenues
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
PATIENT REVENUES, net
100.0
 %
 
100.0
 %
 
100.0
 %
 
100.0
%
EXPENSES:
 
 
 
 
 
 
 
Operating
80.5

 
80.7

 
79.6

 
79.4

Lease and rent expense
9.7

 
9.4

 
9.7

 
9.6

Professional liability
2.1

 
1.8

 
2.1

 
1.9

Litigation contingency expense
4.5

 
—

 
1.5

 
—

General and administrative
5.3

 
5.5

 
5.9

 
5.9

Depreciation and amortization
2.1

 
2.0

 
2.1

 
1.9

Lease termination receipts
—

 
(0.1
)
 
—

 
—

Total expenses
104.2

 
99.3

 
100.9

 
98.7

OPERATING INCOME
(4.2
)
 
0.7

 
(0.9
)
 
1.3

OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Gain on sale of investment in unconsolidated affiliate
—

 
—

 
0.1

 
0.2

Other income
—

 
—

 
—

 
—

Interest expense, net
(1.1
)
 
(1.1
)
 
(1.2
)
 
(1.1
)
Hurricane costs
—

 
(0.2
)
 
—

 
(0.1
)
 
(1.1
)
 
(1.3
)
 
(1.1
)
 
(1.0
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(5.3
)
 
(0.6
)
 
(2.0
)
 
0.3

BENEFIT (PROVISION) FOR INCOME TAXES
0.1

 
0.2

 
0.2

 
(0.2
)
INCOME (LOSS) FROM CONTINUING OPERATIONS
(5.2
)%
 
(0.4
)%
 
(1.8
)%
 
0.1
%

30


Three Months Ended September 30, 2018 Compared With Three Months Ended September 30, 2017
Patient Revenues
Patient revenues were $141.4 million and $146.4 million for the three months ended September 30, 2018 and 2017, respectively, a decrease of $5.0 million. The difference between patient revenues for the third quarter of 2018 is primarily due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements. The following summarizes the revenue fluctuations attributable to changes in our portfolio (in thousands):
 
Three Months Ended September 30,
 
2018
2017
 

 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store revenue
$
139,083

 
$
142,717

 
$
142,321

 
$
396

2017 acquisition revenue
2,348

 
2,348

 
2,244

 
104

2017 disposition revenue
—

 
—

 
1,812

 
(1,812
)
Total revenue
$
141,431

 
$
145,065

 
$
146,377

 
$
(1,312
)
Our average Medicaid rate per patient day for the third quarter of 2018 increased compared to the third quarter of 2017, resulting in increases in revenue of $1.9 million or 2.5%. Conversely, the average Medicare rate per patient day for the third quarter of 2018 decreased compared to the third quarter of 2017, resulting in decreases in revenue of $0.2 million or 0.8%. Our Hospice average daily census for the third quarter of 2018 increased $1.3 million or 20.6%. Conversely, our Medicare, Managed Care, Medicaid and Private average daily census for the third quarter of 2018 decreased $1.6 million, $0.6 million, $0.7 million and $2.2 million, respectively, or 5.3%, 6.2%, 0.9% and 17.9%, respectively. Our ancillary revenue for the third quarter of 2018 increased $0.6 million.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Three Months Ended September 30,
 
2018
 
2017
Skilled nursing occupancy
79.3
%
 
80.1
%
As a percent of total census:
 
 
 
Medicare census
10.2
%
 
10.6
%
Medicaid census
70.0
%
 
69.1
%
Managed Care census
3.8
%
 
3.9
%
As a percent of total revenues:
 
 
 
Medicare revenues
24.1
%
 
24.9
%
Medicaid revenues
53.9
%
 
52.6
%
Managed Care revenues
7.5
%
 
7.5
%
Average rate per day:
 
 
 
Medicare
$
452.19

  
$
455.95

Medicaid
$
180.69

  
$
176.26

Managed Care
$
388.64

  
$
379.68


31


Operating Expense
Operating expense decreased in the third quarter of 2018 to $113.8 million as compared to $118.1 million in the third quarter of 2017. Operating expense decreased as a percentage of revenue at 80.5% for the third quarter of 2018 as compared to 80.7% for the third quarter of 2017. The following table summarizes the expense increases attributable to changes in our portfolio (in thousands):
 
Three Months Ended September 30,
 
2018
2017
 

 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store operating expense
$
112,066

 
$
115,969

 
$
114,868

 
$
1,101

2017 acquisition expense
1,733

 
1,733

 
1,863

 
(130
)
2017 disposition expense
—

 
—

 
1,373

 
(1,373
)
Total expense
$
113,799

 
$
117,702

 
$
118,104

 
$
(402
)
Our operating expenses decreased by $0.4 million, which is attributable to favorable variances in nursing and ancillary costs and dietary expenses of $0.4 million and $0.6 million, respectively, in third quarter of 2018 compared to the third quarter of 2017. This was partially offset by unfavorable variances in salaries and related taxes and health insurance costs of $0.3 million and $0.2 million, respectively, in third quarter of 2018 compared to the third quarter of 2017.
One of the largest components of operating expenses is wages, which increased to $69.9 million during the third quarter of 2018 as compared to $69.4 million in the third quarter of 2017.
Lease Expense
Lease expense in the third quarter of 2018 remained consistent with the third quarter of 2017 at $13.8 million.
Professional Liability
Professional liability expense was $2.9 million and $2.6 million in the third quarters of 2018 and 2017, respectively. Our cash expenditures for professional liability costs of continuing operations stayed consistent at $1.7 million for the third quarters of 2018 and 2017, respectively. Professional liability expense fluctuates based on the results of our third-party professional liability actuarial studies and cash expenditures are incurred to defend and settle existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.
Litigation contingency expense
The Company recorded a contingent liability related to DOJ investigation for $6.4 million in the third quarter of 2018. The Company denies any wrong doing and is prepared to vigorously defend its actions. The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ. Refer to Note 6 to the interim consolidated financial statements for further discussion.
General and Administrative Expense
General and administrative expense was $7.5 million in the third quarter of 2018 as compared to $8.1 million in the third quarter of 2017. General and administrative expense decreased as a percentage of revenue to 5.3% in the third quarter of 2018 from 5.5% in the third quarter of 2017. The change in general and administrative expense is attributable to a decrease in salaries and related taxes of $0.5 million in the third quarter of 2018 as compared to the third quarter of 2017.
Depreciation and Amortization
Depreciation and amortization expense in the third quarter of 2018 remained consistent with the third quarter of 2017 at $3.0 million.
Interest Expense, Net
Interest expense in the third quarter of 2018 remained consistent with the third quarter of 2017 at $1.7 million.
Loss from Continuing Operations before Income Taxes; Loss from Continuing Operations per Common Share
As a result of the above, continuing operations reported a loss of $7.6 million before income taxes for the third quarter of 2018 as compared to a loss of $0.9 million for the third quarter of 2017. The benefit for income taxes was $0.2 million for the third quarter of 2018, and the benefit for income taxes was $0.3 million for the third quarter of 2017. Both basic and diluted loss per common share from continuing operations were $1.15 for the third quarter of 2018 as compared to both basic and diluted loss per common share from continuing operations of $0.09 in the third quarter of 2017.

32


Nine Months Ended September 30, 2018 Compared With Nine Months Ended September 30, 2017
Patient Revenues
Patient revenues were $423.8 million and $430.4 million for the nine months ended September 30, 2018 and 2017, respectively, a decrease of $6.6 million. The following table summarizes the revenue fluctuations attributable to our portfolio growth (in thousands):
 
Nine Months Ended September 30,
 
2018
 
2017
 
 
 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store revenue
$
416,733

 
$
427,001

 
$
422,949

 
$
4,052

2017 acquisition revenue
7,065

 
7,065

 
2,244

 
4,821

2017 disposition revenue
—

 
—

 
5,234

 
(5,234
)
Total revenue
$
423,798

 
$
434,066

 
$
430,427

 
$
3,639

The change in patient revenues for the nine months ended September 30, 2018 is due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.
Our Managed Care and Hospice average daily census for the nine months ended September 30, 2018 increased compared to the nine months ended September 30, 2017, resulting in increases in revenue of $1.8 million and $3.1 million, respectively, or 6.5% and 17.6%, respectively. Conversely, our Medicare, Medicaid and Private average daily census for the nine months ended September 30, 2018 decreased $5.9 million, $1.4 million and $3.0 million, respectively, or 6.1%, 0.6% and 8.5%. The average Medicaid, Managed Care, Hospice and Private rate per patient day in 2018 increased $4.7 million, $0.7 million, $0.9 million and $0.8 million, respectively, or 2.1%, 2.4%, 5.1% and 2.2% respectively.
Our ancillary revenue for the nine months ended September 30, 2018 increased $2.1 million compared to the nine months ended September 30, 2017.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Nine Months Ended September 30,
 
 
 
2018
 
 
 
2017
 
 
Skilled nursing occupancy
79.6
%
 
 
 
80.0
%
 
 
As a percent of total census:
 
 
 
 
 
 
 
Medicare census
10.8
%
 
 
 
11.4
%
 
 
Medicaid census
68.9
%
 
 
 
68.8
%
 
 
Managed Care census
4.1
%
 
 
 
3.9
%
 
 
As a percent of total revenues:
 
 
 
 
 
 
 
Medicare revenues
25.1
%
 
 
 
26.3
%
 
 
Medicaid revenues
52.2
%
 
 
 
51.9
%
 
 
Managed Care revenues
8.0
%
 
 
 
7.4
%
 
 
Average rate per day:
 
 
 
 
 
 
 
Medicare
$
454.46

 
  
 
$
453.35

 
 
Medicaid
$
178.38

 
  
 
$
174.66

 
 
Managed Care
$
392.80

 
  
 
$
384.00

 
 

33


Operating Expense
Operating expense decreased for the nine months ended September 30, 2018 to $337.5 million as compared to $341.9 million for the nine months ended September 30, 2017. Conversely, operating expense increased as a percentage of revenue at 79.6% in 2018 as compared to 79.4% in 2017. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Nine Months Ended September 30,
 
2018
2017
 
 
 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store operating expense
$
332,498

 
$
343,653

 
$
336,064

 
$
7,589

2017 acquisition expense
5,019

 
5,019

 
1,863

 
3,156

2017 disposition expense
—

 
—

 
4,010

 
(4,010
)
Total expense
$
337,517

 
$
348,672

 
$
341,937

 
$
6,735

Our operating expenses increased by $6.7 million, which is attributable to a provider tax refund of $2.2 million from the state of Kentucky during the first quarter of 2017. Additionally, our salaries and related taxes increased by $4.0 million, maintenance and utilities of $0.5 million and legal fees of $0.4 million. These increases were partially offset by a decrease in health insurance costs of $0.8 million.
One of the largest components of operating expenses is wages, which increased to $204.8 million during 2018 as compared to $200.5 million in 2017.
Lease Expense
Lease expense remained relatively consistent for the nine months ended September 30, 2018 of $41.2 million as compared to $41.3 million for the nine months ended September 30, 2017.
Professional Liability
Professional liability expense was $8.9 million and $8.0 million for the nine months ended September 30, 2018 and 2017, respectively. Our cash expenditures for professional liability costs of continuing operations were $4.5 million and $6.1 million for the nine months ended September 30, 2018 and 2017, respectively. Professional liability expense fluctuates based on the results of our third-party professional liability actuarial studies and cash expenditures are incurred to defend and settle existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.
Litigation contingency expense
The Company recorded a contingent liability related to DOJ investigation for $6.4 million for the nine months ended September 30, 2018. The Company denies any wrong doing and is prepared to vigorously defend its actions. The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ. Refer to Note 6 to the interim consolidated financial statements for further discussion.
General and Administrative Expense
General and administrative expense was $25.0 million for the nine months ended September 30, 2018 as compared to $25.3 million for the nine months ended September 30, 2017, a decrease of $0.3 million. As a percentage of revenue, general and administrative expense remained consistent with the third quarter of 2017 at 5.9%. The decrease in general and administrative expense is attributable to lower salaries and related taxes of $1.4 million for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017. This decrease was offset by executive severance expense of $1.2 million for the nine months ended September 30, 2018.
Depreciation and Amortization
Depreciation and amortization expense was approximately $8.7 million in 2018 as compared to $8.1 million in 2017. The increase in depreciation expense relates to fixed assets at the newly acquired center and other capital expenditures.
Lease Termination Receipts
The Company ceased operations at our Carthage, Mississippi, center in September 2017, which resulted in a $0.2 million cash termination payment, net of legal costs, in the third quarter of 2017. This was recorded as lease termination receipts during the nine months ended September 30, 2017.
Gain on sale of investment in unconsolidated affiliate

34


Gain on the sale of investment in unconsolidated affiliate was $0.3 million and $0.7 million for the nine months ended September 30, 2018 and 2017, respectively. The additional gains recognized for the nine months ended September 30, 2018 and 2017 are related to the final liquidation of remaining net assets affiliated with the partnership.
Interest Expense, Net
Interest expense was $5.0 million for the nine months ended September 30, 2018 and $4.7 million for the nine months ended September 30, 2017, an increase of $0.3 million. The increase was primarily attributable to the amendment of the term loan facility that occurred in June 2017.
Income (loss) from Continuing Operations before Income Taxes; Income (loss) from Continuing Operations per Common Share
As a result of the above, continuing operations reported a loss of $8.4 million before income taxes for the nine months ended September 30, 2018 as compared to income of $1.8 million for the nine months ended September 30, 2017. The benefit for income taxes was $0.7 million for the nine months ended September 30, 2018, and the provision for income taxes was $0.7 million for the nine months ended September 30, 2017. Both basic and diluted loss per common share from continuing operations were $1.22 for the nine months ended September 30, 2018 as compared to basic and diluted income per common share from continuing operations of $0.18 and $0.18, respectively, for the nine months ended September 30, 2017.
Liquidity and Capital Resources
Liquidity
Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our use of cash include, but are not limited to, capital improvements, dividends, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash provided by operating activities of continuing operations totaled $6.1 million for the nine months ended September 30, 2018, compared to net cash provided by operating activities of continuing operations of $10.2 million in the same period of 2017. The primary driver of the decrease in cash provided by operating activities from continuing operations is due to our net loss of $0.9 million for the nine months ended September 30, 2018, compared to net income of $1.2 million in the same period of 2017.
Our cash expenditures related to professional liability claims of continuing operations were $4.5 million and $6.1 million for nine months ended September 30, 2018 and 2017, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our inability to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $5.7 million and $16.3 million for the nine months ended in 2018 and 2017, respectively. The fluctuation is due to the purchase of a center in Selma, Alabama for the nine months ended 2017 for $8.8 million.
Financing activities of continuing operations used cash of less than $0.1 million for the nine months ended September 30, 2018 compared to cash provided of $5.4 million for the nine months ended September 30, 2017. The decrease is primarily due to the additional draws on the Company's revolving credit facility in 2017.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. On a per claim basis, coverage for losses in excess of those covered by SHC is maintained through unaffiliated commercial reinsurance carriers. All of the Company's nursing centers in Florida and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $0.5 million per medical incident with a sublimit per center of $1.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.

35


As of September 30, 2018, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $27.1 million. Our calculation of this estimated liability is based on an assumption that the Company will not incur a severely adverse judgment with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.
Capital Resources
As of September 30, 2018, we had $91.4 million of outstanding long-term debt and capital lease obligations. The $91.4 million total includes $0.8 million in capital lease obligations and $18.5 million currently outstanding on the revolving credit facility. The balance of the long-term debt is comprised of $72.2 million owed on our mortgage loan, which includes $63.2 million on the term loan facility, $9.0 million on the acquisition loan facility.
On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100.0 million allocated between a $72.5 million Mortgage Loan ("Amended Mortgage Loan") and a $27.5 million Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60 million term loan facility and a $12.5 million acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2.2 million and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $72.5 million with a five-year maturity through February 26, 2021, and a $27.5 million Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30.0 million. As of September 30, 2018, the interest rate related to the Amended Mortgage Loan was 6.00%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27.5 million in the Amended Revolver to $52.3 million; provided that the maximum revolving facility be reduced to $42.3 million on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52.3 million.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10.0 million to $15.0 million.
Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7.5 million.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of September 30, 2018, the Company had $18.5 million borrowings outstanding under the Amended Revolver compared to $16.0 million outstanding as of December 31, 2017. The interest rate related to the Amended Revolver was 6.00% as of September 30, 2018. The outstanding borrowings on the revolver primarily compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under the Amended Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $13.7 million outstanding as of September 30, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $37.7 million, the balance available for borrowing under the Amended Revolver was $5.5 million at September 30, 2018.
Our lending agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. We are in compliance with all such covenants at September 30, 2018.
Our calculated compliance with financial covenants is presented below:
 

36


 
Requirement
  
Level at
September 30, 2018
Minimum fixed charge coverage ratio
1.01:1.00
 
1.07:1.00
Minimum adjusted EBITDA
$13.0 million
 
$18.9 million
EBITDAR (mortgaged centers)
$10.0 million
 
$17.8 million
Current ratio (as defined in agreement)
1.00:1.00
 
1.18:1.00
As part of the debt agreements entered into in February 2016, we amended our interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and carries an initial notional amount of $30.0 million. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.
Off-Balance Sheet Arrangements
We have eleven letters of credit outstanding with an aggregate value of approximately $13.7 million as of September 30, 2018. The letters of credit serve as a security deposits for certain center leases. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.

Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our interim consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to:
•
our ability to successfully integrate the operations of our new nursing center in Alabama, as well as successfully operate all of our centers,
•
our ability to increase census at our centers and occupancy rates at our centers,
•
changes in governmental reimbursement,
•
government regulation,
•
the impact of the Affordable Care Act, efforts to repeal or further modify the Affordable Care Act, and other health care reform initiatives,
•
any increases in the cost of borrowing under our credit agreements,
•
our ability to comply with covenants contained in those credit agreements,
•
our ability to comply with the terms of our master lease agreements,
•
our ability to renew or extend our leases at or prior to the end of the existing lease terms,
•
the outcome of professional liability lawsuits and claims,
•
our ability to control ultimate professional liability costs,
•
the accuracy of our estimate of our anticipated professional liability expense,
•
the impact of future licensing surveys,
•
the outcome of proceedings alleging violations of state or Federal False Claims Acts,
•
laws and regulations governing quality of care or other laws and regulations applicable to our business including HIPAA and laws governing reimbursement from government payors,
•
the costs of investing in our business initiatives and development,

37


•
our ability to control costs,
•
our ability to attract and retain qualified healthcare professionals,
•
changes to our valuation of deferred tax assets,
•
changing economic and competitive conditions,
•
changes in anticipated revenue and cost growth,
•
changes in the anticipated results of operations,
•
the effect of changes in accounting policies as well as others. 
Investors also should refer to the risks identified in this “Management's Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Part I. Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2017, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of September 30, 2018, we had outstanding borrowings of approximately $90.7 million, $62.7 million of which was subject to variable interest rates. In connection with our February 2016 financing agreement, we entered into an interest rate swap with an initial notional amount of $30.0 million to mitigate the floating interest rate risk of a portion of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $0.6 million annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of September 30, 2018. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.
Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of September 30, 2018, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


38


PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, negligence, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our facilities. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of September 30, 2018, we are engaged in 83 professional liability lawsuits. Twenty lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
The Company is engaged in preliminary discussions with the DOJ regarding settlement of this investigation. The Company denies any wrong doing and is prepared to vigorously defend its actions. However, based upon preliminary settlement discussions, the Company believes that it is probable a loss will result from this contingency and has accrued $6.4 million as a contingent liability in connection with this matter during the three months ended September 30, 2018. The Company cannot predict whether a settlement can be achieved, the outcome of the litigation if there is no settlement or the length of time necessary to conclude. Accordingly, the contingent liability has been classified as a noncurrent liability in the accompanying interim consolidated balance sheets.  The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ, the Company’s assessment of the risks of litigating this case and the effect of protracted litigation or settlement terms on the Company’s business plans.  Because the outcome of this investigation and related settlement discussions remain uncertain, there is a reasonable possibility that the amount ultimately incurred in connection with the resolution of this matter could differ materially from the current accrual, as the Company cannot, at this time, estimate the possible range of loss that may result from either a settlement or litigation of this matter.  The ultimate outcome of this litigation could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement.
Additionally, the uncertainty regarding the outcome of this investigation makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to the practices of some of its employees with respect to PAEs and PASRRs, and the Company provided documents responsive to this subpoena and coordinated examinations of certain employees of the Company.  The Company understands that this criminal investigation has been closed, subject to re-opening at the discretion of the government. As always, the Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
The Company cannot predict the outcome of these investigations or the related lawsuits under the False Claims Act, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of these investigations makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial

39


commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The Company answered the original complaint in 2009, and there was no other activity in the case until May 2017. At that time, plaintiff filed an amended complaint asserting new causes of action. The amended complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over a multi-year period by failing to meet minimum staffing requirements, failing to otherwise adequately staff the Center and failing to provide a clean and safe living environment in the Center. The Company has filed an answer to the amended complaint denying plaintiffs’ allegations and has asked the Court to dismiss the new causes of action asserted in the amended complaint because the Company was prejudiced by plaintiff’s long delay in filing the amended complaint. The Court has not yet ruled on the motion to dismiss, so the lawsuit remains in its early stages and has not yet be certified by the court as a class action. The Company intends to defend the lawsuit vigorously.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. An unfavorable outcome in any of these lawsuits, any of our professional liability actions, any regulatory action, or any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act law could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.
ITEM 1A. RISK FACTORS.
In addition to the other information contained in this Quarterly Report, the risks and uncertainties that we believe could materially affect our business, financial condition or future results and are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 1, 2018. Additional risks and uncertainties which are not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or business in general, may also materially and adversely affect any of our business, financial position or future results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURE.
Not applicable.
ITEM 5. OTHER INFORMATION.
On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, Diversicare of Clinton and Diversicare of Glasgow (the "Properties"). The purchase price of the Properties is $18.7 million and the sale is expected to be completed in the fourth quarter of 2018.

ITEM 6. EXHIBITS
The following exhibits are filed as part of this report on Form 10-Q.

40


 
 
 
Exhibit
Number
  
Description of Exhibits
3.1

  
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
 
 
3.3

  
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
 
 
3.5

  
Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
 
 

 
Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
 
 
 

 
Amendment to Certificate of Incorporation dated June 9, 2016 (incorporated by reference to Exhibit 3.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
 
 
 

 
Bylaw Second Amendment adopted April 14, 2016.
 
 
 
4.1

 
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 
 

 
Master Lease Agreement effective October 1, 2018 by and between the Company and Omega Healthcare Investors.
 
 
 

 
Kelly Gill Separation Agreement
 
 
 

  
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
 

 
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 

  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
 
 
101.INS

 
XBRL Instance Document
 
 
101.SCH

  
XBRL Taxonomy Extension Schema Document
 
 
101.CAL

  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.LAB

  
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE

  
XBRL Taxonomy Extension Presentation Linkbase Document


41


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
Diversicare Healthcare Services, Inc.
 
 
 
November 1, 2018
 
 
 
 
 
 
 
By:
 
/s/ James R. McKnight, Jr.
 
 
 
James R. McKnight, Jr.
 
 
 
President and Chief Executive Officer, Principal Executive Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant
 
 
 
 
By:
 
/s/ Kerry D. Massey
 
 
 
Kerry D. Massey
 
 
 
Executive Vice President and Chief Financial Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant

42
 EX-10.1 2 dvcr-ex101xfinalmasteromeg.htm EXHIBIT 10.1 Exhibit










MASTER LEASE
(OHI – Diversicare)

The Entities Identified as “Landlord” on Schedule 1 to this Lease,
As Landlord

AND

The Entities Identified as “Tenant” on Schedule 2 to this Lease,
As Tenant


DATED: October 1, 2018

    

TABLE OF CONTENTS
Page
ARTICLE I    1
1.1
Lease    1
1.2
Term    2
1.3
Option to Renew    2
1.4
Existing Leases    2
1.5
Sale or Lease of Disposition Facilities    2
ARTICLE II    5
2.1
Definitions    5
ARTICLE III    28
3.1
Base Rent; Monthly Installments    28
3.2
Additional Charges    29
3.3
Late Charge    29
3.4
Net Lease    29
3.5
Payments In The Event of a Rent Adjustment    29
3.6
Avon Rent    30
ARTICLE IV    30
4.1
Payment of Impositions    30
4.2
Notice of Impositions    31
4.3
Adjustment of Impositions    31
4.4
Utility Charges    31
4.5
Insurance Premiums    32
ARTICLE V    32
5.1
No Termination, Abatement, etc    32
ARTICLE VI    32
6.1
Ownership of the Leased Properties    32
6.2
Landlord’s Personal Property    33
6.3
Tenant’s Personal Property    33
6.4
Grant of Security Interest in Tenant’s Personal Property and Accounts    34
ARTICLE VII    35
7.1
Condition of the Leased Properties    35
7.2
Use of the Leased Properties    35
7.3
Certain Environmental Matters    35
ARTICLE VIII    41
8.1
Compliance with Legal and Insurance Requirements.    41
8.2
Certain Covenants.    42
8.3
Minimum Qualified Capital Expenditures    43
8.4
Management Agreements    43
8.5
Other Facilities    44
8.6
Separateness    44
8.7
Bank Accounts    45
ARTICLE IX    45
9.1
Maintenance and Repair    45
9.2
Encroachments, Restrictions, etc    47
9.3
Landlord Funded Capital Improvements    47
ARTICLE X    50
10.1
Construction of Alterations and Additions to the Leased Properties    50
ARTICLE XI    51
11.1
Liens    51
ARTICLE XII    51
12.1
Permitted Contests    51
12.2
Landlord’s Requirement for Deposits    52
ARTICLE XIII    52
13.1
General Insurance Requirements    52
13.2
Risks to be Insured    53
13.3
Payment of Premiums; Copies of Policies; Certificates    55
13.4
Premium Deposits    56
13.5
Umbrella Policies    56
13.6
Additional Insurance    56
13.7
No Liability; Waiver of Subrogation    56
13.8
Increase in Limits    56
13.9
Blanket Policy    57
13.10
No Separate Insurance    57
13.11
Alternative Coverages    57
13.12
Insurance Captive    58
ARTICLE XIV    59
14.1
Insurance Proceeds    59
14.2
Restoration in the Event of Damage or Destruction    60
14.3
Restoration of Tenant’s Property    60
14.4
No Abatement of Rent    60
14.5
Waiver    60
14.6
Extension of Time Periods    60
14.7
Disbursement of Insurance Proceeds Equal to or Greater Than The Approval Threshold    60
14.8
Net Proceeds Paid to Facility Mortgagee    62
ARTICLE XV    63
15.1
Total Taking or Other Taking with Leased Property Rendered Unsuitable for Its Primary Intended Use    63
15.2
Allocation of Award    63
15.3
Partial Taking    64
15.4
Temporary Taking    64
15.5
Awards Paid to Facility Mortgagee    65
15.6
Extension of Time Periods    65
ARTICLE XVI    65
16.1
Landlord’s Rights Upon an Event of Default    65
16.2
Certain Remedies    66
16.3
Damages    66
16.4
Intentionally Omitted    67
16.5
Waiver    67
16.6
Application of Funds    67
16.7
Bankruptcy    67
ARTICLE XVII    68
17.1
Landlord’s Right to Cure Tenant’s Default    68
ARTICLE XVIII    68
18.1
Holding Over    68
18.2
Indemnity    68
ARTICLE XIX    68
19.1
Subordination    68
19.2
Attornment    69
19.3
Tenant’s Certificate    69
ARTICLE XX    69
20.1
Risk of Loss    69
ARTICLE XXI    70
21.1
Indemnification    70
ARTICLE XXII    70
22.1
General Prohibition against Transfers    70
22.2
Subordination and Attornment    71
22.3
Sublease Limitation    71
22.4
Permitted Sublease    71
22.5
Hospital Transaction    72
ARTICLE XXIII    73
23.1
Officer’s Certificates and Financial Statements    73
23.2
Public Offering Information    75
ARTICLE XXIV    75
24.1
Organization and Good Standing    75
24.2
Power and Authority    75
24.3
Enforceability    75
24.4
Consents    75
24.5
No Violation    76
24.6
Reports and Statements    76
24.7
No Default    76
24.8
Adverse Matters    76
24.9
Certification    76
24.10
Provider Agreements    77
ARTICLE XXV    77
25.1
Landlord’s Right to Inspect    77
ARTICLE XXVI    77
26.1
No Waiver    77
ARTICLE XXVII    77
27.1
Remedies Cumulative    77
ARTICLE XXVIII    77
28.1
Acceptance of Surrender    77
ARTICLE XXIX    77
29.1
No Merger of Title    77
29.2
No Partnership    78
ARTICLE XXX    78
30.1
Conveyance by Landlord    78
ARTICLE XXXI    78
31.1
Quiet Enjoyment    78
ARTICLE XXXII    78
32.1
Notices    78
ARTICLE XXXIII    79
33.1
Appraisers    79
ARTICLE XXXIV    80
34.1
Breach by Landlord    80
34.2
Compliance With Facility Mortgage    80
ARTICLE XXXV    81
35.1
Disposition of Personal Property on Termination    81
35.2
Facility Trade Names    81
35.3
Transfer of Operational Control of the Facilities    81
35.4
Intangibles and Personal Property    83
ARTICLE XXXVI    83
36.1
Arbitration    83
36.2
Non-Arbitratable Claims    84
ARTICLE XXXVII    84
37.1
Survival, Choice of law    84
37.2
Jurisdiction and Service of Process    85
37.3
Limitation on Recovery    85
37.4
Multiple Entities Comprising Tenant    85
37.5
Waivers    85
37.6
Consents    85
37.7
Counterparts    86
37.8
Options Personal    86
37.9
Right of Setoff    86
37.10
Rights Cumulative    86
37.11
Entire Agreement    86
37.12
Amendments in Writing    86
37.13
Severability    86
37.14
Time of the Essence    86
37.15
Tenant to Pay Reasonable Expenses    86
37.16
MUTUAL WAIVER OF RIGHT TO JURY TRIAL    87
37.17
Electronic Versions of Documents    87
ARTICLE XXXVIII    88
38.1
Commissions    88
ARTICLE XXXIX    88
39.1
Memorandum or Short Form of Lease    88
ARTICLE XL    88
40.1
Security Deposit    88
40.2
Additional Security Deposit    88
40.3
Application of Security Deposit    89
40.4
Transfer of Security Deposit    89
ARTICLE XLI    89
41.1
General REIT Provisions    89

MASTER LEASE
(OHI - Diversicare)

THIS MASTER LEASE (“Lease”) is executed and delivered as of this 1st day of October, 2018, and is entered into by (i) the entities listed on Schedule 1 to this Lease (collectively, “Landlord”), the address of which is 303 International Circle, Suite 200, Hunt Valley, Maryland 21030, and (ii) the entities listed on Schedule 2 to this Lease, the address of which is 277 Mallory Station Road, Suite 130, Franklin, Tennessee 37067 (collectively, “Tenant”).
RECITALS
The circumstances underlying the execution and delivery of this Lease are as follows:
A.Capitalized terms used and not otherwise defined herein have the respective meanings given them in ARTICLE II, below.
B.The parties hereto are parties to the Existing Leases, which include the Expiring Lease and the Terminated Leases, pursuant to which Landlord has leased the Facilities to Tenant. Pursuant to its terms, the Expiring Lease expires immediately prior to the Commencement Date under this Lease. The parties have agreed to the early termination of the Terminated Leases so that the term of each of the Terminated Leases will be terminated immediately prior to the Commencement Date of this Lease.
C.The parties hereto enter into this Lease to provide for the continued leasing of the Facilities from and after the Commencement Date under a single consolidated lease, on the terms and conditions set forth herein.
NOW THEREFORE Landlord and Tenant agree as follows:
ARTICLE I
1.1    Lease.
1.1.1    Upon and subject to the terms and conditions hereinafter set forth, Landlord leases to Tenant the Leased Properties located in Alabama, Florida, Kentucky, Indiana, Missouri, Ohio, Tennessee, and Texas and comprising the Facilities described on Exhibits A- 1 through A-35 (the “Leased Properties”).
1.1.2    The Leased Properties are leased subject to all covenants, conditions, restrictions, easements and other matters affecting each Leased Property, whether or not of record, including the Permitted Encumbrances and other matters which would be disclosed by an inspection of the Leased Properties or by an accurate survey thereof, provided, however, that the foregoing will not materially interfere with the Primary Intended Use of the Leased Property by Tenant as set forth in this Lease.
1.1.3    This Lease constitutes one indivisible lease of the Leased Properties to multiple tenants, and not separate leases governed by similar terms. The Leased Properties constitute one economic unit, and the Base Rent and all other provisions have been negotiated and agreed to based on a demise of all of the Leased Properties as a single, composite, inseparable transaction and would have been substantially different had separate leases or a divisible lease been intended. Except as expressly provided herein for specific, isolated purposes (and then only to the extent expressly otherwise stated), all provisions of this Lease apply equally and uniformly to all the Leased Properties as one unit. An Event of Default with respect to any Leased Property is an Event of Default as to all of the Leased Properties. The parties intend that the provisions of this Lease shall at all times be construed, interpreted and applied so as to carry out their mutual objective to create an indivisible lease of all the Leased Properties and, in particular but without limitation, that for purposes of any assumption, rejection or assignment of this Lease under 11 U.S.C. Section 365, this is one indivisible and non-severable lease and executory contract dealing with one legal and economic unit which must be assumed, rejected or assigned as a whole with respect to all (and only all) the Leased Properties covered hereby. The parties agree that the existence of more than one Landlord under this Lease does not affect the indivisible, non-severable nature of this Lease. The parties may amend this Lease from time to time to include one or more additional Facilities as part of the Leased Properties and such future addition to the Leased Properties shall not in any way change the indivisible and non-severable nature of this Lease and all of the foregoing provisions shall continue to apply in full force.
1.2    Term. The initial term of this Lease (“Initial Term”) shall be twelve (12) Lease Years. The Initial Term shall commence on the Commencement Date and end on the Initial Term Expiration Date, subject to renewal as set forth in Section 1.3, below.
1.3    Option to Renew. Tenant is hereby granted two (2) options to renew this Lease each for an additional, successive period of ten (10) Lease Years, for a maximum Term if such option is exercised of thirty two (32) Lease Years, on the following terms and conditions: (a) the option to renew is exercisable only by Notice to Landlord at least three hundred sixty-five (365) days prior to the expiration of the Initial Term; (b) the absence of any Event of Default both at the time a renewal option is exercised and at the commencement of a Renewal Term is a condition precedent to any renewal of the Term; and (c) during a Renewal Term, all of the terms and conditions of this Lease shall remain in full force and effect.
1.4    Existing Leases. Landlord and Tenant acknowledge and agree that (i) the Expiring Lease shall expire according to its terms on September 30, 2018 and (ii) the term of each of the Terminated Leases shall be terminated on September 30, 2018.
1.5    Sale or Lease of Disposition Facilities.
1.5.1    At any time after the date of this Lease, Landlord will use commercially reasonable efforts to market for sale or lease the Disposition Facilities. Tenant will reasonably cooperate with Landlord with regard to the marketing for sale or lease of the Disposition Facilities, including, but not limited to, providing such information regarding the operations of the Disposition Facilities and such access to the Disposition Facilities, as may be reasonably requested by Landlord, and Landlord agrees to conduct such activities in a manner that does not unreasonably disrupt Tenant’s operation of the Disposition Facilities. The acceptance or rejection of any offer to purchase or lease the Disposition Facilities shall be made by Landlord in its reasonable discretion and approved by Tenant in its reasonable discretion. All net proceeds from the sale or lease (after payment of Landlord’s closing costs) of the Disposition Facilities shall be paid to Landlord. In connection with any such sale or lease, upon the request of Landlord, Tenant shall enter into an operations transfer agreement in form and substance reasonably acceptable to Tenant with the new operator providing for the proration of revenues and expenses. The operations transfer agreement shall also include such indemnities from and in favor of Tenant as may be customarily included in transactions of this type in form and substance reasonably acceptable to Tenant. If requested, the obligations of Tenant or a Subtenant under the operations transfer agreement shall be guaranteed by DHSI.
1.5.2    Base Rent Reduction; Security Deposit Reduction. Upon the closing of the sale or lease of the Disposition Facilities and the transfer of operations to a new operator, the annual Minimum Rent payable under the Master Lease shall be reduced (i) if a lease to a new operator, by the initial annual rent under such new lease, or (ii) if a sale, by the amount calculated as follows:
Disposition Facility
Sale Reduction
[*****]
[*****]
[*****]
10% per annum of the net proceeds received by Landlord from the sale
[*****]
[*****]
[*****]
10% per annum of the net proceeds received by Landlord from the sale
[*****]
[*****]
[*****]
10% per annum of the net proceeds received by Landlord from the sale
[*****]
[*****]
[*****]
10% per annum of the net proceeds received by Landlord from the sale
[*****]
[*****]
[*****]
9% per annum of the net proceeds received by Landlord from the sale
Future Disposition Facilities designated under Section 1.5.8
A percentage per annum equal to the Market Rate of Return of the net proceeds received by Landlord from the sale
            
Also upon the closing of the sale or lease of the Disposition Facilities and the transfer of operations to a new operator, the amount of the Security Deposit will be reset at an amount equal to (i) three months of the annual Base Rent (exclusive of the Avon Rent) after giving effect to the reduction under this Section 1.5.2, and (ii) any Increase under Section 40.2.or adjustments pursuant to ARTICLE XIV or ARTICLE XV.

1.5.3    Other Amendments. Upon the closing of any such sale or lease transaction of the Disposition Facilities (each a “Closing”), Tenant and Landlord shall amend this Lease and the other Lease Documents to delete the Disposition Facilities as Facilities, reduce the annual Base Rent as provided above and release Tenant from any further obligations first arising under this Lease with respect to the applicable Disposition Facilities from and after the date of applicable Closing (the obligations of Tenant under this Lease with respect to matters first arising prior to such Closing shall survive). In connection with each such amendment, DHSI, each other Guarantor, each Subtenant, and each other Affiliate of Tenant shall ratify and affirm its obligations under this Lease and the other Lease Documents. The obligations of Tenant under this Lease with respect to the Disposition Facilities, which, by their terms, survive the termination of this Lease, shall survive the termination of this Lease as to the Disposition Facilities.
1.5.4    Release of Liens. At each Closing, the Security Agreement between Landlord, Tenant and the Subtenants shall be terminated with respect to the applicable Disposition Facility only and Landlord and Tenant will file or record any UCC-3 termination statements necessary to terminate or release any UCC-1 financing statements made with respect to the applicable Disposition Facility only. Landlord and Tenant will record with the appropriate public records a termination of each of the Memorandums of Lease recorded with respect to the applicable Disposition Facility.
1.5.5    Prorations. Tenant shall prorate all Impositions pursuant to the operations transfer agreement with the new operator of the Disposition Facilities and such proration shall be in full satisfaction of the parties’ obligation to prorate such Impositions pursuant to Section 4.3 of this Lease.
1.5.6    Costs and Expenses. Tenant shall pay all of Landlord’s documented costs, fees and expenses, including legal fees and expenses incurred in connection with (i) marketing, or (ii) any sale or lease, or proposed sale or lease, of the Disposition Facilities (whether such closing occurs or not); provided however that any deposit forfeited to Landlord by a proposed purchaser or replacement tenant shall be applied against any such costs, fees and expenses and reduce Tenant’s obligation in connection therewith.
1.5.7    Disposition Period – Limitation on Capital Improvement Obligations. During a period from October 1, 2018 until September 30, 2020 (the “Disposition Period”), Tenant will not be required to make any capital expenditures to the Disposition Facilities identified in Section 1.5.2 in excess of the required per bed annual capital expenditures amount described in Section 8.3 and Tenant’s repair and maintenance obligations with respect to such Disposition Facilities will be limited to any repair or maintenance necessary to comply with any life safety requirement, routine maintenance and repair necessary to maintain the non-structural components of the Facility and major building systems in their condition as of the Commencement Date, normal wear and tear excepted. As of the date of this Lease, Tenant represents and warrants to Landlord that it has no knowledge of any issues or conditions at the Disposition Facilities identified in Section 1.5.2 that would require capital expenditures in excess of the amounts described in Section 8.3.
1.5.8    Future Disposition Facilities. At any time after the Commencement Date, Tenant may, at its option, identify additional Facilities that, despite Tenant’s compliance with the terms of this Lease, (i) due to age, condition or other factors beyond Tenant’s control, have become financially or functionally impaired so as to be no longer economically viable for their primary intended use, or (ii) due to a rise in the average professional liability costs per resident and associated costs of professional liability insurance (or reduced availability of affordable insurance), the operation of the Facilities in the State for their Primary Intended Use is no longer economically viable or affordable. Upon identification, Tenant may request in writing that such Facility or Facilities be designated as Disposition Facilities pursuant to this Section 1.5. Upon Tenant making such request and providing Landlord with evidence satisfactory to Landlord, in its sole judgment, reasonably exercised, of the criteria listed in (i) or (ii) above, Tenant and Landlord will designate in writing such Facility as a Disposition Facility for sale or lease under this Section 1.5. If no such sale or transfer occurs within two (2) years of the designation of such Facility as a Disposition Facility under this Section 1.5.8, Tenant may, upon Notice to Landlord, proceed to close such Disposition Facility and, upon closure, to terminate this Lease as to such Disposition Facility. For avoidance of doubt, upon the closure of a Disposition Facility and the termination of this Lease as to such Disposition, there shall be no reduction in Base Rent. Notwithstanding the foregoing, Landlord shall be under no obligation to designate more than five (5) Facilities as Disposition Facilities under this Section 1.5.8.
ARTICLE II    
2.1    Definitions. For all purposes of this Lease, except as otherwise expressly provided or unless the context otherwise requires, (i) the terms defined in this Article have the meanings assigned to them in this Article and include the plural as well as the singular, (ii) all accounting terms not otherwise defined herein have the meanings assigned to them in accordance with GAAP as at the time applicable, (iii) all references in this Lease to designated “Articles,” “Sections” and other subdivisions are to the designated Articles, Sections and other subdivisions of this Lease, and (iv) the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Lease as a whole and not to any particular Article, Section or other subdivision.
7.0% Upgrades: The capital alterations, improvements and other upgrades to the Facilities (other than [*****]) as identified and determined by Tenant in its reasonable business judgment to be necessary, required or appropriate in an amount per Facility to be listed on Schedule 9.3(a) hereto on or before the Commencement Date. From and after the Commencement Date, Landlord and Tenant may modify Schedule 9.3(a) without formal amendment of this Lease so long as such modification is in writing, which may, for this purpose, include e-mail messages.
7.0% Upgrade Rent: As of the first day of each month, an amount equal to (A) the aggregate funds expended by Landlord as of the last day of the prior month on the 7.0% Upgrades multiplied by (B) (i) seven percent divided by (ii) 12 (7.0% ÷ 12 months = 0.583333%).
9.0% Improvements: The capital alterations and improvements to the Facilities (other than [*****]) identified by Tenant and for which Tenant requests that Landlord provide financing, the specific cost and scope of which for each Facility will be reasonably and in good faith agreed upon by Landlord and Tenant and listed on Schedule 9.3(b) hereto following the Commencement Date or any subsequent amendment to Schedule 9.3 (b) agreed to in writing by Landlord and Tenant, which may, for this purpose, be via e-mail messages; provided, however, that Landlord shall have no obligation to approve a 9.0% Improvement after September 30, 2022. Landlord and Tenant must agree upon the 9.0% Improvements and the funding amount prior to the commencement by Tenant, or the funding by Landlord, of the 9% Improvements.
9.0% Improvement Rent: The 9.0% Improvement Rent shall be:
(1)    For the period from the Commencement Date thru September 30, 2019, the 9.0% Improvement Rent shall be the 9.0% Monthly Improvement Rent for the applicable month;

(2)    For the Lease Year commencing October 1, 2019, the 9.0% Improvement Rent shall be the sum of (a) (i) twelve times the 9.0% Monthly Improvement Rent as of September 30, 2019 multiplied by (ii) one hundred and two and fifteen one hundredths percent (102.15%) (the “First Year 9.0% Improvement Rent”), plus (b) the 9.0% Monthly Improvement Rent for the applicable month;

(3)    For the Lease Year commencing October 1, 2020, the 9.0% Improvement Rent shall be the sum of (a) (i) the First Year 9.0% Improvement Rent plus twelve times the sum of the 9.0% Monthly Improvement Rent as of September 30, 2020 multiplied by (ii) one hundred and two and fifteen one hundredths percent (102.15%) (the “Second Year 9.0% Improvement Rent”), plus (b) the 9.0% Monthly Improvement Rent for the applicable month;

(4)    For the Lease Year commencing October 1, 2021, the 9.0% Improvement Rent shall be the sum of (a) (i) the Second Year 9.0% Improvement Rent plus twelve times the sum of the 9.0% Monthly Improvement Rent as of September 30, 2021 multiplied by (ii) one hundred and two and fifteen one hundredths percent (102.15%) (the “Third Year 9.0% Improvement Rent”), plus (b) the 9.0% Monthly Improvement Rent for the applicable month;

(5)    For the Lease Year commencing October 1, 2022, the 9.0% Improvement Rent shall be the sum of (a) (i) the Third Year 9.0% Improvement Rent plus twelve times the sum of the 9.0% Monthly Improvement Rent as of September 30, 2022 multiplied by (ii) one hundred and two and fifteen one hundredths percent (102.15%) (the “Fourth Year 9.0% Improvement Rent”), plus (b) the 9.0% Monthly Improvement Rent for the applicable month;
(6)    For the Lease Year commencing October 1, 2023, the 9.0% Improvement Rent shall be the sum of (a) (i) the Fourth Year 9.0% Improvement Rent plus twelve times the sum of the 9.0% Monthly Improvement Rent as of September 30, 2023 multiplied by (ii) one hundred and two and fifteen one hundredths percent (102.15%) (the “Fifth Year 9.0% Improvement Rent”), plus (b) the 9.0% Monthly Improvement Rent for the applicable month;
(7)    For the Lease Year commencing October 1, 2024, the 9.0% Improvement Rent shall be the product of (i) the Fifth Year 9.0% Improvement Rent plus twelve times the sum of the 9.0% Monthly Improvement Rent as of September 30, 2024 multiplied by (ii) one hundred and two and fifteen one hundredths percent (102.15%);
(8)    For the Lease Year commencing October 1, 2025, and each succeeding Lease Year during the Term, (a) the 9.0% Improvement Rent for the previous Lease Year multiplied by (b) one hundred two and fifteen one hundredths percent (102.15%).
9% Monthly Improvement Rent: As of the first day of each month, an amount equal to (A) the aggregate funds expended by Landlord during the applicable Lease Year on the 9% Improvements multiplied by (B) (i) nine percent divided by (ii) 12 (9% ÷ 12 months = 0.75%).
Actual Cost: The actual cost of completing the Approved Improvements excluding financing costs, which amount does not include any amounts paid to Tenant or any Affiliate of Tenant without the written consent of Landlord.
Additional Charges: All Impositions and other amounts, liabilities and obligations which Tenant assumes or agrees to pay under this Lease, including, without limitation, the Annual Site Inspection Fee.
Adjustment Date: October 1, 2019, and each October 1 thereafter throughout the Term of this Lease.
Affiliate: Any Person which, directly or indirectly, Controls or is Controlled by or is under common Control with another Person.
Annual Site Inspection Fee: An annual fee of One Thousand Dollars ($1,000.00) for each Facility included within the Leased Properties actually inspected by Landlord during each Lease Year throughout the Term beginning with the Second (2nd) Lease Year which shall be paid by Tenant within thirty (30) days after receipt by Tenant of an invoice therefor together with a copy of the complete site inspection report made with respect to each Facility for which payment is requested.
Approval Threshold: Two Hundred Thousand Dollars ($200,000.00).
Approved Improvement: The 7.0% Upgrades and the 9.0% Improvements.
Assessment: Any governmental assessment on the Leased Properties or any part thereof for public or private improvements or benefits, whether or not commenced or completed prior to the date hereof and whether or not to be completed within the Term.
Assumed Indebtedness: Any indebtedness or other obligations of third parties from whom Landlord has acquired any Leased Property, expressly assumed in writing by Landlord, and existing at the time of acquisition of the Leased Property secured by a mortgage, deed of trust or other security agreement to which Landlord’s title to the Leased Properties is subject.
Authorizations: Any and all licenses, operating permits, Provider Agreements, CONs, certificates of exemption, approvals, waivers, variances and other governmental or “quasi-governmental” authorizations necessary or advisable for the use of any Facility for its Primary Intended Use and receipt of reimbursement or other payments under Medicare, Medicaid and any Third Party Payor Programs.
Avon Rent: The monthly sum of Twenty Five Thousand Dollars ($25,000), without annual adjustment.
Award: All compensation, sums or anything of value awarded, paid or received in connection with a total or partial Taking.
Base Rent: The sum of the Minimum Rent, the 7.0% Upgrade Rent, the 9.0% Improvement Rent and, through and including the month of July, 2024, the Avon Rent.
Business Day: Each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which national banks in the City of New York, New York are authorized, or obligated, by law or executive order, to close.
Capitalization Rate: Nine percent (9%) (See Section 15.3).
Capitalized Leases: Leases that in accordance with GAAP are required to be capital or financing leases and capitalized for financial reporting purposes.
Capitalized Lease Obligations: All obligations under Capitalized Leases the amount of the indebtedness for which shall be the capitalized amount of such obligations determined in accordance with GAAP.
Cash Flow: For any period, the sum of (a) Net Income of Tenant and Subtenants (other than a Hospital Subtenant), and, if applicable, a UPL-IGT Manager, on a consolidated basis, arising solely from the operation of the Facilities for the applicable period, and (b) the amounts deducted in computing such Person’s Net Income for the period for (i) depreciation, (ii) amortization, (iii) Base Rent (the amount added back for Base Rent is to be the amount used, whether actual amounts paid or “straight-line” rent amounts, in calculating Net Income), (iv) interest (including payments in the nature of interest under Capitalized Leases and interest on any Purchase Money Financing), (v) income taxes (the amount added back is the amount used, whether actual amounts paid or amounts accrued, in calculating Net Income) and (vi) management fees, and less (c) an imputed management fee equal to five percent (5%) of gross revenues.
Cash Flow Coverage Ratio: For any fiscal period, the ratio of (i) Cash Flow to (ii) Base Rent.
Casualty/Condemnation Reduction Amount: An amount equal to the applicable Retained Amount multiplied by the applicable Market Rate of Return.
CIBC Bank: CIBC Bank USA, formerly known as The PrivateBank and Trust Company, an Illinois banking corporation.
CIBC Bank Loan Documents: The documents evidencing and securing the indebtedness of DLC and its Affiliates to CIBC Bank as of the date of execution and delivery of this Lease.
Citation: Any operational or physical plant deficiency set forth in writing with respect to a Facility by any governmental body or agency, or Medicare intermediary, having regulatory oversight over a Facility, Tenant or Manager, with respect to which the scope and severity of the penalty for such deficiency, if not cured, is one or more of the following: loss of licensure, decertification of a Facility from participation in the Medicare and/or Medicaid programs, appointment of a temporary manager or denial of payment for new admissions.
Clean-Up: The investigation, removal, restoration, remediation and/or elimination of, or other response to, Contamination, in each case to the satisfaction of all governmental agencies having jurisdiction, in compliance with or as may be required by Environmental Laws.
CMS: The United States Department of Health, Centers for Medicare and Medicaid Services or any successor agency thereto.
Code: The Internal Revenue Code of 1986, as amended.
Commencement Date: October 1, 2018.
Condemnor: Any public or quasi‑public authority, or private corporation or individual, having the power of condemnation.
Consent to Hospital Subleases: Any consent to a sublease with a county hospital participating in the UPL-IGT Program and covering one or more Facilities, as such agreements are amended, restated, modified, extended or replaced
Consolidated Financial Statement:
(a)    For each quarter during Tenant’s, a Subtenant’s (other than a Hospital Subtenant) and a UPL-IGT Manager’s fiscal year, on a consolidated basis for such Persons, (i) a statement of earnings for the current period and fiscal year to the end of such period, with a comparison to the corresponding figures for the corresponding period in the preceding fiscal year from the beginning of the fiscal year to the end of such period, and (ii) a balance sheet as of the end of the period, with a comparison to the corresponding figures for the corresponding period in the preceding fiscal year from the beginning of the fiscal year to the end of such period.
(b)    For Tenant’s, a Subtenant’s (other than a Hospital Subtenant) and a UPL-IGT Manager’s fiscal year, the Consolidated Financial Statement shall be a financial report for such Persons on a consolidated basis, reviewed by a firm of independent certified public accountants reasonably acceptable to Landlord, containing such Persons balance sheet as of the end of that year, its related profit and loss, a statement of shareholder’s equity for that year, a statement of cash flows for that year, and such comments and financial details as are customarily included in reports of like character. Landlord shall have the right upon reasonable Notice to Tenant to cause any such Consolidated Financial Statement to be audited at Landlord’s expense by certified public accountants selected by Landlord. Tenant shall cooperate in any such audit and shall provide the auditors selected by Landlord with access to and the opportunity to copy at Landlord’s expense such books, records and other materials as such auditors may reasonably request in order to perform their audit.
(c)    For DHSI’s fiscal year, the Consolidated Financial Statements shall be an audited financial report prepared by a firm of independent certified public accountants reasonably acceptable to Landlord, containing DHSI’s balance sheet as of the end of that year, its related profit and loss, a statement of shareholder’s equity for that year, a statement of cash flows for that year, and such comments and financial details as are customarily included in reports of like character and the opinion of the certified public accountants as to the fairness of the statements therein.
Construction Funds: The Net Proceeds and such additional funds as may be deposited with Landlord by Tenant pursuant to Section 14.6 for restoration or repair work pursuant to this Lease.
Contamination: The presence, Release or threatened Release of any Hazardous Substance at the Leased Properties in violation of any Environmental Law, or in a quantity that would give rise to any affirmative Clean-Up obligations under an Environmental Law, including, but not limited to, the existence of any injury or potential injury to public health, safety, natural resources or the environment associated therewith, or any other environmental condition at, in, about, under or migrating from or to the Leased Properties.
Control (and its corollaries “Controlled by” and “under common Control with”): Possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, through the ownership of voting securities, partnership interests or other equity interests, or by any other device.
CPI or Consumer Price Index: As of any date, the United States Department of Labor, Bureau of Labor Statistics Revised Consumer Price Index for All Urban Consumers (1982=84=100), U.S. City Average, All Items, or, if that index is not available at the time in question, the index designated by such Department as the successor to such index, and if there is no index so designated, an index for an area in the United States that most closely corresponds to the entire United States, published by such Department, or if none, by any other instrumentality of the United States, calculated in this Lease as the CPI attributable to the month three months prior to the applicable date herein (e.g., the CPI used to calculate the adjustment in Minimum Qualified Capital Expenditures as of October 1, 2019, shall be the CPI for the month of July, 2019, compared to the CPI for the month of July, 2018).
Date of Taking: The date on which the Condemnor has the right to possession of the Leased Property that is the subject of the Taking or Partial Taking.
Debt: As of any date, all (a) obligations of a Person, whether current or long-term, that in accordance with GAAP should be included as liabilities on such Person’s balance sheet; (b) Capitalized Lease Obligations of such Person; (c) obligations of others for which that Person is liable directly or indirectly, by way of guaranty (whether by direct guaranty, suretyship, discount, endorsement, take-or-pay agreement, agreement to purchase or advance or keep in funds or other agreement having the effect of a guaranty) or otherwise; (d) liabilities and obligations secured by liens of any assets of that Person, whether or not those liabilities or obligations are recourse to that Person; and (e) liabilities of that Person, direct or contingent, with respect to letters of credit issued for the account of that Person or others or with respect to bankers acceptances created for that Person.
DHSI: Diversicare Healthcare Services, Inc, formerly known as Advocat, Inc., a Delaware corporation, and its successors by merger, consolidation, reorganization or other business combination.
Disposition Facilities: The Facilities listed in Section 1.5.2.
Distribution: Any payment or distribution of cash or any assets of the Facilities to one or more equity holders of Person or to any Affiliate of such Person, whether in the form of a dividend, a fee for management in excess of the fee required by the terms of a Management Agreement, a payment for services rendered (except as provided in the next sentence), a reimbursement for overhead incurred on behalf of the Facilities, or a payment on any debt required by this Lease to be subordinated to the rights of Landlord. Notwithstanding the foregoing, none of the following are a Distribution: (i) salaries, bonuses and other compensation paid to employees, (ii) payment of Debt permitted pursuant to Section 8.2.2 to third party creditors, (iii) reimbursement by a Person to an Affiliate for third party expenses (but not overhead) paid by the Affiliate on behalf of or which are fairly allocable to the Facilities, (iv) payment of management fees to Manager under a Management Agreement, and (iv) any other third party fees, costs or expenses necessary or required in the ordinary course of business for the continued operation and maintenance of the Facilities (provided that for purposes of this (v), such third party fees, costs and expenses shall include those paid under agreements with Affiliates on terms that are fair and substantially similar to those that would be obtained in a comparable arm’s length transaction with an unrelated third party in the current market).
DLC: Diversicare Leasing Corporation, a Tennessee corporation and a Tenant herein.
DMS: Diversicare Management Services Co., a Tennessee corporation and the current Manager herein.
Encumbrance: Any mortgage, deed of trust, lien, encumbrance or other matter affecting title to the Leased Properties, or any portion thereof or interest therein, securing any borrowing or other means of financing or refinancing.
Environmental Audit: A written certificate, in form and substance satisfactory to Landlord, from an environmental consulting or engineering firm acceptable to Landlord, which states that there is no Contamination on the Leased Properties and that the Leased Properties are otherwise in strict compliance with Environmental Laws.
Environmental Documents: Each and every (i) document received by Tenant or any Affiliate from, or submitted by Tenant or any Affiliate to, the United States Environmental Protection Agency and/or any other federal, state, county or municipal agency responsible for enforcing or implementing Environmental Laws with respect to the condition of the Leased Properties, or Tenant’s operations at the Leased Properties; and (ii) review, audit, report, or other analysis data pertaining to environmental conditions, including, but not limited to, the presence or absence of Hazardous Substances, at, in, or under or with respect to the Leased Properties that have been prepared by, for or on behalf of Tenant.
Environmental Laws: All federal, state and local laws (including, without limitation, common law), statutes, codes, ordinances, regulations, rules, orders, permits or decrees of the United States and the States (or any political subdivision thereof) in which any Leased Property is located relating to the introduction, emission, discharge or Release of Hazardous Substances into the indoor or outdoor environment (including without limitation, air, surface water, groundwater, land or soil) or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, transportation, disposal, or Release of Hazardous Substances; or the Clean-Up of Contamination, all as are now or may hereinafter be in effect.
Event of Default: The occurrence of any of the following:
(a)    Tenant fails to pay or cause to be paid the Rent when due and payable;
(b)    Tenant, a Subtenant, or Guarantor, on a petition in bankruptcy filed against it, is adjudicated a bankrupt or has an order for relief thereunder entered against it, or a court of competent jurisdiction enters an order or decree appointing a receiver of Tenant or any Guarantor or of the whole or substantially all of its property, or approving a petition filed against Tenant seeking reorganization or arrangement of Tenant under the federal bankruptcy laws or any other applicable law or statute of the United States of America or any state thereof, and such judgment, order or decree is not vacated or set aside or stayed within sixty (60) days from the date of the entry thereof, subject to the applicable provisions of the Bankruptcy Code (11 USC Section 101 et. seq.) and to the provisions of Section 16.7, below;
(c)    Tenant, a Subtenant or Guarantor: (i) Admits in writing its inability to pay its debts generally as they become due, (ii) files a petition in bankruptcy or a petition to take advantage of any insolvency law, (iii) makes a general assignment for the benefit of its creditors, (iv) consents to the appointment of a receiver of itself or of the whole or any substantial part of its property, or (v) files a petition or answer seeking reorganization or arrangement under the Federal bankruptcy laws or any other applicable law or statute of the United States of America or any state thereof, subject to the applicable provisions of the Bankruptcy Code (11 USC Section 101 et. seq.) and to the provisions of Section 16.7, below;
(d)    Tenant, a Subtenant or Guarantor is finally liquidated or dissolved, or begins proceedings toward such liquidation or dissolution, or has filed against it a petition or other proceeding to cause it to be liquidated or dissolved and the proceeding is not dismissed within thirty (30) days thereafter, or Tenant, a Subtenant or Guarantor in any manner permits the sale or divestiture of substantially all of its assets necessary or related to the use and operation of the Leased Properties;
(e)    The estate or interest of Tenant in the Leased Properties or any part thereof is levied upon or attached in any proceeding and the same is not vacated or discharged within thirty (30) days thereafter (unless Tenant is in the process of contesting such lien or attachment in good faith in accordance with 12.1 hereof);
(f)    Tenant voluntarily ceases operation of any Facility for a period in excess of five (5) Business Days except upon prior Notice to, and with the express prior written consent of Landlord or other written agreement of the Landlord and Tenant, or as the unavoidable consequence of damage or destruction as a result of a casualty, or a Partial or total Taking;
(g)    Any representation or warranty made by Tenant or its Affiliates in this Lease or the other Lease Documents, or in the certificates delivered in connection therewith, proves to be untrue when made in any material respect, Landlord is materially and adversely affected thereby, and Tenant fails within thirty (30) days after Notice from Landlord thereof to cure such condition by terminating such adverse effect and making Landlord whole for any damage suffered therefrom, or, if with due diligence such cure cannot be effected within thirty (30) days, if Tenant has failed to commence to cure the same within the thirty (30) days or failed thereafter to proceed promptly and with due diligence to cure such condition and complete such cure prior to the time that such condition causes a default in any Facility Mortgage or any other lease to which Tenant is subject and prior to the time that the same results in civil or criminal penalties to Landlord, Tenant, any Affiliates or either or the Leased Properties;
(h)    Tenant (or, if applicable, any Subtenant or Manager):
(i)
has its license to operate any Facility as a provider of health care services in accordance with its Primary Intended Use suspended or revoked, or its right to so operate a Facility suspended, and the effect of such suspension or revocation is not stayed or cured within sixty (60) days thereafter or are reinstated subject to conditions not approved by Landlord in its sole, but reasonable, discretion;
(ii)
has its right to accept patients suspended, and the effect is not promptly stayed and promptly cured (in any case within thirty (30) days of Tenant’s first knowledge thereof);
(iii)
receives a Citation with respect to a Facility and fails to cure the condition that is the subject of the Citation within the period of time required for such cure by the issuer of the Citation or, if longer, the period of time set forth in a Plan of Correction accepted by the issuer of the Citation;
Notwithstanding the foregoing, the conditions described in the preceding Subsections (h)(i), (h)(ii) and (h)(iii) shall not be an Event of Default if such conditions at any time are applicable to ten percent (rounding down for partial Facilities) or fewer Facilities then subject to this Lease, and if Tenant complies with the provisions of Section 40.2 relating to increasing the Security Deposit.
(i)    Subject to Section 34.2, Tenant defaults, or permits a default (which default was not exclusively in Landlord’s control) under any Facility Mortgage, related documents or obligations thereunder which default is not cured within any applicable cure period provided for therein;
(j)    A default occurs under any other Lease Document, which default is not cured within the applicable cure period provided in such Lease Document, if any;
(k)    A Transfer occurs without the prior written consent of Landlord;
(l)    Intentionally deleted;
(m)    Intentionally deleted;
(n)    Intentionally deleted;
(o)    Intentionally deleted;
(p)    Intentionally deleted;
(q)    A default by Tenant occurs under any other contract affecting any Facility or Tenant or a Subtenant, which default results in a material adverse affect on any Facility or Tenant or a Subtenant, and which default is not cured within the applicable time period, if any; provided that such conditions shall not be an Event of Default if such conditions at any time are applicable to two (2) or fewer Facilities and Tenant is in good faith contesting such default and, if legal proceedings are commenced with respect to such default, will conduct such contest pursuant to the provisions of Section 12.1 as if such default constituted a “Claim” under such Section;
(r)    The occurrence of a “Default”, “Event of Default” or similar event or occurrences which causes the lender under the Line of Credit Documents to accelerate any or all of the indebtedness thereby or to exercise any rights or remedies under such documents to realize on its interest in the accounts receivable from the Facilities, or to cease funding under the Line of Credit, which is not cured within any applicable cure period under the Line of Credit Documents or any written agreement by lender;
(s)    Tenant or an Affiliate of Tenant defaults beyond any applicable grace period in the payment of any material amount or the performance of any material act required of Tenant or such Affiliate by the terms of any other lease or other agreement between Tenant or such Affiliate and Landlord or any Affiliate of Landlord, which default could reasonably be expected to have a material adverse effect on the ability of Tenant to perform its obligations under this Lease or a Guarantor to perform its obligation under the Guaranty;
(t)    Tenant fails to observe or perform any other term, covenant or condition of this Lease and the failure is not cured by Tenant within a period of thirty (30) days after Notice thereof from Landlord, unless the failure cannot with due diligence be cured within a period of thirty (30) days, in which case such failure shall not be deemed an Event of Default if and for so long as Tenant proceeds promptly and with due diligence to cure the failure and completes the cure prior to the time that the same causes a default in any Facility Mortgage and prior to the time that the same results in civil or criminal penalties to Landlord, Tenant, any Affiliates of either or to the Leased Properties; or
(u)    Tenant breaches any of the covenants set forth in ARTICLE VIII hereof and the breach is not cured within a period of the shorter of (i) thirty (30) days after the Notice thereof from Landlord, and (ii) fifteen (15) days following the date of delivery of a certificate pursuant to Section 23.1(a) or 23.1(b).
Landlord, at Landlord’s sole discretion, may deliver Notice to Tenant electing to not treat a default as an Event of Default hereunder.
Executive Officer: The Chairman of the Board of Directors, the Chief Executive Officer, the Chief Operating Officer, the President, any Vice President and the Secretary of any corporation, a general partner of any partnership and a managing member of any limited liability company upon which service of a Notice is to be made.
Existing Leases: The leases listed on Schedule 3. The Existing Leases include the Expiring Lease and the Terminated Leases.
Expiration Date: The Initial Term Expiration Date, the First Renewal Term Expiration Date or the Second Renewal Term Expiration Date, as applicable.
Expiring Lease: The existing Consolidated Amended and Restated Master Lease, between DLC and Sterling Acquisition Corp., a subsidiary of Omega, as amended, and identified as the Expiring Lease on Schedule 3.
Facility(ies): Each healthcare facility on the Land, including the Leased Property associated with such Facility, and together, all such facilities on the Leased Properties.
Facility Mortgage: Any mortgage, deed of trust or other security agreement placed upon any or all of the Leased Properties and of which Notice together with a copy of such mortgage, deed of trust or other security agreement has been provided to Tenant, which with the express, prior, written consent of Landlord is a lien upon any or all of the Leased Properties, whether such lien secures an Assumed Indebtedness or another obligation or obligations.
Facility Mortgagee: The secured party to a Facility Mortgage.
Facility Trade Names: The name(s) under which the Facilities have done business during the Term. The Facility Trade Names in use by the Facilities on the Commencement Date are set forth on attached Exhibit B.
Fair Market Rent:    The rent that, at the relevant time, a Facility would most probably command in the open market, under a lease on substantially the same terms and conditions as are set forth in this Lease with a tenant unrelated to Landlord having experience and a reputation in the health care industry and a credit standing reasonably equivalent to that of Tenant, and, if this Lease is guaranteed, with such lease being guaranteed by guarantors having a net worth at least equal to that of Guarantors, with evidence of such rent being the rent that is being asked and agreed to at such time under any leases of facilities comparable to such Facility being entered into at such time in which the tenants and lease guarantors meet the qualifications set forth in this sentence. Fair Market Rent shall be determined in accordance with the appraisal procedure set forth in ARTICLE XXXIII or in such other manner as may be mutually acceptable to Landlord and Tenant.
Fair Market Value: The fair market value of a Facility at the relevant time (i) assuming the same is unencumbered by this Lease, and (ii) determined in accordance with the appraisal procedure set forth in ARTICLE XXXIII or in such other manner as may be mutually acceptable to Landlord and Tenant.
First Renewal Term Expiration Date: September 30, 2040.
Fixtures: Collectively, all permanently affixed equipment, machinery, fixtures, and other items of real and/or personal property (excluding Landlord’s Personal Property), including all components thereof, now and hereafter located in, on or used in connection with, and permanently affixed to or incorporated into the Leased Improvements, including, without limitation, all furnaces, boilers, heaters, electrical equipment, heating, plumbing, lighting, ventilating, refrigerating, incineration, air and water pollution control, waste disposal, air‑cooling and air‑conditioning systems and apparatus (other than individual units), sprinkler systems and fire and theft protection equipment, built‑in oxygen and vacuum systems, towers and other devices for the transmission of radio, television and other signals, all of which, to the greatest extent permitted by law, are hereby deemed by the parties hereto to constitute real estate, together with all replacements, modifications, alterations and additions thereto.
Force Majeure: An event or condition beyond the control of a Person, including without limitation a flood, earthquake, or other Act of God; a fire or other casualty resulting in a complete or partial destruction of the Facility in question; a war, revolution, riot, civil insurrection or commotion, terrorism, or vandalism; unusual governmental action, delay, restriction, or regulation not reasonably to be expected; a contractor or supplier delay or failure in performance (not arising from a failure to pay any undisputed amount due), or a delay in the delivery of essential equipment or materials; bankruptcy or other insolvency of a contractor, subcontractor, or construction manager (not an Affiliate of the party claiming Force Majeure); a strike, slowdown, or other similar labor action; or any other similar event or condition beyond the reasonable control of the party claiming that Force Majeure is delaying or preventing such party from timely and fully performing its obligations under this Lease; provided that in any such event, the party claiming the existence of Force Majeure shall have given the other party Notice of such claim within fifteen (15) days after becoming aware thereof, and if the party claiming Force Majeure shall fail to give such Notice, then the event or condition shall not be considered Force Majeure for any period preceding the date such Notice shall be given. No lack of funds shall be construed as Force Majeure.
GAAP: Generally accepted accounting principles in effect in the United States at the time in question.
Gross Revenues: All revenues received or receivable from or by reason of the operation of the Facilities, or any other use of the Leased Properties, including without limitation all patient revenues received or receivable for the use of or otherwise by reason of all rooms, beds, and other facilities provided, meals served, services performed, space or facilities subleased or goods sold on the Leased Properties and, except as provided below, any consideration received for any sublease, license or other arrangement with an unrelated third party in possession, or using, any portion of the Leased Properties. Gross Revenues shall not, however, include:
(i)    revenue from professional fees or charges by physicians when and to the extent such charges are paid over to such physicians or are accompanied by separate charges for use of a Facility or any portion thereof,
(ii)    non-operating revenues such as interest income or income from the sale of assets not sold in the ordinary course of business,
(iii)    contractual allowances and reasonable reserves (relating to any period during the Term) for billings not paid by or received from the appropriate governmental agencies, third party providers or other payors,
(iv)    all proper patient billing credits and adjustments according to generally accepted accounting principles relating to health care accounting, and
(v)    federal, state or local sales or excise taxes and any tax based upon or measured by said revenues which is added to or made a part of the amount billed to the patient or other recipient of such services or goods, whether included in the billing or stated separately.
If any of the Leased Properties or any part thereof is subleased, or a license permitting the use thereof is granted to an Affiliate of Tenant, Gross Revenues shall include all revenues received or receivable by the subtenant or licensee from its use of the Leased Properties and any rent or equivalent payment by the subtenant or licensee received or receivable by Tenant from such sublease or licensee shall be excluded from Gross Revenues (provided, however, that in the case of a sublease of space for the placement or erection of antennae or similar device, the rent or equivalent payment shall be included in Gross Revenues).
Guarantor(s): Each party that guaranties the obligations of Tenant under this Lease.
Guaranty(ies): (i) the Guaranty from each Subtenant (other than a Hospital Subtenant) and each UPL-IGT Manager (if different than DMS), (ii) the Guaranty from DHSI, DMS, Advocat Finance, Inc., a Delaware corporation, and Diversicare Leasing Company II, LLC, a Delaware limited liability company, and (iii) any other guaranty of the obligations of Tenant under this Lease.
Hazardous Substance: Any dangerous, toxic or hazardous material, substance, pollutant, contaminant, chemical, or waste (including, without limitation, medical waste) defined, listed or described as such under any Environmental Law, including, without limitation, petroleum products, asbestos and PCBs.
Hospital Transaction: A transaction in which a county hospital becomes the Hospital Subtenant for a Facility participating in the UPL-IGT Program.
Hospital Subtenant: A county hospital participating in the UPL-IGT Program that subleases a Facility as permitted by a Consent to Hospital Sublease.
Humble Facility: means the Facility commonly known as Oakmont Nursing and Rehabilitation Center of Humble located in Humble, Texas.
Impositions: Collectively, all taxes (including, without limitation, all capital stock and franchise taxes of Landlord, and all ad valorem, sales and use, single business, gross receipts, transaction privilege, rent or similar taxes to the extent the same are assessed against Landlord on the basis of its interest in the Leased Property), assessments (including Assessments), ground rents, water, sewer or other rents and charges, excises, tax levies, fees (including, without limitation, license, permit, inspection, authorization and similar fees), and all other governmental charges, in each case whether general or special, ordinary or extraordinary, or foreseen or unforeseen, of every character in respect of the Leased Properties or the businesses conducted thereon by Tenant and/or the Rent (including all interest and penalties thereon), which at any time prior to, during or in respect of the Term may be assessed or imposed on or in respect of or be a lien upon (i) Landlord or Landlord’s interest in the Leased Properties, (ii) the Leased Properties or any part thereof or any rent therefrom or any estate, right, title or interest therein, (iii) any occupancy, operation, use or possession of, or sales from, or activity conducted on, or in connection with the Leased Properties or the leasing or use of the Leased Properties or any part thereof, or (iv) the Rent; notwithstanding the foregoing, Impositions shall not include: (i) except as provided above, any tax imposed on Landlord’s gross and/or net income whether generally or specifically arising in connection with the Leased Properties, or (ii) any transfer or other tax imposed with respect to the sale, exchange or other disposition by Landlord of the Leased Properties or any part thereof or the proceeds thereof. If a tax is assessed against Landlord in part based on Landlord’s interest in the Leased Property and in part based on Landlord’s gross and/or net income, the portion of the tax which is based on Landlord’s interest in the Leased Property shall be treated as an Imposition.
Initial Term:    As defined in Section 1.2 hereof.
Initial Term Expiration Date: September 30, 2030.
Insurance Requirements: All terms of any insurance policy required by this Lease and all requirements of the issuer of any such policy.
Intercreditor Agreement: The Amended and Restated Subordination and Intercreditor Agreement of even date herewith by and between Landlord and CIBC Bank and any replacement intercreditor agreement between Landlord and any working capital lender to whom a first priority security interest in accounts receivable from the Facilities has been granted in accordance with the requirements of Section 6.5 of this Lease.
Investigation: Any soil and chemical test or any other environmental investigation, examination or analysis.
Judgment Date: The date on which a judgment is entered against Tenant which establishes, without the possibility of appeal, the amount of liquidated damages to which Landlord is entitled hereunder.
Katy Facility: means the Facility commonly known as the Oakmont Nursing and Rehabilitation Center of Katy located in Katy, Texas.
Land:    The real property described in Exhibits A-1 through A-35 attached hereto.
Landlord’s Future Rent Loss: An amount equal to the Rent which would have been payable by Tenant from and after the Liquidated Damages Payment Date through the Expiration Date had the Lease not been terminated.
Landlord’s Interim Rent Loss: An amount equal to the Rent which would have been payable by Tenant from the Termination Date through the Judgment Date had the Lease not been terminated (including interest and late charges determined on the basis of the date or dates on which Landlord’s Interim Rent Loss is actually paid by Tenant).
Landlord’s Monthly Rent Loss: For any month, an amount equal to the installment of Rent which would have been due in such month under the Lease if it had not been terminated, plus, if such amount is not paid on or before the day of the month on which such installment of Rent would have been due, the amount of interest and late charges thereon which would also have been due under the Lease.
Landlord’s Personal Property: All Personal Property and intangibles, if any, now or hereafter owned by Landlord, together with any and all replacements thereof, and all Personal Property that pursuant to the terms of the Lease becomes the property of Landlord during the Term.
Lease: As defined in the Preamble.
Lease Documents: means the following documents: this Lease, the Guaranties, the Letter of Credit Agreement, the Security Agreements, the Pledge Agreements, the Subordination Agreements, Consent to Hospital Sublease, and any security agreements, pledge agreements, letter of credit agreements, guarantees, notes, consents to subleases or other documents which evidence, secure or otherwise relate to this Lease, or the transactions contemplated by this Lease; and any and all amendments, modifications, extensions and renewals of any of the foregoing documents.
Lease Year: October 1, 2018 through September 30, 2019, and each twelve month period thereafter.
Leased Improvements: Collectively, all buildings, structures, Fixtures and other improvements of every kind on the Land including, but not limited to, alleyways and connecting tunnels, sidewalks, utility pipes, conduits and lines (on‑site and off‑site), parking areas and roadways appurtenant to such buildings and structures.
Leased Property: The portion of the Land on which a Facility is located, the legal description of which is set forth beneath the Facility’s name on Exhibits A-1 through A-35, the Leased Improvements on such portion of the Land, the Related Rights with respect to such portion of the Land, and Landlord’s Personal Property with respect to such Facility.
Leased Properties: All of the Land, Leased Improvements, Related Rights and Landlord’s Personal Property.
Legal Requirements: All federal, state, county, municipal and other governmental statutes, laws, rules, orders, waivers, regulations, ordinances, judgments, decrees and injunctions affecting the Leased Properties or any portion thereof, Tenant’s Personal Property or the construction, use or alteration thereof, including but not limited to the Americans with Disabilities Act, whether enacted and in force before, after or on the Commencement Date, and including any which may (i) require repairs, modifications, alterations or additions in or to any portion or all of the Facilities, or (ii) in any way adversely affect the use and enjoyment thereof, and all permits, licenses and authorizations and regulations relating thereto including, but not limited to, those relating to existing health care licenses, those authorizing the current number of licensed beds and the level of services delivered from the Leased Properties, and all covenants, agreements, restrictions and encumbrances contained in any instruments, either of record or known to Tenant (other than encumbrances created by Landlord without the consent of Tenant), in force at any time during the Term.
Letter of Credit Agreement: The Letter of Credit Agreement between Tenant and Landlord.
Lien: Any interest in Property securing an obligation owed to, or a claim by, any Person (other than the owner of the Property), whether such interest shall be based on common law, statute, or contract, whether such interest shall be recorded or perfected, and whether such interest shall be contingent upon the occurrence of some future event or events or the existence of some future circumstance or circumstances, including, without limitation, judgment liens, the lien or security interest arising, from a mortgage, deed of trust, debenture, charge, guarantee, encumbrance, pledge, hypothecation, assignment, deposit arrangement, security agreement, loan and security agreement, adverse claim or charge, conditional sale or trust receipt, or from a lease, consignment, or bailment for security purposes, and also including reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, other title exceptions and encumbrances affecting any real property and the retained security title of a conditional vendor or Landlord.
Line of Credit: A working capital line of credit from a third-party working capital lender that is subject to an Intercreditor Agreement. The CIBC Bank Loan constitutes a Line of Credit.
Line of Credit Documents: The documents evidencing and securing the Line of Credit. The CIBC Bank Loan Documents constitute Line of Credit Documents.
Liquidated Damages Payment Date: The date on which Tenant pays Landlord all of the liquidated damages for which it is liable under ARTICLE XVI.
Management Agreement: Any agreement pursuant to which management of a Facility is delegated by Tenant or a Subtenant (including a Hospital Subtenant) to any person not an employee of Tenant or to any other related or unrelated party.
Manager: The Person to which management of the operation of a Facility is delegated pursuant to a Management Agreement, which at the Commencement Date is DMS. Manager shall include any UPL-IGT Managers, but only with respect to the management of the operation of the specific Facility or Facilities subject to a UPL-IGT Program.
Market Rate of Return: A market rate of return on investment (not in excess of 10%) for a healthcare facility used for the Primary Intended Use of the applicable Facility.
Maximum Principal Amount: As of any date of entry into an Intercreditor Agreement (other than the existing CIBC Intercreditor Agreement) a principal amount not in excess of eighty five percent (85%) of “eligible accounts receivable” as that term is customarily used in revolving working capital financing; provided that, in no event may "eligible accounts receivable" include (i) accounts receivable aged in excess of 150 days, or (ii) private pay accounts; except that for the nine (9) month period beginning on the commencement date of operations by a Tenant or a Subtenant of a Facility with respect to which, as of the date of entry into the Intercreditor Agreement, a “change of ownership” has occurred under the state licensure or Medicaid laws, rules and regulations applicable to such Facility, “eligible accounts receivable” shall include the accounts receivable of such Facility which do not remain unpaid more than 180 days after the invoice date, but shall continue to exclude private pay accounts.
Medicaid: The program of medical assistance, funded jointly by the federal government and the states for impoverished individuals who are aged, blind and/or disabled, and for members of families with dependent children, which program is more fully described in Title XIX of the Social Security Act (42 U.S.C. §§ 1396 et seq.) and the regulations promulgated thereunder, and any replacement or successor thereto.
Medicare: The federal program providing health insurance for eligible elderly and other individuals, under which physicians, hospitals, nursing facilities, home health care and other providers are reimbursed for certain covered services they provide to the beneficiaries of such program, which program is more fully described in Title XVIII of the Social Security Act (42 U.S.C. §§ 1395 et seq.) and the regulations promulgated thereunder, and any replacement or successor thereto.
Minimum Qualified Capital Expenditures: As defined in Section 8.3.
Minimum Rent: The annual Minimum Rent shall be:
(1)    For the Lease Year commencement October 1, 2018, the sum of Twenty Nine Million Two Hundred Thirty One Thousand Five Hundred Thirty Two and 91/100 ($29,231,532.91);
(2)    For the Lease Year commencing October 1, 2019, and each succeeding Lease Year during the Term, (a) the Minimum Rent for the previous Lease Year multiplied by (b) one hundred two and fifteen one hundredths percent (102.15%).
Net Income: For any period, the net income (or loss) of a Person for such period, determined on a consolidated basis and in accordance with GAAP, provided, however, that a Person’s Net Income shall not include:
(a)
any after-tax gains or losses attributable to returned surplus assets of any pension-benefit plan;
(b)
any extraordinary gains or nonrecurring gains;
(c)
any gains or losses realized upon the sale or other disposition of property which is not sold or otherwise disposed of in the ordinary course of business;
(d)
any gains or losses realized upon the sale or other disposition of any capital stock of any Person;
(e)
any gains from the disposal of a discontinued business;
(f)
the cumulative effect on prior years of any change in an accounting principle;
(g)
the income or loss of any Person acquired by Tenant or an Affiliate in a pooling of interests transaction for any period prior to the date of such acquisition;
(h)
the income from any sale of assets in which the book value of such assets had been the book value of any Person acquired in a pooling-of-interests transaction prior to the date such Person became an Affiliate of Tenant;
(i)
the income (or loss) of any Person (other than a subsidiary) in which Tenant has an ownership interest; provided, however, that (i) Tenant’s Net Income shall include amounts in respect of the income of such Person when actually received in cash by Tenant in the form of dividends or similar distributions and (ii) Tenant’s Net Income shall be reduced by the aggregate amount of all investments, regardless of the form thereof, made by Tenant in such Person for the purpose of funding any deficit or loss of such Person;
(j)
the income of Tenant to the extent the payment of such income is not permitted, whether on account of any law, statute, judgment, decree or governmental order, rule or regulation applicable to such Tenant;
(k)
all amounts included in computing such net income (or loss) in respect of the write-up of any asset or the write-down of any Debt at less than face value after the later of the Commencement Date or the date on which such asset or Debt was first properly included on Tenant’s balance sheet.
(l)
the reduction in income tax expense resulting from an increase in a deferred income tax asset due to the anticipation of future income tax benefits; or
(m)
the reduction in income tax expense resulting from an increase in a deferred income tax asset or from a decrease in a deferred income tax liability due to a change in a statutory tax rate.
During any period that a Facility participates in the UPL-IGT Program, any revenue retained by the Hospital Subtenant and not paid to the UPL-IGT Manager, shall not be included in income (or loss).
Net Proceeds: All proceeds, net of any costs incurred by Landlord in obtaining such proceeds, payable by reason of any loss or damage to any Leased Property under any policy of insurance required by ARTICLE XIII of this Lease (including any proceeds with respect to Tenant’s Personal Property that Tenant is required or elects to restore or replace pursuant to Section 14.3) or paid by a Condemnor for the Taking of any of all or any portion of a Leased Property.
Net Reletting Proceeds: Proceeds of the reletting of any portion of the Leased Property received by Landlord, net of Reletting Costs.
Notice: A notice given in accordance with ARTICLE XXXII hereof.
Notice of Termination: A Notice from Landlord that it is terminating this Lease by reason of an Event of Default.
Officer’s Certificate: If for a corporation, a certificate signed by one or more officers of the corporation authorized to do so by the bylaws of such corporation or a resolution of the Board of Directors thereof; if for a partnership, limited liability company or any other kind of entity, a certificate signed by a Person having the authority to so act on behalf of such entity.
 
Omega: Omega Healthcare Investors, Inc., a Maryland corporation.
Overdue Rate: On any date, the interest rate that is equal to three and one-half percent (3.5%) (three hundred fifty (350) basis points) above the Prime Rate, but in no event greater than the maximum rate then permitted under applicable law.
Partial Taking: A taking of less than the entire fee of a Leased Property that either (i) does not render the Leased Property Unsuitable for its Primary Use, or (ii) renders a Leased Property Unsuitable for its Primary Intended Use, but neither Landlord nor Tenant elects pursuant to Section 15.1 hereof to terminate this Lease.
Payment Date: Any due date for the payment of the installments of Base Rent or for the payment of Additional Charges or any other amount required to be paid by Tenant hereunder.
Permitted Encumbrances: Encumbrances listed on attached Exhibit C.
Person: Any natural person, trust, partnership, corporation, joint venture, limited liability company or other legal entity.
Personal Property: All machinery, equipment, furniture, furnishings, movable walls or partitions, computers (and all associated software), trade fixtures and other personal property (but excluding consumable inventory and supplies owned by Tenant) used in connection with the Leased Properties, together with all replacements and alterations thereof and additions thereto, except items, if any, included within the definition of Fixtures or Leased Improvements.
Post-Distribution Cash Flow: For any period, (a) Cash Flow, less (b) any Distributions.
Post-Distribution Cash Flow to Rent Ratio: For any period, the ratio of (a) Post-Distribution Cash Flow to (b) Base Rent.
Present Value: The value of future payments, determined by discounting each such payment at a rate equal to the yield on the specified date on securities issued by the United States Treasury (bills, notes and bonds) maturing on the date closest to the date such future payment would have been due.
Primary Intended Use: Skilled nursing, assisted living, independent living, rehabilitation and therapy services, as provided at the Facilities as of the date of this Lease, and the provision of food, recreation, administrative and other ancillary or incidentals services relating thereto.
Prime Rate: On any date, an interest rate equal to the prime rate published by the Wall Street Journal, but in no event greater than the maximum rate then permitted under applicable law. If the Wall Street Journal ceases to be in existence, or for any reason no longer publishes such prime rate, the Prime Rate shall be the rate announced as its prime rate by Fleet Bank, and if such bank no longer exists or does not announce a prime rate at such time, the Prime Rate shall be the rate of interest announced as its prime rate by a national bank selected by Landlord.
Proceeding: Any action, proposal or investigation by any agency or entity, or any complaint to such agency or entity.
Proceeds Date: Any date upon which Landlord or a Facility Mortgagee receives a Retained Amount.
Property: means any and all real, personal, or mixed property and assets, including, without limitation, all types of tangible and intangible property.
Provider Agreements: Any agreements under which healthcare facilities are eligible to receive payment under Medicare, Medicaid or any Third Party Payor Program from Governmental Authorities or non-public entities.
Purchase Money Financing:    Any financing provided by a Person to Tenant in connection with the acquisition of Personal Property used in connection with the operation of a Facility, whether by way of installment sale or otherwise.
Qualified Capital Expenditures: Expenditures capitalized on the books of Tenant or a Subtenant for alterations, renovations, repairs and replacements to the Facilities including without limitation any of the following:
Replacement of furniture, fixtures and equipment, including refrigerators, ranges, major appliances, bathroom fixtures, doors (exterior and interior), central air conditioning and heating systems (including cooling towers, water chilling units, furnaces, boilers and fuel storage tanks) and major replacement of siding; major roof replacements, including major replacements of gutters, down spouts, eaves and soffits; major repairs and replacements of plumbing and sanitary systems; overhaul of elevator systems; major repaving, resurfacing and sealcoating of sidewalks, parking lots and driveways; repainting of entire building exterior and any other expenditures that constitute capital expenditures under GAAP; but excluding additions, normal maintenance and repairs. For purposes of this definition, “additions” shall mean any expansion of a Facility, including the construction of a new wing or a new story on an existing Facility.
Regulatory Actions: Any claim, demand, notice, action or proceeding brought, threatened or initiated by any governmental authority in connection with any Environmental Law, including, without limitation, civil, criminal and administrative proceedings, whether or not the remedy sought is costs, damages, equitable remedies, penalties or expenses.
Related Rights: All easements, rights and appurtenances relating to the Land and the Leased Improvements.
Release: The intentional or unintentional spilling, leaking, dumping, pouring, emptying, seeping, disposing, discharging, emitting, depositing, injecting, leaching, escaping, abandoning, or any other release or threatened release, however defined, of any Hazardous Substance.
Reletting Costs: Expenses incurred by Landlord in connection with the reletting of the Leased Properties in whole or in part after an Event of Default, including without limitation attorneys’ fees and expenses, brokerage fees and expenses, marketing expenses and the cost of repairs and renovations reasonably required for such reletting.
Renewal Term: A period for which the Term is renewed in accordance with Section 1.3.
Renewal Term Expiration Date: September 30, 2040.
Rent: Collectively, the Base Rent and Additional Charges.
Replacement Cost: As to each Leased Property, the actual replacement cost of such Leased Improvements, Fixtures and Personal Property, including an increased cost of construction endorsement, less exclusions provided in the standard form of fire insurance policy. In all events Replacement Cost shall be an amount sufficient that neither Landlord nor Tenant is deemed to be a co-insurer of the Leased Property in question. Landlord shall have the right from time to time, but no more frequently than once in any period of three (3) consecutive Lease Years, to have Replacement Cost reasonably redetermined by the fire insurance company which is then carrying the largest amount of fire insurance on the Leased Properties, which determination shall be final and binding on the parties hereto, and upon such determination Tenant shall forthwith increase, but not decrease, the amount of the insurance carried pursuant to Section 13.2.1 to the amount so determined, subject to the approval of any Facility Mortgagee. Tenant shall pay the fee, if any, of the insurer making such determination.
Retained Amount: An amount equal to either (a) Net Proceeds received by Landlord and/or a Facility Mortgagee pursuant to the terms of ARTICLE XIV of this Lease, if such Net Proceeds are not made available for the restoration of the Leased Property or (b) an Award received by Landlord and/or a Facility Mortgagee pursuant to ARTICLE XV of this Lease, if such Award is not made available to the Tenant for the restoration of the Leased Property.
SEC: Securities and Exchange Commission.
Second Renewal Term Expiration Date: September 30, 2050.
Security Agreement: The Security Agreement(s) between Landlord, as secured party, and Tenant and/or the Subtenants and/or UPL-IGT Manager (if DMS, to the extent required by Section 22.5), as debtor.
Security Deposit: (i) Six Million Nine Hundred Nine Thousand Six Hundred Fifty One and 00/100 Dollars ($6,909,651.00), delivered and held in accordance with ARTICLE XL hereof, plus any accrued interest, (ii) any adjustment pursuant to Section 1.5.2, (iii) Increase (as defined in Section 40.2) and (iii) any adjustment upon removal of a Leased Property from this Lease specifically provided for pursuant to Sections 7.3(l)7.3 (m), 14.7(ix) and 14.8 following a casualty loss or Sections 15.1, 15.3, and 15.5 following a Taking.
State(s): The State or States in which the Leased Properties are located.
Subtenant: A permitted subtenant of Tenant pursuant to the conditions of Section 22.4.
Taken: Conveyed pursuant to a Taking.
Taking: A taking or voluntary conveyance during the Term of all or part of a Leased Property, or any interest therein or right accruing thereto or use thereof, as the result of, or in settlement of any condemnation or other eminent domain proceeding affecting the Leased Property whether or not the same shall have actually been commenced.
Tenant: As the context may require or permit, one, some or all of the entities listed on Schedule 2 to this Lease as “Tenant”, subject to Section 22.1. Each entity comprising Tenant is jointly and severally liable for all obligations of the Tenant under this Lease. Notwithstanding the foregoing, however, no Tenant shall, by virtue of this Lease have any rights to, or title or interest in, the Leased Property or Properties leased by another Tenant or any obligation to operate the same to the extent it does not have the license or other authorization necessary or required to do so under applicable law.
Tenant Entity: Tenant, the Subtenants (other than a Hospital Subtenant), the Guarantors, and Manager.
Tenant’s Certificate: A statement in writing in substantially the form of Exhibit D attached hereto (with such changes thereto as may reasonably be requested by the person relying on such certificate).
Tenant’s Personal Property: Personal Property owned or leased by Tenant that is not included within the definition of Landlord’s Personal Property but is used by Tenant in the operation of the Facilities, including Personal Property provided by Tenant in compliance with Section 6.3 hereof.
Term:    Collectively, the Initial Term plus the Renewal Term or Renewal Terms, if any, subject to earlier termination pursuant to the provisions hereof.
Terminated Leases: The existing Leases and Master Leases, as amended, between certain of the Tenants and certain subsidiaries of Omega, and identified as the Terminated Leases on Schedule 3.
Termination Date: The date on which a Notice of Termination is given.
Third Party Claims: Any claims, actions, demands or proceedings (other than Regulatory Actions) howsoever based (including without limitation those based on negligence, trespass, strict liability, nuisance, toxic tort or detriment to health welfare or property) due to Contamination, whether or not the remedy sought is costs, damages, penalties or expenses, brought by any person or entity other than a governmental agency.
Third Party Payor Programs: Any third party payor programs pursuant to which healthcare facilities qualify for payment or reimbursement for medical or therapeutic cure or other goods or services rendered, supplied or administered to any admittee, occupant, resident or patient by or from any Governmental Authority, bureau, corporation, agency, commercial insurer, non-public entity, “HMO,” “PPO” or other comparable party.
Transfer: The (a) assignment, mortgaging or other encumbering of all or any part of Tenant’s interest in this Lease or in the Leased Properties, or (b) subletting of the whole or any part of any Leased Property, or (c) entering into of any Management Agreement or other arrangement under which any Facility is operated by or licensed to be operated by an entity other than Tenant, or (d) merger, consolidation or reorganization of a corporate Tenant, Subtenant or Manager (except, for Manager only, to an Affiliate), or the sale, issuance, or transfer, cumulatively or in one transaction, of any voting stock of Tenant, a Subtenant or Manager (except, for Manager only, to an Affiliate) by Persons who are stockholders of record of Tenant, which results in a change of Control of Tenant, a Subtenant or Manager (except, for Manager only, to an Affiliate), or (e) sale, issuance or transfer, cumulatively or in one transaction, of any interest, or the termination of any interest, in Tenant, a Subtenant or Manager (except, for Manager only, to an Affiliate), if Tenant, a Subtenant or such Manager, is a joint venture, partnership, limited liability company or other association, which results in a change of Control of such joint venture, partnership or other association, or (d) sale, issuance or transfer, cumulatively or in one transaction, of any direct or indirect interest in Tenant if after such transaction(s), Tenant and the Subtenants ceases to be Controlled, directly or indirectly, by DHSI, or (e) merger, consolidation, reorganization or other business combination involving DHSI in which DHSI is not the surviving entity unless the successor entity of DHSI executes and delivers to Landlord a Guaranty, in substantially the form of the Guaranty executed by DHSI, pursuant to which the successor entity guarantees to Landlord the payment and performance by Tenant of its obligations under this Lease.
Transferee: An assignee, subtenant or other occupant of a Leased Property pursuant to a Transfer.
Unmatured Event of Default: The occurrence of an event which upon its occurrence, or with the giving of notice, the passage of time, or both, would constitute an Event of Default.
Unsuitable for Its Primary Intended Use: A state or condition of a Facility such that by reason of damage or destruction, or a Partial Taking, the Facility cannot be operated on a commercially practicable basis for its Primary Intended Use, taking into account, among other relevant factors, the number of usable beds permitted by applicable law and regulation in the Facility after the damage or destruction or Partial Taking, the square footage damaged or Taken and the estimated revenue impact of such damage or destruction or Partial Taking.

UPL-IGT Manager: The Affiliate of Tenant that is Manager of the Facilities participating in the UPL-IGT Program.

UPL-IGT Program: The Medicaid Upper Payment Limit (and Intergovernmental Transfer) program or other similar county hospital programs relating to federal upper payment limits and intergovernmental transfers and similar quality improvement programs in place in the applicable state, where a county hospital holds the operating Authorizations for a Facility, Tenant subleases a Facility to the county hospital, and Manager or a Subtenant enters into a management agreement with the county hospital for such Facility, including any successor programs.

ARTICLE III    
3.1    Base Rent; Monthly Installments. In addition to all other payments to be made by Tenant under this Lease, Tenant shall pay Landlord the Base Rent in lawful money of the United States of America which is legal tender for the payment of public and private debts, in advance, in equal, consecutive monthly installments, each of which shall be in an amount equal to one-twelfth (1/12) of the Base Rent payable for the Lease Year in which such installment is payable. The first installment of Base Rent shall be payable on the Commencement Date and shall be a prorated amount for the period from October 1, 2018 until the fifteenth (15th) day of October, 2018. The first full installment of Base Rent shall be payable on October 15, 2018. Thereafter, installments of Base Rent shall be payable on the fifteenth (15th) day of each calendar month during the Term. Base Rent shall be paid to Landlord, or to such other Person as Landlord from time to time may designate by Notice to Tenant, by wire transfer of immediately available federal funds to the bank account designated in writing by Landlord. If Landlord directs Tenant to pay any Base Rent or Additional Charges to any Person other than Landlord, Tenant shall send to Landlord simultaneously with such payment a copy of the transmittal letter or invoice and check whereby such payment is made, or such other evidence of such payment as Landlord may require.
3.2    Additional Charges. In addition to the Base Rent, Tenant will also pay as and when due (a) the Annual Site Inspection Fee and (b) all Additional Charges.
3.3    Late Charge. If any Rent payable to Landlord is not paid when due and such failure is not cured by Tenant within a period of five (5) days after Notice thereof from Landlord, Tenant shall pay Landlord on demand, as an Additional Charge, a late charge equal to the greater of (i) two percent (2%) of the amount not paid when due and (ii) any and all charges, expenses, fees or penalties imposed on Landlord by a Facility Mortgagee for late payment; provided that Landlord shall not be required to send more than one Notice of non-payment of Rent when due and payable within any twelve (12) month time period and upon failure to pay any subsequent payment of Rent when due and payable during said twelve (12) month period and such failure is not cured within five (5) days after such payment first came due and payable, Tenant shall pay such Additional Charge to Landlord on demand. In addition, if such Rent (including the late charge) is not paid within thirty (30) days of the date on which such Rent was due, interest thereon at the Overdue Rate from such thirtieth (30th) day until such Rent (including the late charge and interest) is paid in full.
3.4    Net Lease.
3.4.1    The Rent shall be paid absolutely net to Landlord, so that this Lease shall yield to Landlord the full amount of the Rent payable to Landlord hereunder throughout the Term, subject only to any provisions of the Lease which expressly provide for adjustment or abatement of Rent or other charges.
3.4.2    If Landlord commences any proceedings for non‑payment of Rent, Tenant will not interpose any counterclaim or cross complaint or similar pleading of any nature or description in such proceedings unless Tenant would lose or waive such claim by the failure to assert it, but Tenant does not waive any rights to assert such claim in a separate action brought by Tenant. The covenants to pay Rent are independent covenants, and Tenant shall have no right to hold back, offset or fail to pay any Rent because of any alleged default by Landlord or for any other reason whatsoever.
3.5    Payments In The Event of a Rent Adjustment. In the event this Lease provides for adjustment of the Base Rent on any basis that requires a determination of Base Rent which cannot be made on or before the due date of the first installment of Base Rent following the Adjustment Date, Tenant shall continue to pay the Base Rent at the rate previously in effect until Landlord gives Tenant Notice of its determination of the adjusted Base Rent. Upon such determination, the Base Rent shall be retroactively adjusted as of the Adjustment Date. On or before the second (2nd) Payment Date for Base Rent following receipt by Tenant of Landlord’s Notice of the adjustment, Tenant shall make an additional payment of Base Rent in such amount as will bring the Base Rent, as adjusted, current on or before such second (2nd) Payment Date, plus interest on the amount of such additional payment (i.e. the difference between the monthly installment of Base Rent before and after the increase as of the Adjustment Date, divided by thirty (30) and multiplied by the number of days between the Adjustment Date and the date of payment by Tenant) at the Prime Rate from the Adjustment Date through the date of such additional payment, and thereafter Tenant shall pay the adjusted Base Rent in correspondingly adjusted monthly installments until the Base Rent is next adjusted as required herein. This Section 3.5 shall survive the expiration or termination of this Lease with respect to any adjustment which is not known or fully paid as of the date of expiration or termination.
3.6    Avon Rent. Commencing on the Commencement Date and continuing on the first day of each month to and including July 1, 2024, Tenant shall pay the Landlord the Avon Rent as part of the Base Rent. For the avoidance of doubt, the Avon (Good Samaritan), Ohio skilled nursing facility (the “Avon Facility”) formerly leased by Diversicare of Avon, LLC, a Tenant hereunder, is not a Facility under this Lease and the Lease Agreement dated as of July 31, 2014, as amended by the Second Amendment dated May 31, 2016, providing for termination of possession of the Avon Facility but continued payment of the Avon Rent by Diversicare of Avon, LLC through the month of July, 2024 (the “Avon Facility Lease”) has been terminated immediately prior to the Commencement Date. Notwithstanding such termination, the remaining Avon Rent payable under the Avon Facility Lease as of the Commencement Date to and including the month of July 2024 will continue to be payable under this Lease by Tenant as a part of the Base Rent due hereunder.
ARTICLE IV    
4.1    Payment of Impositions.
4.1.1    Subject to ARTICLE XII relating to permitted contests, Tenant will pay all Impositions before any fine, penalty, interest or cost is added for non‑payment, such payments to be made directly to the taxing authorities where feasible, and will promptly, upon request, furnish to Landlord copies of official receipts or other satisfactory proof evidencing such payments. If at the option of the taxpayer any Imposition may lawfully be paid in installments, Tenant may pay the same in the required installments provided it also pays any and all interest due thereon as and when due.
4.1.2    Landlord shall, to the extent required or permitted by applicable law, prepare and file all tax returns and reports as may be required by governmental authorities in respect of Landlord’s net income, gross receipts, sale and use, single business, transaction privilege, rent, ad valorem, franchise taxes and taxes on its capital stock. Tenant shall, to the extent required or permitted by applicable law, prepare and file as and when required all other tax returns and reports required by governmental authorities with respect to all Impositions. Landlord and Tenant shall each, upon request, provide the other with such data, including without limitation cost and depreciation records, as is maintained by the party to whom the request is made as is necessary to prepare any required returns and reports. If any provision of any Facility Mortgage requires deposits for payment of Impositions, Tenant shall either pay the required deposits to Landlord monthly and Landlord shall make the required deposits, or, if directed in writing to do so by Landlord, Tenant shall make such deposits directly.
4.1.3    Tenant shall be entitled to receive and retain any refund from a taxing authority in respect of an Imposition paid by Tenant if at the time of the refund no Event of Default has occurred and is continuing, but if an Event of Default has occurred and is continuing at the time of the refund, Tenant shall not be entitled to receive or retain such refund and if and when received by Landlord such refund shall be applied as provided in ARTICLE XVI.
4.1.4    In the event governmental authorities classify any property covered by this Lease as personal property, Tenant shall file all personal property tax returns in such jurisdictions where it may legally so file. Where Landlord is legally required to file personal property tax returns, Tenant will be provided with copies of assessment notices in sufficient time for Tenant to file a protest. Billings for reimbursement by Tenant to Landlord of personal property taxes shall be accompanied by copies of a bill therefor and payments thereof which identify the personal property with respect to which such payments are made.
4.1.5    Tenant may, upon Notice to and with the prior written consent of Landlord, which consent shall not be unreasonably withheld, at Tenant’s sole cost and expense, protest, appeal, or institute such other proceedings as Tenant may deem appropriate to effect a reduction of real estate or personal property assessments and Landlord, at Tenant’s expense as aforesaid, shall cooperate with Tenant in such protest, appeal, or other action. In any such proceeding brought by Landlord, Tenant shall cooperate with Landlord at Tenant’s sole cost and expense. Tenant shall reimburse Landlord for Landlord’s direct costs of cooperating with Tenant for such protest, appeal or other action.
4.2    Notice of Impositions. Landlord shall give prompt Notice to Tenant of all Impositions payable by Tenant hereunder of which Landlord at any time has knowledge, but Landlord’s failure to give any such Notice shall in no way diminish Tenant’s obligations hereunder to pay such Impositions, but such failure shall obviate any default hereunder for a reasonable time after Tenant receives Notice of any Imposition which it is obligated to pay.
4.3    Adjustment of Impositions. Impositions imposed in respect of the tax‑fiscal period during which the Term ends shall be adjusted and prorated between Landlord and Tenant, whether or not imposed before or after the expiration of the Term or the earlier termination thereof, and Tenant’s obligation to pay its prorated share thereof shall survive such expiration or earlier termination. As Tenant was the tenant of the Leased Properties prior to the Commencement Date, Tenant shall pay all Impositions due and owing as of the Commencement Date or relating to the period prior to the Commencement Date, and there will be no proration of Impositions for the tax-fiscal period in which the Commencement Date occurs.
4.4    Utility Charges. Tenant will pay or cause to be paid when due all charges for electricity, power, gas, oil, water and other utilities used in each Leased Property during the Term and imposed upon the Leased Properties or upon Landlord or Tenant with respect to the Leased Properties.
4.5    Insurance Premiums. Tenant shall pay or cause to be paid when due all premiums for the insurance coverage required to be maintained pursuant to ARTICLE XIII during the Term.
ARTICLE V    
5.1    No Termination, Abatement, etc. Except as otherwise specifically provided in this Lease, Tenant shall not take any action without the consent of Landlord to modify, surrender or terminate this Lease, and shall not seek or be entitled to any abatement, deduction, deferment or reduction of Rent, or setoff against Rent. Except as otherwise specifically provided in this Lease, the respective obligations of Landlord and Tenant shall not be affected by reason of (i) any damage to, or destruction of, the Leased Properties or any portion thereof from whatever cause or any Taking of the Leased Properties or any portion thereof, other than any damage to or destruction of a Leased Property that Tenant conclusively establishes was caused solely by Landlord; (ii) the lawful or unlawful prohibition of, or restriction upon, Tenant’s use of the Leased Properties, or any portion thereof, or the interference with such use by any Person or by reason of eviction by paramount title, other than any prohibition or restriction of use of a Leased Property that Tenant conclusively establishes was solely caused by Landlord; (iii) any claim which Tenant has or might have against Landlord or by reason of any default or breach of any warranty by Landlord under this Lease or any other agreement between Landlord and Tenant, or to which Landlord and Tenant are parties, except where such claims result in a termination of this Lease, (iv) any bankruptcy, insolvency, reorganization, composition, readjustment, liquidation, dissolution, winding up or other proceedings affecting Landlord or any assignee or transferee of Landlord, or (v) any other cause whether similar or dissimilar to any of the foregoing other than a discharge of Tenant from any such obligations as a matter of law. For purposes of this Section 5.1, a matter shall be deemed to be conclusively established by Tenant if (a) Landlord agrees in writing or (b) (i) Tenant shall have given Landlord Notice thereof and a time reasonable under the circumstances to cure any claimed default of Landlord and (ii) Tenant thereafter establishes such contention in a proceeding as provided for in ARTICLE XXXVI of this Lease. Tenant hereby specifically waives all rights, arising from any occurrence whatsoever, which may now or hereafter be conferred upon it by law to (i) modify, surrender or terminate this Lease or quit or surrender the Leased Properties or any portion thereof, or (ii) entitle Tenant to any abatement, reduction, suspension or deferment of the Rent or other sums payable by Tenant hereunder except as otherwise specifically provided in this Lease.
ARTICLE VI    
6.1    Ownership of the Leased Properties. Tenant acknowledges that the Leased Properties are the property of Landlord and that Tenant has only the right to the possession and use of the Leased Properties upon the terms and conditions of this Lease. Tenant will not (i) file any income tax return or other associated documents; (ii) file any other document with or submit any document to any governmental body or authority; (iii) enter into any written contractual arrangement with any Person; or (iv) release any Financial Statements or other financial statements of Tenant, in any case that take any position other than that throughout the Term Landlord is the owner of the Leased Properties for federal, state and local income tax purposes and this Lease is a “true lease.” If Tenant should reasonably conclude that GAAP or the SEC require treatment different from that set forth in the subsections (i), (ii), (iii) and (iv) of the previous sentence, then Tenant (y) shall give prior Notice to Landlord, and (z) notwithstanding the prior sentence, Tenant may comply with such requirements.
6.2    Landlord’s Personal Property. Tenant shall, during the entire Term, maintain all of Landlord’s Personal Property in good order, condition and repair as shall be necessary in order to operate the Facilities for the Primary Intended Use in compliance with all applicable licensure and certification requirements, all applicable Legal Requirements and Insurance Requirements, and customary industry practice for the Primary Intended Use. Tenant shall not permit or suffer Landlord’s Personal Property to be subject to any lien, charge, encumbrance, financing statement, contract of sale, equipment landlord’s interest or the like, except for any purchase money security interest or equipment landlord’s interest expressly approved in advance, in writing, by Landlord. At the expiration or earlier termination of this Lease, all of Landlord’s Personal Property shall be surrendered to Landlord with the Leased Properties at or before the time of the surrender of the Leased Property in at least as good a condition as at the Commencement Date (or, as to replacements, in at least as good a condition as when placed in service at the Facilities) except for ordinary wear and tear.
6.3    Tenant’s Personal Property. Tenant shall provide and maintain during the Term such Personal Property, in addition to Landlord’s Personal Property, as shall be necessary and appropriate in order to operate the Facilities for the Primary Intended Use in compliance with all licensure and certification requirements, in compliance with all applicable Legal Requirements and Insurance Requirements and otherwise in accordance with customary practice in the industry for the Primary Intended Use (“Tenant’s Personal Property”). Except to the extent specifically allowed under Section 8.2.1.4 of this Lease, without the prior written consent of Landlord, which consent shall not be unreasonably withheld, Tenant shall not permit or suffer Tenant’s Personal Property to be subject to any lien, charge, encumbrance, financing statement or contract of sale or the like other than that provided for in Section 6.3 below. Except for those items of Personal Property listed on Schedule 6.3 which shall at all times belong to and may be removed by Tenant, upon the expiration of the Term or the earlier termination of this Lease, without the payment of any additional consideration by Landlord, Tenant shall be deemed to have sold, assigned, transferred and conveyed to Landlord all of Tenant’s right, title and interest in and to any of Tenant’s Personal Property. In connection with any Personal Property sold, assigned, transferred or conveyed to Landlord pursuant to the preceding sentence, Landlord shall have the option to assume, or cause the new operator to assume, any lease or equipment financing obligations of Tenant permitted under Section 8.2.1.4 hereof. If such option is not exercised, then such Personal Property shall not be sold, assigned, transferred or conveyed to Landlord. Both parties agree that Landlord owns as of the Commencement Date, and will own all of the Personal Property at the Facilities as of the expiration of the Term or the earlier termination of this Lease, except for those items of Personal Property listed on Schedule 6.3, equipment that is leased or financed pursuant Section 8.2.1.4 of this Lease, and those items of Personal Property previously owned by a tenant under the Existing Leases that is not fully depreciated. Both parties further agree that, notwithstanding anything in the Expiring Lease to the contrary and for the purpose of the continued leasing of the Facilities by Tenant under this Lease, Tenant will continue to own all of the Personal Property at the Facilities on the Commencement Date that for accounting purposes has not been fully depreciated by Tenant as of the Commencement Date until the earlier of (i) the expiration of the Term, (ii) the earlier termination of this Lease, or (ii) the date such item of Personal Property is fully depreciated, at which time it shall automatically become the property of Landlord.
6.4    Grant of Security Interest in Tenant’s Personal Property and Accounts. Tenant and the Subtenants have concurrently granted to Landlord a security interest in the Collateral as defined in the Security Agreement, which includes, without limitation, Tenant’s Personal Property as defined herein and Tenant’s and Subtenant’s Accounts as defined in the Security Agreement.
6.5
Line of Credit.
(a)     Line of Credit. As of the date of this Lease, pursuant to the Security Agreement, Tenant and the Subtenants have granted to Landlord a security interest in the accounts receivable generated by the Facilities. Tenant currently has a working capital line of credit with CIBC Bank under the CIBC Bank Loan Documents. CIBC Bank currently has a security interest in the accounts receivable from the Facilities that is both senior and subordinate to the security interest of the Landlord in accordance with the terms of the Intercreditor Agreement. If Tenant and/or the Subtenants, or any Affiliate of Tenant, obtain, concurrently with or after the date of this Lease, a Line of Credit that requires that, in order to secure the Line of Credit, Tenant and/or the Subtenants must grant to the working capital lender a first priority security interest in the accounts receivable from the Facilities accruing during the Term, then Landlord will subordinate its security interest in the accounts receivable from the Facilities accruing during the Term to the security interest of such working capital lender, provided that:
(i)    The working capital lender executes and delivers to Landlord an intercreditor agreement in form and substance reasonably satisfactory to Landlord; and
(ii)    The lien of Landlord in accounts receivable from the Facilities shall be subordinated to the lien of the working capital lender therein only to the extent of amounts advanced from time to time by the working capital lender to Tenant and/or the Subtenants with respect to the Facilities and only in the amount of Maximum Principal Amount, plus interest, penalties and other charges under the Line of Credit Documents with respect to principal amounts advanced;
(iii)    The CIBC Bank Obligations (as defined in the Intercreditor Agreement) has been repaid in full; and
(iv)    As of the date of entry by Landlord into the Intercreditor Agreement, no Event of Default has occurred and is continuing.
(b)    Tenant acknowledges and agrees that on the occurrence of a “Default”, “Event of Default” or similar event or occurrences which causes the lender under the Line of Credit Documents to accelerate any or all of the indebtedness thereby or to exercise any rights or remedies under such documents to realize on its interest in the accounts receivable from the Facilities, or to cease funding under the Line of Credit, which is not cured within any applicable cure period under the Line of Credit Documents or any written agreement by lender, shall constitute an Event of Default under this Lease.
ARTICLE VII    
7.1    Condition of the Leased Properties. Tenant acknowledges that prior to the execution of this Lease, Tenant has been operating the Leased Properties pursuant to the Existing Leases, and that as a consequence, Tenant has knowledge of the condition of the Leased Properties and has found the same to be in good order and repair and satisfactory for its purposes hereunder. Tenant is leasing the Leased Properties “as is” in their condition on the Commencement Date. Tenant waives any claim or action against Landlord in respect of the condition of the Leased Properties. LANDLORD MAKES NO WARRANTY OR REPRESENTATION EXPRESS OR IMPLIED, IN RESPECT OF ANY LEASED PROPERTY OR ANY PART THEREOF, EITHER AS TO ITS FITNESS FOR USE, DESIGN OR CONDITION FOR ANY PARTICULAR USE OR PURPOSE OR OTHERWISE AS TO THE QUALITY OF THE MATERIAL OR WORKMANSHIP THEREIN, LATENT OR PATENT, IT BEING AGREED THAT ALL SUCH RISKS ARE TO BE BORNE BY TENANT. Tenant further acknowledges that throughout the Term, except if Landlord elects to perform a Required Clean-Up pursuant to Section 7.3(l), Tenant is solely responsible for the condition of the Leased Properties.
7.2    Use of the Leased Properties. Throughout the Term Tenant shall, except if otherwise agreed to in writing by Landlord, continuously use the Leased Properties for the Primary Intended Use and such other uses as may be necessary or incidental thereto. Tenant shall not use the Leased Properties or any portion thereof for any other use without the prior written consent of Landlord. No use shall be made or permitted to be made of, or allowed in, the Leased Properties, and no acts shall be done, which will cause the cancellation of, or be prohibited by, any insurance policy covering the Leased Properties or any part thereof, nor shall the Leased Properties or Tenant’s Personal Property be used for any unlawful purpose. Tenant shall not commit or suffer to be committed any waste on the Leased Properties, or cause or permit any nuisance thereon, or suffer or permit the Leased Properties or any portion thereof, or Tenant’s Personal Property, to be used in such a manner as (i) might reasonably tend to impair Landlord’s (or Tenant’s, as the case may be) title thereto or to any portion thereof, or (ii) may reasonably make possible a claim or claims of adverse usage or adverse possession by the public, as such, or of implied dedication of the Leased Properties or any portion thereof. Landlord covenants that during the Term of this Lease it will cooperate with Tenant and use commercially reasonable efforts, where necessary or required from Landlord as the owner of the Leased Properties, to enable Tenant to obtain and maintain in force and effect and good standing any licenses, permits, certifications, or approvals needed by Tenant to use and operate each Leased Property for its Primary Intended Use and will obtain and maintain in force and effect and good standing any licenses, permits, certificates, or approvals, including certificates of need, necessary or required to be owned and maintained by the owner of each Leased Property in order to use and operate the Leased Property for its Primary Intended Use.
7.3    Certain Environmental Matters.
(a)    Prohibition Against Use of Hazardous Substances. Tenant shall not permit, conduct or allow on the Leased Properties, the generation, introduction, presence, maintenance, use, receipt, acceptance, treatment, manufacture, production, installation, management, storage, disposal or release of any Hazardous Substance except for those types and quantities of Hazardous Substances necessary for and ordinarily associated with the conduct of Tenant’s business which are used in full compliance with all Environmental Laws.
(b)    Notice of Environmental Claims, Actions or Contaminations. Tenant shall notify Landlord, in writing, immediately upon learning of any existing, pending or threatened: (a) investigation, inquiry, claim or action by any governmental authority in connection with any Environmental Laws, (b) Third Party Claims, (c) Regulatory Actions, and/or (id) Contamination of any portion of the Leased Properties
(c)    Costs of Remedial Actions with Respect to Environmental Matters. If any investigation and/or Clean‑Up of Contamination or any other violation of Environmental Law with respect to a Leased Property is required by any Environmental Law, Tenant shall complete, at its own expense, such investigation and/or Clean‑Up or cause any other Person that may be legally responsible therefore to complete such investigation and/or Clean‑Up.
(d)    Delivery of Environmental Documents. Tenant shall deliver to Landlord complete copies of any and all Environmental Documents that may now be in or at any time hereafter come into the possession of Tenant.
(e)    Environmental Audit. At Tenant’s expense, Tenant shall from time to time, upon and within thirty (30) days of Landlord’s request therefor, deliver an Environmental Audit to Landlord. All tests and samplings shall be conducted using generally accepted and scientifically valid technology and methodologies. Tenant shall give the engineer or environmental consultant conducting the Environmental Audit reasonable and complete access to the Leased Properties and to all records in the possession of Tenant that may indicate the presence (whether current or past) of a Release or threatened Release of any Hazardous Substances on, in, under, about and adjacent to any Leased Property. Tenant shall also provide the engineer or environmental consultant full access to and the opportunity to interview such persons as may be employed in connection with the Leased Properties as the engineer or consultant deems appropriate. However, Landlord shall not be entitled to request an Environmental Audit from Tenant unless (i) after the Commencement Date there have been changes, modifications or additions to Environmental Laws as applied to or affecting any of the Leased Properties; (ii) a significant change in the condition of any of the Leased Properties has occurred; (iii) there are fewer than six (6) months remaining in the Term; or (iv) Landlord has another good reason for requesting such certificate or certificates. If the Environmental Audit discloses the presence of Contamination or any noncompliance with Environmental Laws, Tenant shall immediately perform all of Tenant’s obligations hereunder with respect to such Hazardous Substances or noncompliance.
(f)    Entry onto Leased Properties for Environmental Matters. If Tenant fails to provide an Environmental Audit as and when required by Subparagraph (e) hereof, in addition to Landlord’s other remedies Tenant shall permit Landlord from time to time, by its employees, agents, contractors or representatives, to enter upon the Leased Properties for the purpose of conducting such Investigations as Landlord may desire, the expense of which shall promptly be paid or reimbursed by Tenant as an Additional Charge. Landlord, and its employees, agents, contractors, consultants and/or representatives, shall conduct any such Investigation in a manner which does not unreasonably interfere with Tenant’s use of and operations on the Leased Properties (however, reasonable temporary interference with such use and operations is permissible if the investigation cannot otherwise be reasonably and inexpensively conducted). Other than in an emergency, Landlord shall provide Tenant with prior notice before entering any of the Leased Properties to conduct such Investigation, and shall provide copies of any reports or results to Landlord, and Tenant shall cooperate fully in such Investigation.
(g)    Environmental Matters Upon Termination of the Lease or Expiration of Term. Upon the expiration or earlier termination of the Term of this Lease, Tenant shall cause the Leased Properties to be delivered free of any and all Regulatory Actions and Third Party Claims and otherwise in compliance with all Environmental Laws with respect thereto, and in a manner and condition that is reasonably required to ensure that the then present use, operation, leasing, development, construction, alteration, refinancing or sale of the Leased Property shall not be restricted by any environmental condition existing as of the date of such expiration or earlier termination of the Term.
(h)    Compliance with Environmental Laws. Tenant shall comply with, and cause its agents, servants and employees, to comply with, and shall use reasonable efforts to cause each occupant and user of any of the Leased Properties, and the agents, servants and employees of such occupants and users, to comply with each and every Environmental Law applicable to Tenant, the Leased Properties and each such occupant or user with respect to the Leased Properties. Specifically, but without limitation:
(i)    Maintenance of Licenses and Permits. Tenant shall obtain and maintain (and Tenant shall use reasonable efforts to cause each tenant, occupant and user to obtain and maintain) all permits, certificates, licenses and other consents and approvals required by any applicable Environmental Law from time to time with respect to Tenant, each and every part of the Leased Properties and/or the conduct of any business at a Facility or related thereto;
(ii)    Contamination. Tenant shall not cause, suffer or permit any Contamination;
(iii)    Clean‑Up. If a Contamination occurs, the Tenant promptly shall Clean‑Up and remove any Hazardous Substance or cause the Clean‑Up and the removal of any Hazardous Substance and in any such case such Clean‑Up and removal of the Hazardous Substance shall be effected to Landlord’s reasonable satisfaction and in any event in strict compliance with and in accordance with the provisions of the applicable Environmental Laws;
(iv)    Discharge of Lien. Within twenty (20) days of the date any lien is imposed against the Leased Properties or any part thereof under any Environmental Law, Tenant shall cause such lien to be discharged (by payment, by bond or otherwise to Landlord’s absolute satisfaction);
(v)    Notification of Landlord. Within five (5) Business Days after receipt by Tenant of notice or discovery by Tenant of any fact or circumstance which might result in a breach or violation of any covenant or agreement, Tenant shall notify Landlord in writing of such fact or circumstance; and
(vi)    Requests, Orders and Notices. Within five (5) Business Days after receipt of any request, order or other notice relating to the Leased Properties under any Environmental Law, Tenant shall forward a copy thereof to Landlord.
(i)    Environmental Related Remedies. In the event of a breach by Tenant beyond any applicable notice and/or grace period of its covenants with respect to environmental matters, Landlord may, in its sole discretion, do any one or more of the following (the exercise of one right or remedy hereunder not precluding the simultaneous or subsequent exercise of any other right or remedy hereunder):
(i)    Cause a Clean-Up. Cause the Clean‑Up of any Hazardous Substance or other environmental condition on or under the Leased Properties, or both, at Tenant’s cost and expense; or
(ii)    Payment of Regulatory Damages. Pay on behalf of Tenant any damages, costs, fines or penalties imposed on Tenant or Landlord as a result of any Regulatory Actions; or
(iii)    Payments to Discharge Liens. On behalf of Tenant, make any payment or perform any other act or cause any act to be performed which will prevent a lien in favor of any federal, state or local governmental authority from attaching to the Leased Properties or which will cause the discharge of any lien then attached to the Leased Properties; or
(iv)    Payment of Third Party Damages. Pay, on behalf of Tenant, any damages, cost, fines or penalties imposed on Tenant as a result of any Third Party Claims; or
(v)    Demand of Payment. Demand that Tenant make immediate payment of all of the costs of such Clean‑Up and/or exercise of the remedies set forth in this Section 7.3 incurred by Landlord and not theretofore paid by Tenant as of the date of such demand.
(j)    Environmental Indemnification. Except to the extent caused by Landlord’s gross negligence or willful misconduct, Tenant shall and does hereby indemnify, and shall defend and hold harmless Landlord, its principals, officers, directors, agents and employees from each and every incurred and potential claim, cause of action, damage, demand, obligation, fine, laboratory fee, liability, loss, penalty, imposition settlement, levy, lien removal, litigation, judgment, proceeding, disbursement, expense and/or cost (including without limitation the cost of each and every Clean‑Up), however defined and of whatever kind or nature, known or unknown, foreseeable or unforeseeable, contingent, incidental, consequential or otherwise (including, but not limited to, attorneys’ fees, consultants’ fees, experts’ fees and related expenses, capital, operating and maintenance costs, incurred in connection with (i) any Investigation or monitoring of site conditions, and (ii) any Clean-Up required or performed by any federal, state or local governmental entity or performed by any other entity or person because of the presence of any Hazardous Substance, Release, threatened Release or any Contamination on, in, under or about any of the Leased Properties which may be asserted against, imposed on, suffered or incurred by, each and every indemnitee arising out of or in any way related to, or allegedly arising out of or due to any environmental matter occurring during the Term of this Lease, during any hold-over period, or prior thereto during the term of the applicable Existing Lease for the affected Leased Property or Leased Properties, or which is caused by or at any time arises from Lessee’s and/or Lessee’s related or affiliated predecessors-in-interest use and occupancy of the Leased Properties, including, but not limited to, any one or more of the following:
(i)    Release Damage or Liability. The presence of Contamination in, on, at, under, or near a Leased Property or migrating to a Leased Property from another location;
(ii)    Injuries. All injuries to health or safety (including wrongful death), or to the environment, by reason of environmental matters relating to the condition of or activities past or present on, at, in, under a Leased Property;
(iii)    Violations of Law. All violations, and alleged violations, of any Environmental Law relating to a Leased Property or any activity on, in, at, under or near a Leased Property;
(iv)    Misrepresentation. All material misrepresentations relating to environmental matters in any documents or materials furnished by Tenant to Landlord and/or its representatives in connection with the Lease;
(v)    Event of Default. Each and every Event of Default relating to environmental matters;
(vi)    Lawsuits. Any and all lawsuits brought or threatened, settlements reached and governmental orders relating to any Hazardous Substances at, on, in, under or near a Leased Property, and all demands of governmental authorities, and all policies and requirements of Landlord’s, based upon or in any way related to any Hazardous Substances at, on, in, under a Leased Property; and
(vii)    Presence of Liens. All liens imposed upon any of the Leased Properties in favor of any governmental entity or any person as a result of the presence, disposal, release or threat of release of Hazardous Substances at, on, in, from, or under a Leased Property.
(k)    Rights Cumulative and Survival. The rights granted Landlord under this Section are in addition to and not in limitation of any other rights or remedies available to Landlord hereunder or allowed at law or in equity or rights of indemnification provided to Landlord in any agreement pursuant to which Landlord purchased any of the Leased Property. The payment and indemnification obligations set forth in this Section 7.3 shall survive the expiration or earlier termination of the Term of this Lease. In the event of any conflict between this Section 7.3 and any provision of the Existing Leases, this Section 7.3 shall control.
(l)    Exculpation. Anything herein to the contrary notwithstanding, Landlord acknowledges and agrees that the terms of this Section 7.3, and the representations, warranties, agreements and indemnity set forth in this Section 7.3, shall not be deemed to apply to any Contamination on, under, about or with respect to (i) the Treemont Facility prior to February 1, 2003, or the Katy or Humble Facility prior to July 1, 2003, or the Paris, Texas, Facility prior to the acquisition date for the Paris, Texas Facility or (ii) the Facilities subject to the existing Terminated Leases (the “Aviv Facilities”) prior to the acquisition date of each of the Aviv Facilities by the applicable Landlord or its Affiliate, other than any Hazardous Substance, Release, threatened Release or Contamination disclosed in the phase I environmental assessments of the Aviv Facilities obtained by Landlord in connection with its purchase of the Aviv Facilities and provided to Tenant (each of (i) and (ii), a "Pre-Existing Environmental Condition"). If following the Commencement Date, a Clean-Up is required by any federal, state or local governmental agency or authority solely because of the presence any Pre-Existing Environmental Condition, and if the affected Leased Property will no longer be permitted under applicable law to operate for its Primary Intended Use unless such a Clean-Up is performed (a "Required Clean-Up"), then Tenant shall promptly notify Landlord of such Required Clean-Up. If Landlord elects in writing not to pursue, perform or pay such Required Clean-Up, then Tenant may elect within thirty (30) days of such determination to terminate this Lease as to such affected Leased Property only. In the event of such termination, the Base Rent payable hereunder and the Security Deposit shall be adjusted as if such termination were due to a casualty loss under Section 14.7 below; provided, however, that in no event shall the Security Deposit be reduced to an amount less than at an amount equal to three months of the annual Base Rent (exclusive of the Avon Rent) as of the date of such reduction. If Landlord elects to perform such Required Clean-Up, then Landlord shall promptly undertake and diligently pursue the remediation of the applicable Pre-Existing Condition, unless contested by Landlord in good faith by appropriate proceedings and the right to use the Leased Property for its Primary Intended Use during such contest is not materially and adversely affected thereby.
(m)    Texas Asbestos Remediation. If any Clean-Up of any asbestos containing materials on the Doctors and Fort Worth, Texas Facilities identified in the Asbestos Management Plans for the facilities dated March 19,2004 (“Existing Asbestos Containing Materials”) is required to be performed by any federal, state or local governmental entity during the Term and if the Doctors and Fort Worth Facilities will no longer be permitted under applicable law to operate for their Primary Intended Use unless such Clean-Up is performed (a “Required Asbestos Clean-Up”), then Tenant shall promptly notify Landlord of such Required Asbestos Clean-Up. Within thirty (30) days of the determination that a Required Asbestos Clean-Up must be done, Tenant shall provide Landlord with an estimate of the cost of the Asbestos Clean-Up (“Asbestos Clean-Up Cost”). Landlord shall fund one half of the Asbestos Clean-Up Cost (which funding may be in the form of an agreement to abate Base Rent for a period of time commencing on the date that Tenant commences the Required Asbestos Clean-Up). Tenant shall promptly undertake and diligently perform such Required Asbestos Clean-Up and, upon completion, shall provide Landlord with an accounting of all Asbestos Clean-Up Costs, including adequate evidence of payment by Tenant of such costs. Notwithstanding the foregoing, if such Required Asbestos Clean-Up would not have been required by, or otherwise come to the attention of, any governmental entity, but for the renovations or alterations of the Facility occurring after August 11, 2007 or as a result of the actions or omissions of Tenant , a Subtenant, Manager or other agent of Tenant, including the failure to abide by the Asbestos Management Plans dated March 19, 2004 for Landlord by ATC Associates, Inc. for the Doctors and Fort Worth Facilities, then Landlord shall have no obligation to fund any portion of the Asbestos Clean-Up Costs and Tenant shall be solely responsible for such Required Asbestos Clean-Up. Tenant acknowledges receipt of copies of the aforementioned asbestos management plans.
ARTICLE VIII    
8.1    Compliance with Legal and Insurance Requirements. In its use, maintenance, operation and any alteration of the Leased Properties, Tenant, at its expense, will, subject to the provisions of ARTICLE XII relating to permitted contests, promptly (i) comply with all Legal Requirements and Insurance Requirements, whether or not compliance therewith requires structural changes in any of the Leased Improvements (which structural changes shall be subject to Landlord’s prior written approval, which approval shall not be unreasonably withheld or delayed) or interferes with or prevents the use and enjoyment of the Leased Properties, and (ii) procure, maintain and comply with all licenses, certificates of need, provider agreements and other authorizations required for the use of the Leased Properties and Tenant’s Personal Property then being made, and for the proper erection, installation, operation and maintenance of the Leased Properties or any part thereof. The judgment of any court of competent jurisdiction, or the admission of Tenant in any action or proceeding against Tenant, whether or not Landlord is a party thereto, that Tenant has violated any such Legal Requirements or Insurance Requirements shall be conclusive of that fact as between Landlord and Tenant. Notwithstanding the foregoing, Tenant may from time to time remove beds from service at each Facility without reducing the number of licensed Medicare and Medicaid certified beds that may be operated at such Facility and while retaining the right to return any such beds to service at such Facility (so-called “bed banking”) provided that (i) such removal shall not exceed more than ten percent (10%) of the number of beds at the applicable Facility, (ii) not less than thirty (30) days prior to removing such beds from service, Tenant shall so notify Landlord in writing, which notice shall include, or have delivered therewith, (a) detailed descriptions of the beds being removed, the reasons for such bed removal, estimates of the cost of implementing such bed changes, and the projected impact of such bed changes upon such Facility, and (b) evidence reasonably satisfactory to Landlord that Tenant has obtained all necessary regulatory approvals for the proposed reduction of beds in service, that such beds continue to be considered “licensed” and “certified” beds by the applicable governmental authority and agencies and that Tenant or any successor operator of such Facility retains the right, at the end of the bed banking period, to return such beds to service at the applicable Facility as licensed Medicare and Medicaid certified beds.
8.2    Certain Covenants.
8.2.1    Certain Financial Covenants.
8.2.1.1         Limitation of Distributions. None of Tenant, any Subtenant (other than a Hospital Subtenant), UPL-IGT Manager or Guarantor shall make any Distributions to the holders of its equity securities or any Affiliate if, as of the date of such Distribution or upon giving effect to such Distribution, an Event of Default in the payment of Base Rent has occurred and is continuing. At all times during the Term, Tenant and the Subtenants shall maintain, on a consolidated basis, a Post-Distribution Cash Flow to Rent Ratio (in each case, to be tested quarterly for the immediately preceding 12 month period) of 1.0:1. Solely for the purposes of calculating compliance with the Post-Distribution Cash Flow to Rent Ratio in connection with any contemplated Distribution, all contemplated Distributions shall also be subtracted from Post-Distribution Cash Flow.
8.2.1.2         Accounts Receivable Financing. Except as may be expressly provided in Section 6.5 of this Lease and the Intercreditor Agreement, Tenant and/or Subtenant shall not pledge or otherwise encumber any of the accounts receivable generated through the operation of the Facilities to secure principal and interest on any Debt.
8.2.1.3         Guarantees Prohibited. Neither Tenant nor any Subtenant (other than a Hospital Subtenant) or UPL-IGT Manager (if other than DMS) shall guarantee any indebtedness of any Affiliate or other third party, except those guarantees for the benefit of CIBC Bank in effect as of the date hereof or as may be required under the CIBC Bank Loan Documents or any future Line of Credit satisfying the requirements of Section 6.5, and except for obligations which represent Tenant’s, Subtenant’s trade payables or accrued expenses incurred by the UPL-IGT Manager in the ordinary course of leasing and operating the Facilities.
8.2.1.4         Equipment Financing. The aggregate amount of principal, interest and lease payments due from Tenant and/or Subtenant and/or Manager with respect to any equipment leases or financing secured by equipment utilized in the operation of any single Facility (other than for vehicles) shall not at any time during the Term exceed $150,000.00 in any one Lease Year.
8.2.1.5         Cash Flow Coverage Ratio. Commencing on the Commencement Date, and continuing during the Term, a Cash Flow Coverage Ratio as determined quarterly on a cumulative basis for the preceding four (4) calendar quarters shall be maintained at the following ratio for the following period:
Period:
Ratio:
October 1, 2018 – September 30, 2019
1.01
October 1, 2019 – September 30, 2020
1.05
Thereafter
1.10

8.2.2    Indebtedness. Neither Tenant nor any Subtenant (including a Hospital Subtenant) or UPL-IGT Manager will create, incur or suffer to exist any Debt which is secured by a Lien in any of the Property with respect to which Landlord has been granted a Lien in pursuant to the Lease Documents, except:
(i)    The equipment financing permitted under Section 8.2.1.4;
(ii)    The Line of Credit permitted under Section 6.5; and
(iii)    Any Debt owed to Landlord or any Affiliate of Landlord.
8.3    Minimum Qualified Capital Expenditures. Each Lease Year, Tenant, a Subtenant or a UPL-IGT Manager shall expend with respect to the Leased Facilities at least Four Hundred Dollars ($400.00) per-licensed-bed for Qualified Capital Expenditures on a portfolio wide basis on average over a rolling two (2) Lease Year period (i.e., the current Lease Year and the previous Lease Year) to improve the Facilities, which amount shall be increased each Lease Year, beginning with the second Lease Year, in proportion to increases in the CPI from the Commencement Date to the commencement of each such Lease Year (“Minimum Qualified Capital Expenditures”). With respect to the Existing Leases, the amount spent by Tenant, a Subtenant or a UPL-IGT Manager on Qualified Capital Expenditures, as defined under this Lease, for the final Lease Year under the Existing Leases prior to the Commencement Date, shall be included in the calculation the two (2) year rolling average for Qualified Capital Expenditures for the first and second Lease Year under this Lease. Approved Improvements funded by Landlord pursuant to Section 9.3 and constituting Qualified Capital Expenditures shall be included in the calculation of Minimum Qualified Capital Expenditures for the Lease Year in which such amounts are funded. At least annually, at the request of Landlord, Landlord and Tenant shall review capital expenditures budgets and reasonably agree on modifications, if any, required by changed circumstances and the changed conditions of the Leased Properties.
8.4    Management Agreements. Neither Tenant nor any Subtenant or Manager shall enter into, amend, modify, renew, replace or otherwise change the terms of any Management Agreement without the prior written consent of Landlord as to the identity of the Manager and the terms of the agreement, which consent Landlord may withhold in its sole discretion, and in no event without the execution by Tenant, a Subtenant, Manager and Landlord, of an agreement, satisfactory to Landlord in form and substance, pursuant to which Manager’s right to receive its management fee is subordinated to the obligation of Tenant to pay the Rent to Landlord. Landlord hereby consents to the continued management of the Facilities by DMS under its current Management Agreement with Tenant. In addition, prior to the employment of any Manager, such Manager must execute a Consent and Agreement of Manager in the form attached hereto as Exhibit E. Notwithstanding any of the foregoing terms of this Section 8.4, the annual management fee payable to any Manager (other than an Affiliate of Tenant, including DMS) during the term of this Lease shall not exceed five percent (5%) of Gross Revenues.
8.5    Other Facilities. Without the prior written consent of Landlord, which consent shall not be unreasonably withheld, neither Tenant nor any Affiliate shall own, operate or manage any nursing home, rest home, assisted living facility, subacute facility, retirement center or similar health care facility within a five (5) mile radius of any Facility other than:
(i)    any Facility which is a Leased Property under this Lease, or
(ii)    any Facility that Tenant or any Affiliate of Tenant owns or operates as of the Commencement Date and is set forth on Schedule 8.5 attached hereto;
provided, however, that with respect to any such homes, facilities and centers constructed after January 1, 2018 with funds not provided by Landlord, the radius distance from any Facility shall be fifteen (15) miles.
8.6    Separateness.     Tenant (if other than DLC), each Subtenant and each UPL-IGT Manager (if other than DMS) shall:
(a)    Maintain records and books of account separate from those of any Affiliate.
(b)    Conduct its own business in its own names and not in the name of any Affiliate (except to the extent that the business of the Facilities may be conducted in the name of the Manager).
(c)    Maintain financial statements separate from any Affiliate.
(d)    Maintain any contractual relationship with any and all Affiliates, except upon terms and conditions that are fair and substantially similar to those that would be available on an arm’s length basis.
(e)    Except for the benefit of CIBC Bank (or its successors and assigns) as set forth in the Intercreditor Agreement or as otherwise required under the CIBC Bank Loan Documents, or for the benefit of any working capital lender as required under the Line of Credit Documents described in Section 6.5 of this Lease, not guarantee or become obligated for the debts of any other entity, including any Affiliate, or hold out its credit, jointly or severally, as being available to satisfy the obligations of others, except for obligations which represent Tenant’s or Subtenant’s trade payables or accrued expenses incurred by Manager in the ordinary course of owning and operating the Facilities.
(f)    Except for the benefit of CIBC Bank (or its successors and assigns) as set forth in the Intercreditor Agreement, or any working capital lender as set forth in the intercreditor agreement required under Section 6.5 of this Lease, not pledge its assets, jointly or severally, for the benefit of any other entity, including any Affiliate.
(g)    Hold itself out to the public as a legal entity separate from any Affiliates.
(h)    At all times cause its Board of Directors to hold appropriate meetings (or act by unanimous consent) to authorize all appropriate corporate actions, and in authorizing such actions, to observe all formalities.
8.7    Bank Accounts. Tenant, the Subtenants (other than a Hospital Subtenant) and UPL-IGT Manager shall maintain the cash proceeds arising out of the operation of the Facilities in bank accounts owned by Guarantor, Tenant, the Subtenants (other than a Hospital Subtenant) or a UPL-IGT Manager and shall not commingle such proceeds with the cash of any non-Affiliate third party. None of Tenant, the Subtenants (other than a Hospital Subtenant) and UPL-IGT Manager shall permit its or their cash, cash equivalents, and the cash proceeds arising out of the operation of the Facilities, to be commingled with the cash and cash equivalents of any Person other than (i) Tenant, the Subtenants (other than a Hospital Subtenant) and UPL-IGT Manager with each other or (ii) so long as (1) Guarantor, Tenant, the Subtenants (other than a Hospital Subtenant) and UPL-IGT Manager maintain financial records which will make it possible to identify (x) funds deposited into such account from the Facilities and (y) expenses of the Facilities paid with funds in such account and (2) no Event of Default under subsections (a), (b), (c), (d), or (k) of the definition of Event of Default has occurred and is continuing, a concentration account maintained by Guarantor to be used in accordance with existing practices. Notwithstanding the foregoing, the personal allowance accounts of the residents of the Facilities need not be maintained separately and may be commingled so long as Tenant and the Subtenants maintain adequate written records with respect to such personal allowance accounts.
ARTICLE IX    
9.1    Maintenance and Repair.
9.1.1    Tenant, at its expense, will keep the Leased Properties, and all landscaping, private roadways, sidewalks and curbs appurtenant thereto which are under Tenant’s control and Tenant’s Personal Property in good order and repair, whether or not the need for such repairs arises out of Tenant’s use, any prior use, the elements or the age of the Leased Property or any portion thereof, or any cause whatsoever except the act or negligence of Landlord, and with reasonable promptness shall make all necessary and appropriate repairs thereto of every kind and nature, whether interior or exterior, structural or non‑structural, ordinary or extraordinary, foreseen or unforeseen or arising by reason of a condition existing prior to the Commencement Date (concealed or otherwise) or existing after February 1, 2003 with respect to the Treemont Facility, and July 1, 2003 with respect to the Katy Facility and the Humble Facility; provided, however, that Tenant shall be permitted to prosecute claims against Landlord’s predecessor in title for breach of any representation or warranty made to or for the benefit of Landlord, or for latent defects in any Leased Property. Additionally, during the Term of this Lease, upon request and at the cost and expense of Tenant, and with respect only to the Leased Properties that were the subject of the Terminated Leases, Landlord agrees to use commercially reasonable efforts to pursue any right or claim Landlord may have against the seller under the applicable purchase agreement by which such Leased Properties were acquired for breach of any covenant, warranty or representation made with respect to the title, condition, use and operation of any Leased Property, or for latent defects in any Leased Property, the successful pursuit of which may benefit or assist Tenant in, or provide financial recovery to Tenant for, the performance of its obligations under this Lease. Where such right or claim may be prosecuted by the assignee of Landlord, then Tenant shall be permitted to prosecute such right or claim, at Tenant's cost and expense, and, to the extent permitted by law, the applicable Landlord hereby assigns to Tenant all of such Landlord's rights to fully prosecute any such right or claims. Landlord shall cooperate in good faith with Tenant in the prosecution of any such right or claim, in the applicable Landlord's or Tenant's name, all at Tenant's cost and expense. Tenant shall at all times maintain, operate and otherwise manage the Leased Properties on a quality basis and in a manner consistent with the standards of the highest quality competing facilities in the market areas served by the Leased Properties. All repairs shall, to the extent reasonably achievable, be at least equivalent in quality to the original work or, subject to the provisions of Paragraph 9.1.4, below, the property to be repaired shall be replaced. Tenant will not take or omit to take any action the taking or omission of which might materially impair the value or the usefulness of the Leased Properties or any parts thereof for the Primary Intended Use.
9.1.2    Landlord shall not under any circumstances be required to maintain, build or rebuild any improvements on the Leased Properties (or any private roadways, sidewalks or curbs appurtenant thereto), or to make any repairs, replacements, alterations, restorations or renewals of any nature or description to the Leased Properties, whether ordinary or extraordinary, structural or non‑structural, foreseen or unforeseen, or upon any adjoining property, whether to provide lateral or other support or abate a nuisance, or otherwise, or to make any expenditure whatsoever with respect thereto, in connection with this Lease. Tenant hereby waives, to the extent permitted by law, the right to make repairs at the expense of Landlord pursuant to any law in effect at the time of the execution of this Lease or hereafter enacted.
9.1.3    Nothing contained in this Lease shall be construed as (i) constituting the consent or request of Landlord, expressed or implied, to any contractor, subcontractor, laborer, materialmen or vendor to or for the performance of any labor or services or the furnishing of any materials or other property for the construction, alteration, addition, repair or demolition of or to any Leased Property or any part thereof, or (ii) giving Tenant any right, power or permission to contract for or permit the performance of any labor or services or the furnishing of any materials or other property in such fashion as would permit the making of any claim against Landlord in respect thereof or to make any agreement that may create, or in any way be the basis for any right, title, interest, lien, claim or other encumbrance upon the estate of Landlord in the Leased Properties, or any portion thereof. Landlord shall have the right to give, record and post, as appropriate, notices of non‑responsibility under any mechanics’ and construction lien laws now or hereafter existing.
9.1.4    Tenant shall, from time to time, promptly replace any of the Leased Improvements or Landlord’s Personal Property which (i) become worn out, obsolete or unusable for the purpose for which intended, (ii) have been Taken, or (iii) have been lost, stolen, damaged or destroyed. If any of Landlord’s Personal Property requires replacement as a result of damage, theft, loss or destruction or a Taking, then Tenant shall be entitled to that portion of any insurance proceeds payable in respect thereof or any Award made therefore. All replacements shall have a then value (adjusted for inflation) and utility at least equal to the value of the items replaced as of the date hereof in the case of clause (i) above, and immediately prior to the events specified in clauses (ii) and (iii) above. All replacements of Landlord’s Personal Property shall be owned by Landlord and become a part of the Leased Properties immediately upon their acquisition. Tenant shall promptly repair all damage to a Leased Property incurred in the course of such replacement.
9.1.5    Tenant will, upon the expiration or prior termination of the Term, vacate and surrender the Leased Properties to Landlord in the condition in which they were originally received from Landlord, in good operating condition, ordinary wear and tear excepted, except as repaired, rebuilt, restored, altered or added to as permitted or required by the provisions of this Lease.
9.2    Encroachments, Restrictions, etc. Except for the forced or required removal of the existing encroachment of the Highlands Facility in Louisville, KY onto the right of way of Stevens Avenue, if any of the Leased Improvements shall, at any time, encroach upon any property, street or right‑of‑way adjacent to the Leased Property, or shall violate the agreements or conditions contained in any lawful restrictive covenant or other agreement affecting the Leased Property, or any part thereof, or shall impair the rights of others under any easement or right‑of‑way to which any Leased Property is subject, then promptly upon the request of Landlord or at the behest of any person affected by any such encroachment, violation or impairment, Tenant shall, at its expense, subject to its right to contest the existence of any encroachment, violation or impairment as provided in ARTICLE XII and in such case, in the event of an adverse final determination, either (i) obtain valid and effective waivers or settlements of all claims, liabilities and damages resulting from each such encroachment, violation or impairment, whether the same shall affect Landlord or Tenant or (ii) make such changes in the Leased Improvements, and take such other actions, as Tenant in the good faith exercise of its judgment deems reasonably practicable, to remove such encroachment, and to end such violation or impairment, including, if necessary, the alteration of any of the Leased Improvements, and in any event take all such actions as may be necessary in order to be able to continue the operation of the Leased Improvements for the Primary Intended Use substantially in the manner and to the extent the Leased Improvements were operated prior to the assertion of such violation, impairment or encroachment.
9.3    Landlord Funded Capital Improvements.
(a)    7% Upgrades. Subject to Tenant’s compliance with Sections 9.3(c) and 9.3(d), upon receipt of a written statement from an engineer hired by Landlord to oversee the project, or a written certification from Tenant to Landlord, that a 7% Upgrade commenced has been completed in whole or in part acceptable to such engineer and upon compliance with the procedures set forth below, so long as no Event of Default, or Unmatured Event of Default, has occurred and is continuing, Landlord shall pay an amount equal to the Actual Cost of such 7% Upgrade according to the procedures set forth below; provided, however, that Landlord’s aggregate obligation to pay shall not exceed (i) with respect to a specific 7.0% Upgrade, the amount set forth on Schedule 9.3(a) for such 7.0% Upgrade Improvement, and (ii) with respect to all Facilities and all 7.0% Upgrades, Five Million Dollars ($5,000,000.00).
(b)    9.0% Improvements. Subject to Tenant’s compliance with Sections 9.3(c) and 9.3(d), upon receipt of a written statement from an engineer hired by Landlord to oversee the project, or a written certification from Tenant to Landlord, that a 9.0% Improvement commenced has been completed in whole or in part acceptable to such engineer and upon compliance with the procedures set forth below, so long as no Event of Default, or Unmatured Event of Default, has occurred and is continuing, Landlord shall pay an amount equal to the Actual Cost of such 9.0% Improvement according to the procedures set forth below; provided, however, that, without Landlord’s prior written consent, Landlord’s aggregate obligation to pay with respect to all 9.0% Improvements shall not exceed (i) with respect to a specific 9.0% Improvement, the amount set forth on Schedule 9.3(b) for such 9.0% Improvement, and (ii) with respect to all Facilities and all 9.0% Improvements, Thirty Million Dollars ($30,000,000).
(c)    Funding Procedures. Funds to be disbursed by Landlord for Approved Improvements shall be disbursed in accordance with the following procedures:
(i)    Tenant may not request reimbursement more than once per month;
(ii)    With each request for reimbursement, Tenant shall deliver a certification from an officer of Tenant in substantially the form of Exhibit F to this Lease;
(iii)    Tenant may not request reimbursement for less than Five Thousand ($5,000); provided, however, that if all Approved Improvements are completed and the amount remaining to be reimbursed is less than Five Thousand ($5,000) then Tenant may request such lesser amount;
(iv)    The Approved Improvements shall be done pursuant to plans and specifications and a cost statement approved by Landlord in writing, which approval shall not be unreasonably withheld, conditioned or delayed;
(v)    After the first disbursement to Tenant (which disbursement shall not exceed $25,000), sworn statements and lien waivers in an amount at least equal to the amount of funds previously paid to Tenant or such other adequate evidence of payment shall be delivered to Landlord from all contractors, subcontractors and material suppliers covering all labor and materials furnished through the date of the previous disbursement;
(vi)    Tenant shall deliver to Landlord such other evidence as Landlord reasonably may request, from time to time during the course of the work on the Approved Improvements, as applicable, to evidence compliance with the approved plans and specifications for such work, the cost of work and the total amount needed to complete the Approved Improvements, as applicable, and showing that there are no liens against the Leased Property arising in connection with the work; and
(vii)    Landlord may reimburse itself as part of the Actual Costs of any Approved Improvements for its reasonable out-of-pocket costs and expenses incurred in connection with any disbursement, including, but limited to, any search costs, filings fees, title company charges, and reasonable attorney fees and expenses.
(viii)    The funds may be disbursed by Landlord to Tenant or, at Landlord’s option, may be paid (i) directly to, and disbursed by, a title agent acceptable to Landlord, or (ii) paid directly to the party to whom payment is owed. Landlord may, at its option, acquire title insurance coverage in connection with each draw and all costs and expense of such coverage shall be included in the Actual Cost of any such Approved Improvement. If an Approved Improvement changes the footprint of the Facility, the legal description or requires the recording of encumbrances against the Facility, then, upon completion of such Approved Improvement, Landlord may require an ALTA “as-built” survey to be done and all costs and expense of such survey shall be included in the Actual Cost of any such Approved Improvement.
(ix)    All requests for reimbursement under this Section must be made within sixty (60) days of the completion of the underlying work, time being of the essence.
(d)    Funding Request.  Funding by Landlord for the Approved Improvements shall be available for (i) those 7.0% Upgrades the scope and cost of which has been identified by Tenant in an amount per Facility for which funding has been requested by Tenant in writing on or before September 30, 2018 and (ii) those 9.0% Improvements identified by Tenant in an amount per Facility, the specific cost and scope of which for each Facility must be agreed upon by Landlord and Tenant, for which Tenant has requested in writing on or before September 30, 2023 that Landlord provide financing. Within thirty (30) days of receipt of a request to finance a 9.0% Improvement, Landlord shall notify Tenant as to whether it will finance the proposed improvements. Prior to any funding of 9.0% Improvements, Landlord and Tenant must agree in writing upon the 9.0 % Improvements and the funding amount for such 9.0% Improvements, which agreement Landlord shall not unreasonably withhold, condition or delay. Prior to commencing any work on any Approved Improvements for which Tenant will request disbursement of funds pursuant to this Section 9.3, Tenant shall provide Landlord with a complete description of the work to be completed together with such written documentation as may be reasonably requested by Landlord with respect thereto, which may include, to the extent applicable, plans and specifications, budgets, a work completion schedule, pro forma operating projections and copies of permits required in connection with such repairs or improvements. Prior to commencing any work on any Approved Improvements, if applicable based on the nature of such Approved Improvements, Tenant shall have obtained any certificate of need or other Authorizations from any applicable governmental authorities with jurisdiction required in connection with such Approved Improvements. Landlord shall join in the application for such Authorizations whenever such action is necessary by the owner of the affected Leased Property; provided however, that such joinder shall be at no cost or expense to Landlord. Subject to Force Majeure, once commenced Tenant shall diligently complete any Approved Improvements on or before the completion date specified in the approval materials, or if no completion date is specified, by September 30, 2023 and Landlord shall have no obligation to fund any such Approved Improvements after such date.
(e)    Payment by Landlord. Any complete and qualifying request for funds for the Approved Improvements requested by the Tenant in accordance with this Section 9.3 shall be paid and disbursed by Landord to Tenant or as provided in 9.3(c)(viii), above,  on or before the first business day of the calendar month following the date that is fifteen (15) days after the date Landlord receives written request for payment of such funds from Tenant, so long as such request is accompanied by all invoices, sworn statement and lien waivers (partial or full, as applicable) with respect to the work for which such request is made as required in this Section 9.3.  Landlord and Tenant agree to cooperate in good faith in attempting to resolve any disputed portions of any payment request. 
ARTICLE X    
10.1    Construction of Alterations and Additions to the Leased Properties.
10.1.1    Tenant shall not (a) make or permit to be made any structural alterations, improvements or additions of or to the Leased Properties or any part thereof, or (b) materially alter the plumbing, HVAC or electrical systems thereon or (c) make any other alterations, improvements or additions to any Leased Property or any part thereof, the cost of which exceeds One Hundred Fifty Thousand Dollars ($150,000.00), unless and until Tenant has (a) caused complete plans and specifications therefor to have been prepared by a licensed architect (or licensed plumbing contractor or electrical contractor in the case of alterations to the plumbing, HVAC or electrical systems) and submitted to Landlord at least thirty (30) Business Days before the planned start of construction thereof, (b) obtained Landlord’s written approval thereof and the approval of any Facility Mortgagee, which approval shall not be unreasonably withheld, conditioned or delayed, and if no response has been received by Tenant within thirty (30) Business Days after submission of the plans and specifications for approval then such approval shall be deemed to have been given, and (c), if required to do so by Landlord, provide Landlord with reasonable assurance of the payment of the cost of any such alterations, improvements or additions, in the form of a bond, letter of credit or cash deposit. If Landlord requires a deposit, Landlord shall retain and disburse the amount deposited in the same manner as is provided for insurance proceeds in Section 14.6. If the deposit is reasonably determined by Landlord at any time to be insufficient for the completion of the alteration, improvement or addition, Tenant shall immediately increase the deposit to the amount reasonably required by Landlord. Tenant shall be responsible for the completion of such improvements in accordance with the plans and specifications approved by Landlord, and shall promptly correct any failure with respect thereto.
10.1.2    Alterations and improvements not falling within the categories described in the first sentence of the preceding paragraph may be made by Tenant without the prior approval of Landlord, but Tenant shall give Landlord at least fifteen (15) Business Days prior written Notice of any such alterations and improvements.
10.1.3    All alterations, improvements and additions shall be constructed in a first class, workmanlike, manner, in compliance with all Insurance Requirements and Legal Requirements, be in keeping with the character of the Leased Properties and the area in which the Leased Property in question is located and be designed and constructed so that the value of the Leased Properties will not be diminished or and that the Primary Intended Use of the Leased Properties will not be changed. All improvements, alterations and additions shall immediately become a part of the Leased Properties.
10.1.4    Tenant shall have no claim against Landlord at any time in respect of the cost or value of any such improvement, alteration or addition. There shall be no adjustment in the Rent by reason of any such improvement, alteration or addition. With Landlord’s consent, which shall not be unreasonably withheld, expenditures made by Tenant pursuant to this ARTICLE X, other than expenditures for additions (as defined in the definition of Qualified Capital Expenditures), may be included as capital expenditures for purposes of inclusion in the capital expenditures budget for the Facilities and for measuring compliance with the obligations of Tenant set forth in Section 8.3 of this Lease.
10.1.5    In connection with any alteration which involves the removal, demolition or disturbance of any asbestos-containing material, Tenant shall cause to be prepared at its expense a full asbestos assessment applicable to such alteration, and shall carry out such asbestos monitoring and maintenance program as shall reasonably be required thereafter in light of the results of such assessment.
ARTICLE XI    
11.1    Liens. Subject to the provisions of ARTICLE XII relating to permitted contests, without the consent of Landlord or as expressly permitted elsewhere herein, Tenant will not directly or indirectly create or allow to remain and will promptly discharge at its expense any lien, encumbrance, attachment, title retention agreement or claim upon the Leased Properties, and any attachment, levy, claim or encumbrance in respect of the Rent, except for (i) Permitted Encumbrances, (ii) restrictions, liens and other encumbrances which are consented to in writing by Landlord and any Facility Mortgagee, (iii) liens for those taxes of Landlord which Tenant is not required to pay hereunder, (iv) any Facility Mortgage, (v) liens of mechanics, laborers, materialmen, suppliers or vendors for sums either disputed, not yet due, or contested pursuant to Section 12.1 below, and (vi) liens created by the wrongful acts or negligence of Landlord.
ARTICLE XII    
12.1    Permitted Contests. Tenant, on its own or on Landlord’s behalf (or in Landlord’s name), but at Tenant’s sole cost and expense, shall have the right to contest, by appropriate legal proceedings conducted in good faith and with due diligence, the amount or validity of any real or personal property assessment, Imposition, Legal Requirement or Insurance Requirement, or any lien, attachment, levy, encumbrance, charge or claim or any encroachment or restriction burdening the Leased Property (“Claim”), provided (a) prior Notice of such contest is given to Landlord, (b) the Leased Properties would not be in any danger of being sold, forfeited or attached as a result of such contest, and there is no risk to Landlord of a loss of or interruption in the payment of, Rent, (c) in the case of an unpaid Imposition or Claim, collection thereof is suspended during the pendency of such contest, (d) in the case of a contest of a Legal Requirement, compliance may legally be delayed pending such contest. Upon request of Landlord, Tenant shall provide a bond or letter of credit, deposit funds or assure Landlord in some other manner reasonably satisfactory to Landlord that the amount to be paid by Tenant that is the subject of a contested Imposition, Legal Requirement, Insurance Requirement or Claim, together with interest and penalties, if any, thereon, and any and all costs for which Tenant is responsible will be paid if and when required upon the conclusion of such contest. Tenant shall defend, indemnify and save harmless Landlord from all costs or expenses arising out of or in connection with any such contest, including but not limited to attorneys’ fees. If at any time Landlord reasonably determines that payment of any Imposition or Claim, or compliance with any Legal or Insurance Requirement being contested by Tenant is necessary in order to prevent loss of any of the Leased Properties or Rent or civil or criminal penalties or other damage, upon such prior Notice to Tenant as is reasonable in the circumstances Landlord may pay such amount, require Tenant to comply with such Legal or Insurance Requirement or take such other action as it may deem necessary to prevent such loss or damage. If reasonably necessary or legally required, upon Tenant’s written request Landlord, at Tenant’s expense, shall cooperate with Tenant in a permitted contest, provided Tenant upon demand makes arrangements satisfactory to Landlord to assure the reimbursement of any and all Landlord’s costs incurred in cooperating with Tenant in such contest. Tenant shall be entitled to any refunds of any claim, and such charges and penalties or interest thereon, which have been paid by Tenant or paid by Landlord and for which Landlord has been fully reimbursed.
12.2    Landlord’s Requirement for Deposits. Following an Event of Default, Landlord, in its sole discretion, shall be entitled to require Tenant to (i) deposit with Landlord monthly, at the time of its payments of Base Rent, a pro rata portion of the premium amounts charged by third party commercial insurance carriers required to comply with Insurance Requirements, Impositions and Legal Requirements, and when such obligations become due, Landlord shall pay them (to the extent of the deposit) upon Notice from Tenant requesting such payment, and (ii) provide reasonable evidence of the making of actuarial required quarterly deposits with respect to any insurance maintained with a captive insurance carrier. In the event that sufficient funds have not been deposited to cover the amount of the obligations due at least thirty (30) days in advance of the due date, or reasonable evidence of the quarterly payments has not been provided, Tenant shall forthwith deposit the same with Landlord upon Notice from Landlord. Landlord shall not be obligated to segregate such deposited funds from its other funds, or to pay Tenant any interest on any deposit so held by Landlord. Upon an Event of Default, any of the funds remaining on deposit may be applied under this Lease in any manner and on such priority as may be determined by Landlord.
ARTICLE XIII    
13.1    General Insurance Requirements. Tenant shall keep the Leased Properties, and all property located in or on the Leased Properties, including Landlord’s Personal Property and Tenant’s Personal Property, insured with insurance meeting the following requirements: (a) all insurance shall be written by companies authorized to do insurance business in the applicable States and, with the exception of any policies issued by Tenant’s Insurance Captive permitted pursuant to Section 13.12 hereof, having a rating classification of not less than A and a financial size category of “Class VII” or larger, according to the then most recent issue of Best’s Key Rating Guide; (b) all policies must name Landlord as an additional insured, and name as an additional insured any Facility Mortgagee by way of a standard form of mortgagee’s loss payable endorsement in use in the applicable States and in accordance with any such other requirements as may be established by such Facility Mortgagee; (c) casualty losses must be payable to Landlord or Tenant as provided in ARTICLE XIV, and loss adjustments shall require the written consent of Landlord, any Facility Mortgagee and, provided no Event of Default has occurred and is continuing at the time, Tenant, which consent shall not be unreasonably withheld by either Landlord or Tenant; (d) each insurer must agree that it will give Landlord and any Facility Mortgagee at least thirty (30) days’ written notice before its policy shall be altered, allowed to expire or canceled; (e) except as otherwise provided below, the amount of any deductible or retention in excess of ten percent (10%) of the aggregate per occurrence coverage amount must be approved by Landlord prior to the issuance of any policy, which approval will not be unreasonably withheld, conditioned or delayed; and (f) the form of all policies shall be approved by Landlord and any Existing Facility Mortgagee, whose approval shall not unreasonably be withheld, conditioned or delayed, provided that such policies conform to the requirements of this ARTICLE XIII. Notwithstanding the foregoing, Tenant may obtain so-called “umbrella” policies, comprehensive liability policies and professional liability policies of insurance from non-admitted surplus line carriers acceptable to Landlord.
13.2    Risks to be Insured. The policies covering the Leased Properties and Tenant’s Personal Property shall insure against the following risks:
13.2.1    Loss or damage by fire, vandalism and malicious mischief, earthquake, extended coverage perils commonly known as “Special Risk”, and all physical loss perils normally included in such Special Risk insurance, including but not limited to sprinkler leakage, in an amount not less than one hundred percent (100%) of Replacement Cost; provided that coverage for earthquake shall be required only to the extent that a Facility is currently, or at any time in the future, located within a “seismic design category” on a FEMA Earthquake Hazard Map higher than “B”. Deductibles/self-insured retentions for the insurance policies required under Section 13.2.1 shall not be greater than $100,000 and any deductible or retention in excess of such limit must be approved by Landlord prior to the issuance of any policy, which approval will not be unreasonably withheld, conditioned or delayed.; provided, however, that the deductibles/self-insured retentions for losses sustained from earthquake (including earth movement), or windstorm (i.e., wind/hail) may be equal to, but not greater than, five percent (5%) of the replacement cost of the total insured value of the applicable Facility, or $250,000, whichever is greater. The flood deductible shall not be greater than $100,000, unless the Facility is in the designated 100 year flood plain area, in which event the deductible may be $500,000 or less and the Tenant shall obtain and maintain flood coverage from the National Flood Insurance Program for the applicable Facility.
13.2.2    Loss or damage by explosion of steam boilers, pressure vessels or similar apparatus in such amounts as may be required by Landlord from time to time;
13.2.3    Business interruption insurance in an amount not less than twelve (12) months of income and normal operating expenses including payroll and Rent payable hereunder with an endorsement extending the period of indemnity by at least ninety (90) days (Building Ordinance Increased Period of Restoration Endorsement) necessitated by the occurrence of any of the hazards described in Sections 13.2.1, 13.2.2 and 13.2.56, and, to the extent not covered by such insurance, loss of rental under a rental value insurance policy covering risk of loss during reconstruction necessitated by the occurrence of any of the hazards described in Sections 13.2.1, 13.2.12, and 13.2.56, a (but in no event for a period less than twelve (12) months), in each case in an amount sufficient to prevent Landlord and Tenant from becoming a co‑insurer;
13.2.4    Claims for personal injury or property damage under a policy of commercial general liability insurance with a combined single limit per occurrence in respect of bodily injury and death and property damage of One Million Dollars ($1,000,000.00), and an aggregate limitation of Two Million Dollars ($2,000,000.00) per Facility, which insurance shall insure Tenant’s contractual liability for bodily injury, including death, and property damage to Landlord under the indemnity provisions of ARTICLE XXI of this Lease, and (i) if written on a “claims made” basis, the retroactive date shall be the most recent of (x) the date Tenant or its Affiliates first went into possession of the applicable Facility under this Lease or an Existing Lease, whichever is earlier, and (y) the date that is not less than the longest applicable statute of limitations for general liability claims for the jurisdiction in which the applicable Facility is located, (ii) upon the expiration or termination of this Lease, Tenant shall keep in force the commercial general liability insurance required under this Lease for, or shall acquire or purchase an extended reporting period on the policy existing as of the date of expiration or termination of this Lease that has a term not less than the applicable statute of limitations for general liability claims for each location (iii) if the retroactive date is advanced or the policy is cancelled or not renewed and not replaced with a policy with the same retroactive date, Tenant must acquire or purchase an extended reporting period for such cancelled or non-renewed policy of not less than the applicable statute of limitations for general liability claims for each location;
13.2.5    Claims arising out of malpractice in an amount not less than One Million Dollars ($1,000,000.00) for each occurrence and Three Million ($3,000,000) in the aggregate for each Facility and, if written on a “claims made” basis; the retroactive date shall be the most recent of (x) the date Tenant or its Affiliates first went into possession of the applicable Facility under this Lease or an Existing Lease, whichever is earlier, and (y) the date that is not less than the longest applicable statute of limitations for professional liability claims for the jurisdiction in which the applicable Facility is located, (ii) upon the expiration or termination of this Lease, Tenant shall keep in force the professional liability insurance required under this Lease for, or shall acquire or purchase an extended reporting period on the policy existing as of the date of expiration or termination of this Lease that has a term not less than the applicable statute of limitations for professional liability claims for each location (iii) if the retroactive date is advanced or the policy is cancelled or not renewed and not replaced with a policy with the same retroactive date, Tenant must acquire or purchase an extended reporting period for such cancelled or non-renewed policy of not less than the applicable statute of limitations for professional liability claims for each location;
(a)     Policies required under Sections 13.2.4 and 13.2.5 shall require minimum limits of commercial general liability and professional liability to apply on a per Facility basis, subject however to the current policy aggregate maximum liablities shown on Schedule 13.2.5 attached hereto and made a part hereof;
(b)     Deductibles and self- insured retentions applicable to the coverages required under Sections 13.2.4 and 13.2.5 shall not be greater than $500,000 per claim. Any deductible or retention in excess of such limit must be approved by Landlord prior to the issuance of any policy, which approval will not be unreasonably withheld, conditioned or delayed. Landlord shall have the right to require a lower deductible or self-insured retention (but not less than $100,000) to the extent generally available at commercially affordable rates to Tenant; and
(c) Notwithstanding the coverage required under Section 13.2.5, the Providence, Indiana Facility has and may continue to maintain professional liability coverage of $400,000 for each occurrence and $2,000,000 in the aggregate with additional coverage being provided through the Indiana Patient Compensation Fund for professional liability claims, as the same may be amended from time to time.
13.2.6    Flood (with respect to any portions of the Leased Properties located in whole or in part within a federally designated 100 year flood plain area) and such other hazards and in such amounts as may be customary for comparable properties in the area up to the maximum limit that can be obtained under the Federal Flood Insurance Program;
13.2.7    During such time as Tenant is constructing any improvements, (i) worker’s compensation insurance and employers’ liability insurance covering all persons employed in connection with the improvements in statutory limits, (ii) builder’s risk insurance, completed value form, covering all physical loss, in an amount satisfactory to Landlord, and (iii) such other insurance, in such amounts, as Landlord deems necessary to protect Landlord’s interest in the Leased Properties from any act or omission of Tenant’s contractors or subcontractors, and certificates of insurance evidencing such coverage, in form satisfactory to Landlord, shall be presented to Landlord prior to the commencement of construction of such improvements; and
13.2.8    Primary automobile liability insurance with limits of One Million Dollars ($1,000,000.00) per occurrence each for owned and non‑owned and hired vehicles.
13.3    Payment of Premiums; Copies of Policies; Certificates. Tenant shall pay when due all of the premiums for the insurance required by this Lease, and shall deliver to Landlord and to any Facility Mortgagee requesting such evidence, certificates of insurance in form satisfactory to Landlord and such Facility Mortgagee. Satisfactory evidence of insurance required by this Lease or certificates thereof shall be delivered to Landlord prior to their effective date (and, with respect to any renewal policy, Tenant will use commercially reasonable efforts to provide the same within twenty (20) days but in all events not less than five (5) Business Days prior to the expiration of the existing policy) with copies of such policies to be provided as available, and in the event of the failure of Tenant either to carry the required insurance or pay the premiums therefor, or to deliver copies of policies or certificates to Landlord as required, Landlord shall be entitled, but shall have no obligation, to obtain such insurance and pay the premiums therefor when due, which premiums shall be repayable to Landlord upon written demand therefor as Additional Charges.
13.4    Premium Deposits.    If any provision of a Facility Mortgage requires deposits of premiums for the insurance coverages required hereunder to be made with the Facility Mortgagee, Tenant shall pay to Landlord monthly the amount of such premiums paid by Tenant to third party commercial insurance carriers and Landlord shall transfer such amounts to the Facility Mortgagee, unless, pursuant to written direction by Landlord, Tenant makes such deposits directly with the Facility Mortgagee.
13.5    Umbrella Policies. If Tenant chooses to carry umbrella liability coverage to obtain the limits of liability required under this Lease, the umbrella policies must provide coverage in the same manner as the primary commercial general liability policy and must contain no exclusions in addition to, or limitations materially different than, those of the primary policy.
13.6    Additional Insurance. In addition to the insurance described above, Tenant shall at all times comply with all Legal Requirements with respect to worker’s compensation insurance coverage. From time to time, upon thirty (30) days’ notice, Landlord or any Facility Mortgagee may reasonably require Tenant to change the amount or type of casualty insurance, or to add or substitute additional coverages, to the casualty insurance required to be maintained by Tenant hereunder, which at the time are commonly insured against for property similar to the Leased Properties in the market area in which such property is located provided that such change in the amount or type of coverage is available to Tenant at commercially affordable rates.
13.7    No Liability; Waiver of Subrogation. Landlord shall have no liability to Tenant, and, provided Tenant provides the insurance required of it by this Lease, Tenant shall have no liability to Landlord, regardless of the cause, for any loss or expense resulting from or in connection with damage to or the destruction or other loss of any Leased Property or Tenant’s Personal Property, and neither party will have any right or claim against the other for any such loss or expense by way of subrogation. Each insurance policy carried by either party covering any of the Leased Properties and Tenant’s Personal Property, including without limitation, contents, fire and casualty insurance, shall contain an express waiver of any right of subrogation on the part of the insurer against the other party. Tenant shall pay any additional costs or charges for obtaining such waiver.
13.8    Increase in Limits. From time to time, but not more often than once every two (2) years, in the event that Landlord shall reasonably determine that the limits of the commercial general liability insurance then carried are insufficient when compared to the limits being regularly required by landlords of similar long-term healthcare properties to the Facilities in the market areas in which the Leased Properties are located, Landlord shall give Tenant Notice of acceptable increased limits for such insurance to be carried; and Tenant shall then obtain and maintain such insurance with such increased limits unless and until further increase as permitted under the provisions of this Section. Landlord’s determination of increased limits shall be accompanied by a description of the basis for such determination. If Tenant, in the exercise of its commercially reasonable judgment, objects to Landlord’s determination and Landlord and Tenant are unable to agree upon the matter within fifteen (15) days of Tenant’s receipt of the applicable Notice from Landlord, such determination shall be made by a reputable insurance or risk management consultant or expert with experience in the healthcare insurance industry as mutually identified by Landlord and Tenant in the exercise of their reasonable judgment who shall be responsible for rendering a final determination with respect to the coverage increase in question.
13.9    Blanket Policy. Any insurance required by this Lease may be provided by so‑called blanket policies of insurance carried by Tenant, provided, however, that the coverage afforded Landlord thereby may not thereby be less than or materially different from that which would be provided by a separate policies meeting the requirements of this Lease, and provided further that such policies meet the requirements of all Facility Mortgages.
13.10    No Separate Insurance.
13.10.1    Tenant shall not on its own initiative or pursuant to the request or requirement of any third party, take out separate insurance concurrent in form or contributing in the event of loss with that required by this Lease, to be furnished by, or which may reasonably be required to be furnished by, Tenant, or increase the amount of any then existing insurance by securing an additional policy or additional policies, unless all parties having an insurable interest in the subject matter of the insurance, including in all cases Landlord and all Facility Mortgagees, are named therein as additional insureds, and losses are payable thereunder in the same manner as losses are payable under this Lease.
13.10.2    Nothing herein shall prohibit Tenant, upon Notice to Landlord, from (i) securing insurance required to be carried hereby with higher limits of liability than required in this Lease, or (ii) securing insurance against risks not required to be insured pursuant to this Lease, and as to such insurance, Landlord and any Facility Mortgagee need not be included therein as additional insureds, nor must losses thereunder be payable in the same manner as losses are payable under this Lease, except to the extent required to avoid a default under a Facility Mortgage or any other encumbrance.
13.11    Alternative Coverages. In the event that at any time during the Term the professional liability insurance coverage required under Section 13.2.5 (or general liability coverage as increased pursuant to Section 13.8) is not generally available to operators of skilled nursing facilities in the market area in which the Facilities are located at commercially affordable rates and on commercially reasonable terms and conditions, Landlord agrees that, the provisions of Section 13.2.5 (or Section 13.8) to the contrary notwithstanding, Tenant shall not be required to obtain the coverages required therein and Landlord agrees to accept, which acceptance shall not be unreasonably withheld or conditioned, in place thereof to cover the risk either or a combination of (i) a policy or policies of professional liability (or general liability) insurance limits and coverages that are generally available to operators of skilled nursing facilities in the market area in which the Facilities are located at commercially affordable rates and on commercially reasonable terms and conditions, and/or (ii) an additional security deposit, self-insurance by Tenant, the establishment of a loss reserve to be funded by Tenant and held by Landlord, or other alternative insurance containing commercially reasonable terms and conditions; provided, however, that Tenant shall be obligated to maintain any such insurance with the coverages required by any Legal Requirements. Prior to making any such switch, Tenant shall be obligated to provide Landlord with supporting evidence from its insurance broker or carrier demonstrating the existence of the conditions set forth herein permitting Tenant to do so and the sufficiency of such evidence shall be subject to the advance written approval of Landlord, which shall not be unreasonably withheld, conditioned or delayed. At such time as the professional liability insurance coverages required under Section 13.2.5 (or general liability coverage as increased pursuant to Section 13.8) are available to Tenant at commercially affordable rates and on commercially reasonable terms and conditions, then Tenant shall immediately purchase and provide Landlord with evidence of professional liability insurance coverage necessary to meet the requirements of Section 13.2.5 (or general liability coverage as increased pursuant to Section 13.8). In the event that, as a result of the professional liability coverage required under Section 13.2.5 not being available as provided in this Section 13.11, the general liability insurance coverage required under Section 13.2.4 (as increased pursuant to Section 13.8) is also not available to Tenant at commercially affordable rates and on commercially reasonable terms and conditions, then the provisions of this Section 13.11 shall likewise apply to and include the general liability coverage required under Section 13.2.4 (as increased pursuant to Section 13.8).
13.12    Insurance Captive. For so long as DHSI or its permitted successor is a Guarantor, Tenant may utilize a domestic or foreign licensed insurance captive or establish its own insurance captive (the “Insurance Captive”) to satisfy the professional liability (referred to as malpractice in Section 13.2.5) and general liability insurance requirements (referred to as bodily injury (including resulting death), personal injury or property damage in Section 13.2.3);) (collectively, the “Specified Non-Property Insurance”); provided that such Insurance Captive is (a) a “segregated cell” or Single Parent captive owned, directly or indirectly, by DHSI, (b) in compliance with all Legal Requirements applicable to such Insurance Captive and the issuance of insurance policies in the applicable State, (c) such Insurance Captive is substantially consistent with Tenant’s current alternative “captive” insurance program, and (d) the insurance coverages otherwise comply with this ARTICLE XIII. In addition to the foregoing requirements, and as a condition to use of the Insurance Captive for such insurance coverages, Tenant shall cause the Insurance Captive to comply with the following requirements:
(i)    Maintain a balance sheet liability for reserves, claims, and the estimated costs associated with settling, adjudicating, and otherwise resolving professional liability and general liability claims, in an amount consistent with the expected losses and expenses for each policy year as actuarially determined by an authorized actuary;
(ii)    Charge annual premiums sufficient to fund the actuarially determined expected losses and claim settlement expenses, expenses of operating the Insurance Captive, and a reasonable return on the Insurance Captive’s invested equity and establish and maintain assets in an amount per annum not less than the estimated ultimate losses and costs, discounted in accordance with GAAP;
(iii)    Not make any Distributions to its equity holders or any Affiliates unless it is maintaining adequate capital to cover the actuarially determined expected losses and claim settlement expenses;
(iv)    Preserve and maintain its legal existence and its rights, privileges, franchises, and permits necessary to conduct its business; and
(v)    Not own unrelated businesses, or conduct business of any kind, other than in connection with providing insurance coverage to parties with an insurable interest.
To the extent Tenant chooses to provide any of the Specified Non-Property Insurance otherwise required by this Lease through an Insurance Captive, then Tenant and DHSI shall have all of the obligations and liabilities of an insurer, and the protection afforded Landlord, any Facility Mortgagee, and each Facility shall be the same as if provided by a non-affiliated third-party insurer under the coverages required under this Lease. Without limiting the generality of the foregoing, all amounts which a “captive” insurer pays or is required to pay and all losses or damages resulting from risks for which Tenant has elected to maintain an alternative “captive” insurance program with respect to shall be subject to the waiver of subrogation provisions of Section 13.7, and shall not limit any of Tenant’s indemnification obligations pursuant to this Lease. In the event that Tenant elects to maintain an Insurance Captive and an event or claim occurs for which a defense and/or coverage would have been available from a third-party insurer, Tenant and DHSI shall undertake to cause its Insurance Captive to undertake the defense of any such claim, including a defense of Landlord, at their sole cost and expense, and use their own funds to pay any claim or replace any property or otherwise provide the funding which would have been available from insurance proceeds but for such election by Tenant to maintain an alternative “captive” insurance program. In the event that Tenant elects to maintain an Insurance Captive pursuant to this Section 13.12, Tenant shall provide Landlord and any Facility Mortgagee with certificates of insurance specifying the extent of such insurance coverage and Tenant shall provide Landlord with a copy of the Insurance Captive’s audited financial statements on an annual basis. Notwithstanding anything to the contrary in this Section 13.12, Tenant shall not have the right to satisfy its insurance obligations under Sections 13.2.1, 13.2.2, 13.2.3, or 0 by means of an Insurance Captive. In the event that Tenant converts any insurance provided through an Insurance Captive to insurance provided by a non-affiliated third-party insurer, Tenant shall provide to Landlord evidence of such insurance concurrently with the effectiveness thereof.
ARTICLE XIV    
14.1    Insurance Proceeds. Net Proceeds shall be paid to Landlord and held, disbursed or retained by Landlord as provided herein.
14.1.1    Proceeds of Special Risk Insurance. If the Net Proceeds are less than the Approval Threshold, and no Event of Default has occurred and is continuing, Landlord shall pay the Net Proceeds to Tenant promptly after Landlord receives the Net Proceeds and Tenant shall apply the Net Proceeds solely to the completion of the restoration of the damaged or destroyed Leased Property. If the Net Proceeds equal or exceed the Approval Threshold, and no Event of Default has occurred and is continuing, the Net Proceeds shall be made available for restoration or repair as provided in Section 14.6. Within fifteen (15) days of the receipt of the Net Proceeds of Special Risk Insurance, Landlord and Tenant shall agree as to the portion thereof, if any, attributable to the Tenant’s Personal Property that Tenant is not required and does not elect to restore or replace, and if they cannot agree they shall submit the matter to arbitration pursuant to ARTICLE XXXVI hereof, and the portion of the proceeds of such Special Risk Insurance agreed or determined by arbitration to be attributable to the Tenant’s Personal Property that Tenant is not required and does not elect to restore or replace shall be paid to Tenant.
14.2    Restoration in the Event of Damage or Destruction.    If all or any portion of a Leased Property is damaged by fire or other casualty, Tenant shall (a) give Landlord Notice of such damage or destruction within five (5) Business Days of the occurrence thereof, (b) within sixty (60) days of the occurrence commence the restoration of such Leased Property and (c) thereafter diligently proceed to complete such restoration to substantially the same (or better) condition as such Leased Property was in immediately prior to the damage or destruction as quickly as is reasonably possible, but subject to Force Majeure, in any event within two hundred forty (240) days of the occurrence. Regardless of the anticipated cost thereof, if the restoration of a Leased Property requires any modification of structural elements, prior to commencing such modification Tenant shall obtain Landlord’s written approval of the plans and specifications therefor. In performing such restoration or repair, and as a condition to Tenant’s obligation to restore or repair the Leased Property, the Net Proceeds payable with respect to such damage or destruction shall be paid or disbursed to Tenant as provided in Section 14.1 or Section 14.7 hereof. If there remains any surplus of Net Proceeds after completion of the repair or restoration of the Leased Property, such surplus shall belong and be paid to Tenant.
14.3    Restoration of Tenant’s Property. Notwithstanding the foregoing terms of Section 14.1, all insurance proceeds payable by reason of or damage to any of Tenant’s Personal Property shall be paid to Tenant and Tenant shall hold such insurance proceeds in trust to pay the cost of repairing or replacing damaged Tenant’s Personal Property. If Tenant is required to restore a Leased Property, Tenant shall also concurrently restore any of Tenant’s Personal Property that is integral to the Primary Intended Use of such Leased Property at the time of the damage or destruction.
14.4    No Abatement of Rent. Absent termination of this Lease as provided herein, there shall be no abatement of Rent by reason of any damage to or the partial or total destruction of any Leased Property.
14.5    Waiver. Except as provided elsewhere in this Lease, Tenant hereby waives any statutory or common law rights of termination which may arise by reason of any damage to or destruction of a Leased Property.
14.6    Extension of Time Periods. In the event that Tenant is unable to complete any action required by this ARTICLE XIV in the time period provided, and Tenant establishes to the reasonable satisfaction of Landlord that Tenant has been acting in good faith and diligently, then Landlord shall grant to Tenant a reasonable extension of time in which to complete the repair or reconstruction of any damaged Facility, prior to the time that Tenant would otherwise be required to repurchase such damaged Facility.
14.7    Disbursement of Insurance Proceeds Equal to or Greater Than The Approval Threshold. If Tenant restores or repairs a Leased Property pursuant to this ARTICLE XIV, and if the Net Proceeds equal or exceed the Approval Threshold, the restoration or repair and disbursement of funds to Tenant shall be in accordance with the following procedures:
(i)    The restoration or repair work shall be done pursuant to plans and specifications approved by Landlord and a certified construction cost statement, to be obtained by Tenant from a contractor reasonably acceptable to Landlord, showing the total cost of the restoration or repair; to the extent the cost exceeds the Net Proceeds, Tenant shall deposit with Landlord the amount of the excess cost, and Landlord shall disburse the funds so deposited in payment of the costs of restoration or repair before any disbursement of Net Proceeds.
(ii)    Construction Funds shall be made available to Tenant upon request, no more frequently than monthly, as the restoration and repair work progresses, pursuant to certificates of an architect selected by Tenant that, in the judgment of Landlord, reasonably exercised, is highly qualified in the design and construction of the type of Facility being repaired and is otherwise reasonably acceptable to Landlord, which certificates must be in form and substance reasonably acceptable to Landlord. Payment of Construction Funds shall be subject to a ten percent (10%) holdback until the architect certifies that the work is fifty percent (50%) complete, after which, so long as there is no Event of Default under this Lease and so long as the architect certifies that work is proceeding in accordance with the schedule and budget, there shall be no further retainage.
(iii)    After the first disbursement to Tenant, sworn statements and lien waivers in an amount at least equal to the amount of Construction Funds previously paid to Tenant shall be delivered to Landlord from all contractors, subcontractors and material suppliers covering all labor and materials furnished through the date of the previous disbursement.
(iv)    Tenant shall deliver to Landlord such other evidence as Landlord may reasonably request from time to time during the course of the restoration and repair, as to the progress of the work, compliance with the approved plans and specifications, the cost of restoration and repair and the total amount needed to complete the restoration and repair, and showing that there are no liens against such Leased Property arising in connection with the restoration and repair and that the cost of the restoration and repair at least equals the total amount of Construction Funds then disbursed to Tenant hereunder.
(v)    If the Construction Funds are at any time determined by Landlord to be inadequate for payment in full of all labor and materials for the restoration and repair, Tenant shall immediately pay the amount of the deficiency to Landlord to be held and disbursed as Construction Funds prior to the disbursement of any other Construction Funds then held by Landlord.
(vi)    The Construction Funds may be disbursed by Landlord to Tenant or to the persons entitled to receive payment thereof from Tenant, and such disbursement in either case may be made directly or through a third party escrow agent, such as, but not limited to, a title insurance company, or its agent, all as Landlord may determine in its sole discretion. Provided Tenant is not in default hereunder, any excess Construction Funds shall be paid to Tenant upon completion of the restoration or repair.
(vii)    If Tenant at any time fails to promptly and fully perform the conditions and covenants set out in subparagraphs (i) through (vi) above, and the failure is not corrected within ten (10) days of written Notice thereof, or if during the restoration or repair an Event of Default occurs hereunder, Landlord may, at its option, immediately cease making any further payments to Tenant for the restoration and repair.
(viii)    Landlord may reimburse itself out of the Construction Funds for its reasonable expenses incurred in administering the Construction Funds and inspecting the restoration and repair work, including without limitation attorneys’ and other professional fees and escrow fees and expenses.
(ix)    If damage or destruction shall occur either (a) during the final Lease Year of the Initial Term and Tenant has not exercised its option to extend the Term of this Lease pursuant to Section 1.3 above or (b) during the final Lease Year of the Renewal Term, then Landlord, at Landlord’s sole option, may elect to terminate the Lease as to the affected Facility (in which case Tenant shall surrender possession of the affected Facility and Tenant shall transfer to Landlord all of Tenant’s interest in the Facility, including, without limitation, Tenant’s interest in the licenses pursuant to which the Facility is then operated) and receive the Net Proceeds in lieu of Tenant restoring or repairing the damage or destruction. The election to terminate the Lease as to the affected Facility and receive the Net Proceeds pursuant to this Section 14.7(ix) must be exercised by Landlord by Notice to Tenant on or prior to the tenth (10th) Business Day following Landlord’s receipt of Notice of such event of damage or destruction. If Landlord elects to terminate the Lease as to the affected Facility and receive the Net Proceeds in lieu of Tenant restoring or repairing the damage or destruction, then, as of the Proceeds Date, the annual Minimum Rent (and any 7.0% Upgrade Rent or 9.0% Improvements Rent applicable to the affected Facility) due under this Lease during the remainder of the Term shall be reduced by an amount equal to the product of the Casualty/Condemnation Reduction Amount and the amount of the Security Deposit will be reset at an amount equal to three months of the annual Base Rent (exclusive of the Avon Rent) after giving effect to the reduction.
14.8    Net Proceeds Paid to Facility Mortgagee. Notwithstanding anything herein to the contrary, if any Facility Mortgagee is entitled to any Net Proceeds, or any portion thereof, under the terms of any Facility Mortgage, the Net Proceeds shall be applied, held and/or disbursed in accordance with the terms of the Facility Mortgage. Landlord shall make commercially reasonable efforts to cause the Net Proceeds to be applied to the restoration of the Leased Property. If the Facility Mortgagee elects to apply the insurance proceeds to the indebtedness secured by the Facility Mortgage, Tenant shall either (i) restore the Facility to substantially the same (or better) condition as existed immediately before the damage or destruction, or (ii) terminate this Lease as to such Leased Property upon Notice to Landlord, such termination to be effective as of the first day of the calendar month following the later of (a) the date Tenant learns of the action of the Facility Mortgagee or (b) fifteen (15) days after the date Landlord learns of the action of the Facility Mortgagee, unless within fifteen (15) days of the notice from the Facility Mortgagee the Landlord agrees to make available to Tenant for restoration to or repair of the Leased Property funds equal to the amount applied by the Facility Mortgagee. Unless the damage or destruction is such as to entitle Landlord or Tenant to otherwise terminate this Lease as to such Facility under this ARTICLE XIV and Landlord or Tenant, as the case may be, shall fail to elect to terminate this Lease as to such Facility, in the time and in the manner provided, Landlord shall disburse such funds to Tenant as provided in Section 14.7 of this Master Lease and Tenant shall restore the Leased Property (as nearly as possible under the circumstances) to a complete architectural unit of the same general character and condition as the Leased Property existing immediately prior to such damage or destruction.
In the event this Master Lease is so terminated as to such Facility (in which case Tenant shall surrender possession of the affected Facility and Tenant shall transfer to Landlord all of Tenant’s interest in the Facility, including, without limitation, Tenant’s interest in the licenses pursuant to which the Facility is then operated), as of the Proceeds Date, the annual Minimum Rent (and any 7.0% Upgrade Rent or 9.0% Improvements Rent applicable to the affected Facility) due under this Lease during the remainder of the Term shall be reduced by an amount equal to the Casualty/Condemnation Reduction Amount and the amount of the Security Deposit will be reset at an amount equal to three months of the annual Base Rent (exclusive of the Avon Rent) after giving effect to the reduction.
ARTICLE XV    
15.1    Total Taking or Other Taking with Leased Property Rendered Unsuitable for Its Primary Intended Use. If title to the fee of the whole of a Leased Property is Taken, this Lease shall cease and terminate as to the Leased Property Taken as of the Date of Taking by the Condemnor and Rent shall be apportioned as of the termination date. If title to the fee of less than the whole of a Leased Property is Taken, but such Leased Property is thereby rendered Unsuitable for Its Primary Intended Use, Tenant and Landlord shall each have the option by written Notice to the other, at any time prior to the taking of possession by, or the date of vesting of title in, the Condemnor, whichever first occurs, to terminate this Lease with respect to such Leased Property as of the date so determined, in which event this Lease shall thereupon so cease and terminate as of the earlier of the date specified in such Notice or the date on which possession is taken by the Condemnor. If this Lease is so terminated as to a Leased Property (in which case Tenant shall surrender possession of the affected Facility and Tenant shall transfer to Landlord all of Tenant’s interest in the Facility, including, without limitation, Tenant’s interest in the licenses pursuant to which the Facility is then operated), as of the Proceeds Date, the annual Minimum Rent (and any 7.0% Upgrade Rent or 9.0% Improvements Rent applicable to the affected Facility) due under this Lease during the remainder of the Term shall be reduced by an amount equal to the Casualty/Condemnation Reduction Amount and the amount of the Security Deposit will be reset at an amount equal to three months of the annual Base Rent ( exclusive of the Avon Rent) after giving effect to the reduction.
15.2    Allocation of Award. The total Award made with respect to all or any portion of a Leased Property or for loss of Rent, or for loss of business, shall be solely the property of and payable to Landlord. Nothing contained in this lease will be deemed to create any additional interest in Tenant, or entitle Tenant to any payment based on the value of the unexpired term or so‑called “bonus value” to Tenant of this Lease. Any Award made for the taking of Tenant’s Personal Property, or for removal and relocation expenses of Tenant in any such proceedings shall be payable to Tenant. In any proceedings with respect to an Award, Landlord and Tenant shall each seek its own Award in conformity herewith, at its own expense. Notwithstanding the foregoing, Tenant may pursue a claim for loss of its business, provided that under the laws of the State, such claim will not diminish the Award to Landlord.
15.3    Partial Taking. In the event of a Partial Taking, Tenant, at its own cost and expense, shall within sixty (60) days of the taking of possession by, or the date of vesting of title in, the Condemnor, whichever first occurs, commence the restoration of the affected Leased Property to a complete architectural unit of the same general character and condition (as nearly as may be possible under the circumstances) as existed immediately prior to the Partial Taking, and complete such restoration with all reasonable dispatch, but in any event, subject to Force Majeure, within two hundred forty (240) days of the date on which such Notice is given. Landlord shall contribute to the cost of restoration such portion of the Award as is made therefor, together with severance and other damages awarded for Leased Improvements Taken; provided, however, that the amount of such contribution shall not exceed such cost. As long as no Event of Default has occurred and is continuing, if such portion of the Award is in an amount less than the Approval Threshold, Landlord shall pay the same to Tenant upon commencement of such restoration. As long as no Event of Default has occurred and is continuing, if such portion of the Award is in an amount equal to or greater than the Approval Threshold, Landlord shall make such portion of the Award available to Tenant in the manner provided in Section 14.6 with respect to Net Proceeds in excess of the Approval Threshold. Notwithstanding anything to the contrary elsewhere herein, if the Fair Market Rent of the affected Leased Property is reduced by reason of the Partial Taking, from and after the date on which possession is taken by the Condemnor the annualized Base Rent shall be reduced by an amount determined by dividing the portion of the Award made to Landlord expressly for such reduction in Fair Market Rent by the Capitalization Rate and the amount of the Security Deposit will be reset at an amount equal to three months of the annual Base Rent (exclusive of the Avon Rent) after giving effect to the reduction.
15.4    Temporary Taking. If there is a Taking of possession or the use of all or part of a Leased Property, but the fee of such Leased Property is not Taken in whole or in part, until such Taking of possession or use continues for more than six (6) months, all the provisions of this Lease shall remain in full force and effect and the entire amount of any Award made for such Taking shall be paid to Tenant provided there is then no Event of Default. Upon the termination of any such period of temporary use or occupancy, Tenant at its sole cost and expense shall restore the affected Leased Property, as nearly as may be reasonably possible, to the condition existing immediately prior to such Taking. If any temporary Taking continues for longer than six (6) months, and fifty percent (50%) or more of the patient capacity of the affected Facility is thereby rendered Unsuitable for Its Primary Use, such Taking shall be considered a Total Taking governed by Section 15.1 and this Lease shall cease and terminate as to the affected Leased Property only as of the last day of the sixth (6th) month, but if less than fifty percent (50%) of the patient capacity of such Facility is thereby rendered Unsuitable for Its Primary Use, Tenant and Landlord shall each have the option by at least sixty (60) day’s prior written Notice to the other, at any time prior to the end of the temporary taking, to terminate this Lease as to the affected Leased Property of the date set forth in such Notice, and Tenant shall be entitled to any Award made for the period of such temporary Taking prior to the date of termination of the Lease. Rent shall not abate during the period of any temporary Taking.
15.5    Awards Paid to Facility Mortgagee. Notwithstanding anything herein to the contrary, if any Facility Mortgagee is entitled to any Award or any portion thereof, under the terms of any Facility Mortgage such Award shall be applied, held and/or disbursed in accordance with the terms of the Facility Mortgage. If the Facility Mortgagee elects to apply the Award to the indebtedness secured by the Facility Mortgage: (i) if the Award represents an Award for Partial Taking as described in Section 15.3 above, Tenant shall restore the affected Facility (as nearly as possible under the circumstances) to a complete architectural unit of the same general character and condition as that of the Facility existing immediately prior to such Taking; or (ii) if the Award represents an Award for a Total Taking as described in Section 15.1 above, Tenant shall transfer to Landlord all of Tenant’s interest in the Facility, including, without limitation, Tenant’s interest in the licenses pursuant to which the Facility is then operated. In any such restoration or purchase, Tenant shall receive full credit for any portion of any Award retained by Landlord and the Facility Mortgagee, and as of the Proceeds Date, the annual Minimum Rent (and any 7.0% Upgrade Rent or 9.0% Improvements Rent applicable to the affected Facility) shall be reduced by an amount equal to the Casualty/Condemnation Reduction Amount and the amount of the Security Deposit will be reset at an amount equal to three months of the annual Base Rent (exclusive of the Avon Rent) after giving effect to the reduction.
15.6    Extension of Time Periods. In the event that Tenant is unable to complete any action required by this ARTICLE XV in the time period provided, and Tenant establishes to the reasonable satisfaction of Landlord that Tenant has been acting in good faith and diligently, then Landlord shall grant to Tenant a reasonable extension of time in which to complete the repair or reconstruction of any Facility subject to Taking, prior to the time that Tenant would otherwise be required to repurchase such Facility subject to a Taking.
ARTICLE XVI    
16.1    Landlord’s Rights Upon an Event of Default.
16.1.1    If an Event of Default shall occur Landlord may terminate this Lease by giving Tenant a Notice of Termination in accordance with the laws of the States in which each Facility is located, and in such event, the Term shall end and all rights of Tenant under this Lease shall cease on the Termination Date specified in the Notice of Termination. In addition to Landlord’s right to terminate this Lease, Landlord shall have all other rights set forth in this Lease and all remedies available at law and in equity.
16.1.2    Tenant shall, to the extent permitted by law, pay as Additional Charges all costs and expenses incurred by or on behalf of Landlord, including, without limitation, reasonable attorneys’ fees and expenses (whether or not litigation is commenced, and if litigation is commenced, including fees and expenses incurred in appeals and post-judgment proceedings) as a result of any default of Tenant hereunder. Landlord shall, to the extent permitted by law, pay Tenant all costs and expenses incurred by or on behalf of Tenant, including, without limitation, reasonable attorneys’ fees and expenses (whether or not litigation is commenced, and if litigation is commenced, including fees and expenses incurred in appeals and post-judgment proceedings) as a result of any default of Landlord hereunder.
16.1.3    No Event of Default (other than a failure to make payment of money) shall be deemed to exist if and for so long as Tenant is unable to prevent such Event of Default because of Force Majeure, provided that upon the cessation of such Force Majeure, Tenant shall forthwith proceed to remedy the action or condition giving rise to such Event of Default within the applicable cure period as extended by such Force Majeure.
16.2    Certain Remedies. If an Event of Default shall occur, whether or not this Lease has been terminated pursuant to Section 16.1, if required to do so by Landlord Tenant shall immediately surrender the Leased Properties to Landlord in the condition required by Section 9.1.5 and quit the same, and Landlord may enter upon and repossess the Leased Properties by reasonable force, summary proceedings, ejectment or otherwise, and may remove Tenant and all other persons and any and all personal properties from the Leased Properties, subject to rights of any residents or patients and to any Legal Requirements. In addition to all other remedies set forth or referred to in this ARTICLE XVI, Landlord shall have the right to suspend any Management Agreement as to one or more or all Facilities and to retain a manager of the affected Facility or all Facilities at the expense of Tenant, such manager to serve for such term and at such compensation as Landlord reasonably determines is necessary under the circumstances.
16.3    Damages. Neither (i) the termination of this Lease pursuant to Section 16.1, (ii) the repossession of the Leased Properties, (iii) the failure of Landlord to relet the Leased Properties, (iv) the reletting of all or any portion thereof, nor (v) the failure of Landlord to collect or receive any rentals due upon such any reletting, shall relieve Tenant of its liability and obligations hereunder, all of which shall survive any such termination, repossession or reletting. In the event this Lease is terminated by Landlord, Tenant shall forthwith pay to Landlord all Rent due and payable with respect to the Leased Properties to and including the Termination Date, including without limitation all interest and late charges payable under Section 3.3 hereof with respect to any late payment of such Rent. Tenant shall also pay to Landlord, as liquidated damages, at Landlord’s option, either:
(A)
The sum of:

(i)    Landlord’s Interim Rent Loss, minus Net Reletting Proceeds for such period, and minus the portion of Landlord’s Interim Rent Loss, if any, that Tenant prove could reasonably have been mitigated by Landlord, plus
(ii)    the Present Value on the Judgment Date of Landlord’s Future Rent Loss, assuming the Cost of Living Index were to increase four (4) percentage points per Lease Year from the Judgment Date through the Expiration Date, minus the Present Value on the Termination Date of the portion of Landlord’s Future Rent Loss that Tenant proves could reasonably be mitigated by Landlord;
or
(B)    Each month between the Termination Date and the Expiration Date, Landlord’s Monthly Rent Loss, minus the Net Reletting Proceeds for such month, and minus the portion, if any, of Landlord’s Monthly Rent Loss that Tenant proves could reasonably have been avoided. Any suit brought to recover liquidated damages payable under this subsection “(B)” shall not prejudice Landlord’s right to collect liquidated damages for subsequent months in a similar proceeding.
16.4    Intentionally Omitted.
16.5    Waiver. If this Lease is terminated pursuant to Section 16.1, Tenant waives, to the extent permitted by applicable law, (i) any right of reentry, repossession or redesignation, (ii) any right to a trial by jury in the event of summary proceedings to enforce the remedies set forth in this ARTICLE XVI, and (iii) the benefit of any laws now or hereafter in force exempting property from liability for rent or for debt. Acceptance of Rent at any time does not prejudice or remove any right of Landlord as to any right or remedy. No course of conduct shall be held to bar Landlord from literal enforcement of the terms of this Lease.
16.6    Application of Funds. Any payments received by Landlord under any of the provisions of this Lease during the existence or continuance of any Event of Default shall be applied to Tenant’s obligations in the order which Landlord may determine or as may be prescribed by law.
16.7    Bankruptcy.
(a)
Neither Tenant’s interest in this Lease, nor any estate hereby created in Tenant’s interest nor any interest herein or therein, shall pass to any trustee or receiver or assignee for the benefit of creditors or otherwise by operation of law, except as may specifically be provided pursuant to the Bankruptcy Code (11 USC Section 101 et. seq.), as the same may be amended from time to time.
    (b)    Rights and Obligations Under the Bankruptcy Code.
(1)
Upon filing of a petition by or against Tenant under the Bankruptcy Code, Tenant, as debtor and as debtor‑in‑possession, and any trustee who may be appointed with respect to the assets of or estate in bankruptcy of Tenant, agree to pay monthly in advance on the fifteenth (15th) day of each month, as reasonable compensation for the use and occupancy of the Leased Premises, an amount equal to all Rent due pursuant to this Lease.
(2)
Included within and in addition to any other conditions or obligations imposed upon Tenant or its successor in the event of the assumption and/or assignment of the Lease are the following: (i) the cure of any monetary defaults and reimbursement of pecuniary loss within not more than thirty (30) days of assumption and/or assignment; (ii) the deposit of an additional amount equal to not less than three (3) months’ Base Rent, which amount is agreed to be a necessary and appropriate deposit to secure the future performance under the Lease of Tenant or its assignee; (iii) the continued use of the Leased Premises for the Primary Intended Use; and (iv) the prior written consent of any Facility Mortgagee.
ARTICLE XVII    
17.1    Landlord’s Right to Cure Tenant’s Default. If Tenant fails to make any payment or perform any act required to be made or performed under this Lease, and fails to cure the same within any grace or cure period applicable thereto, upon such Notice as may be expressly required herein (or, if Landlord reasonably determines that the giving of such Notice would risk loss to the Leased Properties or cause damage to Landlord, upon such Notice as is practical under the circumstances), and without waiving or releasing any obligation of Tenant, Landlord may make such payment or perform such act for the account and at the expense of Tenant, and may, to the extent permitted by law, enter upon the Leased Properties for such purpose and take all such action thereon as, in Landlord’s sole opinion, may be necessary or appropriate. No such entry shall be deemed an eviction of Tenant. All amounts so paid by Landlord and all costs and expenses (including, without limitation, reasonable attorneys’ fees and expenses) so incurred, together with the late charge and interest provided for in Section 3.3 thereon, shall be paid by Tenant to Landlord on demand. The obligations of Tenant and rights of Landlord contained in this Article shall survive the expiration or earlier termination of this Lease.
ARTICLE XVIII    
18.1    Holding Over. If Tenant remains in possession of all or any of the Leased Properties after the expiration of the Term or earlier termination of this Lease, such possession shall be as a month‑to‑month tenant, and throughout the period of such possession Tenant shall pay as Rent for each month one and one-half (1.5) times the sum of:(i) one‑twelfth (1/12th) of the Base Rent payable during the Lease Year in which such expiration or termination occurs, plus (ii) all Additional Charges accruing during the month, plus (iii) any and all other sums payable by Tenant pursuant to this Lease. During such period of month‑to‑month tenancy, Tenant shall be obligated to perform and observe all of the terms, covenants and conditions of this Lease, but shall have no rights hereunder other than the right, to the extent given by applicable law to month‑to‑month tenancies, to continue its occupancy and use of the Leased Properties until the month‑to‑month tenancy is terminated. Nothing contained herein shall constitute the consent, express or implied, of Landlord to the holding over of Tenant after the expiration or earlier termination of this Lease.
18.2    Indemnity. If Tenant fails to surrender the Leased Properties in a timely manner and in accordance with the provisions of Section 9.1.5 upon the expiration or termination of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall defend, indemnify and hold Landlord, its principals, officers, directors, agents and employees harmless from loss or liability resulting from such failure, including, without limiting the generality of the foregoing, loss of rental with respect to any new lease in which the rental payable thereunder exceeds the Rent paid by Tenant pursuant to this Lease during Tenant’s hold-over and any claims by any proposed new tenant founded on such failure. The provisions of this Section 18.2 shall survive the expiration or termination of this Lease.
ARTICLE XIX    
19.1    Subordination. Upon written request of Landlord, any Facility Mortgagee, or the beneficiary of any deed of trust of Landlord, Tenant will enter into a written agreement subordinating its rights pursuant to this Lease (i) to the lien of any mortgage, deed of trust or the interest of any lease in which Landlord is the tenant and to all modifications, extensions, substitutions thereof (or, at Landlord’s option, agree to the subordination to this Lease of the lien of said mortgage, deed of trust or the interest of any lease in which Landlord is the tenant), and (ii) to all advances made or hereafter to be made thereunder. In connection with any such request, Landlord shall provide Tenant with a “Non‑Disturbance Agreement” reasonably acceptable to such mortgagee, beneficiary or landlord providing that if such mortgagee, beneficiary or landlord acquires the Leased Properties by way of foreclosure or deed in lieu of foreclosure, such mortgagee, beneficiary or landlord will not disturb Tenant’s possession under this Lease and will recognize Tenant’s rights hereunder if and for so long as no Event of Default has occurred and is continuing. Tenant agrees to consent to amend this Lease as reasonably required by any Facility Mortgagee, and shall be deemed to have unreasonably withheld or delayed its consent if the required changes do not materially (i) alter the economic terms of this Lease, (ii) diminish the rights of Tenant, or (iii) increase the obligations of Tenant, provided that Tenant shall also have received the non‑disturbance agreement provided for in this Article.
19.2    Attornment. If any proceedings are brought for foreclosure, or if the power of sale is exercised under any mortgage or deed of trust made by Landlord encumbering the Leased Properties, or if a lease in which Landlord is the tenant is terminated, Tenant shall attorn to the purchaser or landlord under such lease upon any foreclosure or deed in lieu thereof, sale or lease termination and recognize the purchaser or landlord as Landlord under this Lease, provided the purchaser or landlord acquires and accepts the Leased Properties subject to this Lease.
19.3    Tenant’s Certificate. Tenant shall, upon not less than ten (10) days prior Notice from Landlord, execute, acknowledge and deliver to Landlord a Tenant’s Certificate containing then-current facts. It is intended that any Tenant’s Certificate delivered pursuant hereto may be relied upon by Landlord, any prospective tenant or purchaser of the Leased Properties, any mortgagee or prospective mortgagee, and by any other party who may reasonably rely on such statement. Tenant’s failure to deliver the Tenant’s Certificate within such time shall constitute an Event of Default. In addition, Tenant hereby authorizes Landlord to execute and deliver a certificate to the effect (if true) that Tenant represents and warrants that (i) this Lease is in full force and effect without modification, and (ii) Landlord is not in breach or default of any of its obligations under this Lease.
ARTICLE XX    
20.1    Risk of Loss. During the Term, the risk of loss or of decrease in the enjoyment and beneficial use of the Leased Properties in consequence of the damage or destruction thereof by fire, the elements, casualties, thefts, riots, wars or otherwise, or in consequence of foreclosures, attachments, levies or executions (other than those caused by Landlord and those claiming from, through or under Landlord) is assumed by Tenant, and, in the absence of gross negligence, willful misconduct or material breach of this Lease by Landlord, Landlord shall in no event be answerable or accountable therefor nor shall any of the events mentioned in this Section entitle Tenant to any abatement of Rent, except as specifically provided in this Lease.
ARTICLE XXI    
21.1    Indemnification. Notwithstanding the existence of any insurance or self‑insurance provided for in ARTICLE XIII, and without regard to the policy limits of any such insurance or self‑insurance, and except with respect to Pre-Existing Environmental Conditions to the extent provided for in Section 7.3(l), Tenant shall protect, indemnify, save harmless and defend Landlord, its principals, officers, directors and agents and employees from and against all liabilities, obligations, claims, damages, penalties, causes of action, costs and expenses (including, without limitation, reasonable attorneys’ fees and expenses), to the extent permitted by law, imposed upon or incurred by or asserted against Landlord by reason of: (i) any accident, injury to or death of persons or loss of or damage to property occurring on or about the Leased Properties or adjoining sidewalks prior to or during the Term, including without limitation any claims of malpractice, (ii) any use, misuse, non‑use, condition, maintenance or repair by Tenant or its Affiliates of the Leased Properties, (iii) the failure to pay any Impositions as herein provided which are the obligation of Tenant to pay pursuant to this Lease, (iv) any failure on the part of Tenant to perform or comply with any of the terms of this Lease, and (v) the nonperformance of any contractual obligation, express or implied, assumed or undertaken by Tenant or any party in privity with Tenant with respect to the Leased Properties or any business or other activity carried on with respect to the Leased Properties prior to or during the Term or thereafter during any time in which Tenant, any Affiliate of Tenant or any such other party is in possession of the Leased Properties or thereafter to the extent that any conduct by Tenant, any Affiliate of Tenant or any such party (or failure of such conduct thereby if the same should have been undertaken during such time of possession and leads to such damage or loss) causes such loss or claim. Any amounts which become payable by Tenant under this Section shall be paid within ten (10) Business Days after liability therefor on the part of Tenant is determined by litigation or otherwise, and if not timely paid, shall bear interest (to the extent permitted by law) at the Overdue Rate from the date of such determination to the date of payment. Nothing herein shall be construed as indemnifying Landlord against its own grossly negligent acts or omissions or willful misconduct.
Landlord shall indemnify, save harmless and defend Tenant from and against all liabilities, obligations, claims, damages, penalties, causes of action, costs and expenses imposed upon or incurred by or asserted against Tenant as a result of the gross negligence or willful misconduct of Landlord.
Tenant’s or Landlord’s liability for a breach of the provisions of this Article arising during the Term hereof shall survive any termination of this Lease for three (3) years following any termination of this Lease, provided that Tenant’s obligations to indemnify Landlord with respect to environmental matters shall continue for six (6) years after such termination.
ARTICLE XXII    
22.1    General Prohibition against Transfers. Tenant acknowledges that a significant inducement to Landlord to enter into this Lease with Tenant on the terms set forth herein is the combination of financial strength, experience, skill and reputation possessed by the Tenant named herein, the Person or Persons in Control of Tenant, the Guarantor(s) (if any) and the Manager of the Facilities on the Commencement Date, together with Tenant’s assurance that Landlord shall have the unrestricted right to approve or disapprove any proposed Transfer. Therefore, there shall be no Transfer except as specifically permitted by this Lease or consented to in advance by Landlord in writing. Tenant agrees that Landlord shall have the right to withhold its consent to any proposed Transfer on the basis of Landlord’s judgment as to the effect the proposed Transfer may have on the Facilities and the future performance of the obligations of the Tenant under this Lease, whether or not Tenant agrees with such judgment. Any attempted Transfer which is not specifically permitted by this Lease or consented to by Landlord in advance in writing shall be null and void and of no force and effect whatsoever. In the event of a Transfer, Landlord may collect Rent and other charges from the Transferee and apply the amounts collected to the Rent and other charges herein reserved, but no Transfer or collection of Rent and other charges shall be deemed to be a waiver of Landlord’s rights to enforce Tenant’s covenants or an acceptance of the Transferee as Tenant, or a release of the Tenant named herein from the performance of its covenants. Notwithstanding any Transfer, Tenant shall remain fully liable for the performance of all terms, covenants and provisions of this Lease. Any violation of this Lease by any Transferee shall be deemed to be a violation of this Lease by Tenant.
22.2    Subordination and Attornment. Tenant shall insert in any sublease permitted by Landlord provisions to the effect that (i) such sublease is subject and subordinate to all of the terms and provisions of this Lease and to the rights of Landlord hereunder, (ii) if this Lease terminates before the expiration of such sublease, the subtenant thereunder will, at Landlord’s option, attorn to Landlord and waive any right the subtenant may have to terminate the sublease or to surrender possession thereunder, as a result of the termination of this Lease, and (iii) if the subtenant receives a written Notice from Landlord or Landlord’s assignee, if any, stating that Tenant is in default under this Lease, the subtenant shall thereafter be obligated to pay all rentals accruing under the sublease directly to the party giving such Notice, or as such party may direct, which payments shall be credited against the amounts owing by Tenant under this Lease.
22.3    Sublease Limitation. Anything contained in this Lease to the contrary notwithstanding, even if a sublease of a Leased Property is permitted, Tenant shall not sublet such Leased Property on any basis such that the rental to be paid by the subtenant thereunder would be based, in whole or in part, on either (i) the income or profits derived by the business activities of the subtenant, or (ii) any other formula such that any portion of the sublease rental received by Landlord would fail to qualify as “rents from real property” within the meaning of Section 856(d) of the Code, or any similar or successor provision thereto. The parties agree that this paragraph shall not be deemed waived or modified by implication, but may be waived or modified only by an instrument in writing explicitly referring to this paragraph by number.
22.4    Permitted Sublease. Tenant shall be entitled to sublease any Leased Property in its entirety to an Affiliate of Tenant upon Tenant’s written acknowledgment, provided that (i) Tenant submits an original copy of any such sublease to Landlord for its reasonable approval and written acknowledgment prior to the date of commencement of same, which such sublease shall memorialize that the subtenant shall be fully liable for the performance of all of the obligations of Tenant under this Lease with respect to such Leased Property; (ii) subject to the rights and priorities set forth in the Intercreditor Agreement, each subtenant shall jointly and severally guaranty the obligations of Tenant under the Lease; (iii) Landlord shall be provided security for the performance by each subtenant of its obligations reasonably satisfactory to Landlord, which security shall include, without limitation, subject to the rights and priorities set forth in the Intercreditor Agreement, a pledge of the stock of or other membership interest of Tenant in each subtenant, an assignment of the sublease, and a security interest in subtenant’s Personal Property and Accounts as required of Tenant pursuant to Section 6.4 hereof; (iv) the sole asset of any such subtenant shall be its interest in the contemplated sublease and Tenant’s Personal Property relating to such Facility(ies); and (v) the subtenant shall be a wholly-owned subsidiary of Tenant. Tenant shall notify Landlord at least thirty (30) days in advance of the date on which Tenant desires to make such sublease. Tenant shall reimburse Landlord for the actual and reasonable legal fees actually incurred by Landlord in connection with Tenant’s request. Tenant shall provide Landlord with a copy of the proposed sublease and such information as Landlord reasonably requests concerning the proposed subtenant to allow Landlord to make an informed judgment as to whether the sublease satisfies the provisions of this Section 22.4 and to obtain the security provided for herein. As of the date of this Lease, all of the currently existing subleases and Subtenants of Tenant permitted pursuant to this Section 22.4 are set forth on Schedule 22.4.
22.5    Hospital Transaction. Tenant may enter into a Hospital Transaction provided that provided that:
(a)    Tenant, the applicable UPL-IGT Managers, and such Hospital Subtenant enters into a Consent to Hospital Sublease in form and substance acceptable to Landlord, including the granting of equivalent (in assets covered, priority of lien and obligations secured) security interests by the Hospital Subtenant in the Collateral concurrently with such Hospital Transaction;
(b)    Tenant and the Hospital Subtenant enter into a Sublease in form and substance reasonable acceptable to Landlord;
(c)    The applicable UPL-IGT Managers and the new Hospital Subtenant enter into a Management Agreement in form and substance reasonable acceptable to Landlord;
(d)    Except where the UPL-IGT Manager is or will be DMS, the Tenant and UPL-IGT Manager comply with items (ii) thru (v) of Section 22.4 as if the UPL-IGT Manager were a Subtenant; if DMS is the UPL-IGT Manager, then DMS shall comply with item (iii) of Section 22.4 with respect to granting a security interest in the interest of DMS, if any, in the Personal Property and Accounts located at, used in connection with or arising out of the operations of, the applicable Facility; and
(e)    Each of the other Lease Documents are ratified and affirmed by the applicable Affiliates of Tenant as being in full force and effect after giving effect to the proposed Transfer.
Tenant shall notify Landlord at least ninety (90) days in advance of the date on which Tenant desires to enter into a Hospital Transaction. Tenant shall reimburse Landlord for the actual and reasonable legal fees actually incurred by Landlord in connection with Tenant’s request. Tenant shall provide Landlord with a copy of the proposed sublease and management agreement and such information as Landlord reasonably requests concerning the proposed Hospital Subtenant and UPL-IGT Manager to allow Landlord to make an informed judgment as to whether the sublease satisfies the provisions of this Section 22.5 and to obtain the security provided for herein. Landlord and Tenant hereby ratify and affirm that certain Agreement and Consent to Sublease dated as of August 1, 2016 among Ohio Indiana Property, L.L.C., a Delaware limited liability company, as landlord, Diversicare of Providence, LLC, a Delaware limited liability company, as primary tenant, Diversicare of St. Theresa LLC, a Delaware limited liability company, Diversicare of Sienna Woods, LLC, a Delaware limited liability company, and Diversicare of Bradford Place, LLC, a Delaware limited liability company, as tenant, DHSI, as guarantor, Daviees Community Hospital, an Indiana county hospital, as subtenant, and DMS, as manager, and the currently existing Healthcare Facility Sublease Agreement dated as of August 1, 2016 executed in connection therewith ( the “Daviees Sublease”). The Daviees Sublease is a permitted Hospital Transaction under this Lease.
ARTICLE XXIII    
23.1    Officer’s Certificates and Financial Statements. Tenant shall furnish (or as appropriate cause each Guarantor to furnish) to Landlord:
(a)    Within ninety (90) days after the end of each of DHSI’s fiscal years: (i) Consolidated Financial Statements for the Tenant, the Subtenants (other than any Hospital Subtenant, UPL-IGT Manager and DHSI), (ii) separate financial statements for each of the Facilities, in each case certified by an financial officer of Tenant; and (iii) an Officer’s Certificate stating that to the best knowledge and belief of such officer after making due inquiry, Tenant is not in default in the performance or observance of any of the terms of this Lease, or if Tenant is in default, specifying all such defaults, the nature thereof, and the steps being taken to remedy the same.
(b)    Within forty-five (45) days after the end of each of DHSI’s quarters, quarterly consolidated financial reports of DHSI, together with an Officer’s Certificate that Tenant is not in default of any covenant set forth in ARTICLE VIII of this Lease and Guarantor is not in default of any covenant under the Guaranty, or if Tenant or Guarantor is in default, specifying all such defaults, the nature thereof, and the steps being taken to remedy the same;
(c)    Within forty-five (45) days after the end of each of DHSI’s quarters, a quarterly Financial Statement from DHSI (provided, however, that such quarterly Financial Statements need not be certified by a certified public accountant, but shall be certified by DHSI to be complete and accurate);
(d)    Within thirty-five (35) days after the end of each month, monthly financial reports for each Facility with detailed statements of income and expense and detailed operational statistics regarding occupancy rates, patient mix and patient rates by type for the Facility;
(e)    A copy of each cost report filed with a governmental agency for any Facility;
(f)    Within fifteen (15) days after they are required to be filed with the SEC, copies of any annual or quarterly report and of information, documents and other reports (or copies of such portions of any of the foregoing as the SEC may by rules and regulations prescribe) which DHSI is required to file with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934;
(g)    Within thirty (30) days of Tenant’s or Manager’s receipt thereof, copies of surveys performed by the appropriate governmental agencies for licensing or certification purposes, and any plan of correction thereto as approved by the appropriate governmental agency for any Facility.
(h)    Notice to Landlord within three (3) Business days after receipt of any action, proposal or investigation by any agency or entity, or complaint to such agency or entity, known to Tenant, the result of which could be to (i) modify in a way adverse to Tenant or revoke or suspend or terminate, or fail to renew or fully continue in effect, any license or certificate or operating authority pursuant to which Tenant carries on any part of the Primary Intended Use of any Facility, or (ii) suspend, terminate, adversely modify, or fail to renew or fully continue in effect any cost reimbursement or cost sharing program by any state or federal governmental agency, including but not limited to Medicaid or Medicare or any successor or substitute therefor, or seek return of or reimbursement for any funds previously advanced or paid pursuant to any such program, or (iii) impose any bed hold, limitation on patient admission or similar restriction on any Leased Property, or (iv) prosecute any party with respect to the operation of any activity on any Leased Property or enjoin any party or seek any civil penalty in excess of Twenty-Five Thousand Dollars ($25,000.00) in respect thereof;
(i)    As soon as it is prepared in each Lease Year, a capital and operating budget for the Facilities for that and the following Lease Year;
(j)    With reasonable promptness, such other information respecting the financial condition and affairs of Tenant and the Facilities as Landlord may reasonably request from time to time including, without limitation, any such other information as may be available to the administration of the Leased Properties; and
(k)    At times reasonably required by Landlord, and upon request as appropriate, such additional information and unaudited quarterly financial information concerning the Leased Properties and Tenant as Landlord may require for its on‑going filings with the Securities and Exchange Commission, under both the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended, including, but not limited to 10‑Q Quarterly Reports, 10‑K Annual Reports and registration statements to be filed by Landlord during the Term of this Lease.
Landlord’s right to the statements referred to in Subparagraph (j) shall be subject to any prohibitions or limitations on disclosure of any such data under applicable laws or regulations, including, without limitation, the Health Insurance Portability and Accountability Act (“HIPAA”) or any duly enacted “Patients’ Bill of Rights” or similar legislation, including such limitations as may be necessary to preserve the confidentiality of the Facility‑patient relationship and the physician‑patient privilege. Further, except for statements or information which are already public, Landlord shall not disclose the contents of any such statement, except to a Facility Mortgagee, proposed Facility Mortgagee, lender of Landlord, proposed Lender of Landlord, prospective investor, prospective purchaser, or Landlord’s attorneys, accountants or agents, and except as permitted in Section 23.2.
23.2    Public Offering Information. Tenant specifically agrees that Landlord may include financial information and information concerning the operation of the Facilities that does not violate the confidentiality of the facility‑patient relationship and the physician‑patient privilege under applicable laws or regulations, including HIPAA, in offering memoranda or prospectus, or similar publications in connection with syndications or public offerings of Landlord’s securities or interests, and any other reporting requirements under applicable Federal and State Laws, including those of any successor to Landlord. Tenant agrees to provide such other reasonable information necessary with respect to Tenant and the Leased Properties to facilitate a public offering or to satisfy SEC or regulatory disclosure requirements. Landlord shall provide to Tenant a copy of any information prepared by Landlord to so be published and Tenant shall have a reasonable period of time (not to exceed three (3) Business Days) after receipt of such information to notify Landlord of any corrections. Landlord shall reimburse Tenant for its out-of-pocket costs to its qualified public accountants for their services in connection with such public offering information and interim or “stub” financial information and “comfort letters” required pursuant to Section 23.1(k) as requested by Landlord.
ARTICLE XXIV    
Tenant hereby makes the following representations and warranties to Landlord and acknowledges that Landlord is granting the Lease in reliance upon such representations and warranties. Tenant’s representations and warranties shall survive the expiration or termination of this Lease, and except to the extent otherwise specifically limited, shall continue in full force and effect, until Tenant’s obligations hereunder have been performed in full:
24.1    Organization and Good Standing. Each Tenant Entity is a corporation or limited liability company duly organized, validly existing and in good standing under the laws of its State of organization. Each Tenant, Subtenant and Manager are qualified to do business in and is in good standing under the laws of the State in which the Facility operated by each such Tenant Entity is located. Tenant has delivered true and complete copies of the documents, certificates and agreements pursuant to which Tenant and Subtenant is organized to do business (the “Tenant Org Docs”). Attached as Schedule 24.1 is a true and correct copy of an organizational chart illustrating the ownership structure of each Tenant and Subtenant.
24.2    Power and Authority. Each Tenant Entity has the power and authority to execute, deliver and perform this Lease and the other Transaction Documents. Each Tenant Entity has taken all requisite action necessary to authorize the execution, delivery and performance of such party’s obligations under this Lease and the other Transaction Document.
24.3    Enforceability. This Lease and the other Transaction Documents constitutes a legal, valid, and binding obligation of each Tenant Entity enforceable in accordance with its terms.
24.4    Consents. Except for the Authorizations and the consent of CIBC Bank, which has been acquired, the execution, delivery and performance of this Lease and the other Transaction Documents will not require any consent, approval, authorization, order, or declaration of, or any filing or registration with, any court, any Governmental Authority, or any other Person.
24.5    No Violation. The execution, delivery and performance of this Lease and the other Transaction Document (i) do not and will not conflict with, and do not and will not result in a breach of, any Tenant Org Docs; and (ii) do not and will not violate any order, writ, injunction, decree, statute, rule or regulation applicable to any Tenant Entity or any of the Facilities.
24.6    Reports and Statements. All reports, statements (financial or otherwise), certificates and other data furnished by or on behalf of and Tenant Entity to Landlord in connection with this Lease and the other Transaction Documents, and all representations and warranties made herein or in any certificate or other instrument delivered in connection herewith and therewith, are true and correct in all material respects and do not omit to state any material fact or circumstance necessary to make the statements contained herein or therein, in light of the circumstances under which they are made, not misleading as of the date of such report, statement, certificate or other data.
24.7    No Default. There is no existing Event of Default or Unmatured Event of Default.
24.8    Adverse Matters. Except as set forth on Schedule 24.8, no Tenant Entity nor any of their respective officers, directors, members, or employees have been disqualified from participating in either the Medicare or Medicaid programs. Without limitation of the foregoing, except as set forth on Schedule 24.8, no Tenant Entity nor any of their respective officers, directors, members or managing employees has engaged in any activities that are prohibited under criminal law, or are cause for civil penalties or mandatory or permissive exclusion from Medicare, or any other state health care program. Other than as set forth on Schedule 24.8, there is no, and there shall continue to be no, threatened, existing or pending revocation, suspension, termination, probation, restriction, limitation or non-renewal affecting any Tenant or any Facility with regard to participation in Medicare, Medicaid or any other Third Party Payor Programs or the applicable Authorizations to which any Tenant Entity or Facility presently or at any time hereafter is/are subject. Except as set forth on Schedule 24.8, no Tenant Entity or Affiliate of Tenant: (a) is a party to a Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services; (b) has reporting obligations pursuant to any Settlement Agreement entered into with any Governmental Authorities; (c) is the subject of any government payor program investigation conducted by any federal or state enforcement agency; (d) is a defendant in any qui tam or False Claims Act litigation; or (e) has been served with or received any currently effective search warrant or subpoena (except in connection with medical services provided to third-parties who may be defendants or the subject of investigation into conduct unrelated to the operation of the healthcare businesses conducted by the Tenant Entities or Affiliates of Tenant). Within thirty (30) days of Tenant first becoming aware of such matter, Tenant shall update and supplement Schedule 24.8 with such matters first arising after the Commencement Date and such updates and supplements shall be effective for all purposes under this Lease.
24.9    Certification. As of the Commencement Date, each Subtenant has obtained and holds any and all Authorizations, including, but not limited to, the Provider Agreements, necessary or advisable to operate its Facility(ies) for its Primary Intended Use and to be validly licensed and Medicare and Medicaid certified to operate its applicable Facility in accordance with all applicable governmental rules and regulations and the requirements of all applicable Governmental Authorities, including, but not limited to, CMS.
24.10    Provider Agreements. As of the Commencement Date, each Subtenant is certified by the applicable Health Departments and/or CMS, and is the holder of valid Provider Agreements with Medicare and Medicaid issued by, the applicable Health Departments and/or CMS.
ARTICLE XXV    
25.1    Landlord’s Right to Inspect. Tenant shall permit Landlord and its authorized representatives to inspect the Leased Properties and the books and records of Tenant and/or Subtenants relating to the operation of the Facilities during normal business hours at any time without Notice subject to any security, health, safety or confidentiality requirements, any governmental agency or insurance requirement relating to the Leased Properties, or imposed by HIPAA or other law or applicable regulations.
ARTICLE XXVI    
26.1    No Waiver. No failure by Landlord to insist upon the strict performance of any term hereof or to exercise any right, power or remedy consequent upon a breach hereof, and no acceptance of full or partial payment of Rent during the continuance of any such breach, shall constitute a waiver of any such breach or of any such term. No waiver of any breach shall affect or alter this Lease, which shall continue in full force and effect with respect to any other then existing or subsequent breach.
ARTICLE XXVII    
27.1    Remedies Cumulative. To the extent permitted by law, each legal, equitable or contractual right, power and remedy of Landlord or Tenant now or hereafter provided either in this Lease or by statute or otherwise shall be cumulative and concurrent and shall be in addition to every other right, power and remedy and the exercise or beginning of the exercise by Landlord or Tenant of any one or more of such rights, powers and remedies shall not preclude the simultaneous or subsequent exercise by Landlord or Tenant of any or all of such other rights, powers and remedies.
ARTICLE XXVIII    
28.1    Acceptance of Surrender. No surrender to Landlord of this Lease or of the Leased Properties or any part thereof, or of any interest therein, shall be valid or effective unless agreed to and accepted in writing by Landlord, and no act by Landlord or any representative or agent of Landlord, other than such a written acceptance by Landlord, shall constitute an acceptance of any such surrender.
ARTICLE XXIX    
29.1    No Merger of Title. There shall be no merger of this Lease or of the leasehold estate created hereby by reason of the fact that the same person, firm, corporation or other entity may acquire, own or hold, directly or indirectly, (i) this Lease or the leasehold estate created hereby or any interest in this Lease or such leasehold estate, and (ii) the fee estate in the Leased Properties.
29.2    No Partnership. Nothing contained in this Lease will be deemed or construed to create a partnership or joint venture between Landlord and Tenant or to cause either party to be responsible in any way for the debts or obligations of the other or any other party, it being the intention of the parties that the only relationship hereunder is that of Landlord and Tenant.
ARTICLE XXX    
30.1    Conveyance by Landlord. If Landlord or any successor owner of the Leased Properties conveys the Leased Properties other than as security for a debt, and the grantee or transferee of the Leased Properties shall expressly assume all obligations of Landlord hereunder arising or accruing from and after the date of such conveyance, Landlord or such successor owner, as the case may be, shall thereupon be released from all future liabilities and obligations of Landlord under this Lease arising or accruing from and after the date of such conveyance or other transfer and all such future liabilities and obligations shall thereupon be binding upon the new owner.
ARTICLE XXXI    
31.1    Quiet Enjoyment. So long as Tenant pays all Rent as it becomes due and complies with all of the terms of this Lease and performs its obligations hereunder, Tenant shall peaceably and quietly have, hold and enjoy the Leased Properties for the Term, free of any claim or other action by Landlord or anyone claiming by, through or under Landlord, but subject to the Permitted Encumbrances and all liens and encumbrances hereafter provided for in this Lease or consented to by Tenant. Except as otherwise provided in this Lease, no failure by Landlord to comply with the foregoing covenant will give Tenant any right to cancel or terminate this Lease or abate, reduce or make a deduction from or offset against the Rent or any other sum payable under this Lease, or to fail to perform any other obligation of Tenant. Tenant shall, however, have the right, by separate and independent action, to pursue any claim it may have against Landlord as a result of a breach by Landlord of the covenant of quiet enjoyment contained in this Section.
ARTICLE XXXII    
32.1    Notices. Any notice, request or other communication to be given by any party hereunder shall be in writing and shall be sent by registered or certified mail, postage prepaid, or by hand delivery or facsimile transmission to the following address:
To Tenant:                Diversicare Leasing Corp.
c/o Diversicare Healthcare Services Inc.
1621 Galleria Boulevard
Brentwood, TN 37027
Attention: Chief Financial Officer
Telephone No.: (615) 771-7575
Facsimile No.: (615) 771-7409

With copy to            Bass, Berry & Sims PLC
(which shall not        150 Third Avenue South, Suite 2800
constitute notice):    Nashville, TN 37201
Attn: Mark Manner
Telephone No.: (615) 742-6298
Facsimile No.: (615) 742-2897
To Landlord:            c/o Omega Healthcare Investors, Inc.
303 International Circle, Suite 200
                Hunt Valley, Maryland 21030
Attn.: Daniel J. Booth
Telephone No.: (410) 427-1700
Facsimile No.: (410) 427-8800
With copy to
Doran Derwent PLLC
(which shall not
5960 Tahoe Dr, SE, Suite 101
constitute notice):
Grand Rapids, Michigan 49546
Attn: Mark E. Derwent
Telephone No.: (616) 451-8690
Facsimile No.: (616) 451-8697
or to such other address as either party may hereafter designate. Notice shall be deemed to have been given on the date of delivery if such delivery is made on a Business Day, or if not, on the first Business Day after delivery. If delivery is refused, Notice shall be deemed to have been given on the date delivery was first attempted. Notice sent by facsimile transmission shall be deemed given upon confirmation that such Notice was received at the number specified above or in a Notice to the sender. If Tenant has vacated the Leased Properties, Landlord’s Notice may be posted on the door of a Leased Property.
ARTICLE XXXIII    
33.1    Appraisers. If it becomes necessary to determine Fair Market Value or Fair Market Rent for any purpose under this Lease, the party required or permitted to give Notice of such required determination shall include in the Notice the name of a person selected to act as appraiser on its behalf. Within ten (10) days after such Notice, the party receiving such Notice shall give Notice to the other party of its selection of a person to act as appraiser on its behalf. The appraisers thus appointed, each of whom must be a member of the Appraisal Institute (or any successor organization thereto) and experienced in appraising facilities used for purposes similar to the Primary Intended Use of the Facilities, shall, within forty-five (45) days after the date of the Notice appointing the first appraiser, proceed to appraise the Leased Property or Leased Properties, as the case may be, to determine the Fair Market Value or Fair Market Rent thereof as of the relevant date (giving effect to the impact, if any, of inflation between the date of their decision and the relevant date); provided, however, that if only one appraiser has been so appointed, or if two appraisers have been so appointed but only one such appraiser has made such determination within fifty (50) days after the date of the Notice appointing the first appraiser, then the determination of such appraiser shall be final and binding upon the parties. To the extent consistent with sound appraisal practice at the time of any such appraisal, such appraisal shall be made on a basis consistent with the basis on which the Leased Property or Leased Properties were appraised for purposes of determining its Fair Market Value at the time of Landlord’s acquisition thereof. If two appraisers have been appointed and have made their determinations within the respective requisite periods set forth above, and if the difference between the amounts so determined does not exceed ten percent (10%) of the lesser of such amounts, then the Fair Market Value or Fair Market Rent shall be an amount equal to fifty percent (50%) of the sum of the amounts so determined. If the difference between the amounts so determined exceeds ten percent (10%) of the lesser of such amounts, then such two appraisers shall within twenty (20) days appoint a third appraiser. If no such appraiser is appointed within such twenty (20) days or within ninety (90) days of the date of the Notice appointing the first appraiser, whichever is earlier, either Landlord or Tenant may apply to any court having jurisdiction to have such appointment made by such court. Any appraiser appointed by the original appraisers or by such court shall be instructed to determine the Fair Market Value or Fair Market Rent within forty‑five (45) days after appointment of such appraiser. The determination of the appraiser which differs most in terms of dollar amount from the determinations of the other two appraisers shall be excluded, and the average of the remaining two determinations shall be final and binding upon Landlord and Tenant as the Fair Market Value or Fair Market Rent of the Leased Property or Leased Properties, as the case may be. If the Fair Market Rent is being determined for more than one year, the Fair Market Rent may include such annual increases, if any, as the appraisers determine to be in accordance with the terms of this Lease.
This provision for determining by appraisal shall be specifically enforceable to the extent such remedy is available under applicable law, and any determination hereunder shall be final and binding upon the parties except as otherwise provided by applicable law, and judgment may be entered upon such determination in a court of competent jurisdiction. Landlord and Tenant shall each pay the fees and expenses of the appraiser appointed by it and each shall pay one‑half of the fees and expenses of the third appraiser and one‑half of all other costs and expenses incurred in connection with each appraisal.
ARTICLE XXXIV    
34.1    Breach by Landlord. Landlord shall not be in breach of this Lease unless Landlord fails to observe or perform any term, covenant or condition of this Lease on its part to be performed and such failure continues for a period of thirty (30) days after written Notice specifying such failure and the necessary curative action is received by Landlord from Tenant. If the failure cannot with due diligence be cured within a period of thirty (30) days, the failure shall not be deemed to continue if Landlord, within said thirty (30) day period, proceeds promptly and with due diligence to cure the failure and diligently completes the curing thereof. The time within which Landlord shall be obligated to cure any such failure shall also be subject to extension of time due to Force Majeure.
34.2    Compliance With Facility Mortgage. Except for payments due under any Facility Mortgage (which shall be the responsibility of the Mortgagor thereunder), Tenant covenants and agrees that, to the extent within Tenant’s control, it will duly and punctually observe, perform and comply with all of the terms, covenants and conditions (including, without limitation, covenants requiring the keeping of books and records and delivery of financial statements and other information) of any Facility Mortgage as to which Tenant has been given Notice and that it will not directly or indirectly do any act or suffer or permit any condition or thing to occur that is within Tenant’s control, which would or might constitute a default under a Facility Mortgage as to which Tenant has been given Notice. Anything in this Lease to the contrary notwithstanding, (i) if the time for performance of any act required of Tenant by the terms of a Facility Mortgage as to which Tenant has been given Notice is shorter than the time allowed by this Lease for performance of such act by Tenant, then Tenant shall perform such act within the time limits specified in this Lease and (ii) Tenant shall not be required to comply with the terms, covenants and conditions of any Facility Mortgage that materially (i) alter the economic terms of this Lease, (ii) diminish the rights of Tenant under this Lease in any material respect, or (iii) increase the obligations of Tenant under this Lease in any material respect.
ARTICLE XXXV    
35.1    Disposition of Personal Property on Termination. Upon the expiration or earlier termination of this Lease, Tenant shall immediately surrender, turn over and deliver to Landlord, without the payment of any additional consideration by Landlord, all Personal Property then located on or at or used in the operation of the Leased Properties, other than the items of Personal Property listed on Schedule 6.3 attached hereto. Upon Landlord’s request, Tenant shall, without any charge or cost to Landlord, execute and deliver to Landlord such bills of sale, assignments or other instruments necessary, appropriate or reasonably requested by Landlord to establish Landlord’s ownership of such Personal Property. Tenant acknowledges and agrees that, as of the date of this Lease, all of Tenant’s Personal Property currently located at the Facilities, other than the items of Personal Property listed on Schedule A attached to this Lease, is Personal Property that shall be sold, assigned, transferred and conveyed to the Landlord as provided in Section 6.3, above, upon the expiration or earlier termination of the Term.
35.2    Facility Trade Names. If this Lease is terminated pursuant to Section 16.1 or Landlord acquires Tenant’s Personal Property pursuant to Section 35.1, Tenant shall be deemed to have assigned to Landlord the right to use the Facility Trade Names in the markets in which the Facilities are located, and Tenant shall not after any such termination use the Facility Trade Names in the same market in which any Facility is located in connection with any business that competes with such Facility provided, however, that nothing contained in this Section 35.2 grants Landlord any right to use the name “Diversicare”, or any derivative or trademark thereof, and any subsequent trade name adopted during the Term hereof and which is commonly used as part of a long term marketing program among multiple facilities by Tenant and Affiliates of Tenant, for any Leased Property or Facility.
35.3    Transfer of Operational Control of the Facilities. Tenant shall cooperate fully in transferring operational control of the Facilities to Landlord or Landlord’s nominee if the Term expires without renewal or purchase by Tenant upon separate agreement of the parties (there being no purchase option on the part of Tenant under this Lease), or this Lease is terminated upon the occurrence of an Event of Default or for any other reason, and shall use its reasonable best efforts to cause the business conducted at the Facilities to continue without interruption. To that end, pending completion of the transfer of the operational control of the Facilities to Landlord or its nominee:
(i)    Tenant will not terminate the employment of any employees without just cause, or change any salaries, provided, however, that without the advance written consent of Landlord Tenant may grant pre‑announced wage increases of which Landlord has knowledge, increases required by written employment agreements and normal raises to non‑officers at regular review dates; and Tenant will not hire any additional employees except in good faith in the ordinary course of business;
(ii)    Tenant will provide all necessary information requested by Landlord or its nominee for the preparation and filing of any and all necessary applications or notifications of any federal or state governmental authority having jurisdiction over a change in the operational control of the Facilities, and any other information reasonably required to effect an orderly transfer of the Facilities, and Tenant will use its best efforts to cause all operating health care licenses to be transferred to Landlord or to Landlord’s nominee;
(iii)    Tenant shall use its best efforts to keep the business and organization of the Facilities intact and to preserve for Landlord or its nominee the goodwill of the suppliers, distributors, residents and others having business relations with Tenant with respect to the Facilities;
(iv)    Tenant shall engage only in transactions or other activities with respect to the Facilities which are in the ordinary course of its business and shall perform all maintenance and repairs reasonably necessary to keep the Facilities in satisfactory operating condition and repair, and shall maintain the supplies and foodstuffs at levels which are consistent and in compliance with all health care regulations, and shall not sell or remove any personal property except in the ordinary course of business and in accordance with the terms and conditions of this Lease;
(v)    Tenant shall provide Landlord or its nominee with full and complete information regarding the employees of the Facilities and shall reimburse Landlord or its nominee for all outstanding accrued employee benefits, including accrued vacation, sick and holiday pay calculated on a true accrual basis, including all earned and a prorated portion of all unearned benefits;
(vi)    Tenant shall use its best efforts to obtain the acknowledgment and the consent of any creditor, landlord or sublandlord, mortgagee, beneficiary of a deed of trust or security agreement affecting the real and personal properties of Tenant or any other party whose acknowledgment and/or consent would be required because of a change in the operational control of the Facilities and transfer of personal property. The consent must be in form, scope and substance satisfactory to Landlord or its nominee, including, without limitation, an acknowledgment in respect to all such contracts, leases, deeds of trust, mortgage, security agreements, or other agreements that Tenant and all predecessors or successors‑in‑interest thereto are not in default in respect thereto, that no condition known to the consenting party exists which with the giving of notice or lapse of time would result in such a default, and, if requested, affirmatively consenting to the change in the operational control of the Facilities;
(vii)    Tenant shall not encourage the transfer of any patients from the Facilities;
(viii)    Tenant consents to Landlord, or its nominee, seeking to employ any on-site employees of the Facilities, but neither Landlord nor its nominee shall have any obligation to employ any employees of the Facilities;
(ix)    To more fully preserve and protect Landlord’s rights under this Section, Tenant does hereby make, constitute and appoint Landlord its true and lawful attorney‑in‑fact, for it and in its name, place and stead to execute and deliver all such instruments and documents, and to do all such other acts and things, as Landlord may deem to be necessary or desirable to protect and preserve the rights granted under this Section, including, without limitation, the preparation, execution and filing with the Board of Health (or similar agency) of each State or any and all required “Letters of Responsibility” or similar documents. Tenant hereby grants to Landlord the full power and authority to appoint one or more substitutes to perform any of the acts that Landlord is authorized to perform under this Section, with a right to revoke such appointment of substitution at Landlord’s pleasure. The power of attorney granted pursuant to this Section is coupled with an interest and therefore is irrevocable. Any person dealing with Landlord may rely upon the representation of Landlord relating to any authority granted by this power of attorney, including the intended scope of the authority, and may accept the written certificate of Landlord that this power of attorney is in full force and effect. Photographic or other facsimile reproductions of this executed Lease may be made and delivered by Landlord, and may be relied upon by any person to the same extent as though the copy were an original. Anyone who acts in reliance upon any representation or certificate of Landlord, or upon a reproduction of this Lease, shall not be liable for permitting Landlord to perform any act pursuant to this power of attorney. Notwithstanding the foregoing, Landlord covenants with Tenant that Landlord shall refrain from exercising the power of attorney granted hereby except in the case of an Event of Default hereunder or in the event of a default, which, in Landlord’s reasonable judgment, may lead to the suspension or revocation of any license of Tenant or of any subtenant.
35.4    Intangibles and Personal Property. Notwithstanding any other provision of this Lease but subject to Section 6.3 relating to the security interest in favor of Landlord, Landlord’s Personal Property shall not include goodwill nor shall it include any other intangible personal property that is severable from Landlord’s “interests in real property” within the meaning of Section 856(d) of the Code, or any similar or successor provision thereto.
ARTICLE XXXVI    
36.1    Arbitration. Except as provided in Section 36.2, if any controversy arises between the parties hereto as to any of the provisions of this Lease or the performance thereof, and if the parties are unable to settle the controversy by agreement or as otherwise provided herein, the controversy shall be decided by arbitration. The arbitration shall be conducted by three arbitrators who shall be selected in accordance with the rules and procedures of the American Arbitration Association. The arbitration shall be conducted in accordance with the Commercial Rules of the American Arbitration Association in existence at the time of the subject dispute, but shall not include findings of facts and conclusions of law unless requested by either party. The decision of the arbitrators shall be final and binding, and judgment may be entered thereon in any court of competent jurisdiction. The decision shall set forth in writing the basis for the decision. In rendering the decision and award, the arbitrators shall not add to, subtract from or otherwise modify the provisions of this Lease. The expense of the arbitration shall be divided between Landlord and Tenant unless otherwise specified in the award. Each party in interest shall pay the fees and expenses of its own counsel. The arbitration shall be conducted in Baltimore, Maryland. In any arbitration, the parties shall be entitled to conduct discovery in the same manner as permitted under Federal Rules of Civil Procedure 26 through 37, as amended. No provision in this Article shall limit the right of any party to this Agreement to obtain provisional or ancillary remedies from a court of competent jurisdiction before, after or during the pendency of any arbitration, and the exercise of such remedies does not constitute a waiver of the right of either party to arbitration.
36.2    Non-Arbitratable Claims. Notwithstanding anything in this Lease to the contrary, the parties shall not be obligated to decide in arbitration controversies arising with respect to:
(a)    the payment of Rent under this Lease,
(b)    the determination of Fair Market Rent (which shall be determined solely in accordance with Section 33.1),
(c)    any proceedings for eviction and/or to recover possession of one or more of the Leased Properties,
(d)    any proceeding seeking injunctive relief, to foreclose upon any lien or security interest, or to exercise remedies after an Event of Default;
(e)    any proceeding with the amounts in controversy in the aggregate in excess of Two Hundred Fifty Thousand Dollars ($250,000.00);
(f)    any proceeding while Tenant, a Subtenant or Guarantor is in bankruptcy or insolvency proceedings; or
(g)    whether any given issue is subject to arbitration, it being agreed that the issue of arbitrability of any issue shall be decided by a court of competent jurisdiction, not in arbitration.
ARTICLE XXXVII    
37.1    Survival, Choice of law. Anything contained in this Lease to the contrary notwithstanding, all claims against, and liabilities of, Tenant or Landlord arising prior to the date of expiration or termination of this Lease shall survive such expiration or termination. If any term or provision of this Lease or any application thereof is held invalid or unenforceable, the remainder of this Lease and any other application of such term or provisions shall not be affected thereby. If any late charges provided for in any provision of this Lease are based upon a rate in excess of the maximum rate permitted by applicable law, the parties agree that such charges shall be fixed at the maximum permissible rate. Neither this Lease nor any provision hereof may be changed, waived, discharged or terminated except by an instrument in writing and in recordable form signed by Landlord and Tenant. All the terms and provisions of this Lease shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. The headings in this Lease are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. This Lease shall be governed by and construed in accordance with the laws of the state of Maryland, as to all matters other than (i) those matters relating to the enforcement or exercise of any possessory or summary remedies of Landlord under this Lease, which shall be governed by the laws of the applicable State or States and (ii) matters which under applicable procedural conflicts of laws rules require the application of laws of another State.
37.2    Jurisdiction and Service of Process. TENANT CONSENTS TO IN PERSONAM JURISDICTION BEFORE THE STATE AND FEDERAL COURTS OF THE STATES OF MARYLAND AND EACH STATE IN WHICH A FACILITY IS LOCATED, AND AGREES THAT ALL DISPUTES CONCERNING THIS AGREEMENT BE HEARD IN THE STATE AND FEDERAL COURTS LOCATED IN THE STATES OF MARYLAND OR ANY STATE IN WHICH A FACILITY IS LOCATED. TENANT AGREES THAT SERVICE OF PROCESS MAY BE EFFECTED UPON IT UNDER ANY METHOD PERMISSIBLE UNDER THE LAWS OF THE STATES OF MARYLAND OR ANY STATE IN WHICH A FACILITY IS LOCATED AND IRREVOCABLY WAIVES ANY OBJECTION TO VENUE IN THE STATE AND FEDERAL COURTS OF THE STATES OF MARYLAND OR ANY SUCH STATE.
37.3    Limitation on Recovery. Tenant specifically agrees to look solely to Landlord’s interest in the Leased Properties for recovery of any judgment from Landlord, it being specifically agreed that no constituent shareholder, officer or director of Landlord shall ever be personally liable for any such judgment or for the payment of any monetary obligation to Tenant. The provision contained in the foregoing sentence is not intended to, and shall not, limit any right that Tenant might otherwise have to obtain injunctive relief against Landlord or Landlord’s successors in interest or any action not involving the personal liability of Landlord (original or successor). Furthermore, except as otherwise expressly provided herein, Landlord (original or successor) shall never be liable to Tenant for any indirect or consequential damages suffered by Tenant from whatever cause. Landlord agrees to look solely to the assets of Tenant and not to any director, officer or shareholder (other than a Guarantor pursuant to the Guaranty) of Tenant for payment of any monetary obligation to Landlord or recovery of any judgment from Tenant under this Lease
37.4    Multiple Entities Comprising Tenant. If Tenant consists of more than one entity, then all entities comprising Tenant shall be jointly and severally liable for the all of the obligations of Tenant under this Lease. Notwithstanding the foregoing, however, no Tenant shall, by virtue of this Lease have any rights to, or title or interest in, the Leased Property or Properties leased by another Tenant or any obligation to operate the same to the extent it does not have the license or other authorization necessary or required to do so under applicable law.
37.5    Waivers. Tenant waives any defense by reason of any disability of Tenant, and waives any other defense based on the termination of Tenant’s (including Tenant’s successor’s) liability from any cause. Tenant waives all presentments, demands for performance, notices of nonperformance, protests, notices of protest, notices of dishonor, and notices of acceptance, and waives all notices of the existence, creation, or incurring of new or additional obligations.
37.6    Consents. Whenever the consent or approval of Landlord or Tenant is required hereunder, Landlord or Tenant may in its sole discretion and without reason withhold that consent or approval unless otherwise specifically provided.
37.7    Counterparts. This Lease may be executed in separate counterparts, each of which shall be considered an original when each party has executed and delivered to the other one or more copies of this Lease.
37.8    Options Personal. The renewal options granted to Tenant in this Lease are granted solely to Tenant and are not assignable or transferrable except in connection with a Transfer permitted in ARTICLE XXII.
37.9    Right of Setoff. In addition to and not in limitation of any other right or remedy under this Lease and the other Lease Documents, Landlord may without prior notice to any person set off any sum or obligation (whether or not arising under this Lease) owed by Tenant or any Affiliate of Tenant to Landlord or any Affiliate of Landlord against any sum or obligation (whether or not arising under this Lease) owed by Landlord or any Affiliate of Landlord to Tenant or any Affiliate of Tenant.
37.10    Rights Cumulative. Except as provided herein to the contrary, the respective rights and remedies of the parties specified in this Lease shall be cumulative and in addition to any rights and remedies not specified in this Lease.
37.11    Entire Agreement. There are no oral or written agreements or representations between the parties hereto affecting this Lease. This Lease supersedes and cancels any and all previous negotiations, arrangements, representations, brochures, agreements and understandings, if any, between Landlord and Tenant.
37.12    Amendments in Writing. Except for Schedule 9.3(a) and Schedule 9.3 (b) which may be amended as provided in the definition of 7.0% Upgrades and 9.0% Improvements, no provision of this Lease may be amended except by an agreement in writing signed by Landlord and Tenant.
37.13    Severability. If any provision of this Lease or the application of such provision to any person, entity or circumstance is found invalid or unenforceable by a court of competent jurisdiction, such determination shall not affect the other provisions of this Lease and all other provisions of this Lease shall be deemed valid and enforceable.
37.14    Time of the Essence. Except for the delivery of possession of the Facilities to Tenant, time is of the essence of all provisions of this Lease of which time is an element.
37.15    Tenant to Pay Reasonable Expenses. Tenant shall pay or reimburse Landlord for all reasonable costs and expenses incurred by Landlord in connection with or relating in any way to the administration of this Lease (but in no event shall Tenant be liable for payment or reimbursement of the Landlord’s transaction costs, including legal fees, in connection with the initial documentation and closing of this Lease), including without limitation, search costs, audit fees, appraisal fees, attorneys’ fees, and other costs paid or incurred by Landlord in the analysis, administration and enforcement of this Lease and the other Transaction Documents, the protection and defense of the rights of Landlord in and to the Leased Properties, the Collateral and the other Transaction Documents, or as otherwise referred to in this Lease or in the other Transaction Documents, and all costs and expenses relating to extensions, amendments, waivers, or consents requested by Tenant, pursuant to this Lease or any other Transaction Document or any agreements with other parties or termination of this Lease (collectively, “Reasonable Expenses”). All Reasonable Expenses for which Tenant is liable shall be reasonably documented in a manner that generally describes the services rendered, disbursements advanced, or fees charged or any other amounts for which any party is or may be obligated pursuant to the terms of this Lease or any other Transaction Document, it being understood and agreed that certain documentation may be redacted to exclude confidential or strategic information. All such Reasonable Expenses shall be due on demand; provided, however, that so long as no Event of Default has occurred hereunder, Reasonable Expenses incurred after the date of this Lease which are unrelated to the closing shall be paid on or before the earlier of (i) 30 days following written notice thereof to Tenant or (ii) the date of expiration or earlier termination of this Lease. Any Reasonable Expenses not paid when due shall bear interest at the Overdue Rate.
37.16    MUTUAL WAIVER OF RIGHT TO JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED UPON, ARISING OUT OF, OR IN ANY WAY RELATING TO:  (i) THIS LEASE, OR ANY OF THE TRANSACTION DOCUMENTS; OR (ii) ANY OTHER PRESENT OR FUTURE INSTRUMENT OR AGREEMENT BETWEEN OR AMONG THEM; OR (iii) ANY CONDUCT, ACTS OR OMISSIONS OF ANY PARTY HERETO OR ANY OF THEIR DIRECTORS, TRUSTEES, OFFICERS, EMPLOYEES, AGENTS, ATTORNEYS OR ANY OTHER PERSONS AFFILIATED WITH THEM; IN EACH OF THE FOREGOING CASES, WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE.
37.17    Electronic Versions of Documents. The exchange of copies of this Lease (and any amendment thereto) and of signature pages by facsimile transmission (whether directly from one facsimile device to another by means of a dial-up connection or whether mediated by the worldwide web), by electronic mail in "portable document format" (".pdf" format), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by a combination of such means, shall constitute effective execution and delivery of this Lease (and any amendment thereto) as to the parties and may be used in lieu of an original Lease (and any amendment thereto) for all purposes. Signatures of the parties transmitted by facsimile shall be deemed to be their original signatures for all purposes. Notwithstanding the Electronic Signatures in Global and National Commerce Act (15 U.S.C. Sec. 7001 et seq.), the Uniform Electronic Transactions Act, or any other Legal Requirement relating to or enabling the creation, execution, delivery, or recordation of any contract or signature by electronic means, and notwithstanding any course of conduct engaged in by the parties, no party shall be deemed to have executed this Lease (or any amendment thereto) or any other document contemplated by this Lease unless and until such party shall have executed this Lease or such document on paper by a handwritten original signature or any other symbol executed or adopted by a party with current intention to authenticate this Lease or such other document contemplated. Notwithstanding anything to the contrary contained in this Section 37.16, Tenant shall provide the Tenant’s handwritten original signature to this Lease (and any amendment hereto) concurrently with or as soon as reasonably practicable following the effective date of this Lease (or any applicable amendment hereto).
ARTICLE XXXVIII    
38.1    Commissions. Landlord or Tenant each represent and warrant to the other that no real estate commission, finder’s fee or the like is due and owing to any person in connection with this Lease. Landlord and Tenant each agree to save, indemnify and hold the other harmless from and against any and all claims, liabilities or obligations for brokerage, finder’s fees or the like in connection with this Lease or the transactions contemplated hereby, asserted by any person on the basis of any statement or act alleged to have been made or taken by that party.
ARTICLE XXXIX    
39.1    Memorandum or Short Form of Lease. Landlord and Tenant shall, promptly upon the request of either, enter into a Memorandum or Short Form of this Lease, substantially in the form of attached Exhibit G with such modifications as may be appropriate under the laws and customs of the States and in the customary form suitable for recording under the laws of each of the States. Tenant shall pay all costs and expenses of recording such memorandum or short form of this Lease.
ARTICLE XL    
40.1    Security Deposit. Landlord acknowledges that it holds the Security Deposit in the form of one or more letters of credit. Landlord shall continue to hold the Security Deposit as security for the full and faithful performance by Tenant of each and every term, provision, covenant and condition of this Lease. If in the form of cash, the Security Deposit shall be deposited by Landlord into an account which shall earn interest for the benefit of Tenant, which cash shall remain on deposit as security and be available to Landlord as provided in this Article. The Security Deposit shall not be considered an advance payment of Rent (or of any other sum payable to Tenant under this Lease) or a measure of Landlord’s damages in case of a default by Tenant. The Security Deposit shall not be considered a trust fund, and Tenant expressly acknowledges and agrees that Landlord is not acting as a trustee or in any fiduciary capacity in controlling or using the Security Deposit. Notwithstanding the foregoing, if at any time the Security Deposit is in the form of cash, then (i) Landlord shall maintain the Security Deposit separate and apart from Landlord’s general and/or other funds and (ii) provided that Tenant is not then in default, Landlord shall disburse to Tenant the earnings on the Security Deposit on a quarterly basis. The Security Deposit, less any portion thereof applied as provided in Section 40.3 or the Letter of Credit Agreement, shall be returned to Tenant within sixty (60) days following the expiration of the Term or earlier termination of this Lease.
40.2    Additional Security Deposit. If a Facility is affected by any of the conditions described in Subsection (h) under the definition of Event of Default, and such condition continues beyond the shorter of (i) the period during which Tenant is in good faith appealing such condition, and (ii) one-hundred twenty (120) days (subject to extension to up to one hundred fifty days (150) with Landlord’s written consent, not to be unreasonably withheld), then Tenant shall increase the amount of the Security Deposit. The increase (“Increase”) shall be in an amount equal to the Fair Market Value which the affected Facility would have if none of the conditions described in Subsection (h) existed with respect to that Facility and if the Facility had licensed beds equal to the number of licensed beds in the Facility as of immediately prior to the Event of Default, an occupancy rate equal to the State average occupancy rate for facilities utilized for the Primary Intended Use of the Facility, less the actual Fair Market Value of the Facility. If the parties cannot agree upon the amount of the Increase, the amount of the Increase shall be determined in accordance with the arbitration procedures set forth in ARTICLE XXXVI. Tenant may fund the Increase in equal monthly installments beginning on the first (1st) day of the first (1st) month following the end of the time periods set forth above and ending on the earlier of (i) three (3) years thereafter, and (ii) two (2) years prior to the end of the Term; provided, however, that if the obligation to fund occurs during the last two (2) years of the Term, the Increase shall be funded immediately. If an Increase has been funded, the Facility is subsequently no longer affected by any of the conditions described in Subsection (h), the Facility has been reopened, and no Event of Default is continuing, the Increase shall be returned to Tenant. Pending an agreement between Landlord and Tenant as to the amount of the Increase, Tenant will fund the Increase based upon Tenant’s good faith estimate of the amount thereof.
40.3    Application of Security Deposit. If Tenant defaults in respect of any of the terms, provisions, covenants and conditions of this Lease, including, but not limited to, payment of any Rent and other sums of money payable by Tenant, Landlord may, but shall not be required to, in addition to and not in lieu of any other rights and remedies available to Landlord use, apply all or any part of the Security Deposit to the payment of any sum in default, or any other sum, including but not limited to, any damages or deficiency in reletting the Leased Properties, which Landlord may expend or be required to expend by reason of Tenant’s default. Whenever, and as often as, Landlord has applied any portion of the Security Deposit to cure Tenant’s default hereunder, Tenant shall, within ten (10) days after Notice from Landlord, deposit additional money with Landlord sufficient to restore the Security Deposit to the full amount originally provided or paid, and Tenant’s failure to do so shall constitute an Event of Default hereunder without any further Notice.
40.4    Transfer of Security Deposit. If Landlord transfers its interest under this Lease, Landlord shall assign the Security Deposit to the new landlord and thereafter Landlord shall have no further liability for the return of the Security Deposit, and Tenant agrees to look solely to the new landlord for the return of the Security Deposit. The provisions of the preceding sentence shall apply to every transfer or assignment of Landlord’s interest under this Lease. Tenant agrees that it will not assign or encumber or attempt to assign or encumber the Security Deposit and that Landlord, its successors and assigns, may return the Security Deposit to the last Tenant in possession at the last address for Notice given by such Tenant and that Landlord shall thereafter be relieved of any liability therefor, regardless of one or more assignments of this Lease or any such actual or attempted assignment or encumbrances of the Security Deposit.
ARTICLE XLI    
41.1    General REIT Provisions. Tenant understands that, in order for Landlord or one or more of its’ Affiliate, or any successor Affiliate that is a real estate investment trust (a “REIT Affiliate“) to qualify as a real estate investment trust, certain requirements (the “REIT Requirements“) must be satisfied, including the provisions of Section 856 of the Internal Revenue Code of 1986, as amended. Accordingly, Tenant agrees, and agrees to cause its Affiliates, permitted subtenants, if any, and any other parties subject to its control by ownership or contract, to reasonably cooperate with Landlord to ensure that the REIT Requirements are satisfied, including providing Landlord or any REIT Affiliate with information about the ownership of Tenant and its Affiliates. Tenant agrees, and agrees to cause its Affiliates, upon request by Landlord or any REIT Affiliate, to take all action reasonably necessary to ensure compliance with the REIT Requirements. In illustration of the foregoing, Tenant recognizes and acknowledges that avoiding (a) the loss of REIT status, (b) the receipt of any income derived under any provision of this Lease that does not constitute “rents from real property” (in the case of real estate investment trusts), and (c) the imposition of income, penalty or similar taxes (each a “REIT Adverse Event”) is of material concern to Landlord and any REIT Affiliate. In the event that this Lease or any document contemplated hereby could, in the opinion of counsel to Landlord, result in or cause an Adverse Event, Tenant agrees to cooperate with Landlord in negotiating an amendment or modification thereof and shall at the request of Landlord execute and deliver such documents reasonably required to effect such amendment or modification. Any amendment or modification shall be structured so that the economic results to Landlord and Tenant shall be substantially similar to those set forth in this Lease without regard to such amendment or modification and shall not materially and adversely increase Tenant’s non-monetary obligations or materially diminish Tenant’s rights under this Lease. Without limiting any of Landlord’s other rights pursuant to this provision, Landlord may waive the receipt of any amount payable to Landlord hereunder and such waiver shall constitute an amendment or modification of this Lease with respect to such payment.
SIGNATURE PAGES FOLLOW

IN WITNESS WHEREOF, the parties have executed this Master Lease by their duly authorized officers as of the date first above written.

LANDLORD:
STERLING ACQUISITION, LLC
STEVENS AVENUE PROPERTY, L.L.C.
ST. JOSEPH MISSOURI PROPERTY, L.L.C.
OHIO INDIANA PROPERTY, L.L.C.
NICHOLASVILLE KENTUCKY PROPERTY, L.L.C.
LOUISVILLE DUTCHMANS PROPERTY, L.L.C.
GREENVILLE KENTUCKY PROPERTY, L.L.C.



By:    /s/Megan M. Ames_________________
Name:    Megan M. Ames
Title:    Senior Vice President - Operations

THE STATE OF MARYLAND    )
)
COUNTY OF     BALTIMORE        )
This instrument was acknowledged before me on the ______ day of September, 2018, by Megan M. Ames, the Senior Vice President - Operations of the above listed limited liability companies, on behalf of said limited liability companies.
Notary Public
    

TENANT:
DIVERSICARE LEASING CORP.

By:    /s/James R. McKnight, Jr.            
Name:    James R. McKnight, Jr.
Its:    President and Chief Executive Officer

DIVERSICARE OF CHATEAU, LLC
DIVERSICARE OF RIVERSIDE, LLC
DIVERSICARE OF ST. JOSEPH, LLC
DIVERSICARE OF PROVIDENCE, LLC
DIVERSICARE OF ST. THERESA, LLC
DIVERSICARE OF SIENA WOODS, LLC
DIVERSICARE OF BRADFORD PLACE, LLC
DIVERSICARE OF NICHOLASVILLE, LLC
DIVERSICARE OF SENECA PLACE, LLC
DIVERSICARE OF GREENVILLE, LLC
Each a Delaware limited liability company

By:    Diversicare Leasing Company II, LLC, its sole member

By:    /s/James R. McKnight, Jr.            
Name:    James R. McKnight, Jr.
Its:    President and Chief Executive Officer

DIVERSICARE HIGHLANDS, LLC
A Delaware limited liability company

By:    Diversicare Leasing Corp., its sole member

By:    /s/James R. McKnight, Jr.            
Name:    James R. McKnight, Jr.
Its:    President and Chief Executive Officer

Acknowledgement on following page


THE STATE OF _____________    )
)
COUNTY OF _______________    )
This instrument was acknowledged before me on the _____ day of September, 2018, by James R. McKnight, Jr., the President and Chief Executive Officer of the above listed corporation and limited liability companies, on behalf of said corporation and limited liability companies.
Notary Public

LIST OF EXHIBITS AND SCHEDULES TO LEASE

Exhibits A-1 through A-35 –             Description of Land
Exhibits B –                         Facility Trade Names
Exhibit C –                         Permitted Encumbrances
Exhibit D –                         Form of Tenant’s Certificate
Exhibit E –                         Consent of Manager
Exhibit F -                        Approved Improvements Letter
Exhibit G –                         Form of Memorandum and Short Form of Lease
Schedule 1                        List of Landlords
Schedule 2                        List of Tenants
Schedule 3                        Existing Leases
Schedule 6.3                        Excluded Personal Property of Tenant
Schedule 8.5                        Excepted Facilities to Radius Restrictions
Schedule 9.3(a)                    7.0% Upgrades
Schedule 9.3(b)                    9.0% Improvements
Schedule 13.2.5                    Current Maximum Aggregate Coverage Requirements
Schedule 22.4                         List of Subleases
Schedule 24.1                        Organizational Structure
Schedule 24.8                        Adverse Matters
EXHIBITS A-1 THROUGH A-35
DESCRIPTION OF LAND

EXHIBIT B

FACILITY TRADE NAMES
EXHIBIT C
PERMITTED ENCUMBRANCES

All covenants, easements, restrictions, conditions and other matters of record with respect to the Leased Properties as of the Commencement Date as to each Leased Property, except the following: (a) liens for past due real estate taxes and assessments; (b) mechanic’s liens (other than resulting from the actions of Landlord and its Affiliates); (c) judgment liens (other than against Landlord and its Affiliates or, with respect to the Facilities previously covered by the Terminated Leases only, any predecessor of Landlord not an Affiliate of Tenant); and (d) monetary liens, mortgages or financing statements for the benefit of any third-party creditor of Tenant, other than Landlord and its Affiliates.


EXHIBIT D

FORM OF TENANT’S CERTIFICATE
The undersigned (“Tenant”) under that certain Master Lease (the “Lease”) dated 2018 and made with , a (“Landlord”), hereby certifies:
1.    That it is Tenant under the Lease; that attached hereto as Exhibit “A” is a true and correct copy of the Lease; that the Lease is now in full force and effect and has not been amended, modified or assigned except as disclosed or included in Exhibit “A”; and that the Lease constitutes the entire agreement between Landlord and Tenant.
2.    That there exist no defenses or offsets to enforcement of the Lease; that there are, as of the date hereof, no breaches or uncured defaults on the part of Tenant or, to the best of Tenant’s knowledge, Landlord thereunder; and that Tenant has no notice or knowledge of any prior assignment, hypothecation, subletting or other transfer of Landlord’s interest in the Lease.
3.    That the Base Rent for the first Lease Year under this Lease is $ . All Rent which is due has been paid, and there are no unpaid Additional Charges owing by Tenant under the Lease as of the date hereof. No Base Rent or other items (including without limitation security deposit and any impound account or funds) have been paid by Tenant in advance under the Lease except for the security deposit held by Landlord [in the form of an irrevocable letter of credit] in the amount of $******* and the monthly installment of Base Rent that became due on _______.
4.    That Tenant has no claim against Landlord for any security deposit, impound account or prepaid Rent except as provided in paragraph 3 of this Certificate.
5.    That there are no actions, whether voluntary or otherwise, pending against the undersigned under the bankruptcy laws of the United States or any state thereof, nor has Tenant nor, to the best of Tenant’s knowledge has Landlord begun any action, or given or received any notice for the purpose of termination of the Lease.
6.    That there are, as of the date hereof, no breaches or uncured defaults on the part of Tenant under any other agreement executed in connection with the Lease.
7.    This Certificate has been requested by Landlord pursuant to Section 19.3 of this Lease and for the benefit of __________________________________ (“Relying Party”). The Relying Party is entitled to rely on the statements of Tenant contained in this certificate.
8.    All capitalized terms used herein and not defined herein shall have the meanings for such terms set forth in the Lease.
Dated:    _____, 20__            Tenant:
                                                                       
By:

EXHIBIT E
FORM OF CONSENT OF MANAGER

EXHIBIT F
ADVANCE REQUEST FOR
FUNDING OF APPROVED IMPROVEMENT ITEMS

c/o Omega Healthcare Investors, Inc.
200 International Circle, Suite 3500
Hunt Valley, MD 21030
Attn.: Daniel J. Booth
Telephone No.: (410) 427-1700
Facsimile No.: (410) 427-8800


Re:
Master Lease dated as of ___________, 201_ (as amended and in effect from time to time, collectively, the “Lease”).

Ladies and Gentlemen:

Unless otherwise defined herein, terms used herein with initial capital letters shall have the same meanings assigned to such terms in the Lease.

In accordance with the terms and conditions of the Lease, __________________ (“Tenant”), desires to obtain an advance on ______________, 201__ in the amount of $0.00 (each increment shall not be less than $5,000.00) for an Approved Improvement as more particularly set forth below (the “Advance”).

In order to induce ___________________ (“Landlord”), to make the Advance, Tenant hereby represents and warrants the following to Landlord:

1.    No Event of Default or Unmatured Event of Default exists under the Lease, and no Event of Default will occur under the Lease as a result of the Advance requested herein.

2.    All of Tenant’s representations and warranties under the Lease are true and correct as of the date hereof, and after giving effect to the making of the Advance, will continue to be true and correct as of the date on which the Advance is made.

3.    The requested Advance reimburses or will be used by Tenant to pay for certain costs incurred in connection with the Approved Improvement completed pursuant to and in accordance with all of the terms and conditions of the Lease, which costs are more particularly described in the invoices annexed hereto as Exhibit A.

4.    Also attached to this request are copies of any receipts or other evidence verifying the costs of the applicable Approved Improvement.

5.    With respect to any Approved Improvement with a cost exceeding $25,000.00, attached to this request is an executed certification from an inspecting architect or other third party acceptable to Landlord describing the completed Approved Improvement and verifying its completion and value, together with any affidavits and executed lien waivers from those Persons completing the Approved Improvement or providing any supplies in connection therewith. All partial or final, as applicable, lien waivers and releases of lien are annexed hereto as Exhibit B.

6.The applicable conditions to the making of any Advance as set forth in the Lease have been satisfied as of the date hereof, including, without limitation, the Approved Improvement requirements set forth in the Lease.

7.The following information is true and correct as of the date hereof and will be true and correct as of the date on which the aforesaid requested Advance is to be made pursuant to the Lease:

Maximum Approved Improvement Funds:

 
$ _________
Less: Amount of Advance requested by Tenant:

 
$0.00
Less: Aggregate amount of all previous Advances requested by Tenant for Approved Improvements:
 
$0.00
Amount available for Approved Improvements:
 
$0.00

8.The funds may be disbursed by Landlord to Tenant or, at Landlord’s option, may be paid (i) directly to, and disbursed by, a title agent acceptable to Landlord, or (ii) paid directly to the party to whom payment is owed. Landlord may, at its option, acquire title insurance coverage in connection with this draw and all costs and expense of such coverage shall be included in the Advance.

9.The information set forth herein (including the exhibits and attachments hereto) is true, correct and complete as of the date hereof and shall continue to be true, correct and complete as of the date on which the Advance is made, and Tenant acknowledges that, in connection with making each Advance, Landlord is relying on the information contained herein (including the attachments hereto) and certified, both on behalf of the Tenant and the undersigned, individually, as being true, correct and complete.

Signature Page follows.


TENANT:
______________________, LLC,



By:            __________________
Name:         __________________
Its:         __________________

THE STATE OF_____________    )
)
COUNTY OF________________    )
This instrument was acknowledged before me on the _____ day of _________, 201_, by __________________, the __________________ of __________________, LLC, a __________________limited liability company, on behalf of said company.


Notary Public

EXHIBIT A


INVOICES




EXHIBIT B


FINAL LIEN WAIVER AND RELEASE OF LIENS

EXHIBIT G
MEMORANDUM OR SHORT FORM OF LEASE
THIS INSTRUMENT PREPARED BY:
Mark E. Derwent
Doran Derwent PLLC
5960 Tahoe Dr, S.E., Suite 101
Grand Rapids, Michigan 49546
Telephone: 616.451.8690

THIS LEASE, made and entered into as of _____________, 20__, by and between ___________ __________________________________, having its principal office at 303 International Circle, Suite 200, Hunt Valley, MD 21030, as Landlord, and __________________ Inc., a ___________________, having its principal office at ___________________________, as Tenant with respect to the real property identified in Exhibit(s) “ “ attached hereto and located in ________________________________________.
WITNESSETH:
1.    For and in consideration of the rents reserved and the other covenants contained in that certain Lease made by and between the parties hereto and dated the date hereof (“Lease”), Landlord has and does hereby lease to Tenant, and Tenant has and does hereby take and rent from Landlord, all of Landlord’s rights and interest in and to the parcel of real property described in Exhibit(s) “ “ and all fixtures and improvements thereto, and certain personal and other property as set forth in the Lease.
2.    The Initial Term of the Lease is approximately ____________ (_____) years, commencing _____________, 200__ and ending on _________________, 200__.
3.    As more particularly provided in the Lease, Tenant may elect to renew the original term for ___ (_) ___ (_) year optional renewal periods for a maximum term, if exercised, of_______ (__) years after the Commencement Date.
4.    This instrument is executed and recorded for the purpose of giving notice of Tenant’s interest in the property covered by the Lease and giving notice of the existence of the Lease, to which reference is made for a full statement of the terms and conditions thereof. The respective addresses of the parties hereto are:
Tenant:
Attn:
Landlord:
Attn:
IN WITNESS WHEREOF, the parties have caused this instrument to be executed by their duly authorized [officer or officers] and [general partners] [managing partners], as applicable, all as of the day and date first above written.


Schedule 1
List of Landlords
 
Facility
Landlord
1.    
Best Care, Inc.
2159 Dogwood Ridge
Wheelersburg, OH 45694
Sterling Acquisition, LLC
2.    
Boyd Nursing and Rehab Center
12800 Princeland Drive
Ashland, KY 41102
Sterling Acquisition, LLC
3.    
Canterbury Health Center
1720 Knowles Road
Phoenix City, AL 36867
Sterling Acquisition, LLC
4.    
Carter Nursing & Rehab Center
250 McDavid Boulevard, P.O. Box 904
Grayson, KY 41143
Sterling Acquisition, LLC
5.    
Elliott Nursing & Rehab Center
Howard Creek Road, P.O. Box 694, Route 32 East
Sandy Hook, KY 41171
Sterling Acquisition, LLC
6.    
Hardee Manor Care Center
401 Orange Place
Wauchula, FL 33873
Sterling Acquisition, LLC
7.    
Laurel Manor Health Center
902 Buchanan Road, P.O. Box 505
New Tazewell, TN 37825
Sterling Acquisition, LLC
8.    
Lynwood Nursing Home
4164 Halls Mill Road
Mobile, AL 36693
Sterling Acquisition, LLC
9.    
Manor House of Dover
537 Spring Street, P.O. Box 399
Dover, TN 37058
Sterling Acquisition, LLC
10.    
Mayfield Rehab and Special Care Center
200 Mayfield Drive
Smyrna, TN 37167
Sterling Acquisition, LLC
11.    
Northside Health Care
700 Hutchins Ave
Gadsden, AL 35901
Sterling Acquisition, LLC
12.    
South Shore Nursing & Rehab Center
James Hannah Drive, P.O. box 489
South Shore, KY 41175
Sterling Acquisition, LLC
13.    
West Liberty Nursing & Rehab Center
774 Liberty Road, P.O. Box 219, Route 5 Wells Hill
West Liberty, KY 41472
Sterling Acquisition, LLC
14.    
Westside Health Care Center
4320 Judith Lane
Huntsville, AL 35805
Sterling Acquisition, LLC
15.    
Wurtland Nursing & Rehab Center
100 Wurtland Avenue, P.O. Box 677
Wurtland, KY 41144
Sterling Acquisition, LLC
16.    
Doctors Healthcare
9009 White Rock Trail
Dallas, TX 75238
Sterling Acquisition, LLC
17.    
Estates at Ft. Worth
201 Sycamore School Road
Fort Worth, TX 76134
Sterling Acquisition, LLC
18.    
Heritage Oaks Estates
2001 N. 6th Street
Ballinger, TX 76821
Sterling Acquisition, LLC
19.    
Humble
8450 Will Clayton Parkway
Humble, TX 77338
Sterling Acquisition, LLC
20.    
IHS of Dallas at Treemont
5550 Harvest Hill Road
Dallas, TX 75230
Sterling Acquisition, LLC
21.    
Katy
1525 Tull Drive
Katy, TX 77499
Sterling Acquisition, LLC
22.    
Normandy Terrace
841 Rice Road
San Antonio, TX 78220
Sterling Acquisition, LLC
23.    
Brentwood Terrace
2885 Stillhouse Road
Paris, TX 75460
Sterling Acquisition, LLC
24.    
Highlands Nursing and Rehabilitation Center
1705 Stevens Avenue
Louisville, KY 40205
Stevens Avenue Property, L.L.C.
25.    
Chateau Care Center
811 N. Ninth Street
St. Joseph, MO 64501
St. Joseph Missouri Property, L.L.C.
26.    
Riverside Care Center
1616 Weisenborn Road
St. Joseph, MO 64507
St. Joseph Missouri Property, L.L.C.
27.    
The Inn
3002 N. 18th Street
St. Joseph, MO 64505
St. Joseph Missouri Property, L.L.C.
28.    
Diversicare of Bradford Place (fka Mercy Schroder)
1302 Millville Avenue
Hamilton, OH 45013
Ohio Indiana Property, L.L.C.
29.    
Diversicare of Providence
4915 Charlestown Road
New Albany, IN 47150
Ohio Indiana Property, L.L.C.
30.    
Diversicare of Siena Woods
6125 North Main Street
Dayton, OH 45415
Ohio Indiana Property, L.L.C.
31.    
Diversicare of St. Theresa
7010 Rowan Hill Drive
Cincinnati, OH 45227
Ohio Indiana Property, L.L.C.
32.    
Royal Manor Health Care
100 Sparks Avenue
 Nicholasville, KY 40356
Nicholasville Kentucky Property, L.L.C.
33.    
Twinbrook Nursing and Rehabilitation Center
3526 Dutchman's Lane
 Louisville, KY 40205
Louisville Dutchmans Property, L.L.C.
34.    
Belle Meade Home
521 Greene Dr.
Greenville, KY 42345
Greenville Kentucky Property, L.L.C.

Schedule 2
List of Tenants
 
Facility
Tenant
1.    
Best Care, Inc.
2159 Dogwood Ridge
Wheelersburg, OH 45694
Diversicare Leasing Corp.
2.    
Boyd Nursing and Rehab Center
12800 Princeland Drive
Ashland, KY 41102
Diversicare Leasing Corp.
3.    
Canterbury Health Center
1720 Knowles Road
Phoenix City, AL 36867
Diversicare Leasing Corp.
4.    
Carter Nursing & Rehab Center
250 McDavid Boulevard, P.O. Box 904
Grayson, KY 41143
Diversicare Leasing Corp.
5.    
Elliott Nursing & Rehab Center
Howard Creek Road, P.O. Box 694, Route 32 East
Sandy Hook, KY 41171
Diversicare Leasing Corp.
6.    
Hardee Manor Care Center
401 Orange Place
Wauchula, FL 33873
Diversicare Leasing Corp.
7.    
Laurel Manor Health Center
902 Buchanan Road, P.O. Box 505
New Tazewell, TN 37825
Diversicare Leasing Corp.
8.    
Lynwood Nursing Home
4164 Halls Mill Road
Mobile, AL 36693
Diversicare Leasing Corp.
9.    
Manor House of Dover
537 Spring Street, P.O. Box 399
Dover, TN 37058
Diversicare Leasing Corp.
10.    
Mayfield Rehab and Special Care Center
200 Mayfield Drive
Smyrna, TN 37167
Diversicare Leasing Corp.
11.    
Northside Health Care
700 Hutchins Ave
Gadsden, AL 35901
Diversicare Leasing Corp.
12.    
South Shore Nursing & Rehab Center
James Hannah Drive, P.O. box 489
South Shore, KY 41175
Diversicare Leasing Corp.
13.    
West Liberty Nursing & Rehab Center
774 Liberty Road, P.O. Box 219, Route 5 Wells Hill
West Liberty, KY 41472
Diversicare Leasing Corp.
14.    
Brookshire Health Care Center
4320 Judith Lane
Huntsville, AL 35805
Diversicare Leasing Corp.
15.    
Wurtland Nursing & Rehab Center
100 Wurtland Avenue, P.O. Box 677
Wurtland, KY 41144
Diversicare Leasing Corp.
16.    
Doctors Healthcare
9009 White Rock Trail
Dallas, TX 75238
Diversicare Leasing Corp.
17.    
Estates at Ft. Worth
201 Sycamore School Road
Fort Worth, TX 76134
Diversicare Leasing Corp.
18.    
Heritage Oaks Estates
2001 N. 6th Street
Ballinger, TX 76821
Diversicare Leasing Corp.
19.    
Humble
8450 Will Clayton Parkway
Humble, TX 77338
Diversicare Leasing Corp.
20.    
IHS of Dallas at Treemont
5550 Harvest Hill Road
Dallas, TX 75230
Diversicare Leasing Corp.
21.    
Katy
1525 Tull Drive
Katy, TX 77499
Diversicare Leasing Corp.
22.    
Normandy Terrace
841 Rice Road
San Antonio, TX 78220
Diversicare Leasing Corp.
23.    
Brentwood Terrace
2885 Stillhouse Road
Paris, TX 75460
Diversicare Leasing Corp.
24.    
Highlands Nursing and Rehabilitation Center
1705 Stevens Avenue
Louisville, KY 40205
Diversicare Highlands, LLC
25.    
Chateau Care Center
811 N. Ninth Street
St. Joseph, MO 64501
Diversicare of Chateau, LLC
26.    
Riverside Care Center
1616 Weisenborn Road
St. Joseph, MO 64507
Diversicare of Riverside, LLC
27.    
The Inn
3002 N. 18th Street
St. Joseph, MO 64505
Diversicare of St. Joseph, LLC
28.    
Diversicare of Bradford Place (fka Mercy Schroder)
1302 Millville Avenue
Hamilton, OH 45013
Diversicare of Bradford Place, LLC
29.    
Diversicare of Providence
4915 Charlestown Road
New Albany, IN 47150
Diversicare of Providence, LLC
30.    
Diversicare of Siena Woods
6125 North Main Street
Dayton, OH 45415
Diversicare of Siena Woods, LLC
31.    
Diversicare of St. Theresa
7010 Rowan Hill Drive
Cincinnati, OH 45227
Diversicare of St. Theresa, LLC
32.    
Royal Manor Health Care
100 Sparks Avenue
 Nicholasville, KY 40356
Diversicare of Nicholasville, LLC
33.    
Twinbrook Nursing and Rehabilitation Center
3526 Dutchman's Lane
 Louisville, KY 40205
Diversicare of Senaca Place, LLC
34.    
Belle Meade Home
521 Greene Dr.
Greenville, KY 42345
Diversicare of Greenville, LLC

Schedule 3
Existing Leases
I. Expiring Lease.    
Consolidated Amended and Restated Master Lease dated as of November 8, 2000, but effective as of October 1, 2000, by Sterling Acquisition Corp., as Lessor, and Diversicare Leasing Corp., as Lessee, as amended by that certain First Amendment to Consolidated Amended and Restated Master Lease dated September 30, 2001, as further amended by that certain Second Amendment to Consolidated Amended and Restated Master Lease dated June 15, 2005, as further amended by that certain Third Amendment to Consolidated Amended and Restated Master Lease dated as of October 20, 2006, but effective as of October 1, 2006, as further amended by that certain Fourth Amendment to Consolidated, Amended and Restated Master Lease dated as of April 1, 2007, as further amended by that certain Fifth Amendment to Consolidated, Amended and Restated Master Lease dated as of August 10, 2007, as further amended by that certain Sixth Amendment to Consolidated Amended and Restated Master Lease dated as of March 14, 2008, as further amended by that certain Seventh Amendment to Consolidated Amended and Restated Master Lease dated as of October 24, 2008, as further amended by that certain Eighth Amendment to Consolidated Amended and Restated Master Lease dated as of March 31, 2009, as further amended by that certain Ninth Amendment to Consolidated Amended and Restated Master Lease dated as of May 5, 2009, as further amended by that certain Tenth Amendment to Consolidated Amended and Restated Master Lease dated as of September 8, 2009, as further amended by that certain Eleventh Amendment to Consolidated Amended and Restated Master Lease dated April 18, 2011, and as further amended by that certain Twelfth Amendment to Consolidated Amended and Restated Master Lease dated as of January 22, 2013, as further amended by that certain Thirteenth Amendment to Consolidated Amended and Restated Master Lease dated August 1, 2013, as further amended by that certain Fourteenth Amendment to Consolidated Amended and Restated Master Lease dated January 31, 2014, as further amended by that certain Fifteenth Amendment to Consolidated Amended and Restated Master Lease dated June 30, 2014.
II. Terminated Leases.
1. Lease dated August 23, 2012 between Stevens Avenue Property, L.L.C., as Lessor, and Diversicare Highlands, LLC, as Lessee, together with the Commencement Date Addendum to Lease dated September 24, 2012, as amended by that certain First Amendment to Lease dated July 31, 2013, as further amended by that certain Second Amendment to Lease dated as of November 8, 2013, as further amended by that certain Third Amendment to Lease dated August 15, 2014 and as further amended by that certain Fourth Amendment to Lease dated September 30, 2014.
2.    Lease dated July 31, 2013 between Louisville Dutchmans Property, L.L.C., as Lessor, and Diversicare of Seneca Place, LLC, as Lessee, together with Commencement Date Addendum to Lease dated August 22, 2013, as amended by that certain First Amendment to Lease dated November 8, 2013, as further amended by that certain Second Amendment to Lease dated August 15, 2014, as further amended by that certain Third Amendment to Lease dated September 30, 2014, as further amended by that certain Fourth Amendment to Lease dated December 5, 2014 and as further amended by that certain Fifth Amendment to Lease dated January 20, 2016.
3.    Master Lease dated September 27, 2013 among Ohio Indiana Property, L.L.C., as Lessor, and Diversicare of Providence, LLC, Diversicare of Siena Woods, LLC, Diversicare of St. Theresa and Diversicare of Bradford Place, LLC, as Lessee, as amended by that certain First Amendment to Master Lease dated November 8, 2013, as further amended by that certain Second Amendment to Master Lease dated August 15, 2014 and as further amended by that certain Third Amendment to master Lease dated as of September 30, 2014.
4. Lease dated as of May 28, 2014 by and between Nicholasville Kentucky Property, L.L.C., a Delaware limited liability company (“Lessor”) and Diversicare of Nicholasville, LLC, a Delaware limited liability company (“Lessee”), commencing June 1, 2014, as amended by that certain First Amendment to Lease dated as of August 15, 2014, as further amended by that certain Second Amendment to Lease dated as of September 30, 2014, as further amended by that certain Third Amendment to Lease dated as of January 9, 2015, and as further amended by Fourth Amendment to Lease dated as of ____________, 2016.
5.    Master Lease dated as of June 25, 2014 by and between St. Joseph Missouri Property, L.L.C., a Delaware limited liability company (“Lessor”) and Diversicare of Chateau, LLC, a Delaware limited liability company, Diversicare of Riverside, LLC, a Delaware limited liability company, and Diversicare of St. Joseph, LLC, a Delaware limited liability company (collectively , “Lessee”), commencing July 1, 2014, as amended by that certain First Amendment to Master Lease dated as of August 15, 2014 and as further amended by that certain Second Amendment to Master Lease dated as of September 30, 2014.
6.    Lease dated September 30, 2014 by and between Greeneville Kentucky Property, L.L.C., a Delaware limited liability company ( “Lessor”) and Diversicare of Greeneville, LLC, a Delaware limited liability company (“Lessee”), commencing October 1, 2014.




Schedule 6.3

Excluded Personal Property of Tenant

1.
Tenant’s continuous quality improvement program, manuals and materials; management information systems; policy, procedure and educational manuals and materials and similar proprietary property.
2.
Computer hardware, and related equipment which is integrated with the computer system maintained by DHSI, and computer software, provided, however, that Tenant shall cause all data that is reasonably necessary for the continuing operation of one or more of the Facilities, and which may be accessed through such computers or software, to be made available to Landlord in a reasonably accessible form without material cost to Landlord.


Schedule 8.5
Excepted Facilities to Radius Restriction


Alabama        Windsor House            Huntsville, Alabama
Big Springs Huntsville, Alabama
     




Schedule 9.3(a)
7.0% Upgrades



Schedule 9.3(b)

9.0% Improvements


Schedule 13.2.5
Current Maximum Aggregate Coverage
1. The following Facilities are insured under a policy with a Twelve Million Dollar ($12,000,000.00) policy maximum aggregate:

Diversicare of Chateau
Diversicare of Riverside
Diversicare of St. Joseph
Diversicare of Nicholasville


2. The following Facilities are insured under a policy with a Ten Million Dollar ($10,000,000.00) policy maximum aggregate:
                                                                                                   
 
Diversicare of Seneca Place
Diversicare of Greenville
Diversicare of Highlands


3. The following Facilities are insured under a policy with a Twelve Million Dollar ( $12,000,000.00) policy maximum aggregate:

Diversicare of St. Theresa
Diversicare of Bradford Place
Diversicare of Siena Woods

4. The remaining 23 Facilities are insured under the Insurance Captive which has an overall policy maximum aggregate of Five Million Dollars ( $5,000,000.00):

Brookshire Healthcare Center
 
Canterbury Healthcare Facility
 
Lynwood Nursing Home
 
Northside Health Care
 
Hardee Manor Healthcare
 
Boyd Nursing & Rehabilitation Center
 
Carter Nursing & Rehabilitation Center
 
Elliott Nursing & Rehabilitation Center
 
South Shore Nursing & Rehabilitation Center
 
West Liberty Nursing & Rehabilitation Center
 
Wurtland Nursing & Rehabilitation Center
 
Best Care Nursing & Rehabilitation Center;
 
Diversicare of Claiborne, previously dba Laurel Manor
 
Diversicare of Dover, previously dba Manor House of Dover
 
Diversicare of Smyrna, previously dba Mayfield Rehabilitation and Special Care Center
 
Diversicare Ballinger, LLC
 
Diversicare Doctors, LLC
 
Diversicare Estates, LLC
 
Diversicare Humble, LLC
 
Diversicare Katy, LLC
 
Diversicare Normandy Terrace, LLC
 
Diversicare Treemont, LLC
 
Diversicare Paris, LLC
 








Schedule 22.4
List of Subleases*
1.    
Doctors Healthcare
9009 White Rock Trail
Dallas, TX 75238
Diversicare Texas I, LLC
Master Sublessor
Diversicare Doctors, LLC
Sublessee
2.    
Estates at Ft. Worth
201 Sycamore School Road
Fort Worth, TX 76134
Diversicare Texas I, LLC
Master Sublessor
Diversicare Estates, LLC
Sublessee
3.    
Heritage Oaks Estates
2001 N. 6th Street
Ballinger, TX 76821
Diversicare Texas I, LLC
Master Sublessor
Diversicare Ballinger, LLC
Sublessee
4.    
Humble
8450 Will Clayton Parkway
Humble, TX 77338
Diversicare Texas I, LLC
Master Sublessor
Diversicare Humble, LLC
Sublessee
5.    
IHS of Dallas at Treemont
5550 Harvest Hill Road
Dallas, TX 75230
Diversicare Texas I, LLC
Master Sublessor
Diversicare Treemont, LLC
Sublessee
6.    
Katy
1525 Tull Drive
Katy, TX 77499
Diversicare Texas I, LLC
Master Sublessor
Diversicare Katy, LLC
Sublessee
7.    
Normandy Terrace
841 Rice Road
San Antonio, TX 78220
Diversicare Texas I, LLC
Master Sublessor
Diversicare Normandy Terrace, LLC
Sublessee

8.    
Brentwood Terrace
2885 Stillhouse Road
Paris, TX 75460
Diversicare Texas I, LLC
Master Sublessor
Diversicare Paris, LLC
Sublessee
9.    
All of the Facilities listed in Items 1-8, above

Diversicare Leasing Corp.
Sublessor
Diversicare Texas I, LLC
Master Sublessee
10.    
Diversicare of Providence
4915 Charlestown Road
New Albany, IN 47150
Diversicare of Providence, LLC
Sublessor
Daviees Community Hospital, an Indiana county hospital, Sublessee

*Diversicare Texas I, LLC, is a wholly owned subsidiary of Diversicare Leasing Corp. Each of the entities listed in Items 1-8 is a wholly owned subsidiary of Diversicare Texas I, LLC.



Schedule 24.1
Tenant Organizational Structure


Schedule 24.8
Adverse Matters
This Schedule 24.8 shall be deemed to include matters provided or furnished by Tenant or any Guarantor to Landlord pursuant to the terms and provisions of other Sections of this Lease, including but not limited to those disclosures required by Section 23.1.
Civil Investigative Demand ("CID")

In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").  In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.

In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement.



A request for confidential treatment has been made with respect to portions of this document that are marked ‘[*****]’. The redacted portions have been filed separately with the SEC.

 EX-31.1 3 dvcr-ex311x93018certificat.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, James R. McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 1, 2018
 
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
President and Chief Executive Officer, Principal Executive Officer and
An Officer Duly Authorized to SIgn on Behalf of the Registrant



 EX-31.2 4 dvcr-ex312x93018certificat.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(ii) CERTIFICATION
I, Kerry D. Massey, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:  November 1, 2018
 
/s/ Kerry D. Massey
Kerry D. Massey
Executive Vice President and Chief Financial Officer and
An Officer Duly Authorized to Sign on Behalf of the Registrant



 EX-32 5 dvcr-ex32x93018certificati.htm EXHIBIT 32 Exhibit


Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED JUNE 30, 2017
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of November 1, 2018.

 
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
President and Chief Executive Officer, Principal Executive Officer and
An Officer Duly Authorized to SIgn on Behalf of the Registrant
 
/s/ Kerry D. Massey
Kerry D. Massey
Executive Vice President and Chief Financial Officer and
An Officer Duly Authorized to SIgn on Behalf of the Registrant
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 6 avca-20180930.xml XBRL INSTANCE DOCUMENT 0000919956 2018-01-01 2018-09-30 0000919956 2018-10-29 0000919956 2018-09-30 0000919956 2017-12-31 0000919956 2018-07-01 2018-09-30 0000919956 2017-07-01 2017-09-30 0000919956 2017-01-01 2017-09-30 0000919956 2017-09-30 0000919956 2016-12-31 0000919956 srt:MaximumMember 2018-09-30 0000919956 srt:MinimumMember 2018-09-30 0000919956 avca:UnnamedPharmacyJointVentureMember 2016-10-01 2016-12-31 0000919956 2016-10-01 2016-12-31 0000919956 avca:UnnamedPharmacyJointVentureMember 2017-01-01 2017-09-30 0000919956 avca:UnnamedPharmacyJointVentureMember 2018-01-01 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplicitPriceConcessionOfBadDebtExpenseMember 2018-07-01 2018-09-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-07-01 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-07-01 2018-09-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AllowanceForDoubtfulAccountsMember 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606TaxAdjustmentMember 2018-09-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-07-01 2017-09-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0000919956 avca:MedicaidMember 2018-07-01 2018-09-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0000919956 avca:PrivatePayAndOtherMember 2018-07-01 2018-09-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-07-01 2017-09-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-07-01 2017-09-30 0000919956 avca:MedicareMember 2018-07-01 2018-09-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0000919956 avca:ManagedCareMember 2018-07-01 2018-09-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-07-01 2017-09-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-07-01 2017-09-30 0000919956 avca:PrivatePayAndOtherMember 2018-01-01 2018-09-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-09-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0000919956 avca:MedicareMember 2018-01-01 2018-09-30 0000919956 avca:ManagedCareMember 2018-01-01 2018-09-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0000919956 avca:MedicaidMember 2018-01-01 2018-09-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-09-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-09-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-09-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-01-01 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplicitPriceConcessionOfBadDebtExpenseMember 2018-01-01 2018-09-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-28 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2018-09-30 0000919956 us-gaap:InterestRateSwapMember 2018-09-30 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2018-09-30 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2018-01-01 2018-09-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2018-09-30 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-12-31 0000919956 avca:AmendedandRestatedCreditAgreementMember 2018-09-30 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2017-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2018-09-30 0000919956 us-gaap:InterestRateSwapMember 2018-01-01 2018-09-30 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2018-01-01 2018-03-31 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember avca:OmegaHealthcareInvestorsIncMember 2018-09-30 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-10-03 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember avca:MortgageTermLoanMember 2016-02-26 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-29 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-08-01 0000919956 avca:PrefundedDeductiblePolicyMember 2018-01-01 2018-09-30 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2013-07-01 2016-02-29 0000919956 avca:TrialOrArbitrationScheduleTimeframeMember 2018-09-30 0000919956 avca:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2018-01-01 2018-09-30 0000919956 avca:PrefundedDeductiblePolicyMember 2018-09-30 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2014-10-31 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2018-09-30 0000919956 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0000919956 us-gaap:EmployeeStockMember 2018-09-30 0000919956 us-gaap:EmployeeStockMember 2017-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2018-01-01 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2017-12-31 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-09-30 0000919956 us-gaap:EmployeeStockOptionMember us-gaap:DirectorMember 2018-01-01 2018-09-30 0000919956 avca:ExecutiveEquityAwardsMember 2018-01-01 2018-09-30 0000919956 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-05-31 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-05-31 0000919956 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2018-01-01 2018-09-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-09-30 0000919956 us-gaap:EmployeeStockOptionMember us-gaap:DirectorMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-09-30 0000919956 us-gaap:EmployeeStockOptionMember us-gaap:DirectorMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-09-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-09-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-09-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2018-01-01 2018-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2018-01-01 2018-09-30 0000919956 avca:SelmaNursingCentersMember 2017-07-01 0000919956 avca:SelmaNursingCentersMember 2017-07-01 2017-07-01 0000919956 2018-01-01 2018-03-31 0000919956 avca:SelmaNursingCentersMember 2017-12-31 0000919956 avca:SelmaNursingCentersMember 2017-01-01 2017-12-31 0000919956 avca:TrendHealthandRehabofCarthageLLCTrendHealthMember 2017-01-01 2017-12-31 0000919956 us-gaap:SubsequentEventMember 2018-10-01 0000919956 avca:OmegaHealthcareInvestorsIncMember us-gaap:SubsequentEventMember 2018-10-01 0000919956 us-gaap:SubsequentEventMember 2018-10-01 2018-10-01 0000919956 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember avca:ThePropertiesMember us-gaap:SubsequentEventMember 2018-10-30 2018-10-30 iso4217:USD avca:state avca:lawsuit avca:facility avca:extension avca:director avca:civil_investigative_demand xbrli:pure avca:center iso4217:USD xbrli:shares avca:bed avca:letter_of_credit xbrli:shares avca:investment 6691000 6403000 145000 18 1.01 700000 0 200000 0.03 P25Y 7500000 2 3000000 1000000 6077000 4452000 8456 103 2 76 58 11 34 18 83 20 1 11 497 320 48 23 3 0.0215 P10Y P12Y 2 -94000 -219000 517000 1363000 0.075 0.526 0.249 0.150 1 0.074 0.519 0.263 0.144 1 1 0.088 0.075 0.487 0.539 0.191 0.241 0.234 0.145 1 1 0.094 0.080 0.468 0.522 0.200 0.251 0.238 0.147 1 0 75000 7.06 9.76 0 75000 211000 124000 6.64 7.24 9.32 5.28 9.59 9.95 9.25 8.77 104000 17000 5.79 8.14 104000 40000 64000 124000 60000 64000 100000 6.89 6.95 30000 P2Y 1074000 false --12-31 Q3 2018 2018-09-30 10-Q 0000919956 6518013 false Non-accelerated Filer Diversicare Healthcare Services, Inc. true 27915000 30000000 14080000 14146000 64929000 65927000 -887000 16235000 15348000 81275000 78345000 83956000 709000 1059000 403000 22720000 23267000 766000 947000 259000 14235000 46000 124000 167569000 172331000 72658000 75482000 25707000 43375000 45000 20000 140000 925000 925000 8750000 9675000 8435000 335000 760000 507000 203000 4263000 3295000 3524000 3293000 -968000 -231000 0 0 0 0 -241000 -645000 680000 380000 0.055 0.165 0.055 0.165 0.01 0.01 20000000 20000000 6687000 6749000 6455000 6517000 67000 68000 -492000 1361000 -7351000 -7461000 118104000 341937000 113799000 3903000 117702000 337517000 11155000 348672000 145403000 424437000 147397000 3903000 151300000 427672000 11155000 438827000 0.0475 0.04 0.04 0.06 0.068 0.0600 0.0579 P5Y P5Y 137000 279000 2162000 15154000 15891000 52000 -829000 2988000 8095000 2964000 8692000 661000 1000 -25000 0 -11000 0 13299000 -0.09 0.17 -1.15 -1.23 -0.09 0.17 -1.15 -1.23 20013000 20131000 1366000 733000 733000 308000 308000 5425000 180000 180000 0 0 8083000 25277000 7537000 24971000 -581000 1148000 -7389000 -7777000 -926000 1799000 -7596000 -8447000 -0.09 0.18 -1.15 -1.22 -0.09 0.18 -1.15 -1.22 1000 -42000 -8000 -34000 0.00 -0.01 0.00 -0.01 0.00 -0.01 0.00 -0.01 -345000 651000 -207000 -670000 258000 667000 474000 537000 862000 1977000 2391000 -459000 2379000 8387000 2134000 -168000 2224000 1668000 4692000 1666000 4996000 3989000 4511000 13714000 167569000 172331000 64267000 68726000 96840000 105143000 461000 461000 1662000 5496000 52250000 37710000 100000000 72500000 12500000 60000000 27500000 10000000 15000000 52250000 42250000 0 6400000 72150000 9000000 63150000 16000000 18500000 74603000 77308000 13065000 12576000 0.0579 0 0 6400000 6400000 3 232000 232000 0 0 5000000 500000 500000 27070000 2617000 8011000 2933000 8890000 5374000 -44000 5374000 -44000 -16288000 -5656000 -16288000 -5656000 9946000 5469000 10187000 6114000 -580000 1106000 -7397000 -7811000 -580000 1106000 -7397000 -7811000 -1900000 -4191000 -1630000 -4573000 10 974000 5990000 -5966000 -3874000 13791000 41297000 250000 13764000 41202000 3725000 7503000 88000 255000 46000 350000 115000 348000 0 151000 203000 603000 46000 501000 7856000 8361000 8779000 5134000 -388000 -250000 0 0 36000 115000 1038000 1053000 195000 137000 492000 508000 8750000 0 8638000 5964000 3248000 3829000 18700000 31574000 17203000 1100000 308000 147549000 137430000 69204000 53474000 6407000 0 375000 1551000 24381000 15330000 -14534000 -23432000 887000 -284000 603000 -22829000 146377000 430427000 141431000 -269000 3903000 3634000 145065000 423798000 -887000 11155000 10268000 434066000 10992000 77027000 36449000 21909000 146377000 31756000 223410000 113360000 61901000 430427000 141431000 12404000 10874000 68929000 78200000 26997000 34933000 33101000 21058000 145065000 423798000 39919000 34854000 198418000 226631000 84611000 109150000 100850000 63431000 434066000 8792000 13051000 13458000 16301000 766000 947000 7000 9.62 88000 16000 90000 90000 8.14 8.14 44000 164000 44000 120000 1000 4000 17000 131000 8.91 9.71 350000 150000 30000 8.14 2.37 10.80 5.86 0.33 0.33 0.33 0.3333 0.3333 0.3333 0.33 0.33 0.33 P10Y 0.85 6462000 -1538000 232000 232000 2500000 2500000 6294000 6465000 6400000 6362000 6294000 6274000 6400000 6362000 620000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">LONG-TERM DEBT AND INTEREST RATE SWAP</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company&#8217;s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> allocated between a </font><font style="font-family:inherit;font-size:10pt;">$72,500</font><font style="font-family:inherit;font-size:10pt;"> Mortgage Loan ("Amended Mortgage Loan") and a </font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;"> Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a </font><font style="font-family:inherit;font-size:10pt;">$60,000</font><font style="font-family:inherit;font-size:10pt;"> term loan facility and a </font><font style="font-family:inherit;font-size:10pt;">$12,500</font><font style="font-family:inherit;font-size:10pt;"> acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of </font><font style="font-family:inherit;font-size:10pt;">$2,162</font><font style="font-family:inherit;font-size:10pt;"> and are being amortized over the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of </font><font style="font-family:inherit;font-size:10pt;">$72,500</font><font style="font-family:inherit;font-size:10pt;"> with a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year maturity through February 26, 2021, and a </font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;"> Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, with principal and interest payable monthly based on a </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;">-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;">, respectively. A portion of the Amended Mortgage Loan is effectively fixed at </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to an interest rate swap with an initial notional amount of </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan balance was </font><font style="font-family:inherit;font-size:10pt;">$72,150</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">$63,150</font><font style="font-family:inherit;font-size:10pt;"> on the term loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9,000</font><font style="font-family:inherit;font-size:10pt;"> on the acquisition loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.8%</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan is secured by </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company&#8217;s Amended Revolver has an interest rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the&#160;</font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;">&#160;in the Amended Revolver to&#160;</font><font style="font-family:inherit;font-size:10pt;">$52,250</font><font style="font-family:inherit;font-size:10pt;">; provided that the maximum revolving facility be reduced to </font><font style="font-family:inherit;font-size:10pt;">$42,250</font><font style="font-family:inherit;font-size:10pt;"> on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at </font><font style="font-family:inherit;font-size:10pt;">$52,250</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Revolving Agreement by increasing the Company&#8217;s letter of credit sublimit from&#160;</font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#160;to&#160;</font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by </font><font style="font-family:inherit;font-size:10pt;">$7,500</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than </font><font style="font-family:inherit;font-size:10pt;">1.01</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1.00</font><font style="font-family:inherit;font-size:10pt;"> as of March 31, 2018 and for each quarter thereafter. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$18,500</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the Amended Revolver compared to </font><font style="font-family:inherit;font-size:10pt;">$16,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The interest rate related to the Amended Revolver was </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). Also, borrowings on the revolver relate to the timing of cash flows and our operating activities. Annual fees for letters of credit issued under the Amended Revolver are </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the amount outstanding. The Company has </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> letters of credit with a total value of </font><font style="font-family:inherit;font-size:10pt;">$13,714</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of </font><font style="font-family:inherit;font-size:10pt;">$37,710</font><font style="font-family:inherit;font-size:10pt;"> the balance available for borrowing under the Amended Revolver was </font><font style="font-family:inherit;font-size:10pt;">$5,496</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Swap Transaction</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was </font><font style="font-family:inherit;font-size:10pt;">$27,915</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of </font><font style="font-family:inherit;font-size:10pt;">$661</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the interest rate swap is included in &#8220;other noncurrent assets&#8221; on the Company&#8217;s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$403</font><font style="font-family:inherit;font-size:10pt;"> net of the income tax provision of </font><font style="font-family:inherit;font-size:10pt;">$258</font><font style="font-family:inherit;font-size:10pt;">. As the Company&#8217;s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three and nine month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a </font><font style="font-family:inherit;font-size:10pt;">103</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$8,750</font><font style="font-family:inherit;font-size:10pt;">. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $</font><font style="font-family:inherit;font-size:10pt;">140</font><font style="font-family:inherit;font-size:10pt;"> of acquisition costs and a $</font><font style="font-family:inherit;font-size:10pt;">925</font><font style="font-family:inherit;font-size:10pt;"> recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The final allocation of the purchase price to the net assets acquired is as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Park Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land Improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Assets Held for Sale</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2018, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The carrying value of these centers' assets are $</font><font style="font-family:inherit;font-size:10pt;">13,299</font><font style="font-family:inherit;font-size:10pt;">. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets. Refer to Note 10&#160;for further discussion.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Lease Termination</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a </font><font style="font-family:inherit;font-size:10pt;">$250</font><font style="font-family:inherit;font-size:10pt;"> cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December&#160;31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Sale of Investment in Unconsolidated Affiliate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of </font><font style="font-family:inherit;font-size:10pt;">$308</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$733</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended September 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of </font><font style="font-family:inherit;font-size:10pt;">$308</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$733</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended September, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership. All amounts subject to the liquidation of remaining assets affiliated with the partnership have been settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three and nine month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,377</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423,798</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">434,066</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,427</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Plans</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (&#8220;Stock Purchase Plan&#8221;). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (&#8220;RSU's&#8221;) at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from </font><font style="font-family:inherit;font-size:10pt;">150</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">350</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (&#8220;2010 Plan&#8221;), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from </font><font style="font-family:inherit;font-size:10pt;">380</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">680</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the 2010 Plan after May 31, 2027.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Grants and Valuations</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors approved grants totaling approximately </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">88</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date. Generally, unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. In addition, during the nine months ended September&#160;30, 2018, the Company granted stock options to purchase a total of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price equal to the market price of the Company&#8217;s common stock on the date of grant to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> new directors. These stock options vest one third on the date of grant and one third on the first and second anniversary of the date of grant.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (&#8220;SOSARs&#8221;) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date, and expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the grant date. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.76</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(131</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.14 to $10.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $5.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$947</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$766</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The stock-based compensation expense balance for the nine month period ended September 30, 2018 is inclusive of </font><font style="font-family:inherit;font-size:10pt;">$259</font><font style="font-family:inherit;font-size:10pt;"> related to the vesting of executive equity awards.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.76</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EARNINGS PER COMMON SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(580</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effects of </font><font style="font-family:inherit;font-size:10pt;">124</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">46</font><font style="font-family:inherit;font-size:10pt;"> SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, because these securities would have been anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional Liability and Other Liability Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (&#8220;SHC&#8221;), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least </font><font style="font-family:inherit;font-size:10pt;">$500</font><font style="font-family:inherit;font-size:10pt;"> per medical incident with a sublimit per center of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> and total annual aggregate policy limits of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reserve for Estimated Self-Insured Professional Liability Claims</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company&#8217;s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company&#8217;s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of </font><font style="font-family:inherit;font-size:10pt;">$27,070</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos &amp; Associates, Inc. (&#8220;Merlinos&#8221;) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company&#8217;s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator&#8217;s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company&#8217;s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is engaged in </font><font style="font-family:inherit;font-size:10pt;">83</font><font style="font-family:inherit;font-size:10pt;"> professional liability lawsuits. </font><font style="font-family:inherit;font-size:10pt;">Twenty</font><font style="font-family:inherit;font-size:10pt;"> lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company&#8217;s cash expenditures for self-insured professional liability costs from continuing operations were </font><font style="font-family:inherit;font-size:10pt;">$4,452</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6,077</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the FASB ASU No. 2010-24, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> there are estimated insurance recovery receivables of </font><font style="font-family:inherit;font-size:10pt;">$5,425</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company&#8217;s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company&#8217;s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company&#8217;s reported earnings and financial position for the period in which the change in accrual is made.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Civil Investigative Demand ("CID")</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company&#8217;s practices and policies for rehabilitation therapy at some of its facilities. The government&#8217;s investigation relates to the Company&#8217;s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is engaged in preliminary discussions with the DOJ regarding settlement of this investigation. The Company denies any wrong doing and is prepared to vigorously defend its actions. However, based upon preliminary settlement discussions, the Company believes that it is probable a loss will result from this contingency and has accrued </font><font style="font-family:inherit;font-size:10pt;">$6,400</font><font style="font-family:inherit;font-size:10pt;"> as a contingent liability in connection with this matter during the three months ended September 30, 2018. The Company cannot predict whether a settlement can be achieved, the outcome of the litigation if there is no settlement or the length of time necessary to conclude. Accordingly, the contingent liability has been classified as a noncurrent liability in the accompanying interim consolidated balance sheets.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160; </font><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ, the Company&#8217;s assessment of the risks of litigating this case and the effect of protracted litigation or settlement terms on the Company&#8217;s business plans.&#160; Because the outcome of this investigation and related settlement discussions remain uncertain, there is a reasonable possibility that the amount ultimately incurred in connection with the resolution of this matter could differ materially from the current accrual, as the Company cannot, at this time, estimate the possible range of loss that may result from either a settlement or litigation of this matter. &#160;The ultimate outcome of this litigation could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to the practices of some of its employees with respect to PAEs and PASRRs, and the Company&#160;provided documents responsive to this subpoena and coordinated examinations of certain employees of the Company.&#160; The Company understands that this criminal investigation has been closed, subject to re-opening at the discretion of the government. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to workers&#8217; compensation insurance, substantially all of the Company&#8217;s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers&#8217; compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June&#160;30, 2003 until June&#160;30, 2007, the Company&#8217;s workers&#8217; compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July&#160;1, 2008 through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first </font><font style="font-family:inherit;font-size:10pt;">$500</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an aggregate maximum of </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers&#8217; compensation claims is </font><font style="font-family:inherit;font-size:10pt;">$620</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The Company has a non-current receivable for workers&#8217; compensation policies covering previous years of </font><font style="font-family:inherit;font-size:10pt;">$1,074</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The non-current receivable is a function of payments paid to the Company&#8217;s insurance carrier in excess of the estimated level of claims expected to be incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to </font><font style="font-family:inherit;font-size:10pt;">$200</font><font style="font-family:inherit;font-size:10pt;"> per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is </font><font style="font-family:inherit;font-size:10pt;">$1,662</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The differences between actual settlements and reserves are included in expense in the period finalized.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diversicare Healthcare Services, Inc. (together with its subsidiaries, &#8220;Diversicare&#8221; or the &#8220;Company&#8221;) provides long-term care services to nursing center patients in </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> states, primarily in the Southeast, Midwest, and Southwest. The Company&#8217;s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company&#8217;s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s continuing operations consist of </font><font style="font-family:inherit;font-size:10pt;">76</font><font style="font-family:inherit;font-size:10pt;"> nursing centers with </font><font style="font-family:inherit;font-size:10pt;">8,456</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The Company owns </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;"> and leases </font><font style="font-family:inherit;font-size:10pt;">58</font><font style="font-family:inherit;font-size:10pt;"> of its nursing centers. Our nursing centers range in size from </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">320</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The licensed nursing bed count does not include </font><font style="font-family:inherit;font-size:10pt;">497</font><font style="font-family:inherit;font-size:10pt;"> licensed assisted and residential living beds.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RECENT ACCOUNTING GUIDANCE</font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make an accounting election by asset class not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term.&#160;The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company intends to use the optional expedient to reflect adoption in the period of adoption (which is January 1, 2019 for us) rather than the earliest period presented. For periods presented under Topic 842, extensive quantitative and qualitative disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company anticipates this standard will have a material impact on the consolidated financial position, primarily from nursing center operating leases. The Company has organized an implementation group of cross-functional departmental management to ensure the completeness of the lease information (specifically for new contracts entered into after the adoption date), analyze the appropriate classification of leases under the new standard, and develop new processes to execute, approve and classify new leases on an ongoing basis. The Company has also implemented software tools and processes to maintain lease information critical to applying the standard. The Company is in the process of cataloging its existing lease contracts and implementing changes to the systems, related processes and controls. The Company is planning to elect the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The Company is continuing to evaluate the extent of this anticipated impact on the consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity&#8217;s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make an accounting election by asset class not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term.&#160;The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company intends to use the optional expedient to reflect adoption in the period of adoption (which is January 1, 2019 for us) rather than the earliest period presented. For periods presented under Topic 842, extensive quantitative and qualitative disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company anticipates this standard will have a material impact on the consolidated financial position, primarily from nursing center operating leases. The Company has organized an implementation group of cross-functional departmental management to ensure the completeness of the lease information (specifically for new contracts entered into after the adoption date), analyze the appropriate classification of leases under the new standard, and develop new processes to execute, approve and classify new leases on an ongoing basis. The Company has also implemented software tools and processes to maintain lease information critical to applying the standard. The Company is in the process of cataloging its existing lease contracts and implementing changes to the systems, related processes and controls. The Company is planning to elect the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The Company is continuing to evaluate the extent of this anticipated impact on the consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity&#8217;s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 1: Identify the contract with a customer.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 2: Identify the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 3: Determine the transaction price.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">REVENUE RECOGNITION</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 1: Identify the contract with a customer.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 2: Identify the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 3: Determine the transaction price.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Statement Impact of Adopting ASC 606</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$141,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,903</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$145,065</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(269)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$113,799</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,903</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$117,702</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$147,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,903</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$151,300</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$423,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,155</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$434,066</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(887)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$337,517</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,155</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$348,672</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$427,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,155</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$438,827</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts Receivable</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$65,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(887)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$81,275</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,235</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Deficit</font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(23,432)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">887</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(22,829)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(284)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(c)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">603</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Reflects the tax impact for the ASC 606 adjustment of </font><font style="font-family:inherit;font-size:10pt;">$887</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,377</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,611</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,901</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">423,798</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">434,066</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,427</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(580</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$141,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,903</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$145,065</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(269)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$113,799</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,903</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$117,702</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$147,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,903</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$151,300</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$423,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,155</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$434,066</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(887)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$337,517</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,155</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$348,672</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$427,672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,155</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$438,827</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts Receivable</font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$65,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(887)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td rowspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$81,275</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,235</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Deficit</font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(23,432)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">887</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(22,829)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(284)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(c)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">603</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Reflects the tax impact for the ASC 606 adjustment of </font><font style="font-family:inherit;font-size:10pt;">$887</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final allocation of the purchase price to the net assets acquired is as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Park Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land Improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.14 to $10.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $5.86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(131</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 8, 2018, the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to transfer all of the issued and outstanding membership units of Ontario Pointe, a stand-alone </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> bed assisted living facility. The termination of this lease was effective on October 1, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease </font><font style="font-family:inherit;font-size:10pt;">34</font><font style="font-family:inherit;font-size:10pt;"> centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of </font><font style="font-family:inherit;font-size:10pt;">23</font><font style="font-family:inherit;font-size:10pt;"> skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates </font><font style="font-family:inherit;font-size:10pt;">11</font><font style="font-family:inherit;font-size:10pt;"> centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all </font><font style="font-family:inherit;font-size:10pt;">34</font><font style="font-family:inherit;font-size:10pt;"> centers under one New Master Lease. The Lease has an initial term of </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;"> years with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> year extensions. The Lease has a common date of annual lease fixed escalators of </font><font style="font-family:inherit;font-size:10pt;">2.15%</font><font style="font-family:inherit;font-size:10pt;"> beginning on October 1, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, Diversicare of Clinton and Diversicare of Glasgow (the "Properties"). The purchase price of the Properties is </font><font style="font-family:inherit;font-size:10pt;">$18,700</font><font style="font-family:inherit;font-size:10pt;"> and the sale is expected to be completed in the fourth quarter of 2018.</font></div></div> EX-101.SCH 7 avca-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - RECENT ACCOUNTING GUIDANCE link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - REVENUE RECOGNITION - Adjustments to Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 avca-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 avca-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 avca-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Statement of Comprehensive Income [Abstract] NET LOSS Net Income (Loss) Attributable to Parent OTHER COMPREHENSIVE INCOME: Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of cash flow hedge, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Less: reclassification adjustment for amounts recognized in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE LOSS Comprehensive Income (Loss), Net of Tax, Attributable to Parent Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Trend Health and Rehab of Carthage, LLC (Trend Health) Trend Health and Rehab of Carthage, LLC (Trend Health) [Member] Trend Health and Rehab of Carthage, LLC (Trend Health) [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Unnamed pharmacy joint venture Unnamed Pharmacy Joint Venture [Member] Unnamed Pharmacy Joint Venture [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Selma Nursing Centers Selma Nursing Centers [Member] Selma Nursing Centers [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of licensed nursing beds Number of Licensed Nursing Beds Number of licensed nursing beds. Purchase Price Business Combination, Consideration Transferred Business acquisition, acquisition expenses Business Acquisition, Transaction Costs Gain on bargain purchase Business Combination, Bargain Purchase, Gain Recognized, Amount Number of skilled nursing facilities classified as held for sale Number of Skilled Nursing Facilities, Held-For-Sale, Not Part Of Discontinued Operations Number of Skilled Nursing Facilities, Held-For-Sale, Not Part Of Discontinued Operations Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Noncurrent Cash termination payment Operating Leases, Rent Expense, Net Gain on sale of investment in unconsolidated affiliate Equity Method Investment, Realized Gain (Loss) on Disposal Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] NET LOSS Discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Provision for doubtful accounts Provision for Doubtful Accounts Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Litigation contingency expense Loss Contingency, Loss in Period Stock-based compensation Share-based Compensation Gain on sale of unconsolidated affiliate Provision for leases in excess of cash payments Provision For Leases In Excess Of Cash Payments Provision For Leases In Excess Of Cash Payments Deferred bonus Deferred Compensation, Bonus Deferred Compensation, Bonus Other Other Noncash Income (Expense) Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net Increase (Decrease) in Receivables Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Property acquisitions Payments to Acquire Productive Assets Proceeds from sale of unconsolidated affiliate Proceeds from Sale of Equity Method Investments Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Financing costs Payments of Financing Costs Issuance and redemption of employee equity awards Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payment of common stock dividends Payments of Ordinary Dividends, Common Stock Payment for preferred stock restructuring Payments of Stock Issuance Costs Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities NET DECREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash payments of interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash payments of income taxes Income Taxes Paid, Net Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Acquisition of equipment through capital lease Capital Lease Obligations Incurred Organization, Consolidation and Presentation of Financial Statements [Abstract] Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Number of licensed nursing beds per center Number of Licensed Nursing Beds per Nursing Center Number of Licensed Nursing Beds per Nursing Center Number of licensed assisted and residential living beds Number of Licensed Assisted Living Beds Number of Licensed Assisted Living Beds Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] The Properties The Properties [Member] The Properties [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Omega Healthcare Investors Inc Omega Healthcare Investors Inc [Member] Omega Healthcare Investors Inc [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Number of skilled nursing centers under lease Number of Skilled Nursing Centers Under Lease Number of Skilled Nursing Centers Under Lease Operating lease, initial term Operating Lease, Initial Term Operating Lease, Initial Term Number of lease extensions allowed Operating Lease, Number of Lease Extensions Allowed Operating Lease, Number of Lease Extensions Allowed Lease extension period Operating Lease, Extension Period Operating Lease, Extension Period Annual lease fixed escalators, percent Operating Lease, Annual Lease Fixed Escalators, Percent Operating Lease, Annual Lease Fixed Escalators, Percent Proceeds from divestiture of businesses Proceeds from Divestiture of Businesses Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Director Director [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Stock Options and Stock Appreciation Rights (SARs) Stock Options and Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Executive Equity Awards Executive Equity Awards [Member] Executive Equity Awards [Member] Stock Option Employee Stock Option [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] First anniversary of grant date Share-based Compensation Award, Tranche One [Member] Second anniversary of grant date Share-based Compensation Award, Tranche Two [Member] Third anniversary of grant date Share-based Compensation Award, Tranche Three [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Percentage of quoted market price offering rate Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Shares authorized under the plan (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares reserved for future issuance (shares) Common Stock, Capital Shares Reserved for Future Issuance Grant of restricted common stock (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vesting percentage of awards Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of new directors who received options Number Of New Directors Number Of New Directors Payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Share-based compensation expense Allocated Share-based Compensation Expense Income Statement [Abstract] PATIENT REVENUES, net Revenue from Contract with Customer, Excluding Assessed Tax EXPENSES: Costs and Expenses [Abstract] Operating Cost of Goods and Services Sold Lease and rent expense Professional liability Malpractice Loss Contingency, Premium Costs Litigation contingency expense (Note 6) General and administrative General and Administrative Expense Lease termination receipts Gain (Loss) on Contract Termination Total expenses Costs and Expenses OPERATING INCOME (LOSS) Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Other income Other Nonoperating Income Interest expense, net Interest Expense Hurricane costs Loss from Catastrophes Total other expense Nonoperating Income (Expense) LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest BENEFIT FOR INCOME TAXES Income Tax Expense (Benefit) LOSS FROM CONTINUING OPERATIONS INCOME (LOSS) FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Operating loss, net NET LOSS PER COMMON SHARE: Earnings Per Share [Abstract] Per common share – basic Earnings Per Share, Basic [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income (loss) per common share – basic (dollars per share) Earnings Per Share, Basic Per common share – diluted Earnings Per Share, Diluted [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income (loss) per common share – diluted (dollars per share) Earnings Per Share, Diluted COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) Common Stock, Dividends, Per Share, Declared WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Revenue from Contract with Customer [Abstract] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Tax expense (benefit), effect on operating loss Discontinued Operation, Tax Effect of Discontinued Operation Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Net loss Income Amounts Attributable to Parent, Disclosures [Abstract] Income (loss) from continuing operations Income (loss) from discontinued operations, net of income taxes Net loss Net Income (Loss) Available to Common Stockholders, Basic Per common share – basic Income (loss) from continuing operations (dollars per share) Loss from discontinued operations (dollars per share) Income (loss) from continuing operations (dollars per share) Loss from discontinued operations (dollars per share) Weighted Average Common Shares Outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Calculated under Revenue Guidance in Effect before Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Patient Revenues, net Operating Expenses Total Expenses Accounts Receivable Accounts Receivable, Net, Current Accumulated Deficit Retained Earnings (Accumulated Deficit) Health Care Organizations [Abstract] COMMITMENTS AND CONTINGENCIES Malpractice Loss Contingency Disclosure [Text Block] BUSINESS Nature of Operations [Text Block] Schedule of allocation for net assets acquired Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Debt Disclosure [Abstract] LONG-TERM DEBT AND INTEREST RATE SWAP Long Term Debt And Derivative Instruments [Text Block] Long Term Debt And Derivative Instruments [Text Block] Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding SUBSEQUENT EVENTS Subsequent Events [Text Block] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning (shares) Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Expired or cancelled (shares) Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Outstanding, ending (shares) Exercisable (shares) Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Granted (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Exercised (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Expired or cancelled (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding, ending (dollars per share) Exercisable, weighted average exercise price (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $8.14 to $10.80 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] $2.37 to $5.86 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Range of exercise prices, minimum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of exercise prices, maximum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Weighted average exercise prices (dollars per share) Grants outstanding (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Intrinsic value - grants outstanding Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Grants exercisable (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Intrinsic value - grants exercisable Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Basic and diluted net income (loss) per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summarized activity of equity compensation plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of summarized activity of Restricted Share Units Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of summarized information regarding stock options and SOSAR grants outstanding Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Statement of Financial Position [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Receivables, less allowance for doubtful accounts of $14,235 at December 31, 2017 Other receivables Receivables, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income tax refundable Income Taxes Receivable, Current Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT, at cost Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Assets, Noncurrent [Abstract] Deferred income taxes, net Deferred Income Tax Assets, Net Deferred lease and other costs, net Deferred Costs Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Other noncurrent assets Other Assets, Noncurrent Total other assets Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment Total assets Assets CURRENT LIABILITIES: Liabilities, Current [Abstract] Current portion of long-term debt and capitalized lease obligations, net Long-term Debt and Capital Lease Obligations, Current Trade accounts payable Accounts Payable, Trade, Current Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Payroll and employee benefits Employee-related Liabilities, Current Self-insurance reserves, current portion Self Insurance Reserve, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net Long-term Debt and Capital Lease Obligations Self-insurance reserves, less current portion Self Insurance Reserve, Noncurrent Accrued litigation contingency Estimated Litigation Liability, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total noncurrent liabilities Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES Commitments and Contingencies SHAREHOLDERS’ EQUITY (DEFICIT): Stockholders' Equity Attributable to Parent [Abstract] Common stock, authorized 20,000 shares, $.01 par value, 6,749 and 6,687 shares issued, and 6,517 and 6,455 shares outstanding, respectively Common Stock, Value, Issued Treasury stock at cost, 232 shares of common stock Treasury Stock, Value Paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Total shareholders’ equity (deficit) Stockholders' Equity Attributable to Parent Total liabilities and shareholder's equity Liabilities and Equity Consolidation Consolidation, Policy [Policy Text Block] Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Recent Accounting Guidance New Accounting Pronouncements, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Accounting Policies [Abstract] RECENT ACCOUNTING GUIDANCE New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Mortgage term loan Mortgage Term Loan [Member] Mortgage Term Loan [Member] Acquisition loan facility Mortgage Revolving Credit Facility [Member] Mortgage Revolving Credit Facility [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Credit agreement Line of Credit [Member] Mortgage loan Mortgages [Member] Amended revolver Revolving Credit Facility [Member] Letter of credit Letter of Credit [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Amended and restated credit agreement Amended and Restated Credit Agreement [Member] Amended and Restated Credit Agreement [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Interest rate swap Interest Rate Swap [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loan acquisition costs Debt Issuance Costs, Gross Term of agreements Debt Instrument, Term Period of amortization Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Interest rate percentage Debt Instrument, Basis Spread on Variable Rate Debt interest rate at period end Debt Instrument, Interest Rate, Effective Percentage Notional amount of interest rate derivatives Derivative, Notional Amount Amended mortgage loan balance Loans Payable Number of owned nursing centers to secure Amended Mortgage Loan Debt Instrument, Collateral, Number Of Owned Nursing Centers Debt Instrument, Collateral, Number Of Owned Nursing Centers Increase to credit facility limit Line of Credit Facility, Terms, Maximum Increase in Capacity Line of Credit Facility, Terms, Maximum Increase in Capacity Fixed charge coverage ratio Debt Instrument, Covenant Terms, Quarterly Fixed Charge Ratio, Minimum Debt Instrument, Covenant Terms, Quarterly Fixed Charge Ratio, Minimum Borrowings outstanding Long-term Debt Interest rate during period Debt Instrument, Interest Rate During Period Annual fees for letters of credit issued under Revolver (as a percentage) Line of Credit Facility, Fee Percentage on Amount Outstanding Line of Credit Facility, Fee Percentage on Amount Outstanding Number of letters of credit Number of Letters of Credit Number of Letters of Credit Letters of credit security deposit for a lease Letters of Credit Outstanding, Amount Balance available for borrowing under revolving credit center Line of Credit Facility, Current Borrowing Capacity Annual fixed rate percentage Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Net asset based on interest rate swap valuation model Derivative Asset Accumulated other comprehensive income (loss) Income tax benefit, interest rate swap BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Business Combination Disclosure [Text Block] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Number of equity method investments sold Number of Equity Method Investments Sold Number of Equity Method Investments Sold Gain on bargain purchase Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Building Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Land Improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Improvements Furniture, Fixtures and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Employee Stock Employee Stock [Member] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, beginning (share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Dividend Equivalents (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding, ending (shares) Weighted Average Granted Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, beginning (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Granted (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend Equivalents (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Vested (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Outstanding, ending (dollars per share) Antidilutive shares excluded from computation of diluted earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Treasury stock, shares (shares) Treasury Stock, Shares Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Medicaid Medicaid [Member] Medicaid [Member] Medicare Medicare [Member] Medicare [Member] Managed Care Managed Care [Member] Managed Care [Member] Private Pay and other Private Pay And Other [Member] Private Pay And Other [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total revenues Revenue from Contract with Customer, Including Assessed Tax Total revenues, as a percent Revenue From Contract With Customer, Including Assessed Tax, Percentage Revenue From Contract With Customer, Including Assessed Tax, Percentage Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Unfavorable regulatory action Unfavorable Regulatory Action [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Potential violations of false claims act Potential Violations of False Claims Act [Member] Potential Violations of False Claims Act [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Malpractice insurance annual sublimit per center Malpractice Insurance, Annual Sublimit Per Center Malpractice Insurance, Annual Sublimit Per Center Aggregate policy limit Malpractice Insurance, Annual Coverage Limit Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Estimated insurance recovery receivables Estimated Insurance Recoveries Number of facilities Loss Contingency, Number of Facilities Loss Contingency, Number of Facilities Number of civil investigative demands received Loss Contingency, New Claims Filed, Number Other Insurance Other Insurance Industry Disclosures [Abstract] Insurance policy coverage limits per claim Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Liability for workers compensation claims Workers' Compensation Liability Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefits EX-101.PRE 11 avca-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 medicaidrateperday.jpg begin 644 medicaidrateperday.jpg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end GRAPHIC 13 medicarerateperday.jpg begin 644 medicarerateperday.jpg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htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Oct. 29, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name Diversicare Healthcare Services, Inc.  
Entity Central Index Key 0000919956  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   6,518,013
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
CURRENT ASSETS:    
Cash and cash equivalents $ 3,293 $ 3,524
Receivables, less allowance for doubtful accounts of $14,235 at December 31, 2017 65,927 64,929
Other receivables 1,551 375
Prepaid expenses and other current assets 3,829 3,248
Income tax refundable 862 537
Current assets of discontinued operations 20 45
Total current assets 75,482 72,658
PROPERTY AND EQUIPMENT, at cost 137,430 147,549
Less accumulated depreciation and amortization (83,956) (78,345)
Property and equipment, net 53,474 69,204
OTHER ASSETS:    
Deferred income taxes, net 15,891 15,154
Deferred lease and other costs, net 279 137
Acquired leasehold interest, net 6,403 6,691
Assets held for sale 13,299 0
Other noncurrent assets 7,503 3,725
Total other assets 43,375 25,707
Total assets 172,331 167,569
CURRENT LIABILITIES:    
Current portion of long-term debt and capitalized lease obligations, net 12,576 13,065
Trade accounts payable 14,146 14,080
Current liabilities of discontinued operations 461 461
Accrued expenses:    
Payroll and employee benefits 20,131 20,013
Self-insurance reserves, current portion 13,051 8,792
Other current liabilities 8,361 7,856
Total current liabilities 68,726 64,267
NONCURRENT LIABILITIES:    
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net 77,308 74,603
Self-insurance reserves, less current portion 16,301 13,458
Accrued litigation contingency 6,400 0
Other noncurrent liabilities 5,134 8,779
Total noncurrent liabilities 105,143 96,840
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY (DEFICIT):    
Common stock, authorized 20,000 shares, $.01 par value, 6,749 and 6,687 shares issued, and 6,517 and 6,455 shares outstanding, respectively 68 67
Treasury stock at cost, 232 shares of common stock (2,500) (2,500)
Paid-in capital 23,267 22,720
Accumulated deficit (23,432) (14,534)
Accumulated other comprehensive income 1,059 709
Total shareholders’ equity (deficit) (1,538) 6,462
Total liabilities and shareholder's equity $ 172,331 $ 167,569
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable   $ 14,235
Common stock, shares authorized (shares) 20,000,000 20,000,000
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, shares issued (shares) 6,749,000 6,687,000
Common stock, shares outstanding (shares) 6,517,000 6,455,000
Treasury stock, shares (shares) 232,000 232,000
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
PATIENT REVENUES, net $ 141,431 $ 146,377 $ 423,798 $ 430,427
EXPENSES:        
Operating 113,799 118,104 337,517 341,937
Lease and rent expense 13,764 13,791 41,202 41,297
Professional liability 2,933 2,617 8,890 8,011
Litigation contingency expense (Note 6) 6,400 0 6,400 0
General and administrative 7,537 8,083 24,971 25,277
Depreciation and amortization 2,964 2,988 8,692 8,095
Lease termination receipts 0 (180) 0 (180)
Total expenses 147,397 145,403 427,672 424,437
OPERATING INCOME (LOSS) (5,966) 974 (3,874) 5,990
OTHER INCOME (EXPENSE):        
Gain on sale of investment in unconsolidated affiliate     308 733
Other income 36 0 115 0
Interest expense, net (1,666) (1,668) (4,996) (4,692)
Hurricane costs 0 (232) 0 (232)
Total other expense (1,630) (1,900) (4,573) (4,191)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES (7,596) (926) (8,447) 1,799
BENEFIT FOR INCOME TAXES 207 345 670 (651)
LOSS FROM CONTINUING OPERATIONS (7,389) (581) (7,777) 1,148
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:        
Operating loss, net (8) 1 (34) (42)
NET LOSS $ (7,397) $ (580) $ (7,811) $ 1,106
Per common share – basic        
Continuing operations (in dollars per share) $ (1.15) $ (0.09) $ (1.22) $ 0.18
Discontinued operations (in dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – basic (dollars per share) (1.15) (0.09) (1.23) 0.17
Per common share – diluted        
Continuing operations (in dollars per share) (1.15) (0.09) (1.22) 0.18
Discontinued operations (in dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – diluted (dollars per share) (1.15) (0.09) (1.23) 0.17
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) $ 0.055 $ 0.055 $ 0.165 $ 0.165
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic (shares) 6,400 6,294 6,362 6,274
Diluted (shares) 6,400 6,294 6,362 6,465
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Tax expense (benefit), effect on operating loss $ 0 $ 1 $ (11) $ (25)
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
NET LOSS $ (7,397) $ (580) $ (7,811) $ 1,106
OTHER COMPREHENSIVE INCOME:        
Change in fair value of cash flow hedge, net of tax 46 203 501 603
Less: reclassification adjustment for amounts recognized in net income 0 (115) (151) (348)
Total other comprehensive income 46 88 350 255
COMPREHENSIVE LOSS $ (7,351) $ (492) $ (7,461) $ 1,361
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
NET LOSS $ (7,811) $ 1,106
Discontinued operations (34) (42)
Income (loss) from continuing operations (7,777) 1,148
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:    
Depreciation and amortization 8,692 8,095
Provision for doubtful accounts 0 6,407
Deferred income tax provision (benefit) (829) 52
Provision for self-insured professional liability, net of cash payments 2,224 (168)
Litigation contingency expense 6,400 0
Stock-based compensation 947 766
Gain on sale of unconsolidated affiliate (308) (733)
Provision for leases in excess of cash payments (1,363) (517)
Deferred bonus 0 700
Other 250 388
Changes in assets and liabilities affecting operating activities:    
Receivables, net (2,134) (8,387)
Prepaid expenses and other assets (2,379) 459
Trade accounts payable and accrued expenses 2,391 1,977
Net cash provided by continuing operations 6,114 10,187
Discontinued operations (645) (241)
Net cash provided by operating activities 5,469 9,946
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (5,964) (8,638)
Property acquisitions 0 (8,750)
Proceeds from sale of unconsolidated affiliate 308 1,100
Net cash used in continuing operations (5,656) (16,288)
Discontinued operations 0 0
Net cash used in investing activities (5,656) (16,288)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt obligations (15,330) (24,381)
Proceeds from issuance of debt 17,203 31,574
Financing costs (137) (195)
Issuance and redemption of employee equity awards (219) (94)
Payment of common stock dividends (1,053) (1,038)
Payment for preferred stock restructuring (508) (492)
Net cash (used in) provided by financing activities (44) 5,374
Discontinued operations 0 0
Net cash (used in) provided by financing activities (44) 5,374
NET DECREASE IN CASH AND CASH EQUIVALENTS (231) (968)
CASH AND CASH EQUIVALENTS, beginning of period 3,524 4,263
CASH AND CASH EQUIVALENTS, end of period 3,293 3,295
SUPPLEMENTAL INFORMATION:    
Cash payments of interest 4,511 3,989
Cash payments of income taxes 474 667
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]    
Acquisition of equipment through capital lease $ 203 $ 507
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted and residential living beds.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the nine-month periods ended September, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership. All amounts subject to the liquidation of remaining assets affiliated with the partnership have been settled.
The interim consolidated financial statements for the three and nine month periods ended September 30, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2018, and the results of operations for the three and nine month periods ended September 30, 2018 and 2017, and cash flows for the nine month periods ended September 30, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended September 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
RECENT ACCOUNTING GUIDANCE
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
RECENT ACCOUNTING GUIDANCE
RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make an accounting election by asset class not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company intends to use the optional expedient to reflect adoption in the period of adoption (which is January 1, 2019 for us) rather than the earliest period presented. For periods presented under Topic 842, extensive quantitative and qualitative disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company anticipates this standard will have a material impact on the consolidated financial position, primarily from nursing center operating leases. The Company has organized an implementation group of cross-functional departmental management to ensure the completeness of the lease information (specifically for new contracts entered into after the adoption date), analyze the appropriate classification of leases under the new standard, and develop new processes to execute, approve and classify new leases on an ongoing basis. The Company has also implemented software tools and processes to maintain lease information critical to applying the standard. The Company is in the process of cataloging its existing lease contracts and implementing changes to the systems, related processes and controls. The Company is planning to elect the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The Company is continuing to evaluate the extent of this anticipated impact on the consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION
REVENUE RECOGNITION
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.
The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Financial Statement Impact of Adopting ASC 606

The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:

 
Three Months Ended September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,431
 
3,903
(a)
$145,065
 
(269)
(b)
 
3,634
 
Operating Expenses
$113,799
 
3,903
(a)
$117,702
Total Expenses
$147,397
 
3,903
(a)
$151,300

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
Nine Months Ended September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$423,798
 
11,155
(a)
$434,066
 
(887)
(b)
 
10,268
 
Operating Expenses
$337,517
 
11,155
(a)
$348,672
Total Expenses
$427,672
 
11,155
(a)
$438,827

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
As of September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Accounts Receivable
$65,927
 
(887)
(a)

$81,275
 
16,235
(b)
 
15,348
 
Accumulated Deficit
$(23,432)
 
887
(a)

$(22,829)
 
(284)
(c)
 
603
 

(a) Adjusts for the implementation of ASC 606.
(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.
(c) Reflects the tax impact for the ASC 606 adjustment of $887.

Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended September 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
68,929

48.7
%
 
$
78,200

53.9
%
 
$
77,027

52.6
%
Medicare
26,997

19.1
%
 
34,933

24.1
%
 
36,449

24.9
%
Managed Care
12,404

8.8
%
 
10,874

7.5
%
 
10,992

7.5
%
Private Pay and other
33,101

23.4
%
 
21,058

14.5
%
 
21,909

15.0
%
Total
$
141,431

100.0
%
 
$
145,065

100.0
%
 
$
146,377

100.0
%
 
Nine Months Ended September 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
198,418

46.8
%
 
$
226,631

52.2
%
 
$
223,410

51.9
%
Medicare
84,611

20.0
%
 
109,150

25.1
%
 
113,360

26.3
%
Managed Care
39,919

9.4
%
 
34,854

8.0
%
 
31,756

7.4
%
Private Pay and other
100,850

23.8
%
 
63,431

14.7
%
 
61,901

14.4
%
Total
$
423,798

100.0
%
 
$
434,066

100.0
%
 
$
430,427

100.0
%

(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
LONG-TERM DEBT AND INTEREST RATE SWAP
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
LONG-TERM DEBT AND INTEREST RATE SWAP
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $72,150 as of September 30, 2018, consisting of $63,150 on the term loan facility with an interest rate of 6.00% and $9,000 on the acquisition loan facility with an interest rate of 6.8%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.
Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of September 30, 2018, the Company had $18,500 borrowings outstanding under the Amended Revolver compared to $16,000 outstanding as of December 31, 2017. The interest rate related to the Amended Revolver was 6.00% as of September 30, 2018. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Also, borrowings on the revolver relate to the timing of cash flows and our operating activities. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,714 outstanding as of September 30, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $37,710 the balance available for borrowing under the Amended Revolver was $5,496 at September 30, 2018.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at September 30, 2018.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $27,915 as of September 30, 2018. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at September 30, 2018, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $661 at September 30, 2018. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at September 30, 2018 is $403 net of the income tax provision of $258. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2018
Health Care Organizations [Abstract]  
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $500 per medical incident with a sublimit per center of $1,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $27,070 as of September 30, 2018. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of September 30, 2018, the Company is engaged in 83 professional liability lawsuits. Twenty lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $4,452 and $6,077 for the nine months ended September 30, 2018 and 2017, respectively.
The Company follows the FASB ASU No. 2010-24, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of September 30, 2018 there are estimated insurance recovery receivables of $5,425.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
The Company is engaged in preliminary discussions with the DOJ regarding settlement of this investigation. The Company denies any wrong doing and is prepared to vigorously defend its actions. However, based upon preliminary settlement discussions, the Company believes that it is probable a loss will result from this contingency and has accrued $6,400 as a contingent liability in connection with this matter during the three months ended September 30, 2018. The Company cannot predict whether a settlement can be achieved, the outcome of the litigation if there is no settlement or the length of time necessary to conclude. Accordingly, the contingent liability has been classified as a noncurrent liability in the accompanying interim consolidated balance sheets.  The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ, the Company’s assessment of the risks of litigating this case and the effect of protracted litigation or settlement terms on the Company’s business plans.  Because the outcome of this investigation and related settlement discussions remain uncertain, there is a reasonable possibility that the amount ultimately incurred in connection with the resolution of this matter could differ materially from the current accrual, as the Company cannot, at this time, estimate the possible range of loss that may result from either a settlement or litigation of this matter.  The ultimate outcome of this litigation could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to the practices of some of its employees with respect to PAEs and PASRRs, and the Company provided documents responsive to this subpoena and coordinated examinations of certain employees of the Company.  The Company understands that this criminal investigation has been closed, subject to re-opening at the discretion of the government.

Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July 1, 2008 through September 30, 2018, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $620 at September 30, 2018. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,074 as of September 30, 2018. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of September 30, 2018, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,662 at September 30, 2018. The differences between actual settlements and reserves are included in expense in the period finalized.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION

Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.
Equity Grants and Valuations
During the nine months ended September 30, 2018 and 2017, the Compensation Committee of the Board of Directors approved grants totaling approximately 90 and 88 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Generally, unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. In addition, during the nine months ended September 30, 2018, the Company granted stock options to purchase a total of 30 shares of common stock at an exercise price equal to the market price of the Company’s common stock on the date of grant to two new directors. These stock options vest one third on the date of grant and one third on the first and second anniversary of the date of grant.
Prior to 2017, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
211

 
$
6.64

Granted
30

 
8.14

Exercised
(100
)
 
5.79

Expired or cancelled
(17
)
 
9.76

Outstanding, September 30, 2018
124

 
$
7.24

 
 
 
 
Exercisable, September 30, 2018
104

 
$
7.06


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
4

 
6.95

Vested
(131
)
 
9.71

Cancelled
(7
)
 
9.62

Outstanding, September 30, 2018
120

 
$
8.77



Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
6.89

Vested
(17
)
 
8.91

Outstanding, September 30, 2018
44

 
$
9.25



The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.80
 
$
9.32

 
60

 
$
—

 
40

 
$
—

$2.37 to $5.86
 
$
5.28

 
64

 
$
75

 
64

 
$
75

 
 
 
 
124

 
 
 
104

 
 

Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $947 and $766 in the nine month periods ended September 30, 2018 and 2017, respectively. The stock-based compensation expense balance for the nine month period ended September 30, 2018 is inclusive of $259 related to the vesting of executive equity awards.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE
EARNINGS PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net loss
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(7,389
)
 
$
(581
)
 
$
(7,777
)
 
$
1,148

Income (loss) from discontinued operations, net of income taxes
(8
)
 
1

 
(34
)
 
(42
)
Net loss
$
(7,397
)
 
$
(580
)
 
$
(7,811
)
 
$
1,106

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(1.15
)
 
$
(0.09
)
 
$
(1.22
)
 
$
0.18

Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – basic
$
(1.15
)
 
$
(0.09
)
 
$
(1.23
)
 
$
0.17

Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(1.15
)
 
$
(0.09
)
 
$
(1.22
)
 
$
0.18

Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – diluted
$
(1.15
)
 
$
(0.09
)
 
$
(1.23
)
 
$
0.17

Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,400

 
6,294

 
6,362

 
6,274

Diluted
6,400

 
6,294

 
6,362

 
6,465


The effects of 124 and 46 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the nine months ended September 30, 2018 and 2017, respectively, because these securities would have been anti-dilutive.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
 9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $140 of acquisition costs and a $925 recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The final allocation of the purchase price to the net assets acquired is as follows:
 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675



2018 Assets Held for Sale
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The carrying value of these centers' assets are $13,299. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets. Refer to Note 10 for further discussion.
2017 Lease Termination
On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December 31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the nine-month periods ended September 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUBSEQUENT EVENTS
 9 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS

On July 8, 2018, the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to transfer all of the issued and outstanding membership units of Ontario Pointe, a stand-alone 50 bed assisted living facility. The termination of this lease was effective on October 1, 2018.

On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two 10 year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.

On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, Diversicare of Clinton and Diversicare of Glasgow (the "Properties"). The purchase price of the Properties is $18,700 and the sale is expected to be completed in the fourth quarter of 2018.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Consolidation
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of Accounting
The interim consolidated financial statements for the three and nine month periods ended September 30, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2018, and the results of operations for the three and nine month periods ended September 30, 2018 and 2017, and cash flows for the nine month periods ended September 30, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended September 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
Recent Accounting Guidance
Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make an accounting election by asset class not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company intends to use the optional expedient to reflect adoption in the period of adoption (which is January 1, 2019 for us) rather than the earliest period presented. For periods presented under Topic 842, extensive quantitative and qualitative disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company anticipates this standard will have a material impact on the consolidated financial position, primarily from nursing center operating leases. The Company has organized an implementation group of cross-functional departmental management to ensure the completeness of the lease information (specifically for new contracts entered into after the adoption date), analyze the appropriate classification of leases under the new standard, and develop new processes to execute, approve and classify new leases on an ongoing basis. The Company has also implemented software tools and processes to maintain lease information critical to applying the standard. The Company is in the process of cataloging its existing lease contracts and implementing changes to the systems, related processes and controls. The Company is planning to elect the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The Company is continuing to evaluate the extent of this anticipated impact on the consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.
Revenue Recognition
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.
The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION (Tables)
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:

 
Three Months Ended September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,431
 
3,903
(a)
$145,065
 
(269)
(b)
 
3,634
 
Operating Expenses
$113,799
 
3,903
(a)
$117,702
Total Expenses
$147,397
 
3,903
(a)
$151,300

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
Nine Months Ended September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$423,798
 
11,155
(a)
$434,066
 
(887)
(b)
 
10,268
 
Operating Expenses
$337,517
 
11,155
(a)
$348,672
Total Expenses
$427,672
 
11,155
(a)
$438,827

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
As of September 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Accounts Receivable
$65,927
 
(887)
(a)

$81,275
 
16,235
(b)
 
15,348
 
Accumulated Deficit
$(23,432)
 
887
(a)

$(22,829)
 
(284)
(c)
 
603
 

(a) Adjusts for the implementation of ASC 606.
(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.
(c) Reflects the tax impact for the ASC 606 adjustment of $887.
Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended September 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
68,929

48.7
%
 
$
78,200

53.9
%
 
$
77,027

52.6
%
Medicare
26,997

19.1
%
 
34,933

24.1
%
 
36,449

24.9
%
Managed Care
12,404

8.8
%
 
10,874

7.5
%
 
10,992

7.5
%
Private Pay and other
33,101

23.4
%
 
21,058

14.5
%
 
21,909

15.0
%
Total
$
141,431

100.0
%
 
$
145,065

100.0
%
 
$
146,377

100.0
%
 
Nine Months Ended September 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
198,418

46.8
%
 
$
226,631

52.2
%
 
$
223,410

51.9
%
Medicare
84,611

20.0
%
 
109,150

25.1
%
 
113,360

26.3
%
Managed Care
39,919

9.4
%
 
34,854

8.0
%
 
31,756

7.4
%
Private Pay and other
100,850

23.8
%
 
63,431

14.7
%
 
61,901

14.4
%
Total
$
423,798

100.0
%
 
$
434,066

100.0
%
 
$
430,427

100.0
%

(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION (Tables)
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summarized activity of equity compensation plans
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
211

 
$
6.64

Granted
30

 
8.14

Exercised
(100
)
 
5.79

Expired or cancelled
(17
)
 
9.76

Outstanding, September 30, 2018
124

 
$
7.24

 
 
 
 
Exercisable, September 30, 2018
104

 
$
7.06
Schedule of summarized activity of Restricted Share Units
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
4

 
6.95

Vested
(131
)
 
9.71

Cancelled
(7
)
 
9.62

Outstanding, September 30, 2018
120

 
$
8.77



Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
6.89

Vested
(17
)
 
8.91

Outstanding, September 30, 2018
44

 
$
9.25
Schedule of summarized information regarding stock options and SOSAR grants outstanding
The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.80
 
$
9.32

 
60

 
$
—

 
40

 
$
—

$2.37 to $5.86
 
$
5.28

 
64

 
$
75

 
64

 
$
75

 
 
 
 
124

 
 
 
104

 
 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Basic and diluted net income (loss) per common share
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net loss
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(7,389
)
 
$
(581
)
 
$
(7,777
)
 
$
1,148

Income (loss) from discontinued operations, net of income taxes
(8
)
 
1

 
(34
)
 
(42
)
Net loss
$
(7,397
)
 
$
(580
)
 
$
(7,811
)
 
$
1,106

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(1.15
)
 
$
(0.09
)
 
$
(1.22
)
 
$
0.18

Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – basic
$
(1.15
)
 
$
(0.09
)
 
$
(1.23
)
 
$
0.17

Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(1.15
)
 
$
(0.09
)
 
$
(1.22
)
 
$
0.18

Loss from discontinued operations
—

 
—

 
(0.01
)
 
(0.01
)
Net income (loss) per common share – diluted
$
(1.15
)
 
$
(0.09
)
 
$
(1.23
)
 
$
0.17

Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,400

 
6,294

 
6,362

 
6,274

Diluted
6,400

 
6,294

 
6,362

 
6,465
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables)
 9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Schedule of allocation for net assets acquired
The final allocation of the purchase price to the net assets acquired is as follows:
 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS (Details)
Sep. 30, 2018
state
center
bed
Accounting Policies [Line Items]  
Number of states in which entity operates | state 10
Number of nursing centers | center 76
Number of licensed nursing beds 8,456
Number of nursing center facilities owned | center 18
Number of nursing center facilities leased | center 58
Number of licensed assisted and residential living beds 497
Minimum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 48
Maximum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 320
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2016
USD ($)
investment
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]      
Number of equity method investments sold | investment 1    
Gain on sale of investment in unconsolidated affiliate   $ 308 $ 733
Unnamed pharmacy joint venture      
Schedule of Equity Method Investments [Line Items]      
Gain on sale of investment in unconsolidated affiliate $ 1,366 $ 308 $ 733
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION - Adjustments to Operating Results (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net $ 141,431 $ 146,377 $ 423,798 $ 430,427  
Operating Expenses 113,799 118,104 337,517 341,937  
Total Expenses 147,397 $ 145,403 427,672 $ 424,437  
Accounts Receivable 65,927   65,927   $ 64,929
Accumulated Deficit (23,432)   (23,432)   $ (14,534)
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net 3,903   11,155    
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net (269)   (887)    
Accounts Receivable (887)   (887)    
Accumulated Deficit 887   887    
Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Accounts Receivable 16,235   16,235    
Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Accumulated Deficit (284)   (284)    
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net 3,634   10,268    
Operating Expenses 3,903   11,155    
Total Expenses 3,903   11,155    
Accounts Receivable 15,348   15,348    
Accumulated Deficit 603   603    
Calculated under Revenue Guidance in Effect before Topic 606          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net 145,065   434,066    
Operating Expenses 117,702   348,672    
Total Expenses 151,300   438,827    
Accounts Receivable 81,275   81,275    
Accumulated Deficit $ (22,829)   $ (22,829)    
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Disaggregation of Revenue [Line Items]        
Total revenues $ 141,431   $ 423,798  
Total revenues, as a percent 100.00%   100.00%  
Medicaid        
Disaggregation of Revenue [Line Items]        
Total revenues $ 68,929   $ 198,418  
Total revenues, as a percent 48.70%   46.80%  
Medicare        
Disaggregation of Revenue [Line Items]        
Total revenues $ 26,997   $ 84,611  
Total revenues, as a percent 19.10%   20.00%  
Managed Care        
Disaggregation of Revenue [Line Items]        
Total revenues $ 12,404   $ 39,919  
Total revenues, as a percent 8.80%   9.40%  
Private Pay and other        
Disaggregation of Revenue [Line Items]        
Total revenues $ 33,101   $ 100,850  
Total revenues, as a percent 23.40%   23.80%  
Calculated under Revenue Guidance in Effect before Topic 606        
Disaggregation of Revenue [Line Items]        
Total revenues $ 145,065 $ 146,377 $ 434,066 $ 430,427
Total revenues, as a percent 100.00% 100.00% 100.00% 100.00%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicaid        
Disaggregation of Revenue [Line Items]        
Total revenues $ 78,200 $ 77,027 $ 226,631 $ 223,410
Total revenues, as a percent 53.90% 52.60% 52.20% 51.90%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicare        
Disaggregation of Revenue [Line Items]        
Total revenues $ 34,933 $ 36,449 $ 109,150 $ 113,360
Total revenues, as a percent 24.10% 24.90% 25.10% 26.30%
Calculated under Revenue Guidance in Effect before Topic 606 | Managed Care        
Disaggregation of Revenue [Line Items]        
Total revenues $ 10,874 $ 10,992 $ 34,854 $ 31,756
Total revenues, as a percent 7.50% 7.50% 8.00% 7.40%
Calculated under Revenue Guidance in Effect before Topic 606 | Private Pay and other        
Disaggregation of Revenue [Line Items]        
Total revenues $ 21,058 $ 21,909 $ 63,431 $ 61,901
Total revenues, as a percent 14.50% 15.00% 14.70% 14.40%
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
LONG-TERM DEBT AND INTEREST RATE SWAP (Details)
 3 Months Ended 9 Months Ended
Feb. 26, 2016
USD ($)
center
Sep. 30, 2018
USD ($)
letter_of_credit
Mar. 31, 2018
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
letter_of_credit
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Aug. 01, 2017
USD ($)
Jun. 30, 2017
USD ($)
Dec. 29, 2016
USD ($)
Dec. 28, 2016
USD ($)
Oct. 03, 2016
USD ($)
Line of Credit Facility [Line Items]                        
Accumulated other comprehensive income (loss)   $ 1,059,000     $ 1,059,000   $ 709,000          
Income tax benefit, interest rate swap   (207,000)   $ (345,000) (670,000) $ 651,000            
Interest rate swap                        
Line of Credit Facility [Line Items]                        
Notional amount of interest rate derivatives   $ 27,915,000     $ 27,915,000              
Annual fixed rate percentage   5.79%     5.79%              
Net asset based on interest rate swap valuation model   $ 661,000     $ 661,000              
Accumulated other comprehensive income (loss)   $ 403,000     403,000              
Income tax benefit, interest rate swap         $ 258,000              
Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Loan acquisition costs $ 2,162,000                      
Number of letters of credit | letter_of_credit   11     11              
Credit agreement | Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Borrowing capacity $ 100,000,000                      
Term of agreements 5 years                      
Mortgage loan | Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Borrowing capacity $ 72,500,000                      
Term of agreements 5 years                      
Period of amortization 25 years                      
Amended mortgage loan balance   $ 72,150,000     $ 72,150,000              
Number of owned nursing centers to secure Amended Mortgage Loan | center 18                      
Mortgage loan | Amended and restated credit agreement | Interest rate swap                        
Line of Credit Facility [Line Items]                        
Debt interest rate at period end 5.79%                      
Amended revolver | Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Borrowing capacity $ 27,500,000 37,710,000     37,710,000     $ 42,250,000 $ 52,250,000     $ 52,250,000
Fixed charge coverage ratio     1.01                  
Borrowings outstanding   18,500,000     $ 18,500,000   $ 16,000,000          
Interest rate during period         6.00%              
Balance available for borrowing under revolving credit center   $ 5,496,000     $ 5,496,000              
Amended revolver | Amended and restated credit agreement | LIBOR                        
Line of Credit Facility [Line Items]                        
Interest rate percentage 4.00%                      
Letter of credit | Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Borrowing capacity                   $ 15,000,000 $ 10,000,000  
Annual fees for letters of credit issued under Revolver (as a percentage) 3.00%                      
Mortgage term loan | Mortgage loan | Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Borrowing capacity $ 60,000,000                      
Debt interest rate at period end   6.00%     6.00%              
Amended mortgage loan balance   $ 63,150,000     $ 63,150,000              
Increase to credit facility limit                 $ 7,500,000      
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | Interest rate swap | Designated as hedging instrument                        
Line of Credit Facility [Line Items]                        
Notional amount of interest rate derivatives $ 30,000,000                      
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | LIBOR                        
Line of Credit Facility [Line Items]                        
Interest rate percentage 4.00%                      
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Borrowing capacity $ 12,500,000                      
Debt interest rate at period end   6.80%     6.80%              
Amended mortgage loan balance   $ 9,000,000     $ 9,000,000              
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement | LIBOR                        
Line of Credit Facility [Line Items]                        
Interest rate percentage 4.75%                      
Omega Healthcare Investors Inc | Amended revolver | Amended and restated credit agreement                        
Line of Credit Facility [Line Items]                        
Letters of credit security deposit for a lease   $ 13,714,000     $ 13,714,000              
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details)
 9 Months Ended 32 Months Ended
Sep. 30, 2018
USD ($)
lawsuit
Sep. 30, 2017
USD ($)
Feb. 29, 2016
civil_investigative_demand
Dec. 31, 2017
USD ($)
Oct. 31, 2014
facility
Malpractice Insurance [Line Items]          
Number of professional liability lawsuits | lawsuit 83        
Cash expenditures for self-insured professional liability costs $ 4,452,000 $ 6,077,000      
Estimated insurance recovery receivables 5,425,000        
Accrued litigation contingency 6,400,000     $ 0  
Other Insurance          
Liability for workers compensation claims 620,000        
Workers compensation insurance, non current receivable for excess premiums paid 1,074,000        
Unfavorable regulatory action | Potential violations of false claims act          
Malpractice Insurance [Line Items]          
Number of facilities | facility         2
Number of civil investigative demands received | civil_investigative_demand     3    
Professional malpractice liability insurance          
Malpractice Insurance [Line Items]          
Liability for reported and estimated future claims 27,070,000        
Prefunded deductible policy          
Malpractice Insurance [Line Items]          
Insurance policy coverage limits per claim 500,000        
Other Insurance          
Insurance policy coverage limits per claim 500,000        
Professional liability insurance, annual coverage limit per facility 3,000,000        
Health insurance, maximum self-insured annual amount per individual 200,000        
Liability for reported claims and estimates for incurred but unreported claims 1,662,000        
SHC Risk Carriers, Inc | Professional malpractice liability insurance          
Malpractice Insurance [Line Items]          
Insurance policy coverage limits per claim 500,000        
Malpractice insurance annual sublimit per center 1,000,000        
Aggregate policy limit 5,000,000        
Other Insurance          
Insurance policy coverage limits per claim $ 500,000        
Scheduled for trial or arbitration over next 12 months          
Malpractice Insurance [Line Items]          
Number of professional liability lawsuits | lawsuit 20        
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Narrative (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
USD ($)
director
shares
Sep. 30, 2017
USD ($)
shares
May 31, 2017
shares
Jun. 30, 2016
shares
May 31, 2016
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of new directors who received options | director 2        
Share-based compensation expense | $ $ 947 $ 766      
Restricted Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Grant of restricted common stock (shares) 90,000 88,000      
Restricted Stock | First anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Restricted Stock | Second anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Restricted Stock | Third anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Payment award, expiration period 10 years        
Stock Options and Stock Appreciation Rights (SARs) | First anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs) | Second anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs) | Third anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Executive Equity Awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense | $ $ 259        
2008 Stock Purchase Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Percentage of quoted market price offering rate 85.00%        
Restriction period 2 years        
Shares authorized under the plan (shares)       350,000 150,000
2010 Long Term Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares reserved for future issuance (shares)   680,000 380,000    
Director | Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.33%        
Stock options granted (in shares) 30,000        
Director | Stock Option | First anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.33%        
Director | Stock Option | Second anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.33%        
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) - Stock Options and Stock Appreciation Rights (SARs)
shares in Thousands
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Number of Shares  
Outstanding, beginning (shares) | shares 211
Granted (shares) | shares 30
Exercised (shares) | shares (100)
Expired or cancelled (shares) | shares (17)
Outstanding, ending (shares) | shares 124
Exercisable (shares) | shares 104
Weighted Average Exercise Price  
Outstanding, beginning (dollars per share) | $ / shares $ 6.64
Granted (dollars per share) | $ / shares 8.14
Exercised (dollars per share) | $ / shares 5.79
Expired or cancelled (dollars per share) | $ / shares 9.76
Outstanding, ending (dollars per share) | $ / shares 7.24
Exercisable, weighted average exercise price (dollars per share) | $ / shares $ 7.06
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Restricted Stock Units (RSUs)  
Number of Shares  
Outstanding, beginning (share) | shares 164
Granted (shares) | shares 90
Dividend Equivalents (shares) | shares 4
Vested (shares) | shares (131)
Cancelled (shares) | shares (7)
Outstanding, ending (shares) | shares 120
Weighted Average Granted Date Fair Value  
Outstanding, beginning (dollars per share) | $ / shares $ 9.95
Granted (dollars per share) | $ / shares 8.14
Dividend Equivalents (dollars per share) | $ / shares 6.95
Vested (dollars per share) | $ / shares 9.71
Cancelled (dollars per share) | $ / shares 9.62
Outstanding, ending (dollars per share) | $ / shares $ 8.77
Employee Stock  
Number of Shares  
Outstanding, beginning (share) | shares 44
Granted (shares) | shares 16
Dividend Equivalents (shares) | shares 1
Vested (shares) | shares (17)
Outstanding, ending (shares) | shares 44
Weighted Average Granted Date Fair Value  
Outstanding, beginning (dollars per share) | $ / shares $ 9.59
Granted (dollars per share) | $ / shares 8.14
Dividend Equivalents (dollars per share) | $ / shares 6.89
Vested (dollars per share) | $ / shares 8.91
Outstanding, ending (dollars per share) | $ / shares $ 9.25
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 9 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise prices (dollars per share) $ 7.24 $ 6.64
Grants outstanding (shares) 124  
Grants exercisable (shares) 104  
$8.14 to $10.80    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 8.14  
Range of exercise prices, maximum (dollars per share) 10.80  
Weighted average exercise prices (dollars per share) $ 9.32  
Grants outstanding (shares) 60  
Intrinsic value - grants outstanding $ 0  
Grants exercisable (shares) 40  
Intrinsic value - grants exercisable $ 0  
$2.37 to $5.86    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 2.37  
Range of exercise prices, maximum (dollars per share) 5.86  
Weighted average exercise prices (dollars per share) $ 5.28  
Grants outstanding (shares) 64  
Intrinsic value - grants outstanding $ 75  
Grants exercisable (shares) 64  
Intrinsic value - grants exercisable $ 75  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Net loss        
Income (loss) from continuing operations $ (7,389) $ (581) $ (7,777) $ 1,148
Income (loss) from discontinued operations, net of income taxes (8) 1 (34) (42)
Net loss $ (7,397) $ (580) $ (7,811) $ 1,106
Per common share – basic        
Income (loss) from continuing operations (dollars per share) $ (1.15) $ (0.09) $ (1.22) $ 0.18
Loss from discontinued operations (dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – basic (dollars per share) (1.15) (0.09) (1.23) 0.17
Per common share – diluted        
Income (loss) from continuing operations (dollars per share) (1.15) (0.09) (1.22) 0.18
Loss from discontinued operations (dollars per share) 0.00 0.00 (0.01) (0.01)
Net income (loss) per common share – diluted (dollars per share) $ (1.15) $ (0.09) $ (1.23) $ 0.17
Weighted Average Common Shares Outstanding:        
Basic (shares) 6,400 6,294 6,362 6,274
Diluted (shares) 6,400 6,294 6,362 6,465
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE - Narrative (Details) - shares
shares in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Earnings Per Share [Abstract]    
Antidilutive shares excluded from computation of diluted earnings per share (shares) 124 46
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 01, 2017
USD ($)
bed
Sep. 30, 2018
USD ($)
bed
Mar. 31, 2018
facility
Sep. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2018
USD ($)
bed
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]                
Number of licensed nursing beds | bed   8,456       8,456    
Number of skilled nursing facilities classified as held for sale | facility     3          
Assets held for sale   $ 13,299       $ 13,299   $ 0
Cash termination payment   $ 13,764   $ 13,791   41,202 $ 41,297  
Gain on sale of investment in unconsolidated affiliate           308 733  
Selma Nursing Centers                
Business Acquisition [Line Items]                
Number of licensed nursing beds | bed 103              
Purchase Price $ 8,750              
Business acquisition, acquisition expenses               140
Gain on bargain purchase $ 925             925
Unnamed pharmacy joint venture                
Business Acquisition [Line Items]                
Gain on sale of investment in unconsolidated affiliate         $ 1,366 $ 308 $ 733  
Trend Health and Rehab of Carthage, LLC (Trend Health)                
Business Acquisition [Line Items]                
Cash termination payment               $ 250
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) - Selma Nursing Centers - USD ($)
$ in Thousands
 12 Months Ended
Jul. 01, 2017
Dec. 31, 2017
Business Acquisition [Line Items]    
Purchase Price $ 8,750  
Gain on bargain purchase 925 $ 925
Assets acquired 9,675  
Building 8,435  
Land 760  
Land Improvements 145  
Furniture, Fixtures and Equipment $ 335  
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUBSEQUENT EVENTS (Details)
$ in Thousands
Oct. 30, 2018
USD ($)
Oct. 01, 2018
extension
center
Sep. 30, 2018
center
Subsequent Event [Line Items]      
Number of nursing center facilities leased     58
Subsequent Event      
Subsequent Event [Line Items]      
Number of nursing center facilities leased   34  
Number of skilled nursing centers under lease   23  
Operating lease, initial term   12 years  
Number of lease extensions allowed | extension   2  
Lease extension period   10 years  
Annual lease fixed escalators, percent   2.15%  
Omega Healthcare Investors Inc | Subsequent Event      
Subsequent Event [Line Items]      
Number of nursing center facilities leased   11  
The Properties | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Subsequent Event      
Subsequent Event [Line Items]      
Proceeds from divestiture of businesses | $ $ 18,700    
EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 132 237 1 false 51 0 false 14 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.advocatinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheets INTERIM CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheetsParenthetical INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperations INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1002501 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperationsParenthetical INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 1003000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfComprehensiveLoss INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 6 false false R7.htm 1004000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfCashFlows INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - BUSINESS Sheet http://www.advocatinc.com/role/Business BUSINESS Notes 8 false false R9.htm 2102100 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatements CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Notes 9 false false R10.htm 2103100 - Disclosure - RECENT ACCOUNTING GUIDANCE Sheet http://www.advocatinc.com/role/RecentAccountingGuidance RECENT ACCOUNTING GUIDANCE Notes 10 false false R11.htm 2104100 - Disclosure - REVENUE RECOGNITION Sheet http://www.advocatinc.com/role/RevenueRecognition REVENUE RECOGNITION Notes 11 false false R12.htm 2105100 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap LONG-TERM DEBT AND INTEREST RATE SWAP Notes 12 false false R13.htm 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.advocatinc.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2107100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.advocatinc.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 14 false false R15.htm 2108100 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.advocatinc.com/role/EarningsPerCommonShare EARNINGS PER COMMON SHARE Notes 15 false false R16.htm 2109100 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Notes 16 false false R17.htm 2110100 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.advocatinc.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 2202201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Policies 18 false false R19.htm 2304301 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://www.advocatinc.com/role/RevenueRecognitionTables REVENUE RECOGNITION (Tables) Tables http://www.advocatinc.com/role/RevenueRecognition 19 false false R20.htm 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.advocatinc.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.advocatinc.com/role/StockBasedCompensation 20 false false R21.htm 2308301 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet http://www.advocatinc.com/role/EarningsPerCommonShareTables EARNINGS PER COMMON SHARE (Tables) Tables http://www.advocatinc.com/role/EarningsPerCommonShare 21 false false R22.htm 2309301 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) Tables http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions 22 false false R23.htm 2401401 - Disclosure - BUSINESS (Details) Sheet http://www.advocatinc.com/role/BusinessDetails BUSINESS (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 23 false false R24.htm 2402402 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsDetails CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) Details http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies 24 false false R25.htm 2404402 - Disclosure - REVENUE RECOGNITION - Adjustments to Operating Results (Details) Sheet http://www.advocatinc.com/role/RevenueRecognitionAdjustmentsToOperatingResultsDetails REVENUE RECOGNITION - Adjustments to Operating Results (Details) Details 25 false false R26.htm 2404403 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) Sheet http://www.advocatinc.com/role/RevenueRecognitionDisaggregationOfRevenueDetails REVENUE RECOGNITION - Disaggregation of Revenue (Details) Details 26 false false R27.htm 2405401 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP (Details) Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwapDetails LONG-TERM DEBT AND INTEREST RATE SWAP (Details) Details http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap 27 false false R28.htm 2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.advocatinc.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.advocatinc.com/role/CommitmentsAndContingencies 28 false false R29.htm 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 29 false false R30.htm 2407403 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfActivityOfEquityCompensationPlansDetails STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Details 30 false false R31.htm 2407404 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfRestrictedStockAndRestrictedStockUnitsActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Details 31 false false R32.htm 2407405 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfAwardsOutstandingAndExercisableDetails STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Details 32 false false R33.htm 2408402 - Disclosure - EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Sheet http://www.advocatinc.com/role/EarningsPerCommonShareBasicAndDilutedNetIncomeLossPerCommonShareDetails EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Details 33 false false R34.htm 2408403 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) Sheet http://www.advocatinc.com/role/EarningsPerCommonShareNarrativeDetails EARNINGS PER COMMON SHARE - Narrative (Details) Details 34 false false R35.htm 2409402 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsNarrativeDetails BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 35 false false R36.htm 2409403 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsScheduleOfAssetsAcquiredDetails BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) Details 36 false false R37.htm 2410401 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.advocatinc.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.advocatinc.com/role/SubsequentEvents 37 false false All Reports Book All Reports avca-20180930.xml avca-20180930.xsd avca-20180930_cal.xml avca-20180930_def.xml avca-20180930_lab.xml avca-20180930_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 57 0000919956-18-000050-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000919956-18-000050-xbrl.zip M4$L#!!0 ( -. 84T-G9TYN_8 $>N#0 1 879C82TR,#$X,#DS,"YX M;6SLO5EW&DFV*/Q\[Z_PY^ZZ*\9N]W79+MO5??JI%H:4E*<0J!/P M<'[]MR,!,>0 2""!3 ]5-I&1N:?84T3L_9?_^^VF_^)+5HSRX>"O+_$K]/)% M-N@.>_G@ZJ\O?_]X83ZZUZ]?_M]?_O=?_K^+B_^R']Z\\,/NY"8;C%^X(NN, ML]Z+K_GX^L6_>MGHSQ>7Q?#FQ;^&Q9_YE\[%Q732[<\D6,8\,UZJR E75G*G M)+(8"8FY5O_GV\],7';1I?CXAV6!?IWN7G\F7?/A?]_.?T MSQ< ]6#T;=?_Z\GH\OOWYIY\N.Z//KX;%U4^]?/13&OF)(*PN$+Z@^.5\ MPFW#X[=U#Q?#AJ>+8=WC7[J=N^>_?OWZJM/[,NQVQOF@^ZH[O"EG($W1_/G/ M#:!_K@/\\VAX>=GP?!JJF=)M>'^W[OW=;M;T=%;W. C(99Z0&PXN;CO%N#JY M\DCM:VZJ$T?CFY_F]%I_?- Y'!0^_AD,"Z^WTU)@O-JE'5?70V__#0;3--D M[;2+3K_?.C4]T#(=5LCF5\P>VO":T;BW^37P4,MK-KZB87K1ONA@H/[Q9O+.!ANFM7)FZ8&6Z8VD7'J@87KKU*9IMT76349[Q5"5 MLQ-5"4(:K%NW&/:SGQ8/5Z?CEOE-D_/K)M;#2!VP^6AX.VJ:DL;J)A4-$XJ: MA[->M\'"IY&Z"7G#XW6"E=W\]Y>&QV&D;D(3MEDMJME_)OGX>\.,-)+:7[+I!0V3&P0XKQ-? M,*N,8-EHW>E/LR?F$_I9@U&'@9KWPZ\-TIA&ZB;D@S];H$G#GSNC;/[XH)-W M1_5$*H=JG-+R]V8.WPTW3FT5D)5'6E_1R-V51QI?L6%ZP]3L:H,S6#ISL\<6 ML\:;9XSOGF[05X,Z;348#@:3F_JW]\;%3^/OM_#RX> "GLJ*O'LWKT&S#^J4 M^A9?6'W[L'M[V2"VY5#--YJT=*V.'HZOP6Y]:PAFYZ/U$_MYI\$ SP9KIMUV M&MQ&&*A[_+8A-P0#-8\738FGHC;S5#3X*46=DU(T0%+4 I)=-LJI@"F72P]F M*6[--HGUW8.+F5?#!K:50[50P1--4Z:?JTSI#YK<]G*H;LIM$UEO:^DZ:7AZ M4O/PJ'MYT?M< U#*W,T&FZ;56:.[:;4F*8WD@]:)Y7#;U!H;M3*WSE1-!VO< MFL7,.M-%!W5\/EN5AVK1]WKK#?,+RZSWF X;EA/ M:P^UO.9ZV&^0M.4G6EZ0YYT&%V+YB987#(?=K^TO2$^TO6 \NM[P GBBY06C M:X@>-A/B[K&V5TUNMGC1]*&ZUS3QLY:%6?>B.^A=-GF(B_&&R;)MPV&\&ZX8>J7_S3/^_*? MNDF7MQ?=/IB/!ETP'VZ<6H/D8F(MAC#2; .F@PW3\K9I>>.T9OTX'6R8-NFV MDJ4AQ7'F\.&V:##=-:(XZE!UJF-X8+ M2P\T3&^=VC!M6+,22EH.:]= G?<\?;R6\* 2LZN&G<398,.T5N_@;KQQ\K$TVC!Q]+F9!6FP;EJ=NBNGU"NZ)JM3 M:VWJ#,VHWKX4JXMC^?&&7' :2?Y]'3OG0PW3EA?#RJ3ZW&\:21%FPY?*H;II MX]NB8F/^_Z47M+VE_09.O6^O> MCO.FM9M;28/W4JT[=49;90/.4^I6Q--@R=9V) ME>G->R5+3Q3?WP_S0<,2K7^NY86M\#3"TDST%HHW+-OY2,VD)*"]M;WHN_3# M='#ET7'MHWSZZ'CYT<5+:Q*T@]&XLY2B^-9O>?B_WN2#/Q=/KB=;O]+R4:RU M_JD=#=OFB?-W/ MUV6.)IVC7GT;I4QC.9PH^]>7H_SFM@_X_)1>,ST#UAT.QMFW\8L< MV!]]FOH;_?E'"LIGOFFL2]_G\O?T'P M'PUH<_&7G]8GE]_X:?TCLV_<9D4^["U_%4A0C'UGG/TREQ"$Y],78TL3LD%O MZ7%]0='B:[WYP_.?[KXW_V%&F7I2O2XIQ=YUQT0?(ZVF C.>HH[1!=%WKYR- MW!OU.,6='CW:*QS?#]KR-W;D:,L+3$!S[@_MF4[X[31T@GQ"G5"22IX&J>1N MI)('(M4I6!JYFZ79.ZFF>N?8U:T\A+H51Z]NQ;[5[ MF5Y_ (!_O@/_Y2_IKROP_^6GVE=,O_A3Y9-'Y (T,";XJ<( MZUMR)$5.O4D_>W<9RB._37+WG9NIBQ-<=0?OP\&\/?> M^^M.<=/I?O]'BJ+_"3,G178Z?'X(&5[^DNCP\T8Z'$Y>5@RQ2(',]H9X337O MQV>9"M@Q&J6C(]74O3NOQ6>Y%I_:*5YDJLX"]BP%[(GS>W>NWBP%_H?I_?=D M2L11'!9OLZ^F6U[XRP=7[XOA /[8S#>7=I.SV>?Q^';+8C@B5BQ\SH^+/\?SWH_>29^ M32/<<[7.I[M.OYN>RWJ_#WI9T< N6[)KSJ;36G+WE>?Y_/M3Z,<5RB,V4_/I MVVHJ6ZNI3FL)/&.K,Y^_#W:>U^L1KM=S%/A#K./3C@*/:GVOIWC.'N(/Z"$^ MQG;Q#V(]^OWAU_08X.:'D\_CRTE_!OOHM.3\;#X>QN?S:CW'9N=%^=QBL_/: MVY>E_-3YMD#PO J/9!7NP336,/8TU^/B)/LY.OJ1HZ.CNS,PR\>E,S^@;WJ3 M[OA=\3$KON3=I;,\[XO\"WSJ?><[+-!WJ>C3?MVNYRO+Z1!1'5UGVK&)L$?B M/QW]"GKJC-?6*^C7K <5\NS7"UY[QG)ZAR9,ZO;6'U6 MC(\F;&?%>(*KIY.W=8J>U>-S7S,_DL0^,X9OYSV>E>19 M21Z'DCP&'W*K-7/>)SZB!-EY!1W7"EJJKG).\#YZ@O=):Y^L56\Z*]"3$,"S M CW:\E3GI._1)=+.J^6X[,ULM9P7P%DHCTXHSSL19U:?LZIGAI\]M'-6]6P/ MSZ>A?P16;Y7_.1_P.Q_P>W+%> RYGAU6R]F3..=ZSJOEG.LY"^5Q">4]?-NS M!)\=GG,D>-X>/F\/GU?0@4*&<_[QG'\\CC5S1#[:CU$E[ER-^X>H&7=$U;B? MW":>SOH^5V!]5NOX-"JPGM?K4=GC<].UTUG@/TC3M:?4"*F&L_@-Q^PS$8LX ML\AZ^3AVNGD?<%E9][\.B_$5Q&*CM16>R/=Z,!H7DT20Q>HU\-=>!HSJ?<@ M-XB4IB\W5T56BN5I+;8J918K:HTT>UH[5<+.UL66E#V<&"^5,A87B%R0!;LU\\].D7<^][,/\,D5!. #O>'@-5"@^-P9_/FN--"] M]-B;U_;=A^>S9$Y/I>\ 1IV8S/.MV\C)GL!8E[(%];<2LT=RT]8LW"8W;>WQ M/;EIS&==HK91,6^R,5#MW>7TD;,M7%_8=?0Y@=6]1X<-@WRJ_3ILR[U@CMK\ M?8+1-\/.B67DSX:JV5"MWQ2FO-=L%98,\"^WS2WZ?EM[;*S7-8 M&#^Z&WMOQ7"T)F37W.@Y<7%.7!QU)NY(DOW/099/3]L_'S$^DGW_'RG9\;R6 MPG/*\ASH^ ([!\WGH/D0QQG3Q^=C#T\ORB=_[&'?AV>/+1%Q M7D;G972JENAI-S+/*^&D?:/'.#SR V1YCS/9>4QG+G;>$CX'=.> [J3VT7X0 ML3Q>"3FB=-33QROG4V-'I_^>VZFQO4GSAN?RY=N^B,,E,4 MG<%5.;SJ KR[R:XZ?\\Z_?%UZMWR>O %7CHL1J\'W?-B/<'%VL3M&3 ;V7V2 M^Q&S$BKONF-T/ OPO'">?N'L,0N"$82)SS;5^(#=N[OAOV>]*Q 5GXWRJT&G M6IEY]GO6,Z/9HXMOG4]J/.]8\U!;ISN 4"^>2Z6F-\OG,0;>1YOH7:IKIL_7 M@\_7@_=3UTSO53[E;]1,KA ^.XUGIW'_$BLOD%K:ASC(L:N/( >]23][=_EK MIW];=+KC/-5-'TV*5$"]M"Z#WB=@^NL[]B^$\GV174X2N7R6VC/EG_O9^R&0 MX\0VD.])@[O>;:U$.-H]JT,]O.^-) MD9G50K.)6];$N[-[]R6 M 0MEOI$#C[0^Z 62.ZR/J3.K][8^[M*[I>Q_*H!I[PI3?,['1_NQ3M MNDY1 \6V=8'F_'Y_/?%\'+:\:337WK#F[SS^81.A"5M64?$F30U47%/ZO'> M;L3\!=LQX<=P*"K[86=']60=U0/OW+#?Z,?K3I&-WDW&Z74]<$3.KN?9]7Q" MUW-)XEG:^3ED29:SZ7]61OB1K]V9KYVB=[=%-O\UW-SVA]^S[.-XV/WSM 1@ M!:$%6VLP^D$=J3/'3VS5KE>,.S/PT&GW/1=1VUKMIBV'(N^.LUZ)\^^#?#SZ M\/'W9\'-5MQ^(%6\>26?I>"D5O=V]O7,U).SN9D$Z[O;LO8%V**\J_F M]K;(NGD9$'_(KZ['HX^=8OW,79FLL!!/]]SP)G65GB:VRQ2&F8ROAT7^/UGO M]T$O*Y:^\;[?&4#4&[YE13@LO#\LTY]:=;X;G,@6ZUEU5GEVFJMH8\QXUIY/ICU/**8\ M2\DQV-B#Q)QRR<8F=;EZ8@0\QT_7P\FH,^BE#8]LD"X-I%L!KP?=!/R7+,TY M+7XO8SD_(+0#FH_$ZJ/8LYFN@#7OZ5,^3AMCKP>]_$O>FW3ZJ_>KYXF1A[\FIJ2;ET%VB%EC^()=K.90%/K3M)"S/\9Y*._J3XKN=6?T')G=AN2CL%KLF=7WWK@^+<8>H4H_!EN^QOCS$G^R)7Y4 MHC'3_V>Y>'JY6%7]>VV]DPK M;W8=XQ^3_E(I>#L9Y8-L-#+=_TSR47[7SV0J\EG_IO-V4HQ2F?,L%:P\L3/0 M#=C-I:,)O462XGG9/)UN/$!Q*V#MLM-YYNZ3*L7=+H.LB,.^;@&Q>4GS#UFG M'\H^*N#UFFYWC;I&7KN2[R_?%$+XX:YTSJW\/4$U;3I9= M6:X[GX>7#M"Z[EQE;]ZXI?'3$*146/=!=+DKCK\C87X,$9S6'RF;>2[\M(^3 MSZ/L/Q- )7S)EGK8-HR?AB#=17GUR"TE*>NP>Q1SH\J^E_N]?73'W/:>"1M; MU3YOX=C0"^%!C7S/LMD4)LYE\^*L?IZ,Q6N1SPJ3-T<^*X_OI2_65"8HNBC_ MN70&=70[''7Z?RN&DUO7[XQ&P)!N3=_;Y>>F?\EZ[R[M]X^=?O9V.(:?NF4) M_ G\#-!-J_&OJ3A8UL.;[&-R.!)%;:>?RJ%_O,ZR<7) >KW2C^WTT\OZP]&D M2!7V5[Z<-$-_DGHKU']PR6&[SF;>2E[I-_RL%\(&CBX?=;T_2_>DEQ]'(.:> M:E4BGJEYJ>J>19IY*]WSP*ST9)!/%<]DU%M>-C=9)_'PEWPT9 3+GW__Z.?O MF \MWII>4O/*,ERI>VG)XW)TYW?V.U]'DWS<^-;9^,[OO9PU#6U\\?R!G=\, MY)X*8>.K[Y[8^=V]V1'XQE?/']CYS=W\2][_(R^]O+*CRY?LCUYV W%CX[>: MI^S\]<%D78W/I\[D&OZX.TIE=J49_')XY[?"NGF?%>4.V?*KRRL+*PLWS7@[ MN4G:;KBLMK9<:_]K!9#5%RU]P6>#X4T^:/S&3+.4&WJ;/K+VKOG0'6H;*/,Y M:Y85&-M]Z9?]J/\87O[1+3OL-NN M0=W5UPE>9K%KXE\&UX[71K)2#2"OGAD M\]NG[8=34A&P? ./9=?#?F_>TOYM-GX[''0G10$O>S'3^Q^RRT5R_>6+7M;- M;SK]T5]?7M"7TW1*8TUX(9B@"EP"-7TAE318 A>F\$YNE= M-[SYG!9+VIS/NL.K0=HIGS<-2CVES&B4C4?SMX-:G+<( A\'QF!%]][ KZ]O M;HOAE]+)&JV@O<]-XR;* 86P)@:CR#67Q&L;HV<((R.U-(*M4PXSOB#<(2EQ M1^[51MQNV$]IT*+3?UN:C'>7[[X.LMXJSA4JBM]PZC722!-]%(B)&)!C&JLE%LPM&E8S#MR#.(V$ M!>^W PYR5MR,?IN (YH5_>\Q_P;X@/:[RCXD_OZ:#_*;R3$GTRBKO+.9.#6%Z],X2VZ0Z4!C/L MJMH!#31*'EAP&$M.D3:>>BF9%EPQ[S%9!W1[&.=74J>)RKLV;K]VOB6:O^]\ M3^H'_+6E.Z6# ?RS_[W6PCQ.,]%&X0P"3"MG5#N!N")&BR3 MCZ4#)(K"TL@C@]7/G%4":4_ )^ Z$.=(C0Y KQ"=T?D^1&JE<*D^_&2:%1E> MPN1BG/]/^;?W93Q_.2S>%_F@F]^F),R=>P(LK3H-NW+@8.9NX5W2B&-$VD7! MN.52$<$C-D0)PXC1].4O[PG_=PMQ'TJ?S<2?K9'7 X@?P ?,!ZYS"^/C&B4A MERH;/3Y9E_K-#JX RYOTOM73N_,O)\3>#.\**36I9A1#X. ""D00<=A3S9A# M7C.! J.FX@!*OJQS=J?H@ADK#5N_3SV6U"*V.W,,*U[ M,\R-)1!N1>L8BN![!\^7]= B747FI-]$OSM*UUFPJ>I/#DR1S@+D-_D8UM*< MA4T&_HG-HW5..\,,"";C''EEG,",>D61]1+;=5FE:%E6=R?#%A3\./G-I&O?BV[J//_837P;:<_!.>:("QU!5KU25C //'#$(P-!8\4UP5O2OD+ M5J)#@'M9_B7YA*/QZ'TG[X%E@#4PM00[N]#*61DDQ $"@QJ4T2"K(@[!"J*C M-K22.4!2MJ.U"<0]X[?!\XX.26UQ,!+8I16W7GMDK=,J(.%91;TSQLF>\)O' MH&]@]F!T%X;:K#?:F-U9E3TJK4W^&K(4<^R1IE@1[B4E%$6-EYE4YB 52_MW MFX#8&= #Y6-6<171@(N$;0![S*FC8 DTI\!:>;0$XV+#@JR!N0Q"%;YEFC6X!)OE M!DN0^ BA$\#*(=37,F4YF0/G7R'E1$UF1:X+3@,DVT)A(+IPAATEC.B9 6]$H HT>4 M0]'*Y63K\K[?JEYIA:D"_S0[-IH'V.T9RX-ERQBV%G%PB)'TW NKP.TB*LHH MC4 XQ&7&579L\3K^:SA5<9YY+P:X/ )@W^1?[NHEG^LV*U;44#WWRBL0=Y>=T]]FF9--7,$J:O . MO "GF!-';53,1"\5 L>>2+&.'EU;2UO!?% \I]LBF_!4/D1)"')410[>G/;& M,@V&W BO1 T;U1[0_/AGWN^O;YR5EZ!+^_?H!EU(); WB*@ 5@5YK[0$@\XU M95Q&4N<0$KI&APTX;:#!PHC^/>OWXK"8'41\#V[?N\OZ\WVUNX2M.E:!W==4 M@2 (HBY&-/A,QEJ0"S"L-L;((=RIW\@ M3$CV8[X-= ES(^S MU>0H]G[D?2FU89C$BC*' I;"(1F4AD4!MDH&[)E]^IR5H&_!9F.!E$HQ, MOS_\^@112J0T<&Q0\(2QR!!WE@.N+@7I6HAEAW#I2"6I1;X=M3MZ@/O8S< MS'>&+H?%Z]%HDM):'[)>=G,[W6&:[C*D%'5QUY0)_*?RY\_KM3+*6AAW)YV7 MJU[LG(PTP6,CG<;&"QZ",#H:A1V)%#LF5I9SF:R[T&R1JWM1)@,%>E1,/SX5L7 I]WEZXS MNJ[=^-WJP A3U($O#TH%_FF)IM8IRSWE)DJ!PSHU$L66B;$55'M 8P-3(>:2 MA%D/D$ON,+$49FD=),,&\VI2&U-!'X#'APS4V22+Q? F;;BEA/B_\O&UFXS& MPYN2Y5->IE-N\+_>I\ZWQ6& 6A[]-ML/ E#2#MB[XF-6? $_=6D7MS. R3T' M$E2YJ%/J>7.;+B8L;8*[Z0WAU&#R\C+KCE-QN:5\]-V>=:??G=XD+GV_&6Y_ MF^2])-5 B7*RS4#4LT_#V[PKD*AJ\M4E9D!M*8D8XUQJ9)!7#O['>*3"8USO MA,BY#_(@ZCXMCR" [7;RWK$S2 =BC;,>K CFCG(=)0*G27L!!@?"QEH&<2*> M"8..?P5A&T5,[I#A@GN"K8XD:NQ,3&Z <[4,(DR?/(/>%_D7("1H7#/HO1M? M9^O]-HZ.50%,3R0<[&5TG(+>HT9Q:@QQ2&ABZX^.88Y.@%5'1?/54,%YJGV M,,\B#=$1,LX@HW%*>_D@HJVA.CYRBO_[.;D $*IP9FV$L)6F?0[P,E5$T;O@ M# ?=UN "L-/GT:FX &!;I'<<;#_EPD<-7C_B @)NBXDV#2X /G8+LRV#CG\% M41VHBA1YQS#'%*P,Z#='98A8XFCJ-!RX (*>/(-.SP4PAE'N!,0[Q'/PH#5G MR%I#A!9>:LOK70!V"LKNJ&B^MC7 4HPYW7;D@3B@MR&:VSKU252ZOE1Z+C6[,K14T:]10)+%A0GS%F*P8/'PG/B'5;A%/-" MV_%HQ2EL(H\3G 5X)]%1\G09)F+C%>*$6R&8J3$**0I"YP)XZ36KDX#@\],C]IGWH%!FU0PCP%>2)$@8*"PLY8&B/Z"AF7N M$%6HW@W2S\!(G4A(@803(C!P417FUE#EO68A7;DUF%)6'Y03=OH,:@HIF@CE M@\9$:D&8,4"=M/TNI(>066.E=:C7Q(0>M4/_($(=KTP+JIG6-CC)%7C"U.)@ M%16@?932(M3=WD^QURGX%$=%\[63&J \HC 0B:33DRA8$[2 'Y@41H5:;_O8 MM4CK_19D8>%S4)K$@$DC1EG&#*$D"D]"#'6:\P3PW5?LA9)%(89A%P.'(-6 MZPK^JS-)-.J3\>#7ZV-7E\\J(4_!>54^:BJ4XS8RXPW\,6H?O$0,U_NN2!WU M-M5V/-HJ]C(0A6H.1MY9PN&?1B*)D8%_B9#RXO6QESCV],'SV:\@U%,2#//6 M&PYQL;'1&>>5T%0*H>N#"T[(,V'0)A4L(>*RQH9@6>1(!AU=%!'+P!UFAOMZ MCQ4]E^5]_/I7!49XM$HR[N#?1BN0W4!ED 13$>N/"1!^^E[$KK%7M,PC9;"6 MX&HEF0;'4J$( 9ATU*GZPV.$GKXF/KW8*Y*(&%<2Q50H21/EJ6$10>#LO,$K M=>J68Z]C3U@>^[X75H:I"&Z;QEQ&K#VE1'C$;0!%+_7!8Y&&_L5%D6YSE97! MOR\>F9V=+1M PPYT*W[STY_LL:,]=N,SZ MZ:(A<-,Y9NT@ MDD)&2$(M1XIJB*JBEE%1B+&)J!S'GMOO0['DS//]M:)MO) 0C*.>"T]350("\@R M3AS3UDMK-7%21TSD6IG@195O^0J)O;.@C4+[8D@<%I=9GNJ7);J%;[?Y[(;C MZYEAVYY-AVD=W<0IA604W#,FK.&,Z+0%YUVZ]Q&E\$8W<4J_DGOBU(-(MR_^ M+16Z^\$4Z6;C2:D6R@0G4%!C2PY\_SPQE/"\M>4 M>(85XQ+40=IQ]BHR'P0RM+Y8Y>GQ?7J;M;:&_Z&4[PJ911 6>6:9<9*G* M&^%AH7$L0XS+^Q_SS@D$XT.0>DJ)1R3Q 3V1U2N,2FJ'E#$4PKK ,(33%J6F M!5$#Z0VJ(3$F[*1(O)L+>$#97G8L:)26$L,Y2>7V4=K)-"&5%!2:=E-,';R MHB&":+:Z\U_G725*EK6SQ1D$L7D(1&+&;33@V3BD"27:,R=7#LRN+5BN'\J6 MO=+I&; MU?H#"837EHS['0@_^O#Q]W8&(NPM\U(% 7I76 S>$;%$"V&X2368 MFQFH^9F!NS"P66/?8]U%+AUESGMA,$=*6*TM1\9'[8P7H=&GU:_(F6U[9MO] MUAU*+8\*.M]GVRH]]X247G&-$(Q%QPX8P)T8)&2G7Y M<,2TT07@K^36/MP^:;4W#I7*[.C9P[5E"$P#5H'SF!:+\,0SI*(T1IK&;(EZ MA;?.ENR-4!MXLU4<68T.YZ7 E[3D%+"GLQ0$4\P%B38H#9XRLEQ2+ .)""/E M<5V^? M+L6_Z/#=V/'6:8O,6I4QU>&-*\@?'B;%*")"*=(>&"1:MJ9$+ALYB M<=IBL7D7$WN2JE@@R1SB#&F+221.<8LL#DB2&K$0STQ;+ 453ZV\$7=:!R^T MT)Y;H0Q'G C*N/":&5[K?&[>B=LW?9X;.YYZE6Y6WH)'F?I<&6T]UQ"3X.@@ M& EI\U Q4K=#*PZMO,]B\>3*6YHH/=;P?\,XX=1JZHGP5/*(.&CSIU#>&\2B M4H)Z^QQ$=AP) JP(TU02%SQ)QP$5%CJ"1Q4P"83(6AV-UA?C7LBP/64_?U\\ MLCGA-EXDW'SJSIT-R@>_=/KID1U3E1NYG+Q7WADK6%7$*L1BY)9K$YW'H,P<3IV@6>,I6[&V MWW,TQ'LX3Z?9C7RVVO]6#$>-Y>D?1?-IAB.)1DL7&:?!:@[1 C-&$A93 ^0: MS4=W47P[T&%!W(3-??*M7 >G'K.(W:6FJ")5U@SZDPP+W^YN,#D@N+IYYN^-(?$#[NEWIH^,&5X MA-]:NEDL.NHQ1YPP%'P8#: $@X/FF@;@B@!E+%[^\AN=0M'XE7HP$IS; B%# M])S+(!SX5$19K9QB%ORJ2*0'(4K=%U-CS9:OK ,QA6][EE@966I?Y8/BW$=K M4^Z4>*^3HV<\GH)P@?0%1:N K'QI'8RDBK<1B,B\,QY9!]3W'.OHE/712(0X MP4&D=7+QV^IWTZOGGPN#,5BPU$BMZ/1?@\?^[?]EW[?XKD;""*H"MAA\*"ZT ML0QA2JCT+@@"RB@I<)VVA,7TZ[5?6@-C>',#<4327=-@8BDF:.CL1'3+K5.0 MPJBY"TY#E(.Q"12$% )?:A"CM&[O4W"L (T5B%N 6@4_W&3%%?P*AN;K^#JI MHLY@*UI2G3J*(D.8\T8JBZCF2>]92;S1JQJEY5.KT,2\GQ4.).MJ6&P#!:C? MB'V$E4,51\9:ZY5/KU%^81FJE4^N0O,A MN\K!LH ]3I9P"W"\=-3".J(62VZ$LYI@[R,2@3C0O^[E+^!;@<8O*RF\6#1H M?C&[I#[Z/R]>#[JOEL%;A6$5OH\@0/UY&_1MP&,"$ZI!X@TL?.&#B42G&BQ: M\1 =4 MI/2)\XP.PY./7SNW&ELL"# FVSB*&.(?0U!L+(1,5P48D;>5F"I$: M3R^G;,!E5W1?EZUL<@+F@>UD]T'M MN^&_9[VT8GTVRJ\&4W=L>?;\]]2I=?;HXEMKKWHS'%S!MVX2>JLN^YP0J8'> MF^'"B6PLT!QP"H,1 ]7#;:I*!]X7CHI+:P7X.>L<+]WR;3D^ _=GT^VFGU(# MLN2-?2HZO6SFF=2>"FS9$Z04L8Q[!P8::.,63^,F"#&3#P$XH73^S8;WXO(B#'B M,4M7U SWCBJ4#J]'XT#QS+KDPWQR-OLZ^Q5L-#?%\,!_+$[/;FP MHA86#WU,/D?*B_Y^VP,U 6]G2.^GW$JI.GP.0X!&-[/9^&N6#1HJ?WPN*W] MV&HN00?-*X LL /D7M_<]DM<2A V) >B)+!("1A[I@P85668 5=:*,&%KVGG M=Z'4F75[95WJ+YH> ]S\,"QX5\"]&"'^Y,6G1)=Z!PT8B MKO8P%(3R,_,JMG]+_ME:_FW@D64X'X<6;=X#>)4:4>6-PH$[*;22RJ=[FS85[["5 M%:(@/*\X:8>D1;FKD(+\(KM.3:%3&-(=WF1OAJ,1"-6[RT^=;[NQ/U*&-?+I M0J+GE#J#M",H=67AR%)<\:0EJKAXNP"W5[S:6&EED(Y2P=+]6Z:"QC@:J8PG MQH9(3#6)S(\*L7W']ZO6VC%0:[#<%08E[Y!6$:X21'NPZCCS5&$3I-)14L=H7"\-!/!3(N1#X G,KL/:!R(9F MW(P2*P+R$!B",=!>6^DIE=B%0"WAE8)FFLDG1:1MVS9\R[J3TFGAVDV MG1\$6;2*6,-P GTR@9I"#/.62" KN!/UM7FO?!OBCH6+M.],AA2&(&TC(Z# MPUNF,1#!W <-?[+M,B MEC>WDVE@_.XR=(H!A!BC^:F$NLSO-LN0( ]< CD%G4B= _<=)[<..PRN/,=U M1[37%N(^X'X$0FQ8QDD%12&HELQS1ZPV/$"P8XDTQA!)6X[!'HX2HU$VKCET MV";!C@JA""@EBB6G&)EDXH0#$D0"_EIU+QRLB5A;D>5GMP&D=5,^8D%5:BJU>OTU.%T DD2,(8:&X@8>;!:, 1RARHI4PFN*=D%JK?# M07Q=?'3ZS(3/TUA#'I[B@\Q 5*7M;^%YU$8I5R@QE%EE:80#U<-@D2R M!J5]0/Y8]&ACL89H69ATS 9"AI1?YO \-6!J*(V(5>)E!MX#?S1ZO+OT^>AV M..KT_U8,)[=W19'AUX1E/IB RWZ;32^&WFOA4:ZBQX(X*RF71"HDK"$!G+YH M ]C6"OYUR-\'S$,AV\9LZ3@XYVAZ%$E @(2"#<8BJ:B4L!@JPH\.@.Q\J]AT M@>_3I)<;CB"T*G\HLMYT6[E,B76Z\^%Z0W/G+M:\=.F\7]:_Z;R=%/#(53JG MD6T\V ?^!L&*IYP8XHB!#G3*83#4$-(@5)4*S%8I=4\#5(I])K/(N9A_6/21_AB_*?AZ*7EEAI Q$?V#"P =10 ME/9:$;8VZ*"J80;AM?3:#=D]DVOFD;+E,&3/= J>"@(4T5)J[A$8'G \B/*& MI#ZYJ+*?]RAT?B)APB12:RT3*D X%IV%#S/CL5&( M.%R3HBX-4CN5&G'<0)L%*5_W /C\,B\OX96*<+Z6P82]@9_3Z0WPJ&%L7PB6Q9<2C&"*ZFY$,$H#Q8U".RD!VU7(;)B]'!$OB/#H>A<[U@^!IV- MM81981E%&L(/KZF#\$)0X5&DWE:B17I ,MD?SW1Y@A%C'T"] M6\-QT$Q0B@RF5E:SF&L;'#N!/KH&]J1_+=WM,6/7*8KO(%<-M;=$VY:L$UH8 MI% DJ8Z6U1!N6H>(10A"K_4*:!!B$;$._A8P[0$)V1(Z40KZ'G.9SN!SQ%/C M.P9>26H:I@2CE=") JY/A$0S)S3"-%CA)(3VW')K A6.8?#=I?185JKR4[Z6 M1'PL)%HS%A!CF+01BB!BAS!=&PL+PU 'S@XHLHHX 2<.(D[3DQRPAHJTK'PV M_??N.>[HT\:$QXB#A('NQ18;@4,ZZD>XJ'B[%Z *MD"G'KK]8;5!8^FD:[%+ M.C:=8 7V8!N50LHA$8*M8D76LJL/P>I],4RW$WOV^^\C,$.#"*9IT$WWKR'4 M_E+:G-ID1(F.<*.@$/&O:TDSA\+XVF*\2 \MCX(2R3F$62: (LI"R)" MX&1#](;NB/'6@!X0XPT\!NR89=X(9,&(:672'3P!IB]8KVOV&1\+X]F3!^"Q MBQ2!<0WG MUSJS6U_4_I0-TM6;=+D&;&N*VKZL7-5NNF7C/2,86VT#!BMON:'@$(,A3_T1 M#;>UY5;6+J[LC.G^R#2E$OFU\YWB@Y-*,W!5I; IC."$<@BX&=$!I4NU7M7> MV:0'(M6\=L/=WC[X4?U.4TC]VZKZ6,.*"VJY"XQ3B(G ,^ !E";8#4DB0BQI89)V.2():4<$'2J+#SC(J V< M =\IWA4?RQN597@XG[8Q_EY%) :B,'A3*9' N5>6<*F9\!#] M$"<];>$*KL6C":X'H[$6@:\)EPT@41" 8ZVX8\:XJ)CV0H.]TRUUB/>%QGI% MKAVY8!3!!FFMP5AS983%,G!P&Y15H*)7Q&FNB\G=_= MP+DWU*U$]ZE&ADN6 M54O.0KJ<':E&4FN,TBW,@T*=3,H6=%Y-F4D?"$$6_DLY,D$1\((J[+IC72(P]_QX1KK'W=24,AF7XPK$V% M(#;?9J6\#+D#8Y(;#ZH$4R$5LSH*[$E=Z2'P1WD[P&L5(.X'=>NQ.ZH-5Q V M0PS-(\)I>U* _P[6"80$USJ,'&\0B&N9PO; 5N_ M]U!_J:/>-5S=Q$_WV#''23MQ1%.^/!5Y\H0;JXBO@'G!-%D'M F8A\#<%@U; MT $Z'0E57G$P">">!TH#V&830#%5S@;"BL,'A[GJZ*VEC\$,<.(<2=D+[C4F MUFLO=6 &0K'*^;T+2?FC -V:4E-16$<-)XIR;D!I2<(D5A8Q3F25T!>2W9?2 MZ=#5WX;#7EGH;59!Y>.POU6LLU9:E&BL8JI2!B(B;6K$P*57*MF(4#VZ@[&: MEY'?#,T#8&ZC&>I#Q[I@"FM9.'3Y3FZKLCV#?,&@0Y$ MFZBQ1\I[;@TR5@(=0^K"F@JS5Q0'QC3UF'L,F,]7K^=R)71D#H0HM7PNRW%S MD2X18PC*(H3*%;G2ZQO2A^;0\5V\%E)#K$K!W6$.E%PJ,F]G-%.6JAJYEA*M MF\0#4*U5?RC/F0!#+HGC0@;CA7'@K*4RI*GE=/4 CJQZ:X>!^;P6YY$+,0[H M+C4+UH O0(R*Y87^A$G-(2F,<24,.#"+CF\Q8@?+4,#*,^ U*Z(A(IE602"4 M.&DJ)_@H4T+>=S'.VE>EBX+U.U.MYA"<>F!L*D(H..+)0L$Y$R3VSH,LX,]Z("*J-T8HI8(2Q&A?C_O!M<"=L M#*"S3 2: +^9,-3 BDD7K)TPNGHA&3-)]?[A.ZNKN;I"*NV-Q>BME%@@CXR: MFL$@<*B&K[6NP]ZX<7R:R3L=! 2@1F@M0VI1A&:NE74\KK?I355M,*WD^!Y( MH=:S 39M9UJ3SO=P%[$AU)-T=P'4HT2F$5FG.1\*WWD]S?. ,C*(^RUU M'D=BP?A[-[5D6*8.P=N9_[VQX_@6%+.I@B*83QP%B<81BV:FGJ33Y96SLXPJ M1;8W *N5.&UGE(\^WA99I_=N\,].49Y]3E5,JG=ICJD,Z.:ZF\")8?]+.E>^ M N7:>Y8Q7D$ /M ;#LJR+I\[@S_?E0NBEQY[\]J^^["Q?JO'(LC@K#.,4V84 MM\I(+3$68#Q6[B$/RJXKY583DTM[?]ORZ0?D[6I-U8,S4R%/7$AM]C1H(HXU MCA!2.LJ%P9JM[%PL,_,$6+G=(MD78P_%'\F4]Q["?.P0CV#3$2/ HQ \PUY1 M_@C\6:[_Y"=%LN7;=:1X:N:TG)1Q2J?*"=A(:1E&.'IF""/>A$B#;5!AHHFJ M313:CJ93,YI.+F5%.L,$2J"]:M=1ZZ]6SBYS9,4MD"DY[IFT'EQH:PP*6FKE M@#W"".L;^*&V84@->7]$OC37ZEX^O>D#9DZEPNR.<.I3,QWK:(0PR(!Y< WJ M1BS[9T_ B6=4R+V),2'@0+D14NK #;>&( V!!D3MF1*=YZC2^9\8D07J0 M87Z3#[)WE],']JWPEZIS84V=MFF_BK/H#=&(>RRU!C)2[E_^\I[_NXDV"<4# M$N! XK>R5:#3?3*K4BU[8:/"BJ9:*D )BAPE.V(_O9U?!EZS$B(0?RT*RNQZ M5B:=#A#,<.E2 MP?IT+Q5K"&5Y3:$J(O7#89_>RLG*.=4N:[6Z;X^.TUH)N, ] [,,81YW2AJA MC#66.">Q-^M=\ !_+$@M 2HXU2$^/4GPJ?-M5M0HVU'26!!26.=3+,,#089$ MY\!]UE10%MDRY!L0G@A5IM/+<.*W!&G7((4T> DM5- M2:XTW@>\LU2*S0;99;Y[84 7O+2IRG?PFL> @BO8%R6;URHU[[P/ M1;5PTBH'7H'E&'L+HBM)*J,& MK$"I!1^/0DAP^2MZ7Z&U.]N'@'G#?A4$V@QS'9P7CANE(#R,$'8[@13S2%;V M^X@6ZPKD(#"WT1E+HXVRFC&9CG2!Y;?"@?>>2DJDJM45.@N]OAZWA'GNY+:4 M?#QHI6E"6"!"!IWNR8$)LF"3D.=$ **4VKF+B.MKK<+O']YW;;4X7H=S!TKXP+G MD';6@&_+.6.P0J4A6/, ^(IJ=ZI5).\+X\%0;;T$(#R"6%%*P0!5#1&9X8(H MZA6H4%ISI(62M0.>>\)XO<9Q2E5WM]&HRVVZF0"OS3(OA%(\J'0B'\-25-K: M2$$--=V%ND"OT%*JI!:6^P'[[Q9@"3A!7L5GO: K"*J!R\ &"*FK=NA)?(BQ^A?E!@&TA++AIS@@4 MD05W(/6Q19@"7T L#Y5]-[NYNX*N.F2/R$*5AWE%-PWH35G MZ?XVAT6I_3V%=@;-?0%NH:_''DM&F=&4@ZD+"G$>+;):@D%/;7GO);@/@;== M>$&Q@1YP0;B .)BM5%\M76VCW%'+9;-6:!?>!P+<0F!!4]*2:.MI*@)GC. X M&5J5[L*0]4S U@);.EU>/P>""RR%-9&EFR95 MZ/%:H:3=H"\[9_R:C:]3%:5Y4>X/6:>?;H"FVK&IT>Y"4FT[W^S^&^6#\3Y@Y*;)- M;E\H"M&+Q> A":RXK@1IDM*C0^[)143+9"&\"*FSK@[5M1#7>I3ZOCMDF<+*RRB1Y5I7*[E3I(X.N2>7$&X049X2CQ#(2FJH M9@F$8)%QL((@QP]@'",0HV,L @0AG#** &SPG,#O M%]4ZH(\%]H94$?(^2)7C-L)!5*C].!"W'C2GGF*M'4_Y5?B7 MT!C/"(U!AU<\HWM!G VRHM-/*><>C.>C<3$]H]S2-JZ-RMS#0YP+3YSE!#&; MVOAY9V ]\J"K)8:3,5J5CG: '@I[:Q(?] :B,?E3CEO$=*2*:9*V\F,J>E!M MC$.D?#3@-XBW4I(JFIHP1\\E*!/B>9"!IIM=QJ+*#H3D]%%A;^WMA:QWPA#0 M(Y@+H5/OG4!AK3I-(@F5I4F8EOB^P"^Z64X[?I7I,@C8-M1.;*.]Q\Y2;(P! M>\,) ^\J@L";&*/WU-74$.1J%?S-,.T!@]8L,P: 633((\V93M70"<@1 2DR M6(M*#06,UQI)'QZ#3>I=2FT4!X$7 N3?*2N9)YA2S#"UKMIK'I:+?GP46O=L MJ!%"*BM$N@N&B-4J=4%E5(%K9GW%L%Y(N:9_]HW"])K)W3Y[-OHU'PP+\/CF MFX:PX%;?4N\0[KZDM RIS@1W5*5BXZ"#@Q%:1H\9HH+7U(0F8D=2[ VY8Z)I MFWR9=)K12BZ"YUQ; Q8#.Z:Q-"):YBK^!%ZO*O$CTG23V4WMQ7%T%GO!0Z06 M*>.I)=%!%!)4S9KE^BRHFT)[AYB"^)Y[""^4H<8;Z57JJ"4A *W>L+Q0C.VJ M")^(J.^SHMS1J*DYN,6>!0M,I*,EBD6NA+'1.8HAS T0YJJX[4;;CE#N&\&6 M%'P$K6]QZD1IP8^UUC!PNV%541UU6"WPM[['H8X#O_8]$0CLK1>)@0KPBT09 M)G'4Z2H?J)'U2A6->R)/C& + R%D AQ%Y(PASB#>#L@[30F#GXA6C=5PTQX* M>3P$9WLR]UJ$J?&, /^7@C'EE!$+CHJESC@+?Z3-967OLPB7X=P_DBU\= 8B M>&,%(=Z7@JHQ 15KHA/25"*R!RW$ ^+8OAB]MYZE='@PFEM%%!8Q2B^EC9*Y M]?J&#UN,AT6R[;A#P!J<$N0M=NE\E(YEIPH#HALU:M4X.R_([9"L+X0_+UUG MQN,B_SP9IRN2GX8?LMMT#G)P-6T6NGM@3@5!FM)T=)0+I U$@TZGVX;>4F&K MY0Q;G(@'P/UXQ&CUJA '&1 <>R"&44%#C.R#\&D#EJ)J>BOUGC]E\"PJ9H44X&^H6#DZ>-&6\#@):K3&AM1;%&2(FJ)TZ=#(**@. MT7G0(%%6BVA2=ESD>)!CK:G@,BKP/(GA"&PZZ$@6C7$\55S$J-G<-N')&<(J\X<+2R(0-SDF^?OAA3ZS>APOT0-==10R!"3RE $T<,;AZ M)+6M$J#B"5^_ZKDO=C\*XAM.RRH5!5;6VJ30/$M)(:F)3%NG2+*6F.78&=Z^ MOJ4C(7#C(D_['R1H++4SQF,/*H[IQE84AV3X=O<;6XM-)\^#<.>I83P88@D5 M-$# !HX'DZ2Z 4#7^G)M<3MP7W1_#7JZTE+\H.! >%]:!7ZYQ76DM#J#*:1\VLEX)2:04% MWX74AR7;H9J/WG;Q7N2V]S58QQZRR7_J@![\4DY4# MW3M+:[!@%H#MCD3!531*(J$QC99CXQRI%K[0U2WU>\!Y"$PW52JW&OR\=!=2 M@]^'L!')S74(%J9U-84,4G>7@V/ZOLAN80W-;^S/%!.\Z-WX.BOJ[C!OQZM09+-3]V7[@_9OW+ MI7/)9:?+G0G/J.9)CQNA Q!O(6 ZHB6JV$XN*<[$%7/O 9%-?=6P# M!5]0IPJ:Q*:[9"$$CV%A2%_3HH@0LHD5FS&9^G'W/10K).?&:Q:,D=QKKC'\ MG;)4SD@%495Z+"K$7P%@5]A:)1O%5$5)I[)"W$=B4X$AI,'RPQ*5ZUONX"VM M5ZYX"&R;*M=CFTX?@J_$-&<4&7 ]I5#8,$\AS*\H>J#;^MF:!\'61C>D@&B> M*8MC+,LS&9V[I:YXYB8Y,O>N)/FX96W?)*UD"M!&5^7P:FW)=S?95>?O6:<_ MONYVT@FF=!)I6(Q K6V(+Q77PCC/! V@AH(S'(54OD6!*4[57&J*P.%5U;F) MP"O,6/B(J3M(:K=W/>SW8/KT(-5N,5. 2(2BF-KHT71).W5-"R#*'G-G,:G> ME0&=*U:%>A- #P.^M<:8@!@O_3\BR2U.Y1( E:@0)9:9:GX(I[0\W@?P][I/ M["D2J2TLL<+P&(5RZ2B6=F,X(@&^3"PW,;@7 M/#F1.'BAK?315/U_H>3:X>"MX;MO+1/)HU<0BUD&ME[[=,W.NX@9^/ 0NXB* MQ==",=0$8GWICBVA;",DXRXR$W79R(_HJ'T($M$ EE\C5G/J'X&BH/<&LRPV MLVW5DOM)+L3T#&$=&!8%._6._3.1&DQ M]BCI<_"%/:?@;::R;TB!>_P$>'^/PR).TA74]\-^WOT^2T9NJ%BVN O[:Z=_ MF^ZMY:GIQG@'S(30:OKM37E7 MC*TF7 EP2%+%-M#+E!KMO4,R6E$]%R_6DEV;<%ZESZ(0[]R/F)'1#HMB^#5Y M&9U;&&FP,D?CKS2[QA!36H$(2MLAJ>&4E0H11VF4J=58Q59SIM?5\_8TVD3; M7SO?\IO)S1:TE;^1HZ3M:A5]3FU(';P,!G$U(!'<(2PH\X%@ZZO"RDEYUWD# M=9NHM#_J'JODKK59832U:5;*QE2WV2K/E8]2N:53Z3$%I%4[QX\=R% +52S\&CVGQ.BZ\$*C#<1E2*GB0Y4 MA4 Y%M@XR2'"HXQ2C6FUK9.<*H(S30_266.MPT_@VG #(0GU'&N3;B?&8%TJ MB$=#J/ &GWFSS^X::TH]M61(N=:4>PU<*>.]L@IBKG20H'JV59R>\GEJLVF" M X@]:';%@X1 7 ;OO:2."XALJZ6QY9&(._-9EZBMS&:9^GILPZDAHJ6:@^^1 M3N^38(U$S@@;$/7!Q6K:ZUA$MR2L/E[""DG ;**()<-<0+2'(U$\@MA2+1VK MIN3XL1#V77>,3L&5=I102H"X3G .^L!0AU.:4'#*F*U6)3R"0&4:!5(SN4+X M!"A,.'A_GE,AP0'T&)F@G5L&A:RJ?3WW2.%Q?E5F@&:[I??-DP:'%,4^ M6,2L\$YKZE$ZKFTBB82(RI;$"NR-,-P;U+8#16L\3*X!7@_JE6HQ!2?Y M'NC4[<8]#*M6?\CK(%@0B!L.2\,9%6RJ4:DY5=97VV%A\ W$_K%Z?]<]TV:= MU 4XYM]2'=?%S8M'Z9&TZIEC:A1$DQ#N@-H0RAFK-;BW"C/M"%TY@-74.'0W M'%>I,QI-*S1<98/N]_37UX/W#=VC-_5*\MHYSQ5$R!&!'T(-A!E2(<4=B#-O MZ\G2 L9#H&T]Y(I)3*5=E24^,.6X$\$(R[&.S!%;T=8'AG;3Z4;#5$AMW\NM M>L_ 13%3VAICR/JE\[J XC PMUZGP"%$BUU@6B=;YZ)1B<(@&R$54CD0S&^S MKZ[?R6]&,>]GO;?EDEF!?=8-]A^3_G<\OBXF*7&JR^K:BZC+I5-UB\,"PW$Z M0=#I_S,?]J>:9G@9 >-L^B73K;JCRS#EV&Q7=X,WQMDPH!*P$!/?UUPWG_5OT1G".@ M.K @5EE+4C.KH"A%1.+@<67CCU!2$9=U(.X%9.M17L% -VL$L:K0C$L6+4MU MEBWWX/^Z1P)R@[:0D2%MHM$>F73V$40#SR@IP9MH*U^]-_C:^Y0%E,I(PJ.4 M,1^-T'Y&1&]TM2KX#O#5'04R@\&DTW>I1CN8Q3?Y3FA6WG6+\ M?;5X_L>_NV3O7:L/=H:&-:3[/ Y8! M:RQ5:H1L/6<6##%QR#-K*@%:)5.])?TVD7R6&)S/ :4-M,I[%:.%\ MJAC/%>7 !C#+45@/$3*U@505PWKLMQL5#T#_AQ)RUV-UJ^3S&"(=T/X^6L.1 M#F"^.$L=?C#5),A*?OH@Y%NS>N4%QD[_]T$OG6=,DMEKCP\>7P97$ZLJID[G M@BJ'N$400CANO;5!(VV!M-6=520;J;B9%ML1$23B)D],&-VCLC.V'EN+:&I0 ME6XV&\M@G2G-D(S4L&H[=X'EE@@MP[4G3%IOHCD44W07())/)V^4%L AZJ50 MWM1L7BBT=I7E\3#9X%P8C7WJAR%2(\I(D4' #!TD.#J8H?7>O%?ES:<'8?(V&T-H<0T+_0LHHI[] M_OLH!>H]0HBN #A :""Y"VFDH!JQ=V MMH=M7QAM;)1-D)""&18D9[3LV,.5=8*)%%96R_2SQT5HRN\'=E. J"V%$5;X M$+E5H [ @_."68*M)+JRG![ MCIX#XGY)O:"G0HIJ>&$XMHYS2*"X"HZXETZ MF[@_]MX3\>EUN8>M2N526W>0WP V.5V5I8J$U,8),TI\M4']!42_2FV#9PUT M^\)I4PL6JTFD6&A',9<"+!I%T7F::J59X&6UA0EHH$=%:2\K$V/*4CT\GGI\ M(LHM#28HAJ.EX%/YJGP^A'7[$]&]K,VH7.H4"V&,!=$%5Y(Y@ADX+LJG&K#5 MTD\/8/$]49\]_*#5&<#_TI%K;&BJ?X:- Y,)XFQ)-)Z[BO+5FFV%90UL^\)H M$^,8\](Y%<"GY$@*F^H)8!4%BJ!;0R51S-G:S==#8[0?HXD"K$$)6D8]"I$PKFB[]5[=:@6[R_V?O2YL;-Y*T/^_^"D2_GAT[@BWC*ASMF8G Z>E= M=ZM7DG=B/T)D4<08!#@ *+7VU[^9!8 $"1X25:1 J28\MDCBJ,K*?/*HK,P# MI\F//;E(IDNPZQBQL>L244WL=N$XV6TB@N7GCS?S92' YQ>ZP#XR MOH4] &2B8Q-)(PA=+U1#$YO==^S5CV2M-^#*ZY\WKIV>FN[*EF=XH>,JQ#)\ MR]!#7PM<576(;W=/#(.?UL&$@\:UQ^\R%-E774\S-!D67O%<1R$ZJ]+IN'C\ M<$/3*KO#\X<.;"?!9%A) XQ5"X^ @SNKNS:>,-. D(KN=,O%F-::;_NT@3GW M49Q4=:"];#K-TO;)]BUMZ/?PH*:9\$^@^T2!M;9 NV$RA..!2ZOZQ.B$2W?S MX/X!\I[;SF4)=,T*3,LPC)!@5%VWW" ,%3.P-5WMYB#NYN,3SVU? S?0T!KF MNX-FP](.CHVUO!S9MSP=6P ]4Q9./[F=.],R,64]]&0%_7G5!1="]0B&D1W5 M=H.N>;U;GIXYN2S-&DU0/>/00D8V!B$)> HN>.UVZ+J&K5LJEA!7 Z*0#9Z/ MO1;3W3J6PP>\TQ@$V?9-VS14L/=M##2:CJ ][7 ME0"02F5J05=)8-F 6[H::*:GFV 4N5U&P>RT8P]XY[X?>(FN#W:+X@7@2NAN M2+ GO:OYG@:NY(:N$L34#A@PVY^^'%]C$E_Q.?W')!Y.JHX!E2'SA)[1:\@(.DK6Q8LLQ!M#A;@]X_GO;P+U)!QI9J& M$IH:&(4:Z&36J#-P/L85_9:4&G#& X9XLY"R&80.JHF)(2A12S--U@I8-PP >T8J(X18#]0I6M_:=:!J\W2[8HK M[#-?2=VV@F,[48N8ENS[:&('Q O C_%TU?1<&6Q&0M;;*K#*4FLPNW,\+QOX MSE">X8.':>BJ#D:B!]HX#'PPQ'';DL@.Z=8*5M0UH^-X ]>;'?0K&B4!PZ"J M NM\BIE$N!\[RV%:S(GS:3',XQG^>3D&/Q!>5B=2LSWN7)H!ZZKN !,,CC>5M!14\"AQA:!XC_PG25@95-8SA@D#NK)9FJ"C:52K#;3^#K $7@ZEJF(H>&OJ&L MI$G6LN2?-DBPS$$^)T!HEESH(ZCJ,\:JZ+68'.I??Y M,EVFZ1\N0+IN!&YH:V:H^P3L%"OT?=,,@Q#,%ANLU&[TY.G,=^ <7H-$NRO' M@ANG$B 4'NH /U\![PA+00*7@]O=G7M5LFRI>F@J+M@ N@SLH6#1>D?W75??4"A=66N% M\THD^CW-P?B-_X^.?HWB%%^V\B@GCPNL@3C'PS?5:86#40CSX&T] #&SL#J> MYSJVH1 -:TFK;M@]]J%N,CZX3N$5"+0;@T"DP- !)P,L1P=,G4!S->*'FF=8 M2M@]K?OF"+0'@13 '\,)B.-;!I %(^6A&H#V#OU MMP.2#_1_C@K^NS$($/7 M#-L,_$!7B8*G)/! HFPZEJEJAM6Q[\$0/36!7EJBV;)#XJD>]N4QB.S9E@IS M!I>+.(YM&W8'1$R+;&""W660GSS07;Y6H 6ZXF+8!$;L!S;F^[E@:7JF!LZ, MUSFV8FG&AL5XWD /=5XU70Y#'[,K/#"!-/2U077IIJ6 QQAVJP=;YEJWE>T# M.72XNTAKNBZ6;P8DT&5L\6AI\ _@9>C*5F!TTX_)>D^29PP7?XJ*R\:WL@S[8K/&R11U3%QV.#IDU<&*2O8+4& M'[PZNV-Y;1CGVA .'>5.'E#![P\\*_!D#%L8ENU[06B!40UBIZJG&N6^73A= MMD$KJ"YV/W,MS0VQ?ZKK*K*B^9;302UM [CR&^G.\" 6$R":8KF63@(;.=;V M7<\,+-UP0JLC4QM]VMU#_18]HHW-*H-C>E$Z*EJ;SL]O.&-91--4W'_5B$=T MQW'A#]G57.2+U.?#SJ@$P+4RZ :B.CKQ/((%CL&!U<$["T#5=GM^V&3+D%<' MMNM#"9,,@U Q= 3C1?4_KC-PRUQ3RWB&]USEX.SY&S#<%O291BJ17L&3.;;CPYNN^LO&6X@1ZH%I"/C=>,]B7?JJ9E&8'CX'E$6!!7UUA3PB $X]_U.RE" MQ%[;&#QP1E4?QHW]%P]R"35#"XU0,50':QBH@67I)JA. @*#61F=L DLX-K* M[!_1BR>PRY^1 ]R0 YDE7D".'C M=930KUFYN>OZVJGXRD)CB4?(5&Z4(/Q>3RA%9G-&H[ADIXWQ84E6P)0*]W'E MS<7NKBY%*V]@TG!SW"GS=SV_+>B_YKB=?$];7H$"'*TYBN=W.V;C"2Q]Z]2>-=8C37B?4T+ _+$],#=EEE5C M@X<'EKX!&EO6W6Z5(#P4JAUWPBA@E^.J5]H76DZR475JB2'W\_/<-%LU5=O3 MW" @X'0[IDS"$$QG!RP2$G3.&"G*#E[=.31.\]EW:AH;1OH!N(RHQA73Q2"" M8MN*KWO8&[##H>LFX8'3V:PF :/64^;VEMA3/!BQ3@S948@-PN6!K6B#KX:= MU0._NR"Z2?1U[;%K."\9^,X6;+9O::X=ZBJ1@?*VXQNA+IN^[YH&GB?=X/+H M6H>77CKPCI#OS?,Q+%\U0O"! Y=HNN6XEJPZLB(;F@862+<%'S@^'4C;.I;# MQ[R+U*YOAI;*TC14S.AQB2WK'I9=(Z82R!T#">;5A>&GCOD^QI(?89;[V?RV M',^3II?Z\^,ECHEM4K40S[-@ZJIA>3K6.# 460_53K8)6*?F^JBWCN;P4>\[ M\.!ZAJQKFB^#/:?:AHNMOE6':*$<.KJ]JQS44\?;:J"-Y]\.VD9Q'2_P'C(QB$<,,9=;.NKH49,._0T1R>^JS"8LSS9 ML@/'\+N[60I9VU)_PB!G"Y=^GXI]OJK4'4MU?4M6/(=8X&8YX);HX ?+@>>: M6L=A5'7-6A__TX?';UK[0E7@F1!-]L!/,4CH8V*FJOI^ #N.\&&6"#1UF#[ M\&F5$9BSHR#*4[#@BY6$8/ ZU@NA[9,!<'LML+?!252 OT+;T65+=WS%M0W3 M,_UN/CQ5.7U^##\!2 RI M2\L'2M,K"@[2WBC?1]^4$ M]ZR;8INZ"0Y1"((5@.N*M8_9NA'5!Y6_89_4>@7\.(>%6\:)GK9V[L:UVWN" M(\!6:&#FA+ZN*;9O$(\ME^WK@=%-'UK/KSKM:KV0DEZ4#*NW_9Z.:+Z3CD^D MG^N#AP\ZTW-L[!/A.*9O!!:8XJ$>@BVY0=^HZY'*YY*0#9J52 52876R?\3E MQ ,NSJ8T#[[7P3R,=,(_HT.R$BT8?D# "E:(1X+0MPW+-<$_DD,-K#6EV[!0 M-S1S'7Z?/@2YK ,$&6*:R;<*<-=/7/$S/ ?8?E6KR;S=K#!"%XG983A+JM:9YFNWHHFXP)-,^W-J2J:79'J0LFZ)F=YLD:L<"= MU;U0E7U'57PE8&N*=95UK1/3UHR.6]Z[->V?-1=HIDX,+ 'AVIH9J&H0VFC- M*<2WO,#N[COJ9+T[3T_HO#.(+#NR173PS1R#^)@H# 0^*IERXXF=U-O=54S M;:NGLSP'A'A=DT!WP8!W%2W4/$_7=+#L,060!,#COF-W'?)N)$6L];F;!%H@ MNYX>:I:)N9^V"M8!8P(?T,U4NC6]%44A?<6U<^""D]@$>'#&"RP'SWYH6+(6 MR[2C9)NZ"3;@AB*9JM%[&.^A46#;-K$URW6(Z=MZH*BRQ4(\\#_/9' ]828#ZLA4Z>+7N;7-+\'6&GU4HW2Z(Z.O"BG? 7A".NB$UW! MC7#L"4&PW[6C&;HI&Z86A*[A=1/$9=M>W^EY-EU?:5GH"(@>C_J_)JHI^[ P MGJ8ZK#6)9>".KZ;*MJH:W8X+IBD_+Z36MS4Y SE1?!,<1TUW34*($X+9)_LJ MMF(S/!O=G*[KJ.O/"@KU9TV^L?.W]%OTV"3\]GYU0A/+LNI8?BXD00BNF:9Y MX-X;5@"*O=LJ355LN;>KTU\RJ[ZB!(&/#;Q"X@(1%<^Q=-4+-=EVP.E_^9;& MJ>C\OV]*B1N:[1AAJ"JR%Q#%UAW+U3TL7F 3S7>[-JP&NOY9ME6/EN51:X[R SW0[;BL8.(I_CHIRA&G?QH*<6*D0)'*)IIJ7:JJ:2T,"O MW6X#= /4^+-V64^Y.OTE<^C(CJ>&,IBM+B&V"BI:).B>M7C^GOU) MZ+RO Y]B!+C!8SB:18CI6)Z!:;*6*7L6>+8;MB&>NV=_PED^UUC9<210]F56 M/MJ6":@CH(2LAF#8A40WU U9MJHN/VL/K,=$Z;%(NF&H6):AVG[H$9WX%O%5 M8FBZI=DZ<>Q.E5=%7J].?3[+LF+![6A\@[GYAJRZZ'(;KNOCQKL>:& _@5W; M 2G#LCLI86=)D1YSJ6YK)'2(XGJJ0W0_L&Q+"4%GF :KC-*!5%#@L MR5XXM513<4-,770-L%B(!5I5!LG%NH->H'5K=QNVW5=-^E:,?%#ZJDL4T'26 M02PKM&S3D+%)B>THQ/0Z*D[3UWOOGLV:;+/QMTNP86'Y/A][.1'##EW3TOW0 M5V1/;0>$=&,&BDR> MM1=YRM7I+YEES]==Q\5:U1JQ;=\.;<=T;170V]7]KA \/T'I5'3>71C>=V57 ML60;O#S/]BS%IP8VZ6YY@F=$ M>NG_/#>"O:-+B>5KKN]KFFH3S2.6'WAR"*SH8A%>I]L R+9TY5S%]UP\:&G;3 '&[OI\QI><&];?G5!NA;6/17%,."#B& M-O%-5;;!67=ETY>[Y^8KM %=?P 6H]HEH;0FVR]=:(TV/> M-;5 U555]S2#D%!5'4\EV&G4T72'J%VSU=!Z&K7O]QZ0HH5>(-NJ;^@^D1W% MU3W/L$/+E6U/]MV.)GM^/N8^.E_39/PY+>8YSN&*%L"[]*"2,[KN6XX.MI%B M$>*J'A[$\@(GU$('ONN6/[;,M0S&'2,Y>,"[RS)J0&+P.K!BDJ(9=F H =AY MIFQZNB5W=Z8T>:T S0M&?&@I?\]R L,)'4W!%"O'M&37"#W+]74=R-PM:*9H M^EIL8O=H7C+N7<1V7$>U++!$;,XBJ!$U@6:"@=CYZJFJ*Y,+ PL('FG3#[FF!N M'L8A ]T38H Q>;[IA9;*&L*[KH-%E"Q3<4W;,[O]\VS=Y#)0)X>UN*MJ=3XN M+ZG+QCH/43ZJJN7!LI7YO"H)A-KO9A*EEZRE)QYV&-,8(/5SC<7[3TK@PH-8[>;?8<+%U?7O^^ 7J],IH.$"S2:NZ=JRZW M"IQ? :O\!-(=A3 G78\YS/4?-+Z;P "<>YI'=_17>'CI@_8+HSC_GRB9;ZWI MSVNIU#;N.99FA&9 9#!$/-O'\GRFX5N!3 PY=-;L$: 8FS_P^H6AGG"YGD2W MTZPD>V^Q7:S, ]9J[Y:/[L@:&#"Z"JK2 %WER<0R7<\S5;!;P@WBM-8(Y53D MZ,<2/$E<@NDLR1XI?@&>)P,V5C1T5$/S% W,8- J8.XHQ P"#1-\O U+L-8J7BP!)^T>!J;F&\26 M?;"+7".P324,?4/Q/=\E_HJM_ Z7XECJ?0]>M96Z:SB*XJNA[B@V<8CA6FZH MR::L$-77'$W=IM2M"T4__2+U4J_WRDBS+I.H 6R:6B.*D3A^?0_T%(#+] GMDT4 M\/!#<"!]VR&>J0>A; //.YM$03V5J?8J2U&IJ,_I,*=PKT^K_Y[ A53!$O," M#2OPFT0+-4134*AG&@A-M/D#-?C,"&Q_0!\F3#4+ ?TA0,K M8P)^8;L[QW.5E38/"[AZ!ROS/TPV3QADL1W3LD$>0E_6";$]6]-US[5TGQ!3 M)61CD.544>-58IS1 APF$EJ BP&NO04>O4)"5_'< #.#?!U4NKLI?J]HIX*K MUU^+'KCXCJ]ZQ/1E7_%US$MRK5"QS-"W+,U65-W=[A+:RND7J29%E(ZP!Q,.G:W,MWD^G,!+\8[NZGS^ M&K81T=1MQ=15W0A4XH&#:;S#>-<+*DM]'A=$2N:?PE>M24 M(Q,Z4(,@,'166)78JNUXG@ONHZ(16W=TP]ZD>LZ"T!MC91L:P!VF+:JGKZ6_ MW<0EMM;[G(ZP>_@\2M;J#N9T6&;[$@K-,'157S4]Q5!]#YQ)V;$]UP=;P/ 4 MLM&;USBMQW:2[5^1]35DJ64M4B$O%L%WF@]C8$PLG'F%P_DM>Z!Y]5<\76\U ML7=IF!2T7E* &+"/SFP&Q([9R*Y0+HKK*._T1SU\(NYC=RJ;1]2][C+=D 2] M*I2>&@:N >MNR2$ALFJ'.B9%*\0FIFN:VDL"T'P62C $/X8 &-_'$(0$5FB M]Q4Z!C$,W74#2P&35 %C1?%D:QM#J!>:>>8,\?ML]MX8X@D(88>RX7F:9NF* M30S+L,!]M'0W(+KINY:UE2$4^<+:JRKXK)3@B)-"A&V"V6!ZOAJ8(;&PG77H MR9JI87%"55WOS[WD"')A&:_$$+?[;93;=1N%_0N]HSB]JU8)IC*$7\$O.BDG MU&-8[:B^V?)B;\5\W\EFT597DF!EW;=UQ3=ML/9"/%1O*ZX3^*YAJ8[5=DQ3 M9CY_^)M\H6EK*\B;LF+I)O1FDM,]BQ?J7@AVFZ$IGD9<)P0M[2AN:/NNXX+? M&HK%>[7%VP2@[:4CCN[(OA/ZBA;@EIWMAY:NZ1H8X;YB"[D[E2^LKS3RLPV+ M.)83VJZI:(ZN$!U<87"0/<^UO6#+FHA5X;(JQ]!T[=4-%%WU/%4%Y69HJNZ[ MON+CZMJR[1-/L\3J]GAU-^)I>W5US2:*XH&L6DH8:H$=*BZNKJ\34S/=;:KP MW:[NQNSL8QN;@6UHV(&&Z(I##!!!0S<5Q3%"3785927*+I3>49;H"4:E'ZK8 M'LK5/$RFR0G?\?I(E(YH7U8[Y\PZ9JW:@FY;O M^+8>$EW704 =[*SFXVZG870;J>O&VE'^S@">.[Q=9\F!DPT3, ./#A);5AQ@ M:-,R":Q(X(9FMPN@@C7\GCZ^&\Q>F^>/[*HJA/<\^ED*,7U?T159Q^[4H>4% MINS;G@.F OZQ82M2U58IN&$,SQ[B+AIJ0$'5M2P;!H<9MXYB>*:A6*H5DM"W M-,Y#W)"GLH^(3NA[EJ;;;FA;Q'!4-Y0=6_'4P#=MV>E6SU')6I';[@">.[Q= M!%3D4-7T0/,U5P$<();K6#JV@/()6.]!I]S%,X>WEKG2[/C[<3)'%;[<4-'/0>91*Z>#Q1\1P;*_%8#M&P$YRU*7/.4.W5?-)GCI'W M]':51# # TP)'Y.3=*+IOF-H1%8=-71LS=5-?]/T]+7BDJ\YO3U%]<%"PA[H M#@8!B&(YCJ.# E(M6S$,MJ:"^$^OYA'RG=K.BBE*H#DVS$_6T/-27$)"9$G7DMU MS>=?394LQ]3VR-Q M%BQ7@ (6*C[19=<-/ +_A<^6[?OJIK/$3Y6X4TQMUZK9?H!!#%-W/(]XA@Z* M07$518/O S %-ITK>*JT/6%J6?X'&&%M:_BW.+J-$[#)ZE)*8*T?6G5( 5PT M/<7W30>4=&"ZNN]JEND&IH75D[J=;-8.%3UW=#@S=#8^_9:E=S_#[3>^,TPG,N5R_#Z?Y$18KJUS& M3W/<$,>754_\[?+KKQ]O@JLODA^X-Y+SU9<^?X7/P?6-=.7CA+#W$YD2*I>$RQE&5)I6PLW4;I'X4TSG+X89KEY1W&I>S?!?>_F']:QC[PR0>3F"^HW@7.#)8/+Z01&XLSR^-$TF0V$0WFQ]9E?8!Q?79IA9)_+J3;+,^S M!T:_:!8-T5P$9]AFNJ \!KE MZBK^^*'AGDTLS6O\JLEO_ LV6PY]17:0MS;."3&^B(N2,3:OF1D<^6>)-&-@ M504&<9,8548])9;EZD!EO75 ME1YH3A$#XA(T!IX[B%-V833-YC '6%5.W#I0#)43G7#]8-2W%/$K0J7"1I[A M?'#L7%XS!JN&RX,^/M(HK_BP!O^EQKSHCK6G6I^E^'7U6-2HR<64*I6ZP028 MY=E]/**C'5Q:V0^IE#7J#W1<.HQG\-=ME&"!3'X,R1/^:[NGCWPWCT(7TN9E#EBZ@H^*V+:HN M!HWDES9)YP6>N^H7\)WY*B-.03,)G3 /PBHH9':(_GH#1(#G2 M#%<#Z%BC]68! 8)35N*;W2>-X^\(Z"6?Z9$+T^9$\MD\+^81W B>"@Z[8:X< MU4SQ$,T6^B.N"J)+:8:S1X'B;,UH_"S47=#5*+V'B!/_H]93""][M>!&T&LZ M*]D>=>7D*X;\2^W96IQ$H_93T&+DQ@6&QH^8;81<=5>63-WF=UZ3,"[DWD'B M#S8__Z^FZU;?ZNCDM?A0=Q=, ( 7=#C/,4CRR&?<5=R;IIP6X2&%L:6 WRSB M1)'4!:HKUG5"HK V,Q:NJBS1)*;IY!#/,G\<9@F.(Z\=8+RC^F%$Q]$\@1%6+]@4A^P\EEF;&[BIWY;,*@=M MHGESU?SVGV IH I.\ Q7T:S3-/H>3^?3EJ9%,2O@-[ DAJC+@ RMO=/YPI_, M&](MK+YE9^QGZX MIJ"J1A5CU?'L^JME++CY[<-/S!;"CQN9O.+;K;>O18<[O+P(#8_S;(J7++5S M[YS%Y=#J %;7> K#A?Q;_JFT/A;_UYVS?E5N]'@5MNI(%:K-$2O]^V+9G0$IZ(SZNW M)4%?,CW)()0W_BC\O-#ET/C#I$+X.W:U6OLM&4#:'%[O?$SC5-FM%11Q.$DRMG1G2I_2F+I,5(QB1(6 MG$,[)J$%\Q)2/KRB7,@*'QN&EV$%(^(:V.*5V63B&[5:C04W8:QLZ'PZJ5+JK%NIL\ ]ZF9WM[\#['U)FDE4[W,PKG>#I.4S(P?AI7DSB675=46=: M>E7XDPUQ,1)&5?S_*3\LM/%Y*3%-E@%ZTJOFW8 MM@2WIMI,&4;%1!HGV4/!: *>N93-**IZ%%6T8=@<<4,R3>=1(HTIK09=N4M% MRU^*BV(.9-B!4FR.//A$XQ9!7>3"5*'/)>>MQ(U9:)A/<#[!WLA\QMY=@CJ9 MIB]U@C'QRBVP4F[<@HN'IUUS\67V+9=-Z*W9?O IY0P>CN/6C^; Y**4Z!L3!U M!%W6-%JZM1E:;\U&U#V3U2J07&G% M4B>WI1*=LUG[=8505Q@6H=K8PDKC(\ M&.B"5US,X9F+EY\/9YR#FUE]Q,L_L73G8?6D19;:%9HWUYA(A(4^BHAM.9[! MO!KW&;RWLC%&UCE])=8(O%<='\&C([MBDANSK)9';6I385I%]NLW8[9O*_\W MJK=84*/0'(?XN"H+(UH 39AMC?O)FUZ("9P+*U.:T-$=72@N&N4I,U=1FK*4 MI@L2L.L&4DJK;Z+O%(0Y1HTZ3NB01 (IZG,)G*OV8 M9$6!AR$^LU,/_YRGC#^6F?>=TT55H+4=6UL_G[-*^XUQV17KBW.I*9\ M 8]=)OBQTT.,>(O,X%%KF38&_ZH,X3JSH<[P1#6[GE['=B[Y*5C5'-@*G^34 M\[(/]RYM3IE76:QP#[#8-/J#UI%7=MNLJK12-.S'1',8)9U2+E*/(^+^K3 F9@EJ_@Z MHHBJ<=I.LMB410Q@,8%E@RDO*+55*-%!9MGNN*],$[BDTGNXP8*:!PG/T9,R M#$Z[&^>R@A7AQU&<+V,16]:-&=7#9#ZJ3K&U8EV55D^7I^W9JA2M^%,I2B+,DKH[?-BYH,:&TK 99+?5:='<9Q-LVZM:0VW'&'9;(N:P=K@@? MMM=EC<^(&F-PLB FV(55[E51'Y3@9+P07OSO%+LYLR,$N+%:YM&H.24TC?(_ M8-KT>\6+%2:V)"HNVL@X9WO[40O86@>.1G%1&?*CECT>@79\!-6 4A 7BX^- MG=W8_RF,:5BB';&R@;S3T$%=,T>UE=VB7UV=@V+3^5B-*DYG<_31*RG"D6/M MPRF3H/$<#%Q:J_25UQ1/@'.8P# !D:YRA4 X?Z/W@.]J,^X6 2/KYY*E@MB]E%VV>+?8$TZJ"H%] M896Y&&5/$ YJ_O[+S\\O'=(NI8*U58K+L5,%1&&)OP$(#Q^K?S^GV(BKV$%@ MR*:I:1[Q/=,![R((-<^T UF1#>?HQ49>PP#A?;B=1^&V&SQ8:GM,T(CQ<.H]'F2G*>@@6NV^ MWSZV\;XZ&YK- 0OG+-C?/@7'0OMSMN<(<\WI'=H.F";?@-0U)O77NXYP15"K M 'SX-"X*=DC3HSF+@<8I<,"T K\JJ20K0950!OI)ALB!N@4N29+'%;-E(SLM MYK,!$J.%+#>'7G$.=^"/Y.SA\#LRQZ(8 ?;PA$_7)8NTPMR<*=!X&+7(AWEN M8"6AHLJE;!J7>$.;5BRPNI%8>$Z5O2:;Q6EM!("(1U7ETH:4B_5H3J6PCSB% MIXM8K1&E*OT)*8F'8- H93IWA"!079E2W.;%8!(,'4A9X$A0Y22/6ZV!Y2MG M67W4Z5PLQ<$BG =3G2=5.9%Z$QG9N8M-7%Z+ ,<':P1*\D1)=@1KF570K/Y+ MGS[,DBS_]/]8^3I9<$!_.6#[>;L5MWM597&"NB,GA U8> DW_^]12^#!*HR^ M,>5>=?W=HT/.*??M;$*EK73]*&5[.$J3:OT ^F:4,6NDTD\L]%ZM!5HB2U/F M&O,NHARD__<9VU/Y\8-S_?N'GZ2OV04^3/\HVX,C>7E\&.(*\XK 461LZ=4> M>Y-L!F3/IIAY\N,-&$I#R9"-GP;(CF@?SHO*&X>YHHFF,5#1&QOUR182YH@E MR2*9!1_2MCY7'.<2@PTAR+^DR!__NV4*SF>C)@+'=M@?EWYX"OY;42\3GV2& M4_EQN^TBH7;X#"EG^ST+ZSMFC@X+Z- [\C*5QF$XKGN.0%^#V):/JK&4:PE@U' 1N3^:\%]8Q#1J)HE3PX\MGIZ8O3J>7&HE<@5QE*! MD8"LM[ @N&[^ LV>$[DR9%WS%-4,-=LB@:>ZJD,,V]$UWS!"V0G>2)E<]_?K MSU^#ZVO)#_XG^.WRVY?@Z\TUJY9[>?/WX$JZ_OSKU\_A9\_Y>B/=7#E?KQWO MYO/EUVLN0'[<(UU;U#8R,Y@0B]HD9S"32C3GB^35EM0OSO@V0 M_'F:+B[^.QA. ^ES.KP82/_(LI'T+QJ<:3[O@L+Z5%+'=&S. MCC3GA&JQ67HS6VRT/Q>K%M_"SEOS$( =AK13 @OOP9(J,9MUIS-#2;?(?]+AY+Z&#E7>OBWJT*A6M04#]TD4A3+ D5 MLU (J $,$7XZAN*LEN(I]E+SD(2.RT]R\Y08=R2JS^W75H'_52<2KUD\N&3; MW$.:)/4U?_T@?V"?"RQ34G]^OJ4W!3Z.TVJ0T;S,FB]R-BSVS4,\*B>?B':A MJ.1/O]RB'.15?:Q903\U?[2)A$]K#3U?_(4>"0XX_>L'\D'*89'8W\KBVI_+ MT?+/?.,3ZCE6HS)@1"L/6KY@XT/7[]=?=KORLMM5^Z2OWT/1>S0^P&>K%_$V M*\ML^LL*&V-(1" M7&_4_MIY#H+ MKL'[;G-IF( W^-IX%W[T3(W@='^L0OXKQ_'YCI:#587'-T\0M^TNK^NBQRIT]?>(6; W6\ M.1\CFJ]KW#R=OJSD>P^"'9.VOT7I2)@\?8K:\R3BJX;K3>/X^XI]$:-W$C4Y M-A))GZ=8T:G*-Q5&WNG1Y^Q 1M&%N2/,G2?3-ISG:8S%Q092&'\OV=ED5E^G M:60L;*$>H=&^7?JW8RMI_+RV@XG6%QE])[94[\12T(>;U/'*8#B'#>/3)2J( M?(3#\A'.@8LX@O[/[!C>INM/-K #SRWV@ZH]&'SU$2]?+[I@5;4 "NGO-*D. M6U]'R>[TXGY67QC'>5$NVKYFX[IH56T M7-38K"MK#>'!>,H8SP/?TG9=9BS5WRQA$6&/M-MY*8WB474XF>Y]5L[JVE1/ M8M6M\2IL0;@\0]UIW530)&D68%95U7U[TY\6)YYSR.LRO#53;YO*H>@H;AKIC<9HC[/NKIZZ4^0-Z M7=$Q%@7)6'DQ29&7EA<^>SS/6;'\NA 95K4] U'>CDZF]!O%_;[>69I-SDV-?^[S1*L%!P4V4%Q<,#D)M$6, >RZ'\^*%] MY8>?6*V FF"T[I2(1&P*RRZQAUEB^,!9QKJBM,H/+(N6+%_V!0LEPS^S67Q1 M]WYBW1M7ZA: 9L3*O,L%:WY@@QBLSHJU&V@:/35DJ7MI<9'.'U1.=4^J*JSM M:=4==.H*)&LM-RJ*MR]GW2MGK+W,$T6_5;!L MY[#@M-A2>P7U15L91%O40=4I*V;: IX7)0MM W?7A9HCF 7V%+B+AP!A\;AN MC84=M'Z$03V [F,5/GYBW1G^B=W;60'*M2XD?UXID\1JM MG3N@6/62651#67;$P$KF8'Y4MLTCIZ()5<,:6KN $#B.FT&&@PT;S M-2]D=OG2!BM:)<]H$E=F?%/TMIX?:U?2]L4G$2<(S7AU < (0/F(,8Q)AJ-' MJX;2IF ?VIDPEY$T:D5PMJ@YH<2%$G\W2ORT&GREQCR@V3_1]>+S[!:*P>5E M0L^LS+QH%]:C>O2B79AH%R;:A6T4#-$N3*#D"C.(=F'OEP-$NS#1+NRDEK)H M%\:>(MJ%]9([1;LPT2Y,M M[]79AS][%:>\!>>V@]_-;W3N:0QQB$]73%>+) MEF.KOF[:MD]L7=4#ZZ2M[L5^R#'W0Y[)EKL8J\V ?EPT#9K@PLMQK>MO,"GZ M.9RH:89+;-5Q%-4FNN=8&K'MP'44*S" 2[6C<^().*]J0L,V=%CKEF(^G0(W M_!_%$$[+1!JNFDC#A8ET^XAY59@EFWHZ3JB ^O_XPA[L.0+DX!_XY*MPZCE]5$NSI=F6[8+M 7#+@74M#-'GPJ M504KOI 5R2MPXM./K;XVFVX,E8ES]D?G.L%5@JL$5SV;J\P?E9^$YNP)M[UO MS>D4BY-[_8(Z;C4S!&>>+6>;8%3!J/UBU.="J"@0 MN9U5OU#, HA?51V==P,IT7OWR:0RK(&M=LNZB.:[!Q0 .RE^G0=[Z=9%-X/F M6.1;0OE;*6SXIUZRWAMSE$^G//O"5KW0C[W!*-,:J++H$]%+J.D-DQ#MXOA6 MTD&*K"]\)725T%5"5QU;5YD#63V^1=V7Q1>ZZB!=I5YTR[((776(KCJ3S!D")!:(=' MS@H&CK#-R%&\\K?3TU11![JLBW"I")?NH)IUP>V0RSN/EIX1/I^OO?N&T%D> M6*9 YUY*5V_0V;S@UZ96H+- 9X'.3T=GVU8%.O=1N@0ZOSET%ID&OWS+XWNL M9?PMJIH<9E@[5(2,,62L#129VQY+7]9;A(QWA8RU"VZNT?M T/Z!Y?F:L6>' MD*HRD FW.%Y?>%\@Y"X'1>=G? J$% CY]A'2ED7:P;M"2'+![5SC^T!(D7:P MHUI]5D8)MVC/2L4<;?9=&F5SK)/^HI(Y9UU^@M])MWVT??ME311=&>@:MXC) MX10]"\X[MA)].4.^OFQNO M;_W=FH#H&RKZAC[I]G?5/[%GMPO:"]J?Y/5GDHO=.T]Q.=QWWS?T*VAZT3;T M]3GQ377NL0^CI;V52T6#1]'@4;0-%5QU)E@EVH;VB-O.2G/VH>>=Z,8H.%.T M#16,*ACU8 @5Z?FB;>@Y;-R__7UYVQKH_+R\\^8;O.]L2L>Q56-@<#R==M9\([3G,1K ';]PG]">0GL*[2FTYRMH M3PU\S^,W[#X+OA':D[_V5/K:ZOLL.%)4/!6]50\BAJ4/#$44.3V!J=0;J%4Y MGITY"%'[PB6BA-\1ME_?'$(JLCU0"#>)Z0OS"XCH+/%L7:10&>!S@*=GXK.RL DAD#G/DI7 M;]#9%+:SR#7@12O1775'"4!X3V#RW/UXX].X@T-)[M ME/K"^P(A=[=7Y59W6R"D0,AG>OJO6R#R" B*[5>/U)"NO\G@1_?[C\TFKXS M_/S_)Q+J;2.TR'L0[5W/_X2?: NCJ]K M/E5"!%M85Z7(=_>(4+1%J8O.O^, MU'OOW#6AXX6.?S4=K^D#V>"W12YTO-#Q0L<+'2]TO-#Q0L?W T%U31[HJFCO M*G1\7SE4Z/B^Z/ACM7?MAY@^<;#8UR$>/W(=[X_*3Y)32&F&'2.B6S!0!M(L MC[-!2(18K$OZ+COWX(?>QK]=_:_][X'Z1X M!%]$P_*CXNJ!YQBRZKB$D-!Q75=3=#G47-6"+YT/?UM;W?:J[&G4NTD4.\S! MB1,8CXWH,,L9@3ZQ1<6754^\OKGT_NNCZUP'ON1=?OD6?+UV;CY??NTK3Y^1 M#%8?\?)/<0EO&%9/N@05.#+M/Z?2?\Y3*JFR M; T8"*#H1>DC0$8V8VUIX#MG=)\!5$B?T^$%NU2Z+E'DOLWSX02DD4U:&@,* M_1=]E+[1O,C2E";2CY638ZFJ_,N&.Q:_*K_\="'=P(LV/7:69_?Q"&0/GX^C MN5%E M6(_'\1 &?B%M'4B4@"M82+,(S848GEJ]F";P&/QC7L8)4%>*)(3."DFQ94J- ML+=L<%$2Y8\#>&4ZCQ)I&!43Z39+Y\5 @MDU0\*Q+O!O97(PLS*/A[@PS3SS MSI> \C&,K4W]J^O?_URTZ2W!JV M(<6?HGIJNY<5J06_CC!W'JYLR :+RE:U(112M=:72X6X:C3/44X>)O%PPJZJ>>8A3I+*0L OES($W$=1 MXP-"@<2E(^#*2?8 BCNOL*'#:$,TG<=H1C1/K4P.:403>%!>M;5:O'F2)4AM M'%IK-$,0ANHNL'I'(!M% 7 'MS*)*&99@7^/F]F4&Q<2EGB)98H!XC3/VR\M MT. !)$&S"409;(<1V@_-\#8M/OP4I\.L<& T!V,I MA[5JLU8%C[A47-9^4UFQ@WBHG@=,E,OS-+[CNI"^9A78,QY!!IE&([I'9*-Q M";\Z !R)I)(!<(-J[;9=>Z:/ZZ'+BKQ4R M= !^F<5G2!1"Z690SZ?"7ZJRE MN?$QTF\9S."&YE-4X,#T*.*,5FT-P:Y!IMX^U!(':@K]707A% MT.*E',JU.ET\O%&B;4L#Y:PHYK21('@+J,]JOA4V#1IXG^&7Q?)(5 U#^+E2 MI>@:2-$#T 38IP4(YG,!83EB?C"P?"8_+-"L?F*!P7=<^[&@Q6(, ;Y$CY*F M,/DWST+^M_@6P;_F2WG!020 '(+9='7E. 8L2+Y7:/)B-3;NC'=M"0D2&X/ E!DLN# M#M5:#1K74EYBBBMR#?OA>SP%&Y.7$6YSPB9NQ+'A3U4DZQ&7O1EU]2#P5MM>SB(,<+'JV"W?7#[.,*8/'',/OW'2M1HO M5[=R4\=Q7I1@V]!AEHYJKRC.\:\4G: M4U![+6\*?:@2[BS&- =O[$)J03'>B']7#M1@Z?5)T7"8XY*F&[T^X(3;>2FA MX36+XA':>ZA.4-+!-ERRX K?S6?P9_U&F/+\]I]UU&1E)!CJ*9B)UV6(SC N MMBP]#@RMW#)IN9]@X$GW&7M+[>\"-U8VY JG74B_KXP4J-SV-JNGYW2*4,4L MS&;J@[9_BBII59OL4 2K<3>VSCB9%8NW'0.**FQ$$O%A:[X6Y/K*@^B"44:_ MTWP8P^@K>:?_PO!7O3B;D* F1^.,*.8ONT,]E7CPLEZY16E2^K ,-%9@5="U MM64 E:6TEOZ-$V,>S_HE##_83PL(:8#CL:'CRF/XV,$G,!B_L2TM#JNY:BZN M;YS@7D-/K)^DR#HF$%Q113@N4]!CU9].VSN^JI!L)>UQ5URVV?DMZ=L!NY1^G\%J<0K@<4+W7.1=)! M@^)FQ[QL5&?+I$0=/&6AY7G1_.PFT?"/C]?#29;0XN,7,&516S<><;U7O:I1 MRRS[ XP4M'R!/\'$R>M]%;AF32W5:T\KG_MNZ7/O%Y?M6JFR4YK1S(LJX@3\ M1)G5XRU]L9*WIU M\8HD'F^>6VU"Q<4?P$4 4$ EBM:.E.,$P'JO FKUK'Z_N+X :Y)&Q1P4S&-, MP;XU\!.5Z/@4&9!'%"'TPQ@DK2[JR M:3C#;6A<05 7!646Y2W%5-:C3!A9D.9/R8E8R3Z3FZ?$8".GU>?V:],LGT;) M:A .KUD\F.46@4.;)/4U?_T@?V"?BUDT;#X_/YL#*'T7I]4@HWF9-5]4*5WL MFX=X5$X^&>3"4,F?FO0M,#>2:%;03\T?G>2EY=#;9YH7*5WFQKH'3S\578U* MM_ZT/V=L8RY<=;^JO^Q^Y86O?]VW:R=]_9E4N^M=*OQ1ZS?MH=4YT$?PSQ/Y M1^L%_SQ=F3Z30NSC0Z5/;[-D5#WH'^P+.GHJP01*O0F4.C&7U2&!GP5L"=CB MPE .S#6Z>W*K'X%:9UCYK?=,6(=8!::='-/>);L%38CR&P8>CPI]/3IZ?'TZ9/NR=;+8AFV@/IQC[\T92Y5?UW?1"*,_XM8[G MV_C5*GA!*8+>X(QQ88A^:&_,SSDF"7^MTJ9>$V%Z(SL;$KI$\?^>R4+O%.[; M[8=A72C<5,E;$0CA'FZG;>-PKI"P]1E=A9H&*68'<=1M[WEIBX_+MP4G=!G[[CKEGUA M'JF">'\K*@H_[D3;?(OSE]+6\_>B$BLWTBOJD9JAB3K!PG4\S1ZCJ*9^Q!U* M44W=O! 0V6<;Z?7AL3EZ9\%S7ATJ>Y;'WFM:";XZ@*_ZD<[>7UH)1V_OAAV> M!7X[CEYO+!5%[H&ATA=6$^Y:3_7J:=VUOK#C>7ADO8$R\T+N08_*OC /1[_J MY4U^7GUBHO+)LRN?6*JL*:+ZB:A^ M7?);B$6KL?>;*)&$^_D;5&CZ7D[]J)T"CL5Z%*4:.I9P(AW,,='<6;EF'8 M'OT^2L"_YQ;I>9M.H7 )>\D?[U5#O9UJ3(;P@H07] P2_@_KURZ[SZ/92NZI^ M]D[QO0U9['&FRE-)>/;H95V81[+TWRM\/:E"Q,D&=IP*#^]P^-?SZ33*X;N1 M% W+^#XN'Z5L+)43*BV/$TDL_5[Z/8W+0AIG.?OYNLR&?TC?YOEP$F%'VR1* MI;B0(KPB :U2?#J8!*(FQ^2385S8MJI8IJC)(6IR'/SZ,W$5>V>)]NP@:>_H M(_CGB?SS+D^-BIH< J7Z0!_!/P*E1$V.OC!9/T!*U.1X0RSU+G%+U.3H'72] MRR()K:"@P+;38]N[Y#E1F(,G@XK"'(?33A>'L'K)(&],'7!7E[WG-E&78S4Q MDM@":-Z6GR/JVHB['LQ6.L-3Z MR!_O54.]G>-AQH4EO"#A!8FZ'(?4Y> 6R.VN]_$(T=^3RT(#O6D?R19E.82/ M=';GD+F2^SR.^''<@#N8NN_BY-\9B7KO-.7+^([K_MY9\.KICCJ_9'?P/ #2 MOE#Y%;,4$/E$$ZGGAZ-;5/SGO"CC\>/K$_(5QWN#!YDOKYVK0@(K3KJCV%2 M^/LM+1\HK28RC?(_:"G-\AAOK+X;125["/U.\V%<4$8!_&'Q!;O\0D+B>=D4 M1/91HK VTPC/BN.5959&":/:75J=+8='S-/6%T.XCZ9%A/2&"Y/JUJR]&-4$ MLGI)Y@6 ,'NXFP#6?+P>3K*$%A^_ *G@$?1?+X@8O*6Z@R#*_J@:*S:6L@4)>M3# 2V]_W:(* M+[W]O&DOENYL1W]62W5JP6[B>+\)V2W5F$"P7,"X@3/G3_/"9S;;LZQ,]>"YP3.]93G1 VEC?2M MI]54@\"G_(!EBO$D^ ^*?&')O(2Z1[3LG;1S1\/>E]@4/296"\5HZM$)TI>E MQ_M$-:P> LW;+ EN'%^#"DV0)32XTN< ;/M'5-QU$52\TDP51R87%K0NB0&?^].D!__ %X7/" M6G*A%/+;M)D"@-R!PA&BE:! JQ.%#<0 M(#2B$ ([ZUMCX*TO[( M;5BOL:/JQ]NH6.^C2[_CWU2*"PEF^G$8%1/6<#7&WJS#9(X=C*-"BMA=0 IX M=3:6[FA*\RAA5T:C:9S&19G# ^_IXH%9+F4SBE^F=XLOJP',9W7;X&$2%44\ M!D9G8X$'L_>O#' 6Q:S++U[?-/VMVB!36JPV%%ZT7*YZ"1?[YLRK<>P/MFYR M>1"C)Y\AF48WA^N@(=7MJU_ZL T99RG("9\Q3N'+B03<%F>C0J(I\@"7)Q^[ M)3"_!8'! 8A1,:-#%.;DL1*PO9)T&R6LCWC3.AR7=F55ZD59T%-JR+@ MF@+!@YM$JL3FLT"M/N,XL7ML6@Z 5O4Z'\XKR*L:B4B[57U8B\KRN)Z$N741?)_BUCW]^(&U(6;P*K\ M[=__[2^;'K6\I?U0)\^QE#-[A/O8>:R#,U@\&I8Z1;5T1<=__1#ZN%K_K?WO MC?]!BD?P130L/_JN;?BRK*B:YA&BN(X;FI[K*J[FV7)H^!_^MJ8;VW3?TQEZ MDP6R5;6B'C5.H$:;SN6@]E!"<-F!%5BG^XH)5G472$6!'#X#F<(J$R/IEJ(! MU>7RY]H2&R;\;EN#&^3"4 F_[N FE^;@NO6R1K_JZ_9X5E_W[9KHDMQW!ZQ_ M!7U[1Q_!/YPB'Z?AGYYWD18H]290ZM0E%F=HBQ8_"]@2L,6%H9[9=E*@EBCB MR9\)KR^OG2M1&_LU-J'>([NMM@ X*O3U:*?TF!O.K4 MW8=MY]ZD-:B*]YS916&;E)-L%O[-LO5_ZEP+-F?@Y MQR0A:T;U]'A6CXZ]\9<=C5OMM[ZL[K$UL5"XQXU4/L.EXB\.6*)?"(1P#Y]* MV\;AYJ9,WJ8G^*,BGZ[?Q9)+CD-)X:DECUR8W11#X1L) MWVBK0IO%.1UA7OP0M^*3NBSU]U[?56U9E^8 MW(K_[B-.7R1'^'$GVN;K'O\X#JN)P\]XGZBBT9?(9H]DO7>J]F5\QW43\BQX ME=\.Y8LA\^P1TKP0$-EG&^GUX;$Y>H=G]E\=*GN6Q]YK6@F^.H"O^I'.WE]: M"4=O[X8=G@5^.XY>;RR57A2RZ@NK"7>MIWKUM.Y:7]CQ/#RRWD"9>2$?*<+\ M'K'L2570GEI:-NUR.4&4IR DQ3>:L[N>4_C&OOUY+ MWX(KR;O\\N7RJW3]=^ MLG);HSB98R6>E)98>2J;4NE'X+#B)RQ5A?5[IG![@0RQH7)/50XMFQ?PI&(@ MT>]#L'39C>R.3P?393D?^S RV,]4Z[L&(XH*3>!JF5]%(<7@4U+(?-6B/,I+ M[S_KV\][]"^\73[KT9_5Y,\D4K[$5>LPA67QB5F:_<[0X7LX?;6**ONQ"?MM# J^+AN=?O..E M[@_/S08!<8*S5CB+6R:ZX*R^<=;3LW#>/:!Q2U@2/'F^//ED*'R>13<%3DAH MKRRZE_/B5UI*&&(^!B>^3D[.JTNJT*Z"?P3_"/X1_--/^@C^X6T2/3$K33X% MNZT]4)]][^R(\MW8;V_3C_-LRE(TXG0>8R^FJLU#>9QJ)TH8K507, M@68=OX!'5\R.1Z3^5A00";4"B 00;0$B8AV_F+. (0%# H8$#.VTATSS=&7W M!1 )(!) )("H>Y\R4'1^IT7[OO9XW^G**FS<7#M)P.C$T:%17-0!(JRXN(@/ M#=BACVS 6-1C%#H(0MG45>"I9ZXO8O%0+"FD2 MTK1==6E'*ITA=)>0-B%MZ]*FJT+:>$K;V><*]"RQ\ADL)PK8\";?FXA08>J M?:2>!(?0[&WCGXBE'RF6+K!.8-U3LA/X]1<32">0[NTCW5F4\SX/&#R/*O)@ M#UK*D6*V1T?)L^!6 :$"0GO'E )"N29]]*$H[%GP'=[7PXJQHFPEX\W7+EMI MVQ>ZHLN&2GI7O9(8KUK&SSKK&H3G/'?U'<_]/:V[J-TFB@@^U901E2Q[Y?R] M3R;LAV/4,[40-3\.2Q:F#"7/NT M4W7L!,[=39AVMU0ZE'5/2-USD/G>$.OM@J7@.,%Q@N,$QPF.>Q\<]WR3;Y5* MUKF;=M_6NVE6-+141?FE:L=Y#!Y\CZPF BV"?P3_"/X1_--;^@C^>87HF*6? MNPTE"I_W*E'[39SH4RX4][97#M-8&CM@<=NDO=;5A0[ MJY\?$J[<5[_R$&!ZU?J4BTU(E1LXOQ6A$F%\(1="+H1<"+E8"U-QJ^TDO$ A M+T)>A+R\U)EY+]O?^T^'O"BI<+B8IGY[(-+VI&BJ!U[X+6 D$%@IY- M H% 4(&@ D'[SY0"0?FF/FC]H:= 4(&@ D$%@IX1@LH7_,IAB;+EG*.DJZ+] MML]3C^)D7M+1(5L0XD3:X1L3[UCM"OX1_"/X1_"/X)\>TD=L*8L3U6?A0KZ% MS'UQHEH$PEX=\04."1P2)ZH%#@D<$CCTVC@D3E0+'!(X)'#H]3?GQ(GJXT6, M7B$PM/9 <:*Z#R=^Q,E1$<;G$,87G%8IL;)&-_38VXL5Y%A&V[EW86B"H0-"S22$0""H05"!H_YE2("C?Y =Q MIEH@J$!0@: "00^AI3A3W=.DCRF 4T)? 1Z/2<)_4!P2'4D.S#:ZHY)7Q4*O M,19:2)?SLBBC% ?_Z9#="'$X[? ]BG>L?P7_"/X1_"/X1_!/#^ESK-UEQD"7Y=?W?_K"4B]U<404Z 0Y5>]*/%5;%^(IQ%.( M9S_%4S/XG3T5XBG$4X@G7^UI"NW9ET.;Y^]P^H>7/7VQ5)ZA\)W2L^P+BQQ; M!0I-][YEZI3NH) I(5/O0:9.Z<,)F1(R]1YD2C=.=S3JK SH.O+:^>J8./*9JQRD)0M$\ND!YH#-;\/ MD_F(CJJ"0R70=YA-9_.251I"&M=G<25@F13N*KHG=^.4W??2,=>QDD:6\2GP M0LJ'%##:A+E,SR M"$8VI%@^R\NP:M8=38>/?EP,DZR8MVYDI=?APQ4=__5#Z..2_;?VOS?^!RD> MP1?PF(]68*N&3FR;V K19=G1/"OP5#=0=%?7;.W#W]:@L4W#FW@*1/A*'Z2K M;!IMMT!V(2LGU&1X/*+#K"H=]FD. I#CRZHG>I=?OGR^^1)\O;F6G*^^Y%U^ MO?G\]=?@J_Q5$.N'7]=T^ZBHL_)"_*85YY,0 V M&%Y(/S8U*%3Y%[AF\4GYY:$!]H;A MPT,812/D0#:!RH!B,^=FP_Z@#&1><\"5+#- 4_@KG>-_[NYR>A>5M%F9Y3IP M(C^WP5](E>0PD&^X"^E?VZA+69IE>3F&Z61,5AHY*2=Y-K^;2/=1'F?SHBW4 M&P3F81(/)PV?2@50)8GR#KMNXHD!^Q9L$::5*^G)T$YJ$1L &< 6A:4973VA M2L) DN: F> =%BV)6@KSAEF5D\V(>-%=QT.4G_4:JOX*9IW?5\HM@!=.(\3_ M:YJ,/S+5#A^V6 ,>TT[GHO;=I:W=OD3+&VCR81@UWM<"J3D?[)4?C M=$0;S&E>&]=L#3H7)!5U/HR-+A9X/"_G^<+"X(9$JCF035XXRF];":KK-48;]+MO 13HUPN5+4F@UTW+Z[%F^)59^KHV,&=1#+!ZCZ8%>&2#%1:J1@5( M"U9N5I0K+ZB-$S:8RA2KC3<$51"=?U96; 788+M@E>9YRN;#,)M)&[L4GL.^ M1Q64S9%(=U'.WH'L/\M*RBSGEJ"@.-RCM8UOGN)CJ]<"VBP&MU@H)N/M";5E M?)7DM:0LEFTT9U8KC5"#P?NR446?J/7.2L6T8T/M%[?I75$Z70)._;KN6W9[ M_T\!W#K^:ZR%OT_L>M'[*)DSLC.ZC.B_YM&PMIF9C]00'[E$@A^!WW- 3L8A MX!C0:?RQLJ\PDM(&Q9R6$? #W 5/RD:4:X64QWK##2=BAI=!$RYA:553/: MPGL=164$VB%/:T^1B05.75/88[Z"="&22IJ,OS#.?*11?K&D"@QQ"J2&Q9J7 M\)+_@S5N^<3L!94<(VOCQ,8YK#[&FM@;$$ZZOML,O95&72$D1=)TGI3Q1WSY M0@+C= 1\FS]6;\&GQ2F0:%K1'[I\RNWT);G D##^:7EO4P"T[VX@DD]G*#\*U*6W9;25O%T,U!JBJ+-0"4YL89DEA:%&2TVCTN)0OYH@RCF?O0.%X MH*#=H@K$5N"F_?:5D3?\M)#JELJI3+BV + 7U>9%>^@,GNYC^M A4VNY:K&O MB-F>(PA(T0;0"\EMY'\;P=?Q<4&MBA3ML54L@7$EO*SUHI8L@9JF\7U;-7;! MNL;U1J,R'5D!Q!3,X[*.A+35*(RLQ7.H3ULOW"#[;;A!P2HK"5X\8[DR-2I7 M9G,UKEH]+!<41Q-).(-X.$\6J 3@_HC6%*X7$GD^>T ;!BX>90]I]?=&'>>D MC/> "8O%)E&#^R-:?<^T%. 0F_NRP\5"BU0CJ-P75(W,YT7^67U<\YIMCZOM MD.4C+Z2SP3#G?/R(56B-<;_M#NP"QGY<7F!U:UP=%J?;K/ :E-^@X ZR%Q] MJA_YC'BA@%A@I]+'(&K%$*R<>=)$59F!B&*#\%3I5*P'P0^VI' MM#+ZXY(MUB(\SP+V+3QADL7\?XSXTW+U91.P8. -(%(W6\ 7'C"IU!(\V M4?]RE_L5_.MQEB390V68ALZU*SG7OX/S=H'K)G]4]8'TX5L57ED8=8NMW#JT MRQ;FJ@[K+'^\6D18!A\JJ -[*R[ 1LIND-7 A_0!)-V.:W51@N^<&DEKIC-K1OJM]]B3 9LK"F:IXN@$@!C M 2;RTMG>$DT:8J 5EK,)."RCJ9T;'FL#-V+;"U623YTG5.^F?*@VTKW:,\0 M BV+#VQ2]6]?L[1Q')M?%P9ZRBJ;L9>[4<)>?3VAM(1AGH^Y@W/)J\W6)].2 MXZ:9KG93*P^+_IX+0#@)4.#!^'"5VZQ*,Z3!"E MR\WPVHUG/T7L$54LH-H!J,8_CE/F(E9(M^*T/WGK:SW>':?,@[P#C9@V;B6N M,A)]6&>MP.BB/V!*&)(K&!)%M3\Y>.K+40V@OWS/8A0@!Z!7AA%;I/4@^G*M M5K&_X6$68$TK][OI HGD&R=S?"?N$#]B%!'^8LQ8/V7#1"^D@ 5])E%ZM_3$ M6R]M[?TP*W\4 V3AF".6F+-U\HM [2(YM%F^M$Z$*9@/L3 ]&\*G=;B,Z;K% ML!;>/-)PM"=1L"=IR=7'SK:T%]_'"1@=]RA%=Q%+N?'I%,GSXP?OL_]A=SWA M9^R#6&O[(,?=A6?W?4ZK/*UNDA8FEJ>T9=;\GK*-X.N2!;$<&#'\_KC@AR^L MMJ?D8Z0Q'C)N7"8Q_?C!O_S/#[C34,7,,#,*@Z5#1MMX2=L*'I:[:?=QEM3N M82U38904"[/0@1?]^"'TG \_<=N-.@W5+X=EAG$_(+R^A_"KY'D +"G*J-IS MK<*M8X K@.PJ]:J@$V53*AXR/ =9.8:Q" <7\ M%K=GFX7/\OB.:9,.T]RC+=T6R L05P3:E%:S9LJ282- ++P%\YW+!TQG7C!_ MM:,V-]0Z^.%?.AW22GG'SM[30II!\C%-(ITA%(.LMH&OW$ MQ':4#>"Q9(AJ2<$PI1^=Q4.NAR 9:9/N=$6+RN*\8OM,U2.OKZ[6'\K4 M$$O/J[;N[O)HRF-WX'2*X?^W]Z7-C2-'VI_M7X'0CF/5$9":]R'/3 1UC7O? MF6ZYI;'#'R&B*,)# C0 MEK^]6]E5A4.7N)1( MD;FR,6SS JJS,)^^LK!3F M8^Z\& MBO9>)//_ @F^>2]!&$RC$7QIP##@K)0+Y]B_!:_L&^*K(_)+07[EF65E-I$7 MTV?^B=1#* +>QY98Q[D32M7Y+T/8(*&**Z /N'Q0,P MM@LU@DN2K#C.U?NOTEW9) JD'R<-0F46"H^DC]J[L% X(L?B@M6VNN0H:0[ MV:/AGX'X%'<>++Q'4OIIB"I'2NF'B>T#X3RP M,SQ,0J21JV<9N8H@@Y$[VW*L*2FU!.N38A!%AJ32;@$2 M2#>1048'PB<1"# $1+A0!V&N+$\Q2\;G1+^7A6-9L@:4Y@R(HCK/4"$4+*C8 MA<2L%>XXU.E%*83Q[WO1'[($4:P>Q<"+1.Q!N>"BJ13=B#"(0>UA!5WJ7V03 M]6KQRZL-GJ>1!UZ,Q2T$#G&9,\S6\>:D8X[$(@ EXLB+(9"_/8::D$SX)Y$I MB%PX$;>H@*K<#X\\=:PS$6=U[J.W7+!D'DR8B-),PCRN&W0!C;PK7QYXJ"S:0T 6,'N F^FQ#C!7"B@8K;0(PDB^S, MFP (8B0AOC( MH+N ?YJ+-2O^Q'K-C@.3J#+CR%6 MO808^GOA4 ^;W][/W4KO"8 B"EW)D+^37>)!_>NL[*(I9V4OGG)2YV- MF:K@C$$,/Y6QP%// A\MTV_P-;!C49:%]9E&_7*X 8R7>$;IJH5#%<%6<06< M ]4&9?$/:C]<(OONJ&BIJ"02F+#WM< MZRO_&]OE+H*)-,@%Y !VA2P;STT]E1VR$ 7S*'Q/Z]2$O4E[2!N#HQVP1HV"HW'/5-M@X('?-R?;O*>:O9Z$+@$VL("VX MN;3N0<$":,]F52MU3K#8&RU^L[W<:%O[7!.2IE&D7'?S;-('-\1/;>Q-QS)/ M*'!56*Y82N2G'Q=='G*'F73%0.QXE,%J;%&N="S56E>*?/5<>9[B#N M2^MWV:$+;C6^-/>L.?X20>;0S"9=Y)2HZCE7'IX"4B9-+CCZS4? J%'-RXOG'RX=%*F*'@J3JRZ>S M/)%V860;#Q+G'YH2,B7.&=H+\QX?D6UK73HOX"F7X(:UO02 \+P >+?I(Z==XR?7PK$@*9AEXQ.@-+6[YC 84:B)%40LT*_#)Q M+D.:O_25^'/J6=8XIB?ZS'PV\"36SSN/8%T*LXDIA: Z6\1,$SWB6M.IY3UN MXW$S<9K,LH!6H2R.)3-&9#-,,DIA)A>2'9N6HZ2J%)7Y\CBAB4Q(*&87#:(Q M6Z2[9CJG9]J4YSHDH5\Z_P5M6JUJMQ:,0#T!O28BEU!@$B59?EG9E>W/$BZ; MY)1<52S"H#"+\JU+6,L&D:M-QYYM--$L.PKMLP,M%E\&7](FB??GG?6JU=[M MW=UU_:99;]Y=MWKMQFWO[K[>N+F[;MS?7!_)O+/KWQ\_?;Y[+,-H,_S>K0>Q M9)&;_AM"#?[S4:;85:]V'+R() L:_8#AR7 7S+=G>KDS3\RT[X3N(1JSPO(@H@:^23ES\$N/RZ*6Q2QIP*P>NI?F*\'H3!< ['TI-U;2NXC M1_LA3)>RH3[ME<$_0/+Q=?CSTIR-*+_Y27(9.$&$]H M69'-%B"C*(NS@R+9F!7*L198XCM*'GQI]9**FIGY KGUSL[VPFJ: +,X#@Y! M8C'.- #;/61#)D+1,[4?4<*-F89B?QJ'JJ0GFDY 8656EZ'?_T9+.KO4MA?- M'4O&GGWB.MGQ81*9PUV+*#N1[#&A8R^+:&C6\OMM3:-T9P4%@5;+HSMVHZEID=RE!@O$358+\R#R M!F_PZFLR%G5VSXU$[[:6!S8UK4LF]F8._M+Z,@WGN"%4%>SP$!$NUK*(AJX^ M)4W>65U7U&L%IRYZRQ(A33=@$7;@*=6@A\A=3?VURYAE\BW9+,; MN@/S5GW.YF>O/1&JY<]_" ,_@)H0=%IZOGN#'1;1)S_[&>C(F8Q8M,E4Y)M* MI].JWCK=W/SY7>1E.N+O 5G2:"]ISU'C> ?\[5P7UE?>PD35@8 MFDI\UPG=B!N[P213):[,#1WFW'X:.V3MN6SJN$\:J!;N]CJ F2OG9] 6??;! MXI8MU*K*_NC4CH/G752Z=OK*5_:-01,9*B@(*$!\0=HR-WQCP1B4V?E3,/'Z M5JO2^J"F&G''!X@$86. Y!&;<0C&@!2T":@]8$9V, ME\:HI9QJB\.U1%6G"*AA%D),N.(0_>+YHG1E &[L+><^+)"M-M$Z;L_DR20# MBBHY+"Y/)OJ(JAUY>IFU_)_C8\-(557ECH6?L?$>6%1/]9-Y#E8W+ M16WO)Z"M(YJ1K*Q$[]Z8O_,'K\#/'Y)2?'[.G<@,[O\=!(I*+:_7*AY09 MTQGS8@1(?W;0XA"&Z,M<&)(1TZ@3&:C#5Y+D:7[D:Y9OT@%L2WD&V[:4CN.T M#AE.G,432'5>\@U!ATPG3X#%%" G_,$X)TTQ=J)J71'Z%1T.*K>0TF(=1;FV M>E260])IE4U'*F2'%R,Y+S'*CGT394-R(@-L:,!AG"\%]*0U1:_06:(#29H6 M2U,R]W0=>>K8UAIB= 4]=MBWS1\ 'YDY]*1\F"U]&ON.+929.0 +9O4EHI*( M'#S_FS.2>06.XI%D?)5]Y7+,7F3%. ?=F77.C'907Y+3-K!+3=1AXI?#],O) M*F9?RRXHG=63FYFS8@NOW(Y&8\3OBZ9LV'LB8A?!X"(S!Y'Y;N85>5&#W '_ MZ=?WU=.3>%.HI#FI-T#$2887R[ R' 3U5XAP^Z+"C8MKU83$#^4YZ0R0 MRI M-#]P<^\&]=Z;8KI;QLF8M*,XR2/L_%T74:JJTGDW."@K*2-6';W9#K",]961 M$FFWR;(4[+[D#"6.D"\7NCB\B)^I,XH^J/&\,9ZBZK)2&:6LNZ!/E>4]/6Q\ M4\._U34$N15GRB)31U:0+].FQ,5@T9>?&:YDCB2PY]PGR\2W,KKQ+L]V;6M# M;^2QS^4:)WRC9RS-MXS;D6_K@,A(XXW_627AQGH3OBO**+^22=SD2FYMD7>$Z)UTHV)=!< M'45<&% 3H46N]S\)KKR>QA!=G7[_\?O9!Q@/1^DML00V)^ Y_<+(5[&$%C9Z,CG2#7$(L(?)D&G)8XH^2<" *2:*T*?@M M<6M%@2+[#O=<<73Z8*=/\?#V*CFLG']N[/S!9,.VDB*,4\JF27&22"YG*2TI;@]-K?%48XJO*#H+79F)9N(.>B M6DWD\\)Z@I9@'&V:" F#Z02W&P91=*%Z*7!J)82T M\9.C[ A0&*B)->.)9$!?II]IG!C)>Q+2\5?G*NXG9BEPK@$SL9\D[G G&%N$ M8T) BG,V(*<-P#E?U]M_Q0]GYX[.1K4'2O 7YT)LV0(@KI:!=^3H3%''R!5( M?QI#/=T$X2@; 'W#C\NGBVNSN*;&<4'RKHBYYB(H1$R(#B9[,(A?(<(:!\$H M4E>#I#\/6('J;)Z,?2A$!+!5N32%3VF6)PT3RFG .1#1.MNI&=G1 M-R'Z^?F#^/[F5@1S1'PY1@Q5KC0^^G\X MHKQ4!72S&!>)64II!E!IA^2"-Y'R4_20F\FSA7"?W]3IH2&!VY>8G$W324Y> M2M=,S1_L0WG1(DH=9^=.Y>XNV43N57AN@0NC!B^L1%,YP4;L$V%(_GPVNC63 MN,HG13/[=3)%N-F("+R==38CU6T-1,8>$[B\@;U@I%[.@&"*A5;FE[4.M#S$ M6-'<+)#E$>JZG:F2^.1S>HF)&1:WVXLGX3=DX2ALY] MDG/.P@?*NXNF$\R (S;$3(TX](3EE6'#M)+@^4V>%'*[-X9^H##G&Z#ZP#6, MDC6, D=R:I!Q2^05@6I-5G*C-EC9,\$B[A\Y7F@!L[&D/5V,K %%_FY7XRA[ P\,9<]0P%W'_Y"6YUSJ,LR*\T,.;?E[ZG' M):9[=F?1%$(G>!72 D+G4P@+3!/E24CCU<7>*Q\L%$[^_S)Y+])S+B,72YVF MNK1F.Q+[P4A47=@)X>"18$JC;XB-<;D34V[5@IL29Q:BU%S6RIGS-41@/'$, MWG4WNNI*+[PM2Z%PXK(MTVL8XA7$?!%C83+8%*=U'>EF<@ /Q1@9N^ =8,X8 MD]F)5IQS62GB2//IZ/?BF'#%XBU_U#?4*&+;?V,N&@\JK%)M>),W>3(U7US$+]4)#OGC6-:'!_,IP-MT!2WTUJTU$/O-3P+WHCZRI*Y47Q"H],0I@$3-\[1@ M?PM6BR:J,N^P3@ %#4.TPF5*A-M7,1L\DT@:EYG;2]"R3ORXG(I?\,MR-*:Z M?#3S:3&T#YUNF/FB/'NQ>^S!$93AXC2WMC3@@N?.Z1:RF9GQ&6)A4%L=0ZJ; M%GJ@.116A1 P9V;@F%NQ*"@9XZ:ZT3T)U/N???3H'Z!D2898KK+ M*XE<:$_>&9!_C)5?$E\1QF:0.9*]N$E/7)^6[=X='("]:XUA%EHWP=\G:?!3^P4!9%,8=BYC3B)H.-*@H <"UT%?]M M)G];.&M)H B^#$N[F=S"*%(9DO19:0LS1:W+ MUY]?=EIUFWPN5W$TPIE?2R.&,Q5=.X>5%Z6N5P245TC[P<6U1-*:E-2^*ZK- M1%0Y\Z:>9[L!8M@#M9]8=X]W-]8#5]$OH3,91M;#-(RF\A9?>(N+^F"0-0&O MI]PMX?_"7ZM6.];YV6/O6OUU]B$7\X=ISOPA(>YB90B^<>>6AMZL M-7N]'G"&EOCO)GU=]_>M>OVN6:_>7#>;O6J[T[ZYJ?4ZS?OK6N6^TNP4WM=% MW474743=1=1=1-U%!H,(=1=1=U'IRP*INXBZBZB[B+J+AM1=1-U%),/4743= M1=1=1-U%U%U$W474743=1=1=1-U%U%U$W474743=1=1=1-U%U%U$W474743= M1=1=1-U%U%U$W474743=1=1=1-U%U%UDI!JA[B+J+J+NHK)(*W4747=1@=U% M"[N!LIU$LK+]GB.?ZM?X)U^.:M;8O(^HV>O4KV_N[N[;E7:S<7_;K39;U_7N M?;U^=]>I=F_WUD>T)QG^XL_V6>3OW59UV@OK FZR]2#G9[W'F[,/V%,B2E#3 MDI&YCHPQXZ#L)IGJ3'QX14<%LGYR<[2*8<(SL.Y59:L6>'1\9;BN%*Z'WHA) MYV#Q\]K6*Q/URMQ;2+)/.767/)ACVZ[WKXD_X>-77LR/NZ^:NN8Z-_3<]'8N M5_XAXRFCR\"IR$+IET"^$60]LLY&[,7IOV&"\6RFDB9#7TXLX<= .4/J&F70 M;J(Z S,!9.E;PYJ]GE4$LK/?./>Z_ M>-S(+5$2FO%<&0B'G2<)U[3?Z+MHI)#5 &#*C0251& /-\J=(;%I">H1RRPI M0R49NTL=8I$?P@(#08Y_3]T7$<9#*T&EH]5&%B!P-K& -](B]RIJ0_5!-K4S M"$ 9HOZ!M4N?[(1D?S97&/?/U6]>VO8,A>9A]UJ^X-06U)Q#DP&+!M" 6 M6+G/RG9R#6[:W(:4H7BL1]J\4JHK UY8SG^.A;L?DEA:S+U?OND( M0T[.$H*4QS=Z6'*@H@P4#P\^J M4W5G&GBAB@$Z.D3T,.F$24U!1.TEM\HGA@8GTC,WS49HC27[26^G5XE Z)N- M';S#5D8M(,!J9U0GQ%LSQ8K)*2P@-6I>Z/.6]]++ X6/R@8 F3)_LT3?=;2@ M8EUUBB_A]+(P>O9(Y5:P(L@9O6&I3.()S)CD2#=N>7-#Q O2#FVDS()2#:"M M*"J2'#'+*)''E\J]5I;:RO1\[GU\@&IU9@JBJA(0Q MM^]4317T.GG<@0YQ"5"ZYL&EVL(W4/49LK!2+>CB^>TBD>>T? >*.Q55P#T/ M)W!W+^8_L\8G6JO>^'D:1BI.%%O?N'^&M9R8T\ XWV^<+GW'+OCK 3-L#)J-;:NG+G3^%2]PMJV_<6?,@\X+$*Q_@-J%7/<@Q9A(\;(K M0B"8C0Y%L84K-T!6 Y*XVD_(NO(H*94L4@(E)=PZB7,I[^J'F^=>Q^@M0-.^VW"%WGN\1>&_)""$(4][4*')""^ M[PD#(:FRF 4.P;[GWKI&H5H/[6D=77_#D*,'!%T8QRX@N4 M58580QC)$L*7D$FAE'K#"]T+J'1ZDX\1O*^4 ":RDN[G. DI9EA?1?33I@$7 M(>R%R24!;(0A.)5B2UC'G_V!S$2(B,7QB"5N8Z;4%)<%W55!OS\-.7QQMSLM MB%16A9?*_ P]X RA;AP:SD2:6)ENR3$OYZ@4@;U8_L:S:!9"[4==VF"0.@ ,$5L*7/(6*KG#=@LY_(]R5E%RJY. M(P>"E7/:24J*%ZMR:^'F)T>F%!&BUQPCI'E>,!8$B*JE3_V1K!B6QD':P Z? MB 5AHND+7ZJ,4*SZ,4X%U=DQE+EAU1^BLB)"@4YDS8+<\#,#NREKE6%%L..%HEH*>A$=%VNDE"Y,&P5_RN-"\V;V))L MY=$H60%/?2\X\B4D?'Z3^ #GHBQ<+/X-6<;F%J6:2RQW-)5\)! 9' MEM!G.?G+B.W32@]CML,%B@DM-G(FP$WX(S8LW04["! S/<1DS=(M4]!WGX3O M$A,FKU.5G&%W%^PX+P\)1BBO0500*,$3G4D>7S\P'/ M+%' +D"+#,B5E>>Y;%'*^J+?4A:HR=5QZ!BI7LZY/2P(.BZRUOE'9;3SHEJY M:#8OH&F]EZGVY2?"^HYJ/TFR#> C8.KP)I-'4/4KBRJX9TP=.11*-E?)K*JL M[']Y@;$E<=8$6BS(V+'B)X""\ 5P*^S6W#O+XC;SB0T1@P0;SN.&E=P#+G;$ M_!?^'M1B^S*U*-O82ND$6]^<6+2;?C&370]*YGUT75 R(7H]WJLWG4Z&;I3,W2(1N-$KQNE._O:^V M:Y5&O=FXN^O6;YJM^TZ[>M/NWM>[E<)3H)HX$WG>!?,+A?(*,WCP8S*U=O>/ MN\^_WUE?[VZ^_/+YT].G+Y_+(FZ4M*6D+25M*6E+25MS,U^4M*6D;4F/E)*V ME+2EI"TE;2EI2TE;2MI2TI:2MI2TI:0M)6TI:6N 1J&D+25M*6E+25M*VAXF M:;MAN$[G@<'WGD,QA>:G,Y\SWMG'9(EFK7=)9FQ!-S',]I%W9.$H:9SC(Y#$ MP'V5[1SF!#U)#>? ^MVDKY3B]-8T.00!4KW9#%5N; 28>/-PJC232AO/9+(Q M+I&-.BBI5L,=WAVLD+N]9&Z%JW/;R;4& I#<)C@!&@_FW8.1# M.C)5IJ6WS\UE. ("_:5A7S$\=IVJCUP>HS)S72;\G?T9']3U**<@J_"9Y,&Q M\&^XARP_\]-9Y0S_CCBZJ+\WKU<9<]WB^6*1SC0.U MH0HI77CTW'O)/!7_KB:?_1B[Z3_#A4^0 M&Q1+JG?^\M?<@](?6/C0V>_#T>[R_>J.7V_O]OW&?G?_SI&@8<2M8,D%8HCH MS*6Q,Q-%LW_+H:/9EP0+PBOO+C,C=F! 073I:NBY7-3T DLR,7YUV5N.Z,ER MFV>K:26%2U*B.OENH1JP_J>"_U<$+1?0;Q76=;MZ[:OV$!/5E9M>8<\R(_?79Z?\!F7W?!;\F"*_^I]]G? W:#F/M YAQA'H-,LT+YK3- MY%::0P=E-,V.])'')8X_5*MUN]WM4C1Q/S[Q<7&/5N_V:$BC MQ8D]#5(I#&K;[4JM4.5FD*E0G-9["N ":]T:STS2%1$5:=OU;IN,T^..&YO" M;Q0:-DRK'C\-)RDTWU/:HF%2TM(?KW];QD7RR]Y36=\V7F'HIDI),M1N]V+UN5 M;KW=-*XDO;MC3?BNWZ>2=(HJO6NY4$GZ\I+TSS"_A"K2#?3H3K*&DBK2B<&H M(IV8G9B=*M+W7T]-%>DE*\9LU" #O[:!2FF';:=<$44->2 ME""(?!X>J5JE>_6 <>M[IM*DJG:K2CT^^S:%:H79/Q:ZUR 2G MLG0J2S="'G^HU]MVLZJM%N_4!>^TN$>O%WLTM-'BK)X&J20(-3IVJTUUZ527 M?N <7L3-B3KM)P!8E/XC6+ IJG5XZ>A"O-V[$YM;:.?"M.I,-WHPO2RS?D_ MY=KT1K51:=7,*T[?<5[ZH8O3=_SY'8O3-_UY*OZEXG3=Q>D]O%"$"M+-<.5. MLH22"M*)P:@@G9B=F)T*TK4=QJ%R"3U!8E!I<(TRQGW6YV-3Z&=NK66K:7?7 MC\%1LJ&&\&WIVJ76O37'>S$)WJY-/< M/*_5[4:]1I%0JJ/?@GVX^UU>QB$GNV G^RC@L69W:NO? M)T6Y^"(BG2>5/3JO=1K4;[,NJO9)-,FST MN3)[QW*]D/5C*V3NM*_VX*@L?IAD\?ENG=AZ#:8CUQHZWYCUS)C/WQ^,^+>Y MI^]$EC/B$H!%%?!D-Y@^QX/I*'V8YR/)^H&/)@0&")Y%N885#1G#_@6@:X"? M<]Q@4@ZB]CE1OPI*1+CTV/D.G.%PNBI&D3O@NP+B \? ON;VL\WO_[#($]SF M0=N3UVA0F$'[SN1[@6T@2VRE6R]R7EY"]I+@A!S9J(.CB^AD>1J"&(-$0[F4 MZ &)IN.Q$_+/ 3#@ZJU!&(Q!HN/0 >9_]>*AU>?+"<8LC*SG-VOBO'$)B()I M*'$!*[+XSP9N!)59$=@1KG7N0B,'QZ-Q!BN":>3X;O3AZCCYDGI[AOS3%7U- M/=6.EJZ>32]-T-V5L^OW=_QZ[; _3[0O+?&(]M3,5G1$)%UN^P#=;+OTKG6V MHU=G:>_:TS!DJVY6H>#<$?=5KE]R( ^M7]N+TWZQ?>KT'8E1B5+,8 M=5,(+7M;1I&ISM^8R_?N'50=+25U$5T8VBGX@R[2OS4ZE_L;I)!"^8'HIYTC_V(DZQV9H[P_Y6D* M6QFA'XW!J';'KE4JA9/$E,,OE98SADF:]X/0MW[1JK7L M;E<;_IIRQ$7#;*G1M-J]K.HFQ'&#IGGX:)P=?[P(66_8W;JV+F-3>)\0KV8U*@\*E%"Y=0;7.Y?X&]AXW:)<(G\MK[QX1.E?L3IO0V4CI,@:= MVY>[7Y9 Z$SH3.B\.3IWNS5"9Q.EB]#YZ-"9*@W^^A!ZWYR860_.F^7XKA7$ M_+,4,H:0<=VN5K3E6$PY;PH9KPH9UR^UN4:G@:#F@65YS=C2(62M:E>:VN)X MIO ^(>0J!Z6AS_@DA"2$/'Z$[%:H[."D$+)YJ:VO\300DLH.5DRK#V)GI"W: MDYN84Y]\Q[LL1FRWD3FE'C^AK]/M/=H>_UB3:J-J-^K:(B;;4[04G%>T$MV= M(8]O,DJU4M&GG'3CB<=?YPZOJ@;N>G>4+HW]#3O3S3LZT1[HOU> M?KXDM=C&>8KIZ=I0XJJ2 M8!5=&VH0MY5*&$J,2HVX-H52>3]>&EB%Q?_QY^6[';NCS M\LK--_"]THR.*0=_-5JF#F4L!4=27=RAZ^)(>Y+V7-Z*76O9+8W=::7F&]*> M15P 5_S@/M*>I#U)>Y+V/(#VK'/?L_@+NTO!-Z0]]6O/JJE7?9>"(VGB*=VM MNA4Q.@V[5:4AIWLPE8R!VIK&WIFM$-44+J$1?@6D7X\.(:N5KEUM:I,84YB? M('(51#;I(\(G1MVITFWJQHI7<:@KKACAR$UEBAF?5,RXKJ_! MZ#0@U#RT+*\=6SJ(;-5U7J=D"N\30JZ^7E7;W&U"2$+(#3W]PPZ(+ !!X?K5 M@BZD,[<8O'"_OV@V.3 "Z_/_UR34<2,TU3W0]:[E[_"C:V$:M;K=[NJ;$$+7 MPAR6(8^OB9"NA3%%YY=(O1OGKI&.)QU_,!U?;]B5EKX4.>EXTO&DXTG'DXXG M'4\ZW@P$;=0K=J-&U[N2CC>50TG'FZ+CB[K>U0PQ77.Q<*^#-WC3NM[SZ@>K M%UE^ #=&.,_<0+&M2>@%H37AWPGX:V/.D7%D#9UO##YF/3/F6XZZ9()S*PNM M>,@L9S(9<:Z/O<"W@@&^- Y<;^#Q3X4L#H-HPOJQQY\R9O$P<"]7G[W\]X\? MI]'%B^-,KKZR;\R?LOLP&-_P+X5./_ZG%P]O^#J",0N?.)VN1T'_CY___*^T/F3D?LR^#."7TN(=$#"Q^'3LBNG@*>21W")\('N M7]G@I[/[6[C2ZN_U?SW=GEF>RU_@OWS1:73K]4:M>U>Y[C5KG<9U\[[1NKEM MURNMQLU-K7/V\\S!9@_DG3MZ%TGA'%]D(:#%Y5TG4WSR!W _,1[E*Z9Y,8OXC?N-I:7M+][' )U28&]9K"2Q=):[E( MNJ7E(NE&^Z0OU*7-'^SK![[!_)0V7Y*VCQ17=[AD24-17MEN;=[)S)$.EEPZ MOCEW1=73,&0ZKG$VC^6,"T.>)A,N9KO3NCQ\N2]^6#2L'X 1WZ'DAJRYJ_M# M%SD7 W'$67"9,W'6L7*6B9>*&PIH)W ++O&D-BC!M*2[2-KV)&V- M&DF;3FDK?:V 8865&[!,(Z4X+Z4HQP:X<,%B.<8O<'NQ4"XK9TKQ%@E""4".9DB!4 M:]%'A6Y-V'O)R.XS:=,%TMA*Y,U#CZWL=B\;U4:E56L:-[VRV3KH&+].J6<0 MEGGOM1/>^RF=.\UNHR&"ZYHR-,G2*.?O-)EP,=O1)$L3T) F<)5L*MQQX!^Q M'3:?@)#,P\L^I*\7X,H6CG]?)MPY7OS*[Z0G8H*5_O0-/&,)IZ5 M)0U/,R,I:&UTH>Z.?0D!"4$)00E!"T1 M@E8N]8W#HK'EFJ.D>=$^[GYJUQM-8^9NDX*@CK3M$Q,GK':)?XA_B'^(?XA_ M#*0/I92IH[H4+N0Q5.Y31S4%P@Z.^(1#A$/444TX1#A$.'1H'**.:L(APB'" MH<,GYZBCNKB(T0$"0S,/I(YJ$SI^J'.4PO@:PO@D%R07)!1B*=^%@I;&Q>V)@0E!"U-"0$A*"$H(:CY3$D( MJK?X@7JJ"4$)00E!"4&WH27U5!M:]#'FX#1B!X#'(DGX3P9+8J[5X[MU7IAU M(V*ACQ +C:POTSB*'1\6?[5--H*:T[;/49RP_B7^(?XA_B'^(?XQD#Y%99>; MI3>FKC<KB4!1H#S55)R6>M6Z#Q)/$ MD\333/&LM_3UGI)XDGB2>.K5GFW2GJ8T;9;?X;S=?NSISE)90N';IV=I"HL4 MK0))TYVV3.W3'229(IDZ!9G:IP]',D4R=0HRU6CMKS7J6&0JXU]]C!V^PX6? M7_#O'S].HXL7QYEHW.?:5U=_;SS!EFS^/)&[/(XBNUO@9C9[G49[X^ M\GQV,<1"K*MJK?*7[%"??T^CV!N\:66+7F0Y5LBBZ2BV@H'E3":C-TXL*QXR M:QRXWL!C+G\_#H-HPOJQ]XV_S.)AX%IQ8#EN,(FMWN.-U:JT;/S.(!AQF(,G M."ZL%P_$>F4A_Y[C,OA6, W5W"#^,?';T>J*LC4)9(;0K+G8/J<,"]?AB1S" M5B9RT)/G4 ^$J?"9Y, JOU6>CD?S,3V>5,_R;(U-?_;TY M-X^=\,7SQ2*=:1RH%X3"Q%=>/3<>\D]S0DC@Y$KGO,T#!FS?N/O#2/KCD.C:SVR23"R9&'0+2WDO3+F^N:V3095=]95-@E#CQ!!B,&*P]&N?_'[( MG(A9Z]JB12[F_):)U= 8+V+V OCKVADYW+OGOFID>0-T-":7&/5N_V:$BCQ8D]#5(I#&K;[#3(7BM-Y3P/E-N\8S MDW1%1$7:=KVK;PR@.60KEXXTB'"E49['3[/BM>KQTU#B7+-JU]=ORMRX'OT8 M:XBU+Y;SK67UL'([L@9!B*EV;SSAC.W%UB3T^@R*YOLLBKS AXKQ9\>U7/8< M6TSH]TLS]_6\9%_8,8 A7=B,+&4WM2K?>;AI7DM[=L29\ MU^]323I%E=ZU7*@D?7E)^F<.A%21;J)'=Y(UE%213@Q&%>G$[,3L5)&^_WIJ MJD@O63%FHP89^+4-5$H[E#/M4(IR]6K5KC9W']ER,@%U+4D)@LAW(;+>L"NM M5J$^O$',6A+!&J%"M+-<.5.LH22"M*) MP:@@G9B=F)T*TK4=QJ%R"?*>.5!I?>9]P[C/^GQL"OW,K;5L->WN^C$X2C:4 M,]E0BFIT/565YG&B68F(/1WF5H%+ N_-P+M3M6MMFNMN%J)3G7R:6V[9M?KN MN>73J$Q>AN=4*&^B@).]]M=JTZXWJ(K^4%7T:YM'1Q "F(ZG(R=FKG7+!E"8 M4(05N77<2\.X?6*<66FCTOOB2^]+-#M]KLS> ML5PO9/W8"ID[[:L]."J+'R99?+Y;)[9>@^G(M8;.-V8],^;S]P8 ME(.H?4[4KX(2$2X]=KX#9SBA3T__CYSW_Z/'Y.MU/T+[@#3SF]J*(\0?W M_S/EO.OR'_C531X-/ <

N>.HUZM7GV\PR+98GZ M3J?#(HTQQZ%9'=69?"^Z4^6)\^3 \YT1BFT_@2\LF)J&_2$4#(I^(BF//A=0 M!RG/15J0WO*PSFH0@.1'5UM+YXJ]GVS72[-^6=79\=+4TO'2:AZV963'ZQ#V MVV]#7D\!Y:Q$GW2Y2X. I6GHV8F"^.=<2\^#$_YA/8R<_MJ5IV5/Q!=IW#XH M6^ !; %=0FP0\8R3;NWHMY38190M:&? '_;&NSD>2 M+;CG7,0>B6@\X4JB68N4T^NI-X*E'8\N/;@L:J>/*;RBS8$J;L]%1/,;&IJQ MY<9-.!HRV[KWOL,_(@MPY^X_ M4V\"J$.VD$%HM-<16P>%L;H^KVUKHIDBHR=B2QDGED0?;5*GJX*A# GC_14J M4#W"=O4(9> BC:"_7OOZJLY4+?VCBUM3'X=.R*Z=B+D/SAL8G+U7)W0?8_Z% M+]BY'/W#&4TQ%8E/%:]MW)G:KMY5*M7K9N^VUVIV[RO7MXU.]?K^YO:VT:S? M]5J%=Z;NHQ,5.T@Y %BB[Y)3:^R$_'/0-3Z 7DWL3PW9"ZO'[9==]>OEYOV='2E77VICHY\;/*Q3Z":<\]= MZ/_$%^A*O[)DOLI>44C\4S9 ,HX^Q#^$/\0_A#]4$5\6HA%]RB9T>_9">GRO MS@N-[" C@/#(#/J<-AY]\N/0\R.O3QQ%B$2(9 1]")$V0J22."I[)N-7F/!N M!0.22Y)++0QU]YV%?8^F#1ZOH;!GAOH%*\.(G0B?M+ 3E':R"V(JPBC"J!*P M$V%4D>Y-N2X)+=!:%;

6V5%<\/.6'SF6U 1?9_E"M7':*GV5'TJX? M#8T?=F/$377F#,:XK-<*)X@I1P_?VV7D!0%-04!3W%BQ0\H636,UDT%.2;)( MA1^]"A=,TZE5:\6+FRD<0'AC*-XQB!J\[+3.B3Z$#H7@COF@G"9L+9Y69N?!GKB]U@0")0&! J(5C9('$@< M2BH.I!-U;%K?B'Q3CI$@X&0@@#0BB0.) VE$THCFQ=LHZ$_9D@,6*N^1B&4@ MG#'$*AO'K2;"Z:1L.:Y=J]:TF=#;D_$L>1(M&F2"JD M2$B1F"[6I$BV(9S6BV1UW/:ZXA[99WCR33">,#_"AWQE41QZ_9B)W^CY[LPK MO_L>7&(;>]^\^&WC6V5;W>9U_;Y^76FWVLW[^[OK9K/2O>Y[$'CZ$/\H\E(VP__&'[A):$4H12A%*&4T1=B$4@=!4CM^S*,Q%$G MW"+*&%8^P+A3V#4D]% M9O RHW1MZY;UV?B9A5:]:ENU2K6M2ZB/;(CK9A6J:<;M&:F!1NL:'* M#=PI_>( ,\])(,@]7)>VM]XWCXND:]W]9^I]0DK1%O:VL3 M%U,XGYRDXFA[X_C0$*)/V;R7USU.S^E<7[IQ5_J=MG(S2&S+J_6.Q_'J7K;H MUC9RO+8K*7EDDUC6E%2PID3;'.QW6^NWRHR78T!!3=\5,>\.** Y!.3N'8TL M&ERILBX)2X]>GU$%I;?6SCYPQH$(;Z-PT"LAVG8'SH1LQY&CF]YD>7 )T938^N=+XBH:9XD:UDAJ''V(?];DGY/L&J69'(12 M)M"'^(=0BF9RF,)D9H 4S>0X(I8Z2=RBF1S&0==)#DG(! 4)V_:/;2?)#TF".[6G7H"8L(QGDR-2!=G5I/+?17(Y\862S2T!S7'X.S>78U^PL760P MY72+UL2D<(^XY8SF-4-=3QM(>U+COD!9$71',Y MMIG+H2V0.W_>Q1'"W,YETD!'[2-U:2P'^4BEZT,^P1O4-2;@Z )U\M6.IJ.Y MU+RZOU;G7;*#Y0#([F5-WS!+@L@U3:3ES=&+_OWCQVET\>(XDZO'_I"YTQ'[ M,L"ZNFFSQ'[SY3Y\=TWB.@F'^+D]X'&7]G@I[/[6S!?_E[_U]/MF>6Y_ 6G M'U_4NKW[:J/;Z]W=M9OMV_O>=??FMM7HW=1N.G7^]]G/,V>6I?\[C;&+CGRN M,5C3F2,KN:P?A$C:*\ZU+(0?DX6-OU\_WOW]][O/3];=/_A_'U>RP9J-S/^> M1K$W>)O!],8DWZ=\@:\K,ZPH*VL=<8'V9 M,#AYL-D_^?U+BS\L#AT_&G#3W1F-5 .\%T53Z(OW72M([?SLKTZQ(YY_7#WY M(8"%V'QM^'%.)TYP:X[6VQ"F.3^/9YO'6,^PI2CR($)FC3A:\"T-G+XWXK!Q M:3WQ?7-*CCT?14.0PHLLSCZ%"]A/G/X6MG^.K9!R$*7\;LQ;'^QIQ1/.Q##?8]M*PX6A<:1U9^&(?\G!XO@U>?$>'Z3 M6T.)11D7K]YR;@TC#_8J.#P8N7EZ9>@R"0/(>[HXZ +%6Z"%$ 8M.ZC5]1 B M^L.#D:"6/^6[XV*L"./Y%E?K3F1;_X^_,NW_\69;O9'S[(P=F[_C^_Q\&4>I M>VZH>2Y_#0CV9>@%EU:/:R?8*X=!_J4,X11!(STDJ,Z'V7;BA1D.0(UN16SB MP)H%$R-=?N.@'DQ#+TN:3QS7'3]'!F 2P1DY2.+1' M0I UK2W0LS ]\J))^P.5+*Z[N%O!I3R:.VC.R>,QASK@9#AFQ_>G_-2%%AAX MW[DDL(B[APZJ"VV >%EM_D67>?/B^3Z@X9QYTB7S1+]YHD+=J^P3W^IQA1.G MPZ)FS9/D;V6BW$]',3^_SU*Q =!^94/G&:Q4H8M__?7&MOZ&F/NF/OX0!I-^ M(-ZZ]OAOO0:!^^Y#'ASWA<6Q=3."U>:?\D]N%ZWU$'@]^? O(R=Z"5[5D\0> MKZ=O''2%414QKA/@50?H$N&W$P\$7D]L#I2QG!H>R-W:LR^K]CUF?)_TL_!8"\MXOD#9Y1V11.6(=7X.B-G!,X:A[4) MPW%EH*D9(-EDQ&+D0OS<@"M^SEO_F3HA:#J^R_=]E@6!FF4!%(BR\"/XXVH0 M!+$?Q.Q7_H?U'5\* ]C9,(XG5Q\_OKZ^7GY_#D>70?CRL5:IU#_"VQ_A@V?R M\_';A'\><9J;HF?PZ(]SS_[YSS]^A.=X5_#?G_\_4$L#!!0 ( -. 84T9 M_/?=5A$ ..F 1 879C82TR,#$X,#DS,"YX] M!\),)LEN4CNY8L"3^(X!%C/)OET)6X NML1*,@/[ZZ\EVV# &-LPP5FF*E7+ MV-VM_E)WJR5K?_O7PO>,.>:",'I;NWYU53,P=9A+Z.2V]FC7FW;+LFK_^OC3 M;_^HU_^X&W2,-G,"'U-IM#A&$KO&$Y%3XZN+Q3=CS)EO?&7\&YFC>CU$,O2/ MA7 _"&>*?60@*3D9!1+?,^ZW\1@%GKRM!?3/ 'ED3+ ++'A8#;$!D'@M$9]@ MV44^%C/DX-O:5,K9AT;CZ>GI%7+GS$&24.>5P_S&ZZOK7Z_>WX!8("@5']#< M047@/4*_;< O1MQ[Q?@$(*]N&NKU" D<@U-&:>"G([B2-^1RAAL 5 G(L.YQY6)R( M'TWK6(:40YZ*(4VK#$-9CKR'G5T4]5<]QJNK1_7KU\=QL0X)Q;B(\4[!Q?L& MXHXR-9C-D76\F'F((LGX\A[^SL>9Q_D&%7--1+'X7K%X_>X(%C5EBB1G M*8EU4CX*J"7&.'K\])20AXTD9C=$/"$WY3@IST9Z^LHY?V($-?#;8D,*[+R: ML'G#80&5?*DBTR]Y0EH:7OQ'?4VD)#,!YU"#E> FB;CZZVA^7$P.QGJQ#TG] M*!/=-XCAA3,MSL(*2_\ZF@E"YUCH0N.FB%$2:-'O^II$.4XH(HXH[!UKK/#G MT7XAB*/(71=A(L91/^IKY)(,R!DO[A8K+/TKPRT0I4QJ2NI1_' V(W3,PB?P M3&7M#W'J'N"QH>OC#U'BS*ZB&S/.9IA+ L548B&A"4PY'M_6U&JE'B])_NL@ M[Q74W3'(S@";185.4H#B!)X6HK-F,J:@PO9M38"V/1Q)_MV%&A65"5"P5U%Q9AP7%0=0!"S@2SF>(C $ (/ XO(N$(1B(6J&>OPXL+(6 M[WKH%49,-::[=IN/KZ\A]%Q=&76C383C,1%P#'_B10]C3>;0;QM+1+P2:HX1L[3]YNH:_NW3 MMO%S1..?%ZGW.?;83'6[1).Z/3G%W"832L;$050..:("%E\P:"G;Y">>/5O> M9\P6HVU^,3N]_H/9'=I&L]LV>L//YL"PK4]=Z]YJ-;M#8SAH=NUF:VCUNIZF&JAMXN#=N"H$! MW/DS(!R[W\-7#HU]T'5N3NDZ,3<&&QLA/T;,T(LSY3/H$(T\_+P^$PV1Y1HW MJL3<7QL4=8V?PR$OR?0MYOM$QN9H,0IFFV#JD"+&S2*271J\2RD-6KV'!VNX M-EJKUQU:W4]FMV69EY3_,[1:.&3GH)4=@M^EU."9AKK(0 J*%&AJEW@Q^T&CE)C&QPV4/<=?IU3H1SK! M2Q0H8*4^(!5-O$>.E.40KZ_@7TK0/](AXK$OR2/B8T]@(A-2KUQ:=,RXK[G* M;^U,*AF6O+JZ@O"NXWM\_"KQ$U'7",D9"7H79!P3<0K5D.ACKLHD1NTIXCB_ M6?;@9R?<7U,2KMD<=*%^LHT^+%)4<073R/[<')@7;PP5UQQP^S;Q HG=+I86 M!?WC#A-;D(53ZJD&S$ZMOZ:DUKWF5BT*S8">FQ$+!O!@A$P8/RLV_FD (T;( MB:%9N5%KT4/Z[<.V3;(';/A6S[:"-H250W*,"Y]]Z[5< M;]Q"8GKOL:?C9F$ZQ6Q+OLDY&Q/K/U@7MIKV9^.^T_MZX?-R0^/,!_FFF HH M E1Y=SI;[E#.MNE-.9OV'F#Y_]GLVM87T^CT+NH];&IT<(E+#8N"B+S#$-,*B534*B16RQ@YMMA3>I M5OAB=A]-98W>IZZE\M%%J[_I_B\0X2&-(8O* 3H98!%X)?:*2]+/CGEO4OK8 M*694+J;5+U;&T&X^A M-\=19RJCD5XLK(D6[6/OI9#=PWZ3TL-.L]@%=J]MR9QO=PBP53,$4U%PXWT/ M?G;&^R4EX]G#7NL_];NF;;9UQ\3LVLT+2WOINBR_7Y>37G:T^R4EK>VSUV/PS@/\FH?H>HL5KF9.->- -=I)>EAML?$<0L:!^ATP8 M22X,S<:+NZ09[PEQ5_0"J2Y247='J?--"\P=J"L@4YW>6?*-=]!5WI9V% @/(2UYN'%3U+L!NL&R8FCVZ8 "5;;>O((K(AX'I[<;^]#.0\W4.CB]^%5LV*)5>2:5[,K\EY3*?*^5+[$\#T8"_QF .:\V-<0 M.YB9)?GU55I)_GAGF[\_JG:@6BQ=U%F1;?45CYE["&1&O>NKE,;YCAG^[J'J MM\;6C3#1@XU[8_2M,=%]E@8:06Q'CKRM21[@FK:@NFOCO^N6>'RV'EC!EL0^ MF%)=@W-;RP8AGJ>"3DQ8@%4ED8'BXA-GP>RVIJ^!_$ OF:$]V^$3U2VH1-% M1TE6,\*G,\P)PR&MZP)=\-3R9YS- MXR\!0WT\\Q@5\Z*5:M6&K 5P7'^;TF+ )DP#Y'4#9?W>N/=$L=L-."AGTL)J MBJPT5@ZUO"((D)A@GN5-922&/*J^@\?<%[\'B .;WO*>+& ^3-7%Q0/E"@^0 M,:=3DC_>P+6H"@"-'>,PXAK5E!%]5ZXJ1*SS/.WTVY0[18.]LIM9E.N(+JR_A\MADAK322#_9< M"Z>53"9$#+;$^#-&GIQ"$0!(8+ 'M%#9O8^6BKT^5"G4)7/B!LAK@HJ1YRUC M28^B4+$R3ZM15/:H@Y7309"6V@&[^7RH$ZR,)\Q M!#B:D[(+JZTSOFU G^L]^_5220SQ0MYYS/FV4D%!I"/B@HS)'&]QIOH$\95. MRW#!R\:1"?6%(K%TAP'/OB!^0-Y,!7&BZHXH&X4I1ZUL.42K#O&A1L8\]M%8 MO%*855M"YM"#'8R\2)"PD7%8 6DH/Y3D-O;&^@_5"!#J>U/B0JA6+6!-/DL% M.7#/$L5*5;$/B((CNRW$M]:A:2^J5X0_@#(D.A"PJ5BWJ.^RN M\G8VR-DS=LQ>%S^U"<>.9'R']:UWS\IS(;5O[ CLEDR'P:JC_G06]8ZBFU.> M%7#5I=*[.3F%BF$K(U,?BNZPM8N\>+MNV4%/(B!RQ_,. 5=$*A8=O7W ,%\7;8NR^KHPQXE31!,\1$KL=,D]- M*@<@*R=/(O4!J8T)OT^P;)3*2&A_ U:V=Z@?J8NY#LK;TAT&KZADZ[C\&7ON M/>,V\G"7R3[BLC=6A\)TAR+ ;O+>C"SA2U(\6YC96\/V?#Q!82->+2K"R @% MDT6=S7(V#^#Y*]O5)Y_:(\-&A/ZI#R.8PH$ELN(ZZD.OA"N,]HR-ZCQ^OLFP MN9#JKIVX9YPNU2Y0!3K'FRQ:ZE0C\M2**5V&38#*\;].TDE]"[WWB_>8Y2#. MN6+JWI#19U*=!4/>%\+"TZM"-70]@5L>(K[Z'F$S=!1!J-XJO\_Q.% '!=O8 M#1Q)U-ZD.@*ZU<8X#%9%T=16 ^ZC9?S_1=F6:>_[\X=Z6*0X& JL>"MLS+@E M1* ZH /L8G\6;JGI&SF%L@R'5*7\<(X1=?7CT?:W%?J+.0#S K4?J;^_Z,TV MRH'O/FIE6^:@B3E1L0JJ'QV\0 1SH,W6I MEIY57XF\HXU<2R1,VV2[PTC]N?6@(AO+<0Y MP2FE8\;[ZL7$^'LW5=0/.22M'F]RF"5+0U(RMA MR^-74!G8\]'F>F_+M!D YT\1\;WJF^&VR3FB$PUZMUR#1/%'G\()C^(DOHZU MJ#H\)8CS!7G!:B(_(_V*'7-Z!I5^Q60RE=AMAOODT1NL#Z*>7L$'1CLBI&H& MCEW/'2DHQ)HQ!GZAYM!?EL](U'.PHM7>=U#VL3P\IPF^1[1('&1[EFB11?]O M&BT2(H?+Y-.K(/&PP.)N&CU95GA.=4WVE2 MN> BE6D5:)JVI$W3(:"9,+B5P.F!7B M:"VGTSR_+Z?>3)9C9L:7Q>V<53@IQ?,=#-C?24_LZD'='-[G-YMQ[)#PIA4U M,X2-=AKLQ?$JN(V0$&(WJ?4HWB]S-OB/)NKPB141-0E>/5&'4V"5 1EU#&Y3 MK/17%12!0X(*#[7I:Z"F:,3&+:32V 1W.JW$^RT!2R!64?SM_]$\?#84)]CGP2^_K8VEJ\4 MYKEWS\)K. 5$%1]]_.G_4$L#!!0 ( -. 84T;?*[L2!L "HE 0 5 M879C82TR,#$X,#DS,%]C86PN>&UL[5U;?/FQ3__\9>__P]" M_SY^__;H=.RG5W$T.3JIHYW$(S1]'J1Y?'?UK7/\QN+$(W18Z MFOUC.!C]\;?\X6P3CSXW@[\U_C)>V;=C;R>SMB\GD^N_O7SYZ=.GGSZ[>OC3 MN+YX23%F+[^6>O*)_!M:/(;R5XA0Q,A/GYOPX@AZ.&IF;;=H9/'XYV^>_\1F M3Q-CS,O97[\^V@R6/0C5DI?__O7MAUD_T6#43.S(QQ?_^,O1T2T<]7@8W\=T ME'_^_O[-@TILN)DA,_(_^?'5R_S(R^-I,QC%IH&&9^4OZYA^?F%OO(4^$XT- MP[G'?WW\W.3+=?SY13.XNAY"_UYV%^ T3NQ@V%J.1X_O0)R;.!Q?9U(VKT;A M?'(9ZP^#B]$@#;P=33[6=M18GUFV@<@;5[G/;OUFZQIJN8D;CTSG)O;9[3RU MPG08S].KIHGPN/]S.JACV!T*+5O<)R@?K1O&7?3]8<6]=?%D?'4UF"P$.!F/ MX,\7L 8-UG>B1=$28K:D6_L:>A1ZU(R'@S!;8J'18]L,FO/TKHX-B#'[]CR] M'HQ@81K8X0?X)L[D6]^5;O7NO8.MAZR7ZO?>W7=0J-V$ZJ?^WCJ\,#9!EC.8 M+Y,O;T9I7%_-)%G7F39E>Q/TS-8CF,[-NUCG>3X>?;BT=5PGXNI2.Q8N#ZX' M<$X'PRG8\;_%R1NP_*_BVW'SZ,F6LZ7G9G;<_4UMILUJV;'P[1;Y-F5[$_3- M:!+KP=6="HF@/H;9Y?EP&>/Z-:5M^6("OP.L1F /3< 2&G:5?FEEN^S*G7(^ M3R>VN7P]''_:9@Q6UE.L ^.KZSI>QE$#,RTKCJX=>:J^4ATZOXZU;>61;EQ1 M^2YTG2@;U-I;Y]Z.1QK^M%R^*EQ&VYA&U6 M2V_"OX\^FV'>CZ7*8Q[W@I;(^ZZ!-'4RCBQ^#YMK$MGRZQ0Z%> MA?^;-K<.Y,?Q?**,+M['9CIL[=%TJW6'G3L=-/;BHHX7N-P$_3,;^#[#%8\B+'ZQ\K7RHU:5V+-RF%OIFM>Q8^'L[A1Y:!_?S M/)W].86?]Y]Z!R9BVZG;=SOE /ADZ]"<3R?Y#4A^LY0]\L^Q]C!%@>M]=7^C M5HIU'A3II![XF9D#3X)0C[[Y':9]LQB[GK#HU.B.H6FG%]N4[4_0J6OBGU-8 M L]NVFQ_/O7\S@1J2XO5Q9X4#PQL/QW.$'X+O\\?SY)L_$[RMHWX>1)'(8:^ M6UG:H=TUMN4[P ,0:/6B=P ";O0B[:N\6=J%O,.Q?S =YC+.7NLGV[C92_AI M@RZLO7Z9I\G+" ;MXIO9Q$&8S*,$_CK_NEIT!;2.&XQF:,QML__$\"9 SZ S M60L]%!MZ^Q:^'@S!A(L-_&UZ!5_.'EET96A='/[\ L2N=M=8]4IR8[26)Y@K M\?I4&L:X$9B24Z[-V2E_".PP#^6XGO/@^2![/!T,\Q)?"MRO[56&<7JLV)EZ M;; X/GMEN)2GBN 3 /ST#!^WP??>3'M5^Z-Q'6+]\PORXNA3'%Q<3F;_O*W% MUOZ;"?@P;F7^Q$L0\_;-!AI,XM6B?(['.1S*C0]O@ "^9T?^MV#>%N)];JHZ M.<:&Z)/7V)PP<7KV^I@8*=7K,RDHIR?Z]?:4I_^E?-&Q6<_V;VW*_,VV5K18[-:W&L3K?G-/M1 M.'UH@_0<57G>J)F9RX7T^=?VJA.BSHXE>2VX.A.@*0Q_Q:4^Y51S@%K0[2< M_U$FP"$-T!WY__YRF3>W+S=OV89-W]YGZRC @@T7<;O[B<([%*D.&K+E 6Y] M2]<^8JWOEML$HI5ILV.X6,&MH@>BO;H!6;*R^SB>BY@WL"_'0U@3FUF?5BSQ M&]94\: D$4X@8^%#1\80#?"1.)8Q1HI-\FT6\-W@5U[!LWZK%*0STMZ$J M2Z!87[@R/#$2%4<$VX0H\P9))3"*DIH8L/<\ANW-ES+;,#L=\7$!2$M9VP^% M/QTT_E;^&.[$!S#/TT?[^=5D4@_<='(+Y?MX/:[SBGRK2EMSKD,;E7"&$6LL MTF!"HA"214DEC'P4A!B#/7'XT+=+]D?-LL@7,9FW"1HNL\Z6L,PW"^DMN'2O M?3,S=PF-#$&!LX44YQ$%JC#B42E0C@:^\,R0=I[R+GMQ,JWKU3L(#YZK@C+! M>^*182$B''U U 6!E">)4NZ-,_K0E\]MAF?<+RBE%L <$EBHHPQ"5W2&AIA2*! [/@Q1; MC>BX#&:E.#,/F6UR "U(#XH>%M$6>F)%L(E?6_P?V*]W3=6E_ZT?-5=,[P1& . M,"V1B#$@PS%%"2<<69J]#%N]%88E=N3H]7:Q*3-F -49>P6HLE):2)I40M=(B$228;%9;!$@J6(>U3AR1/EU'?U@AB/\>QCGKWY?7>4-Y/_<'H]ZJI^K MO>5>FJBPQ=H':Q H88:B C.0)6\0LY1YJ0(H?]F+7D+/D8)[A+FL??7;>.1O MU^69@_#QTH[NOGHSNHG-UU"3K>C:6R,5F*,D:@,V"J$.V1 9HM[!P"JI ]@4 MR?@.*K.D_]_##O*>$"W%S=.8(G0E?/59YKU>:88]7:B2@G.KN$1&4(Z(DP1% MR@3"/' =F$F$=%!V)3>:RP_\>(+U"5 ]I74 MV:!TA:D"E1^A/]@%Q###L"I(A5@@VMMD.)7D>2QK>R//;N$NIJ/:[Z0\QGN5 M]MJ^UBKQX+P6&ED"$AL',$7G/-()ZR2"-MZT"OC;_X[Z_O5:T6$H1=E[[Q1: MD7'I\U4(#L/LXXA2+,"I)Q@)AR-*-E'O@R+*QNUI5G*;?N\TZPO@4@2Z?Q1E M%.Y'^=TFDUG!I75%*\DT48%CE)0PT%?C$1=6(.W@/R9C$-[L+XJJQ?&196$U M3Y>J$O92)YZ0BIZ@P+F"KEJ%<*)*2NM=#'*8WHV9:Y[#H][&)]4ULI5Y6%ZR8CC29E%#"*J%(HT<6$$"* MP$Q,TA A#WXKI'^Z] Y:N<5G,B?S)AQ94:H2P<-:J@/2@L$:&W#NIA?(](E;4_=O4/GFZ4.62N[ M=7L 2Q\U>6>_S YFUJ!'VY\T65*J$MHX*5G((1H2^FH="DF T:[ 5F=**4\[ M*)SBAFL?9.D7KE+4.+NZ'HZ_1#"S9]$[&RU$:\M6#D>J*(F(9R*K#I"1/YQ(U!+CJ?HPK KA?&"FJ%H^G@DS#N MU*_N!;-B61KNDN.L3E:IH",5+!Q\/JNN M@[7D!7%'C$J-_,<:?/9I_:75V'_[<*6P8YC!%'%"Y+<-08')E01B,C"CP#!/ MNL-AQD*G/WH>_EY@*K8#$L+LWBX[?&<'XH5B# 2!">80%E$3![A$V4$]E'%T>^;'3E KEX-C8@>C&!9IN1X<<$H#/UB= MD&-=XA5-E7B:;S]NNEN%5$&P<+A44B)@\6K$@K, M@ A"J,0[V/#%,I+OBTW]0ELP5]+-H $97X_KT_'43=)TN(@A6<&C5<4J1;&A M1# D V6W*0J9E@"JD"39)#SMLJU09AMJCT3J&=N]I?^8I[$\CJ.85NY4K2E9 M16V-=2GW-#"D5" H.>F0-"S%)!FEYN"3A.Y5,?4-;T'[Z8&W\V:T+"QEM0W5 MHH**:^U\A/8MB1PI&F%F.4)!/=-$N&;8V0Y>8YG=J_W:4;M!N=@+^OEM4CF% MR56>&^O,J.4%*H.]\\PZ!"ZY0))CA1QSL-93EZSFWB32X;Z$,E$=>^11;ZAN MG3SF+I/-7?O'X]'TR9MGGRQ061WSW38:<28(RGN[B)+ YSE+@M&4=- IZGOE M0N^H%@T]S,=\ +#;E7:^S*X+/EQ6IJ+&8A_M,%_/ M_HL=C/*[@O/1(CA]!24WK:I*T=L4A7]'=W9NMWDS.OOL8S./6H'Y\N"V]<=>9MORE726)LTETH%8 M9!(V.1^)G[M'%BO6Y;HMPKY;%NT:YG*']IOF+DG:E_PKV NST)$5VFI%J4H9 M[XQ*#O%H&.(6@ZUK:$ I:2V,E8QTV7PGW_WN>[_8%CNDT@ZMY= MBMB0[]'T2%CJD>1.@1=#78%$ZJ@T]452BFIC30>P[WNEWQ.P84+JFD MHEH*$1E'W!@8 ^42\@+\?1$B-@8'[&6'<\!E*+?O@,)^<#T\AO434-BRXHJ0 M*)4%>]490Y!Q)B(?53ZKPKBAV#&I6Z7&/)3Y@G\JO,T&VYF%/2)?+LK^_0ZCMM MMZX3<*)2&*&02#C?C4XQ(LF!T#A8G_?[8WBN1_!*<+(D\*5W7\[35P1G]ZRV MV'1Y7*32+A!K%$'!P$^THS+YVCX]8Y-W(YFN6S5D> MG//KI^R^/4A1)<-8\"0"M(JB$)E%L)PL+H - 4SY#AF\]QJ#L$O>/H^A*J]) M3P=Y"$:A:9=Y;W7!BN2-"T\-4@D^DI<:!9\28C+IJ%("2[_#OJ+X@;1J3_"6 M)]1,TL6L:K\\?UNLBI93*@A#A+J0PST<-"PE4IYQJJ5DS'6X3DG^0&3J!=Q] M;DPO@:N7C>G6]5: $+/">G#6_4JGR26 26C\^ \4(35LA*)Y *R4JN M"<:FE2>^P\.FVV?W;)6/,DKM(\,<$1TY,C*?':(R'R!B5BM0ERP<_"6RO8WP MLN.E_0-8]*SR$O%_']7?GI< #7!CLS?0O*H'3;Z%85K#Y^U[E@YDV[ZQ"G,= MO<84407JV3)0U#@:BX27B8&2SFF5#IV:_5.H)4>+XKYO1N?NO8]^:)MFD ;^ M=JC#_TUO0Q7R/N&K\Y,W#P#HJ#^W;*TBL,1;8B3B%E9_@L'\]8+#!U:@I\#- MB;&?0.-=&OY[(W59Y N^L[WKWNI7L'?/59: Q)9PE'AP4"45^:AESNSDG. " MPY0]_)#U'2W<79$Z!+/[6\>ON+V]R(X/Z\-L@_!T,)Q.XJHC9D^4J#A.)'GA MD792(*ZX1#XXC#RU6 K!O&>MPC]W=E1]3890Z,^\*[-NK4!@X[HJP13V6'KD MJ*=($D[ *]2P\#HKHI?F=/+N&^8_A@FQKZT=B_@@P_AC P^<6$/?@?Y8+GP>&.D%_S+!?S>1+"<%I#6 MUD_^-9A1Y;D$VSP?UB]';=%;17Q$G.?(@J6&"2(R<%:3B*C M7<2$89_K32&E8,GW):?5@] M6#[!QHR=76O-&%8T4-_AK'VIS=B>Z=$#2B7'_CS],AZ'V6W3L;X9^-A\& ]7 M;5$]72BS7%AH"Z60.TF# KX'@[P,) A%C.B4!*G0EFJ7X5O"A=ZP*F[1W";W M>@^+[AR,U?'\*\M5GD68/"I +XU$WF&!B#<4:1]!"4KGG3SXF/U>N=$W7*7H M\:L=7N#:97ZP+[VE50&>,X5EB!'-(AA5E$V&&+@I0&%##C M5':(JBIT]K)/PNP,MU+,^26.@/+#G.\T7 U&@V92S]XQKL\ OZ9D9:714E*/ M1) :&:<56%9@;6'*M?#!"ITZQ!:7"7SOE2O] U:*),_MPK8RU];T2H[G>07; M71C.PNO*I]4&HW746%FNLDI%[C1'1 :!?-[-Y4P(Q)P&=XT%3![?:G^ @>3] MJHZ>\2K%C^>6T[7,W32]4N-Y)FG];3P:/_3QUQL<3Y:IO&!&:XR1C+!RQJ E MLEQYF \$RX@5PUT.Q)?Q8Y[+;FV?HU"*;=]Q=OPR;US[&?-#3'O?[PU:CU!: M%X?[;8DJ::8YAV70<5O0.%] 6.K>T$[KTAUBY-_2W M>GG]TO;HR7*]_D+'N\,@Q+S\!DRS=R(8&C13I1@8P604@3E-<= J+Y+!I=G$&!R9>>8FM7ME$)9QBQ!F875P(%<"=0 M K6+?!2$&(,]<<\A[^=.X@C+XEK,AWH4EWQLFX%?P;6ESU#.+-, M&R:](P?O)?8PXMN'_Q[_UVS;;=X'M9AO'?0B1&XUY.!O]O\>G0R;RYM5YD>931<>'/O0:P/ MG^SU7AL_C1,[&#YU-+$G&?(5S*/)_+I1(/ O4QB9T6-^]-_J+#X2&A]?C ;W MW\Z5:N_N2'/SF[ M:7666>KX<4Z\?;3YFZUOPQ^*H+U+/#>H\A% MIMO4-?'/:0XCO+E_D*I,:^O!G1L?^2,GROS'7_X?4$L#!!0 ( -. 84WG MUC!";#L %+7 @ 5 879C82TR,#$X,#DS,%]D968N>&UL[7U;<]M(DN[[ M_HH^O<\]KOME8F9%F\[_]#/\"?OXIF4^R:3J__MO/ MOW_\17TT%Q<__]=__MM__)]??OD?_>'M3S:;+&^3^>(GDR?Q(IG^]"5=W/ST MSVE2_/'359[=_O3/+/\CO8]_^67=Z*?5+[-T_L=?RQ^?XR+YZ6N1_K68W"2W M\=ML$B]6[[Y9+.[^^N;-ER]?_O+U$GU>/G7Z>*AP=.'Z9OU'Q\>_:[K+WCU+)12 MOEG]]>'1(MWV8.@4OOF?W]Y^7$'R2SHO%O%\DOS\G__VTT]KY/)LEGQ(KGXJ M__W]P\6S3N+I_0K$^>0OD^SV3?G(&[TLTGE2%.'%J_8W>7+UMY_C^TD7B)LD_IM?S]"J=Q//%ISR>%_&D5,@C2#ZZRU.R]2[.\]#+?7*T9%J_XI1L MET-KNIPEEU>J*)+P^.1?RS1/IOVA4/.-IP3E4_QYEO3!^_...V/19+>WZ:(B MP&3S\.?KL%REAYFHT70(,FNJ6_T>.B1Z7F2S=+I:C<-+=5RDQ>75^SPI AFK M;R^O?#H/"U,:SSZ&;Y(5?8=9:=?OR1FL+;).NC\YN^]#HWH#JIO^.V.XLDL# M+2Z,E\6WB_E5EM^N*#G$3)VVG1'JXGP>AG/Q/LG+<9[-/][$>7*(Q/VM>B:N M%.XD@&/3V3*8_.^2Q478)-PF;[/BQ9,U1TO'K^F9_6-MIN-ZZ9GX>HM\G;:= M$7HQ7R1Y>OLXA21A^IB56YZ/-TER>$VIVWXP@M\'K.;!'EH$2VC6EOJMG?7) MRN/D?'EEXN+&S[(O362PMY_!&,AN[_+D)ID78:25$T=;1G;U-Q1#EW=)'M?: MD1[=T? LM!TH1_3:&7-OL_GUIR2_MPXWKIC/@/R:0TPR:3;+G:\_RZ#'(O76$'R#W4KD,"[Y/Y,C299&'G6\>V MW-VB1Z+4]/\MB_4&\E.V&2CSZP])L9S5WM&TZ[5'YFQ:Q-?7>7*]V65LGFC, M5KW^>F2HGHEVJ%UG!'Y<9),_@BV>3,O%+ZQ\M?90^UOU3-RQ%OIQO?1,_!-/ MX22\/6P_+Z_^*_:/>,ACS82)=Y.ED9>:$)P-1+[[Y/0S[HI)=1UBT>FG/T-2;%^NT M[8[0Y>&SDL\LWV#4FO+5:E.?ZM7C$=)::6^TL(12@+BP@5:(N;(&4J5('8H? MY:KRR4]9/DWRO_T,JY8;!3]J?BYS>+J&/.L04R5PQXIZ3VAV$()J$),$1H! M3H2#$!C'$66""6 QT!A;*B7TU@THXYW6R:.$&PKEI4C[ 6<\4F?2:P,DU"1P M)(T3C@++9)CQ*-'DS$4#!Z((2$XB" M-:&(9 Q#)B2S@0O98IU$HY1;"]X;RFU9_'(=QW=/9+?YYJ7\-E]'[Y8E<9=7 MJRA<<3'_YTTZN5DGS*RC (UI$E)/P/'##64QT8=C(L(X 2AYA%U(YG MK'9N'/<'TV'UV+'/J4AYM\S#'O#:)&44T,>3=!;@W2KK.LTB*1@S5"K+!0B3 MDE4(2R&1081I9Q$;S\#N9P?4+3ZMI?LVG01;(IENR-')]*!DMS2)F%6>UT\^F9G)>,.P2I+V&_3UUJW][6,B GFI/8X;!/#=M$Z M2:@))@?WP@CH!&TL;WZ>\FX-T:.8_^/-"W0"J7]T&YII> 2QMU!11V<%:X67 MNMG;5K2OCND5%?L[PU%UFD62" 4%A1Y*:Z5PEDEJ2D^ <%AIX)N$I+KA]C'_ M8PL#A?[VY-.NT%;3KJ(PBI#S##LJB0=<<$[P&A7KH*:U4.DS[-6M:+-!T1I? M6"R)9ZXH71EA(@B3]O)V.2L3N6URER>3=)6J8Y-BDJ=WZ^3+]WD6UM?%MWVA MM#9]!O-<*>J<, 1S9(@#6+"-Y"!! @VH?K7";_UK3G8::'L-[-3@XUU\FSPR M8)_%41IHW+;N(N85!X(&YDWINQ6&(E=#:D^- %SO@LP&1+//V>G1DEAG__^6+&ZR MZ<7\/ED?[OG^VR0ID=MCDK7I,C)24\&1=;I,&9&$. ,WR"#D4*W,O8[B0>.S MR 9$MD^=VT7FWG5O?Z-(:"N588@10+0BC!I'*NZT\6B\QM4P0LUZ1O*UZYT2UPIU2,=:F]W8M%[;:1H]X*#I4$$@#E'&>@LMHQT(*. MT\;H3)(U-*,+O/X#R(;UU )>T@J@ ML18*92J*G;*#&H[[K88>I)#U -%8)U-88T*OTTU$.0?4:8N- M"-K,.$&J8@=Y6'R=M<8)A+6NW#]42J3&DZH] M](35/7JM,SH__I'.9@]+[V.&\=^3V=1G^<=XEKS+%N_C/(P*FQ:354'P93+] MOJ3CKLS/]F^(5!AEAGH$@17&.$[)W#6O0:86N@A6&+ C6P, C+X\H= M29US(TI$[W4B&P["H53MH8#DZAQ%\:$,:'PMZW>Z_JTB5(0RG$]B!7F==1KLSE.EW67[Z<5T-ACXX< MVU4DB%?&$4Z D(KK\F#>@S&IL6B^OQ-GI38]XS;.,Q%'W=1SYD<2 & *&2,D MEF%O;K!F6G&A$7,(&F-J^:A?WY$$AX $"DDO**+6$&6D]%YXSQERV R9)]G\ M2$)MT;8]DG <6D,>23AA5!E8B8CFVBH,J0(!#J $@IX"C]FPJ;;]1I5K2[]F M5/DXX%Y'I) 3)8W37D#EH0> 2R%6);(8UF&TPC.K']:9B(^.)78,Y.O0+N0Q M#JN P5))2CR33 %+D:<&!=//#UE@L'TLT12Z:!%0!*'Y;I ";0O-SY0<.!UQ#@ M\U"6]M9MCYC]V4)*##%EH (.<44%H(I)8WGX*6$8P (VUJC3Q, [U*CNT3NA M;CU2?C$-YK(_QC4M0&NC7>@#>F.=]%]<7N79_?/KVE_N8GM M\YUASV@E8F'?B$R98"@UYH[;8%<12@3DS0\,GR8EX%A]'!O YSB%EH'.N]O] M62N]O"_R6#"",*:(2$H EAQ;1P#!G L 1//C9Z=)4!C#9-H4W'&&H[?=7-=Q MH;[RBO=T41%C5AE$U\E\DI[NO:<.MO\6S^[R4@*3Y&)>+//R]N '+=\S2>QM M%R$)G0*8$>4%=!Y#;[A15EG/7-#)6BG>?8?;MW%0/\*^LW7D!8+2"D&I4@I( M B'7&]Z%YK!YOFC'0?6.)+@SJMX50CT%TG?6'4KCV66N\L_I(G]V9^BG]#:Y MRG?7@SFF>:215$0 *H&P.A@7"EM?0<"!'=UE6+V(-^L=N.;1J\W+RZSF[TF[ MO$_R=T'E/GU)9O?);T'_;HJ= Z)'J(\3Y.\N)A/#J3A M[7@^$A R81QY76,2@K)&=O0&SZQ$9D)/($B6!4=X*3P%WPCE564G*!<-LP,25D]L6PV(YE*YMI?=@>O>> M5A%U3!G*@4 8AW=*R^DCGTCB<9H=@TDWZQO)UZLYH[)#SE%A3J,H[_/L*BE* M,./9$XRJ".FWG1;.<1U$0G#@'08 0^BQQ$YBN>%>&]OB;M?>M=UVH=WTDDB2HQD )+&\P]'7:'HD+! M>MF\*.;Q.:RC,6![@^\T2K0A_J#EL:=5Q 5G1!F-I2*$((B9H1L^C126C=MF M[4.@>W6F"_!>K[*,TDP=N8Z<1C=^GU_%]UE>SJ8?DNOR)J8L_Z96"6X'C=*# M;2,A(;%$.NJ "Y_CL\>[42"6;\X]>ER?QN0OEZ?OBQ=D;L#<=\_ M&%GON(.&,T.\9 )SRBM7HK7<-R]E>?SQ@Y-;&IU -)R@2]M\;RAEU^.155P) MC!Q$I>X21#BH.'(>0#-.NZ&M>'9*N34RKT'FHUK^QR#JKEP)V:+<-\>S?Z39 M;%V>-+OR\:Q(S"Q.;XNPIAQP*M3M(')6!&Z$9@9*H[F&85&J.&(4CNQ.R?:" MR09 :2B;;MLJ]EO\-;U=WIKL/LGCZ^1]DE\$&WBZ_V#-<1U%A#K&A5*( PI8 M6#'M@WWD)>3-SWCW9NWUDU+>*VR-)X]M5*GY?!G//BX_S]+;=!&(6A=IV35] M'-%%I# 6#,# $->*.6*#D51QI95NGE'1FW^R6V7H&;!3SB5K#BI5?ENR<>0D MLJ6'"$'"$2<:8\X\,@PH7P'L$6R1Q-=;A8CA9H_V>)U 7UYLI=5DD@!,^X !*VMS/T%N=AMYUIW/4&B\\ MU<5%3\-R#[&XM_&78IGN/I]>JW$$(.4D+)K>4PRMU\8I5W%"%6]>0ZNWP@<] M+#9]0-6IM?$QF5VM/B33UG0]9Q+3&!@D7E/A"<5IU:#YJ'1WH[X][-L= A2XPGCI>-]# 94AWKTA]5@.O+@_ON0%$E^G]2Z M[&A/JRC8PL91@9CV# LM&'.PXA-*W>+P*3@SI>@,I*&4856RY0&!B_ET62SR M;^4%3+.LM'H*]3E\$8#:HQJU^X@(@1H;;!UB'$&-G&2\PD HV2+"?69.S[X@ MZ\'?^S1KX[7BWYZZ>(FF4I! !@+F&0A /JJ.['#,HF^\^>O-^]B"_ M>I[0CC <:GKY9Y;_D>1E.:SREJYX75UIL\DVZXE1S:>U%J!CNXHXP!#!8(4' M$YQQCX2PJ$($:=K_+=!*?Y>[K)"F*]WER MFRYO5YOP7=//\3U%Q$LG#*4,6&BM"ZQB]3!T*&^>G]>;/[3GZ:=W#!OKB;N] MFV7?DN3O23Q;W+R,%[Z/OY44KL*%T_0^G88)]:;P; <;JNTF1N#TOMEF=RX/C*ADWF0V]ZJ\(>:1IJ& MY3H,#F!$^ 87AG@I2-B/JU-4J'U-+M]_86;RM M4;JR?B<1MII932@K9Q]LO:8.>024#98.IFP4=2QW,%&_E.6^#L+^56(*N?02 M0 HHER2 P*@5PE/OQU/-L@^A[CRFWR%B\8#71-9*:CW$Y???)LF!(E-MNHRH M9Y9H 34QBA)IA8(0<^>8%$@AU?R&XL$J97:C+=E)\.PS?7H7F7N3J/L2H93)3: '=P3:H-E/&VE^$,2S\JK M-\J["\N(_>7D0]Q&7)8EJ.-$J"\=?BEO3> MXE<#[*=Z1G'$OIV5SZKO2T=L-EG>KL,U;KX(2%_,K[(P72^>;%MZ>;&+\WEY M(UUY%B.[O]/2,( %^])$G/SLY#+W\?EX',FV213AYG M_:$H>9P4+J],7-SX6?9E<#B>$9'=WN7)3;FQN%^-E%,2;B)6I&H&A,A,-(X*\ M(1L^:=CBZR$WKWL=^AU)Z[OX83>X#.FV/UYADK(J0[ KYM>KMZ\J!1XH@+>C M2<0%0-X";@P3P&#BE+ 5+):3(6M3'.5^[T#0+U6G&X@&RTS80N[A(F4[&T4< MHC#@"!"4&V9I&:&HN+184CK.PC3=":^&-K1"ZK7JQ:C\X6-4AXX\H9>WR76\ MSJN:!"MU[5#):ESX<+!AQ D5"H$C22L+ %C'*@X"%2,J'A-E^+(>L1HN--> M\^O%QI*O8P5L>3SR ")%I/9.< 0EL!BRBC/J6ASWZ_DVJ!XL@/;PG$KP-FUZ,,Y5?@3B[VAU_RW+ M%]?Q=5*Z9=YF\>YBLGN>CH )I&G''(<6,E N=V)#JT,(#FJJU2T?VP[TK&M0 M6@OP0W*?S>[3^?7SA:F>//2X2T9."!$PV;GYWL+,M.\?CDHF-*?$8NN4UP$P+3=<>:9XK33E4URJU;V)UAJ1<62'% M02&_>#(R3&.!J0G:CQAQWE*YL4,94%(/>E5=3>NMA5!>%EIL!<90PCW6=J_5 M+F* $$&8#D:.\S3,@5A7H4Q A1KAS6,="KY+:(:+H"P696'(NK/YEL R%"R+G>F%_-BD:]3*??OS+Y_."HI-Q1@ M6A;.MUH 0=R&*\C"+K>QG'N^+:[[G5EK<$XC\KW'A0XUB;QRADHN 5#*0L)@ M6>QQPZ''0HU[A]9&9'NEWQJAUZ@+H]RMC4$%.O+ JMM5@F(\GWY(BC*[<[J> MWM1UGJR"Q/M]L#6;1Y(+"SP*VQQKPYXVF"] 5=QHJ4=X9*B]8++><1IJP/\C MSM/5Q7*!\ .K_R# M\_KW#T<24(^XZC7,E/*>Z3Y3Y, ML_GJ],+G>/['Y=55$N:XDNRW%_KRP^&->YWV$0/2$6.UXTP0R20QLH(1<8(& M589ZZWT; 7Z?%-$Y1,/9]GEZOSIZ]VC\?$B+/PYN\G_)9(>-]_N'U^R[>3;_C-M$Z$:(.S6C,[Q>LX:,TI@8GV*<1B%>'HT\:%-L;Q !YJ4/YABG MPH5UDCHJ0,5=6"$'K4I5UVG0A;"R'M 92O9_3Z;7Z?S:)D5Z/5]7@-AO.6QO M$%98H[D V'(K(;>"$EP%/C!#NODUK\??FG1BFZ$3@$XG_H/KP*XF82M&B$54 M.Z:-@U9@S7C%HN].4VZB:AR6AMNO?7,0+0Z[/* A+JH\/L>DWYH/ M'8$VW.QRE>2!@74ML61UT>BO^9/B/%OGE!UM(DN!=U BI@R'5 3[3%9Q/4H0 M;QZB'"3CK#O%Z JATV0CE.>8:N]*SZM^2*>CBO'FKNI! MDLZZE'M+:!KG()2T9R_W3.']A5VN*TQE5^HVRQ?I_ZX^K6\0OLKR]WDZGZ1W M9=6RAW),[^-OSRZ*^.XBUQ[>%5E5IF0R*9049<%YMQ6F8,IM/';W=A-2M M"HT%V=-,.:OZEA_O\B2>7LZ?AI%@[8EH=Q<1,9@JB!CG@GA%-0R(5 @XX)H; MN+W=EC3$]-098*=1F:KN)OEMM MZ!:?X1(VXK+$YK=#M0V?/!8%BTUX$,PLBQ5T1F<(83)KT8;#8+TTP>S]8UXB^O+K_,RYO.\Z+<8"?E5+336&W0582 "/LT81Q7 M0"A/A375\L<@HLT'>6\7S?=@B_8/7/>;G8WSY6(^RE\C^>K84^1PP&^ M,L&8!B,)(R^AK5R,C'@^QAOGA]RI= 5<9W/'?3*/UWOQXO\NXSSHZ>R;3[\F M4W,3Y]>EP9MFOP5I!*+KSB%'=!D!YH!"$",*I Z_:$DV1]D8QY",\=[Y 2:3 M_A <, ?TH93U_E3/A\""=2 .XKC@A K8XJ'-F_M$6J)Q^LVF7 M>5CRUKZ71KO,IQU$4&LC$ (440L,$-I867'/B&J1H'/6OM..\.K4Q/#)DQUN MP'JUX[E<+HI%/)\&"H\Q,@[U%4'%O2<<I6U"QJYN(D ],ZIY.X M-()6>Z2GME'-K]Z- *:6VR]UQ!"' 8"8;1R\H9%6+6P2,[$_]D1,D/)6DTFR]MEZ9Z= M7BYN5C?P/5ZT]G@QX;MD<7GU*?ZZ1Q6.["EB6D(KE9-04$Z,UK@J<ZH,>E:1T6NE^7Z;3,77Q.2,?W 7Y( M[I/Y,@GOSJ[7/0S\.C7]?\O-M<.?LLUMC//K#TFQ#,/EU-<1;LB]*$F-9^KN M;I9.GN1]F?6,$R:8=0+&ISP.T\T&EX-W%K;O/'(<8^ Y]YI)#@F"B@.CK"HO M:@ZZ7"M,.C+D#MU^V*[CR #.*>% >HF5AM(J+3:(H; ;&?+XS=XK$H=4CN_K M=@Z'<#SFRQ:/A^# ,=%F'49*>J^L#?+$E!L*08!R RDF09H#*NU1QTB'TJ3O M5OP!4![.(CR6F8-G$YMV65Z$)HVP1G%A=7F+'A.\0@A9,O*B6'VK16LM;(7R M#WW\'JG3Z.&!L[2O10V[2A9*5X6EPCY')XLO23+?+!K5[N=BOJ;O#H+FM>)[VZ_WKUK9^0EF+ -A92ZOA#*HOK]\ M;>0Y8 8S ZWB5?'B.N[_-L'GZ=K(SHXH O_ZA^@A6#.((,.JR]H5YA;66%!5>H M>6[7\=N@&"FL]];SR/5!& MK1RWQ[TG*6:] ?>:5&.4SN\1:\3),@(LCL'W9.>U$^'UN8.<@#:4@FP78!X2J:MS_ M3!7CT8:2*VY#)M% MR(W#4"AH*HXTM,TOU^O-Q7YBS6B!WL!V35$F-:?WY5[P7;+8G ,[;,YL;181 MBQ2B$@74G$0B,&BL*6OZ(JFDQ,U3VGOS M'.FP06R3O><@#C>.A 7<4ZRT1%)2AVT8+-5(4:A%E?7>?,\G-60ZQG.0$Q0O M3Q?8M(BOK_/D>H7:Y=7FB5.?*]A!UML:IP8.-8V08H!ABK4N;^<)[[>D/ 89 MON-A6X-J73HU*->',O[W-8N098I[ 9R6C@*@E=4,6FT!E" HXI [V[WY_-V) M[;MH46?H_,C%KY&'65ZG:@'!6&A( 50*4(*-L<$" U23%@?]^W7D=Z,GW63: M'X?AGS&S&7H,K> &"*BAUX"X8+$Y&K[0V&/M(\")486$?"T*64.,T(%X$Y M(+VSI$7^9,^Y&9V:=!VA,X"Y^/% @S-'=AS&@MJ8,8"+59WPGQ M'IR9>=5>=M\K0?^HG8>J8(>IQA1Q#@DU(' 2WN:A"= RREH4V.G#CAE($8[# MI'%*_F_)-*R"Z71_/OWSIR(H+#,:.&A,H-!I!1&6UG +G%= #GHF=/^BWQ'& M65=8M)13?N!@Y?.G(L" IRQLKA"3E'HJN=." +5<.::A--XBQ*G4(SH%U8>T6L+16&#O5\7O MDO?QM\#)JJK9?KGM>CXB5#)H*)($::J]DMH[PYG&2#M"1?-2UIU'3GL07T>H MC"3AZV+>9<+7MMXBZG38+C!L+(;4!$4W7,%@[2E , %Z1$MH[]&5_N%K/#DT M(&WOW7SM.XT4YI+XP"*E@ :#4S)#A;14220%9LU+&/26XM6YX@R.XDG"ZBL7 MPZ[P>3>5 C\NLLD?.@[HE)4\P[YG):$3O/)=G.>A+(7.WA$1KCUG%@7['U'-/*)E1E^)H]($HB&7 MW[TI#4.J3#8.L$>=(?$I792(7,RGZ7TZ7<:S PD06Y^/A.(*81IP(5!A!["% M:@.("6O?D,>*CG*> E7IXZZ@#/P0Z@O:2UM$\^)+,55,5->O<]#^]'9*"QB' M5HB#*\7S!R/'J AP&(T000AQSBVJN!&0HW$;%\T$LT.ZK1 Y=SF/:LJ4 M9"4>^@$:Y$88?F@JE&P(@#H2^J=D7EW+=C$O7=7I_=%BW]]')!!TQGOJJ(4< M8X&99QN^O))VA.&#[@7?*42#'?9=&27AE8=*9CU]+B+(*6BQ9-II1HU#2%5; M'6\M;)YC=WQ.P9E9<&UP'$HGFF/SR-U\6MM Z.-U$>#,4R/*+ \OH0,=)MM?3ZR MWC(3.-+461_V)$AI6O$&F*QU8GQ8@_NT(OXN1Z@]J(V-]-4K+U=%TE;Y7)Y-TAZ1 FVFQ&IP;:H.:EA-$. W5B9W-=DLER=,OO7,EU\6[%]0&_V-(E@P,,:(@R" MJ 3J"]HMH" MU?S:NM[J.HU'1;K#=:BUR-W>S;)O2?)$N0^N1SO;1%8RSCA52C@9,)) @@<> MA8/-0WJ]U7H:A>YT#>Q0RO./L(:6"9'[_0=/GHJX!5!QBF!Y73?R4ELN-GQ MJ4ASH^5X!3DS[T%S% ?6AH,[IV?/109Y*P5#3H=Y$6BB%945+P;@D=].V4@J MVR7;"H_SEO$HM[7#BW94?I/5C!4FM3#Q7(,*DQEY9Y H5 U%CE*QR\ M$T,FC(Q,5YIB-")=":_K8F9YTD]$/$1<0PXY,X8RK0"&56ZZU2VJ@O2V>QU, M7QJC-*C&?#Y\-.'S2\OZ(=I>W@Q[>15:WV;S=1Q^?4#KD'KU\M((60YU$*<2 M@ M9EI2B#RASP$:8WWC*PR%CD4,[IVX3\"I7]$/AJ+WNWD[>$ 7C0DMEM!-: M>>2\D6KCZ-:8"#C"K(T3Z.9I01]-X'07@^^6I<0V+I%"+1$?RB5?K((F/@N7<2S->%A M2";Y?3+U6>Z7BV6>7!3%LJR9MT=EC^XKDMI#3*0S2')%K!:./ QSX5JL^Z?S M@O>GDGW#._I9=!TJNIB'Q6*Y\A^OBIU\NHGGFUCCKZ&+17&QVS88FH0("H<< M5-A:(H7Q@B)E*PDPAYM[\7N[DN$JGWL?MMD:>(6<_" M?*$(]L *Y%"%*]4M)G/^6E7[I )H[)ZH3/AWR9?J>.DV5=OY; 0DXT(H##PF M#B@-PCLV=!)(5//C6^(5*4I7\(U^>79?[]+\2;'S/I;DE^^(#$1.4:D!9LP& M_(,\JD@'46$U:*R"\A6IX*EA'^S\TFPEX&2Z'>/-58M[]+)>!Q%U" DGO2,8 M"& MD@^&!U&L14(D!*]0ZWH!]5&E>BN7M]W-^YCWI2:+]#[LQRZOUONRIT^5 MZ7_%CT)S^Q5*>ZD H5B$J8,170:MK1-(.JZXYO!'H;F:"80,,RDHII!+((R" M3D"RP9$JP-2 4<6^"\W55IG>"LT=!W8\YD)SS8[[&NX01LIKBIVWE%&(4 6 M12T*MIQ-8;G:*K#WN.]Q.([&>W$&9R:YMM8@2J"V$'(#L6>X0A92*L>=0-Q0 M2X8X/-D,V!^JVQW"H\R+/F.-[3+1YQ2G-QU$EA/ A86,:N,AHA783%G"A]27 M$QZOJBWF5J 0?TY7)1+.)Y6EN)' M3')/&*4V##'B'DQ[ZYH'U,:<&]EX/S,&&32?+IM2OSX^^X3XM5]]YW3:\7NB M,+40)27&QB% H4;6Z@H?REMXF\>GHQTI2C8><;13UWUN\\\[W.;KV%YZ()3; M^3LB3HPTI,P?-2S $':JOII5A&#B'&LZ#*VFIQ%%?RJZ,Z7H:Y)/TB+9ETW6 M\1LBBKT4G ,IPMHGPA@6Y $3)]R0!>->HWKV)8CAE_N TU62EJF>I8'^&(2L MIZR]O#$2( QBK$H6B<5"*&M5A1EQ[!P+6IR#"="U8(97YLWP*SW(/5FMW[TA M"HAPYHV3FH<5B'#L#-]@(A7CS95U?(9 \SW5:4$_0S?!/Y/2,Y),U7V2Q]=) MM:ZLCMN5,\35D"Z$FL1$P)J@%$)QX@!ACC@.1"45KFSS(QCC,SI&Y5[H1SXC M<#WL8ZQ_A\2^MT<$<\'#7(.,TIY"Z"Q^F($T%?Y5NRDZ5[A^7!@="K"_P;#? M%_\B=[F7 =$9!9'%R$D%I;?4*P2PQUAN,%50M*B..CY;:&R#XE1"/-G ^&ZK M?8JQ<10141G*HA0Z;BF3$I>'=GV%K P;JU=D'YW9\.A3CJ>RHPYNYT]@7;6B M*7(4<.B\L08K!I%F2E;!885,BXIVY^ 7&K/--:183S6X\@=#>O;*SIP M45ME>CMP<1S8K_# !;8&4L6 ,0HAY#WWE0BX-TXW#Y>?S8&+VBJP]\#%<3B. M)BYS!EGK0'EGA8!.,0.A0T9RL)DD0-B+\G,Z<%%;2P:YK:H1L#]4MSN$S^# MQ5EI[+D?N(">>>\UYU)Z1@3"S%?V$("*M3CZ?U8'+FJ+N=6!B^/ /NVTM_KV M21W,W\.>,W_"\:HB@/[VW#56BN" +=C#VR(#I%($,JFE<09:_CV?#=?V5F^+L--822$4H(:'U@B(!B!R')><8,( M:5[^;V!;>""9[C*%NX.X)X79=X/3,I@=O\NGIM1%!85.*K?!005:N,9Z[*C+BM!KT M"L/!HMF-PT'CD<19ZOSO=W>GT/D7KXVH0=H KY"&S&JLA :T0MH"U-Q;.KX< MVI'I?#M)_#@NL2\-!G'".(!42^$I1%0AZRLLJ<*O\\*@8[5ZO +I6+D;#M"J MPO?3Y*05T\;JY^^+%'"2ECF)4A#&E)725:$F##AH?H9YS%<+G7AV M;B6"<;'T,9\;]!XYN.V M AE!AO\@\_'.]T5,(* =QI0*:9@W!,O*.,,,H]=Y.] IYN.N1#""O/WJXMMD MD_0QG[[XYO?PWJ*Z4.%'&O^!(R7<$H\-U&%^\@X0!ZI35)(PHVNYT7^D\2>1 M5LX!P9&'#$L!$;<8;G!$#+;P9HTOC;^VRO26QG\9;;3&6OL:31UVZ;AP\??=R:GU&H7.>HI$8 ! MPBASE!O%'WCE7C:O?')>*?VU19[U!^Y0BN1N[V;9MR1947Q0?;8\'3'J 9"" M:DV ITP3Q&QE4*.P$3_#2/B02M,>TM&LCCL+@ZXNA;R8A]&Q7,%[N;A)\D\W M\7R3QO4NF]^'L9-,>[YVHQ$AD0HFN>5*">.T1(8IZ$@E#4GHZTQO:KQ-'K-L M7M%(V5DX>7 :(DXP-511922%L"STJW4E ^SEV20_GUY)AQ]+C41X_L/H>9W% MDXRBYR24\ZV#5FLDH6 : (/8IH:\I-2TR+P:7S[A:QE$K21X_F-HS?;%?)(G MH:U-UO^>9"QM)R7B/DC$2"P$9AXK0:5BE40@8DQ"%#:GEWE'OD&9EL()#\3"[<=J\D/KXDB=?RUAJ)<'S'T.;:JG%58V ML(T7B8_3?)62-1H7WC&41B;8ZIPH"Z4"%E$)I:]TCA'^JNZ)/ L?7X_"&SYO M]2#;NT\#?<]XYUFNG5(7:>*PI(@ $=1)$*2XX)4LD+"OZ>[J4VMS-Y>VG5#Z MY[\L[KVOI=;8'1V-D13, 48 4%QCZY3ULO(%I]-DOGKP/IZ5C[1;64=#9824U(P3X#QTW!F'"*]\8<)! M\9JN;QS)^#Q_+3C_E?:Y,VN<*^V1-$8:2FVPS,/H3#XNPO2XFG[C63R?)!]ODF2A MYE,UG:X$%L]L6I2TE].K_A8^W&5%//LUSY9W1>ABMBP=C>4S@95TODRFEW?) MYI;* V=,AR$@$L!2KBUBT$DMD=24L4ID,*C$: ^OMM*_[ RP'LHX/HJ/6@<:.R;Q W#<-+?.^K[/J4OKK%N0 M1J 4QZU!V]I&7DA&,.,> :N\I5()5/&L'<3C-I4ZDVA]36F%VY]#9T9IH8Q7 M54:@(NL/8=&]TM\^QK/D7;;8OA8?K(30IMN(&ZL$A A CS2WAEO-D@Q"N20 M!;":&#+MI+]/K_H%LJ'*%?GBB;J%3R]5+7P5F6PY7R3Y79POOI6&W X[9M>C MD9$PF&J E57>/5 0$5K!QY"2S:\V/SZK8WC#I2-4^I3OA^1NF4]NXB)1UWFR MVOR]I'CGBG-4^TA+B*E7AD("(*704U>9[,PZ.-+:8^U%F T'UI]#449EGHQ4 M/SIR;%S>)M?QWY-XMKB9Q'ERL8J$9WFYX]_OYCC8,"+2&:F=$H81"AQDY=F, M-0<< #.HFVR_K="39+(>X1HLG^;%*GFX8NJ.%E$PV8U"3%KG&$9AT&#_P)\& MH+F#X_B;"(4-F^:6(B&"AFLL+ <5C]Q9-4[SH#/) M'=:$5CB]3IT8E24P/E48A0H<]#AL?3X"2GKC;5EJQGNGG70/#GXN:E; '_B\ M77LY[9=\(V0:FW[5=2KOEGF1SJ]-4AH[/IZDL[2,P[PMZY=L.PE=OW'$N,;! M/B*8:BT% E+9RD06C)OFM3>&DO';QME3O:'44M[9U<<_TMFL+*#VA*9B=07/ MVQUUD(YI'BGA%';2., 4 -PZZWW%C<>ZN3^HOU-X/JM M%R6J\>Q3DM_NW-CM:A !JY@26MGP@P05M1P_Z"G"$ND%I(9ZS:1T%) -Y=+8%KD'_1T&Z5',[=#I2*YJ/E_& ML]6O/OV:3%TQB6_?CQ$>KP B!$) !4 !A=F-A+3(P,3@P.3,P7VQA8BYX;6SL MO?MSXSB6)OK[_A6\/1$WJB.<721!D$3?F=W L\H[67:N[:J>&QTW%+)$VYJ2 M1;<>^9B__@)\2++3E@$0(%F].].193N=.M_Y#O#AX'7PK__CZ^,R^%RL-XMR M]6]_BOX2_BDH5K-ROEC=_]N??KW^@*_I^?F?_L=__V__^G]]^/ ?Y.ICP,K9 M[K%8;0.Z+J;;8AY\66P?@K_-B\WOP=VZ? S^5JY_7WR>?OA0_Z.@^F*Y6/W^ M5_7'[713!%\WB[]N9@_%X_1C.9MN*]L/V^W37W_\\KM>_J5__P54 MOQTAA'ZL_G;_JYO%:[\H/S;Z\3]^^7A=^?EAL=ILIZM9\:?__M^"H*9C72Z+ MJ^(N4/_]]>K\373H1_4;/ZZ*>\7WIV*]*.?7V^EZ^W%Z6RPEC.K3'M;%W>L? ML5ROGWV"8@@IAJ)4,?0O[WSP]MM3\6]_VBP>GY:2GA\[X+< O/T>K"]T%0D7 M-B!/L?KR QWCO9%=MW"+^/N/=(RY;FA\-??1?E]^K&/L;B%[;1GE=KITW#*^ M^\@W,2_5;WV47S6_J#[]A/Q6QAM1/?K@XNNV6,V+>26:SSXZ6,S_[4_RJ\EN M\^%^.GV:L,5FMBPWNW5Q>4?+QZ=BM:D&EJMBJ:#30PA0DAF&:80I#G"8\9C/&?3-C\/D[K8E/NUK-ZD)/PU1A?>_3? M#\"#\BXXAAXTV(,*_%E0P?]0X0]:!X*_MR[\?__ZXX&;9U$K9Z\UPPKXW71S M6Z%O:)1>1/F/Q7*[:7_R0?WD0Q@U@_J_N.'[92#+6=^!K..R5$E0N6XZT+-V MCM>SH%S/B[5,SMI_-%W/WFD S6_\."MEQO&T_?"L+:@D;1AGRT$Z2\VQI.0U M?NUUA!R#NI%*122EOT^D6B0P%SP$*>24"BBBJ!$2B'%.)S+9OBV; =:=GKR! MAF0A@E# E#,!.>$D2D0D"& QRVF(C03E&+BVKES?7-)__T#P-6A\!V#^0>3^*[>VFJ\$Y9U M15Y.%LG1Y=[Z:E8\%7LT5NG7Q( $N/A?-3]NA)H0 A'1%$2"2>F ,(TI M)&G$40AYCC7UP[59?WJQ1]K*Q1YB4&,<+.,SY/"$ /B*QC@ZO#?ORG[:M%F' MOBBVM9V/Y68SH2@GA N20)RE"&4X3-/6!B(YG&SW2QSO]EFS3S;ID=LWUEE. M=,L+?A-\O+R^-LN>#,G1TS)_O)@IE<312M(/"LJ? [S=KA>WN^WT=ED$VU)F M,6O9//M5J6?LG- @.Q;'H3"6V$L7[[ MXC_+:=WY;SPXOY#?\[^:R5,?T='3M)&%Q4P(*_"OYVJU,)X%2BME/B>]&"Q] MZT[Q"37M,7[CD. ^'2X'ZRMNQ/[7E;2^7/Q7,?]INE@IF);Q>J>[=;RSQIXZ\8D@0A1@$A*,.=0\!2$X1XH(:E)/CD /,])*7V0WQ7! M8A7<31?KX/-TN:M6F6;3S4-PMRR_! _%_+XX"U:U_&RG7]T,$#XCVFW &$DP MG0\@![\"Y5B;<9>KX,B[H'$OJ/T+:@>/1Y]Q##GV0;(8@GIH$>,>DOH@0'.( MZBT6+N8G5\5L.=UL%G>+^J 4GO_G;K-5"RY"QV*S^6NP?@$_F.[Q!W?E.I@^ MECNU!R)_K[Q?5=HGE4^-98N* G>3'6^A[C[[&33&OD:SETX%^"CRZB2C\NO% MX#:^8:Q#>"RG4KX;P[@'LEX8,)AL]1,-ETMM$Q13@ 6@40ZB'&5)S'G4FD8$ MT\EV?]#,R9K-NP:-9DAO'(([H475N;F@K!1I]DR17 \A^A2[6Q%SRJ['-:_Q MR'5'_34F?OR":NZ2Q7*4(5^ZDO>*U;U%&J8"TUA$E'.4PEQ:R1J+<9HB;J)T M7>QX%KCGNP#F.Y2=*-13LK[8,Q,P3>DZ&\6FY@D*3RB9"^+'(6!./"G=-TLS MN2*[S6(E9[[2\NUB5:6,AS.U>1XR%DUL()C7(-MA9TBZ41_98EH(41$2A,-I2<&_>\7=3B54/;OD,> M0SX+;K\=_R#X>X7[[=[94TSTI&_0<)C)H?M(^#GQ:7Q/=S?K[>2JF"[Y1AT^Q:LYGLUVC[OJ1#DK9#XU6U2ZSXK-;+UX4E]> MWGU:ET_%>OL-?UUL)B3%&'*>TP1D,4UX"/*TQL.C),YC'0'VC\+W:=+I8]7W M6TPR$Y*H-'6VAQB<%MQQT6^FO*;,Z^BJY.-(4^5W+_6T,V&O"&M_01A687OT ML^R[>;O57-6T#T!8^3A=K"9R'IN%.916*4H9R2F,>0L%RC]J\:^QE8'>>U$_A]#6;NY:"BJ#OA\3T^GGV?3R%Q\_TJ.__Z5XO"W6$P AYDD.0 8%05D: M)VG6@B"IR'24U)-ISQI: 0IJ1(&$'%28J_N)#>JS0.(.?CC^Q3_K":RO8)R6 MUA'$P4Q4[4(0_+T&KCG8^8K%O*E;5G7P,B$!8#7EV MC+TRV'FF?MAASK=S92_-5W^J<%@AXO_8+;;??BFV#^HJR.>B/IOT_4^+0HVZ MU^WI@Z]!*"X:MMN>0T)V\HFR,BA]"Y5F$48C"$'.> MI6&[E E"P]I_W:T-H$-G08O1< KLD&-[=?)';W>=,F&V-\UZ1IBA>MF1/5X= ML_1'0]&Z,*4UA;XNEH_3B]U:51ZA,GF36M D;TQ.RUF8*3-A1!F+6[CB8\JU@%+&B0!0TT@UE=!^XT9LC]T&:F3J\R9C,A[D"=P42X'PKM)L"6 M5.K->]]T_*WY;G>F1C#/=>!$Z;3U=,XQ/\H?G&^+Q\T$)3F.9(D- (&+5>;A:2M M^N9F/5UM[HKUNIA'$YAE(>2$ 9K+##;-DABWM[82]>Z138+IQ+!G0?\D?_Z@ M7GG^M):!LJ3CZ)BB^JF?W"LVDSGM(K&?SO4?#Q9;1$<#ZB&"U0\9*INO[Z6+5IFFJ;8<(Q;AC[NH"@FS3NBWSFS[ M9MY%CMM@#EK09_63)0?<9T&-?/"<5X-=L^S79;C&)<>^G'P_(W;/J<$Z;WEW M_?MBN=PO5HCI;+&4@T2Q^;E8SD6YOIXNBXMR^VFZED.&>G.YE,/%:E?,+Y^: M)'XSP7* H%#$4FZ MKR__ M=KH)'J1SU;L@&^F>\3)I/X'47I4>70QM%[$;-_9KV ='S@+ER@?IRP?ES%D@ MW5'5D[?!Y5UP[%%P<&FD835>+!]=>+NNK?<49I,U>1<PT"WFR*[>9"LKY;JX+Q$\!H MQ*(0\XB$+(H0$Z"]"@(YYZ')%,TG#L\#?XW'9C#O)0AZ$[6Q\&\V:+>H@PKV M6; '_H9,RVE:!5Y)>@N_WRE;!YY/S-OZB-XX)F^]>%KVWS<,7\:J[:WN/ZI' MD#=7JDY$O3!_46PG*4="E4(6-%*O2K(0[ROP0,13:O3$<"=+GI67JE>!Y;][ M;.;5P=/TV^.I+NV#3#U][8]',P7=XPIJ8.HEP]4V:+!5[\;T_-;5*:).2* ; M@L?FLE4.&=(7J]9HV5]\_F=M(["1/!*8\R9(P1S@C/(K#_1X$ ;G1 MD17GQGM:\%<)I)JA+O:8U2NQNY5L/9MRN9BK"J/!].Y.SB'DEV9BYSX@>OHW M:"S,)+&&&M18@^-J-BW<[QXL;T#WJY2FE)X03V_1&8>>^G.O[*F5&[XAI"H2 M*\N7=RI%$LORR^'9(D@R 0!C3, HBD4.&4XIIEG",Q"11+=#=[+AK_/N8=75 M2F5^6"$;[&&N4S2=Z)!.V!U'YW/CRLM'8]SQH]NI9)*D3'U:EY\7\V).OOVZ M*60GWV=5>+9=?*X6]?9 (:4@PQD,4H8(C"&2=0 25$2PS#,9' M'/0D;^ &.YG%=M:_UJXZOVM'Q1BF4S^.3C,^PZH!Q-)2Z R4O(9I]L- ,T?_OX@M^< M?O'85_<[4'"Z9UE0-9I.8X/]^_Y@S8!N4S\8$-*+US<#VV=]CU]ROBFOBJ=R MK;IE?;YS$J&<"881S$-&@$AE/L0:?!AFJ=&!]OY0>5YD>;8Q5!H>TQ@@1GJI MR3C#8Y:Q/'NQ/%!=^*W#%N-[SMP9_R?DM_\8CT.Z!_"['+IW=1DR: U.&CTZ M/0)1Q/(T8BD*PRS&A*&\G1/C2$*Q'PNLS'D6^59*E@UA.E)].YIMY-P[ MPYUU^H#P#Z32K]&J+;^=8C)&7>WFT$G!=,"5KA+B^7_NZD7WC1)?Q<1B63Q+ MVV]*TRFME&L8(LQQQGF89I!'(F^@DI0EP&P9;Q"(WA?ZCKQ2O7O=^A4L-*58 M_:N5U(N96K-Z.EJS*OGE5OTCZJZ<=_U;<\4BQG'W$< MLQ1D .SN["J-X8T!>59E)^C.HL MD-\MBSV=QQ"KP]1RQ)[O9B?9]7.>^FWJ3IV7=D#X.'32B2^Z MM4=7W229-_ADYEL#-%.N;JSJ25=O=)IIUW,>6V !?H]'+QIUBJ,3(N6$VG&H ME!M72@]-SS2[JDM7U7G?S?1KU;#:3)8]33UG62;).9EIN:!Z'CCGSYKN,RR5+!MM&:W45A!7U?\]7U\7R M[GRUV:VGDHZK8E.L/Q>3."8HBF+ $211S&).]A-5B@E(S43-D=&>,[&-Q/AA MH4"JYSC7Y5VQ47\W70;+Q?167>;^=E8M7Y9WS0IF?1/-?(?)242T=YGZ#H7Q M3E,%+/BAA?AG=1-&H0SV,(,&9^];21KK3\5Z49L54U38UD\@NEKSKXL?% M=G%?KZO-#AC;NJ!F)4CV-ZXM+,V%3,((C6&=!]1-58:Z"UJ^6G>#HA("Y M8'81)C4ZW1*[56@,!*L#:1IC03]\ M6>Z&'H,Z"TA_Q!E(>S\$VFFY%9%ZPOVFVV\I=7>>1B#-#IPHG;8=PQJBVX=B MK2J52IVO]YV;3>=)GE">H##/<$Y%PA+(HU;LF0 BTDOGN]OQGL)7T R+A=JS MIK=*Z)DNNR*A"E/0@-K?XFAP]7P4Y4U^3BQ*=.=T'*L/#OQX61/4$3/V1T[V M5R3H]&FQG2X/5;RR""01P2F&>4RS%(FT7=!@*6>=CYU8&_:^F4$?Y'?U8L*T MKBVOCMRW!TW4/:CIW5TQVQY=H.MR.\YE3/0T;J!@F(G>&X=/#O?2&JB#74K3 M9]'H&$KG4(Q#*WTX]NYQ%$?4]E3L"4QW$ZRJ!1D3:JIYS!ET*W1&XH77M"(J1E-GP.U;ULO+E M7<&R9\A>HSZMBZ?I8M[.=YN$$Z_F53):OZ Q24*&XUP]@L@2C 3F7+0[URQ$ M8=)5O)R Z&&/J4*Y?W6[2@3+:C969X9=9UU&'52$:=AFFL^NK6R7>%UP.G]HK=VUNUM-YL;^+JW;VJV)657F! M&NQ>J+OJLIN(V.IR[\%PHLLMZN#346 :X,$1\J'U68==(WUV&JZQZK-;)]_5 M9P^)CA[O<+D6%\I,*PLV5,DQZ'L?3EK_9*! XYUE5X3T1L/ M0F=8Q'$B4 32'-)4SA02T6)"D!L]E><7B>_35"Y*NGN.A9ZFCR<,9I)N+.=O M%';O5] [L7U"S_N)XCCDO"=?RR'ZB:^T?9)@F"&'[Q&[_V\J)B MISAT4M*^ N!44?>@QU"PW)Q8_6.W M6!<2DE3^[;=/LM%O\6JN;B _J5^9)#0!:0*R+ RSC&<,9TF[#2E8DN=F9S$< M&O9__D+^_*&Z]%C>J;2UPEGM*Q4M2,.2O Y9UY/8ONFVN^';@%1O0C0P@Q;G M65 A/:MHY^_2[J>"KS:))V340R3&(9\^''M9Z]<7=UWDLBIX_[EH#VMPE1PG M<2HRFC'.\T2T-3I%)')B4>2DNU$+A;2H:O)IKXP*YF9AL?SJ@%][/?3 J4L9 M;. - M@2>DD3G01B)-+KWZ_O7'KPPYWZQ\O7G+G&4@Y M&(6(X$3FH5E3\S,/R'*'Y(]Z(LMA+.Q/9 T3!FR-)FV_!$EOLHCD/.>_)5XT26 M+X;=I^R3/$()0#1!A&=YE&%(HOUH N47?M+S=\WVG8HO]M+@^#26%>>NLVZG M='O/L,>:2CM)F[5#,0Y-]>&8=3ILR%U'M12+U70U>_UD0@8 HPFA!)$,J#+C MB, 6".*QXJ:-\)N+S[6*[N;XKU(RMNU3DU[/Y&U1ZLVAN829E#>+IL'Z0Q35;>L!IJ)9 ?VPE4@#!?7LZ/NV!&)5.SZX/$2B/JW5_O7!IWYUUX3M$XKK M)6CCT%H_KI4]-'K[@P[GF\U./1?Z/A@Y/$Q8&@JI\#D+12YB*A@+F].W>01P M9)CC^L/A/=5]OC>_:,"W,FQ_^,%Q.,P/0PP7ARZ'(\Z/ O!=::HSRB=O<1C,UXSW4/<]B9 F1WH-:6R_%84U>TL=1WARW0] M-WP/<$Q,:K[?.";(/:2_/[2N_KEZ>7/?'GXX^/MGU1IJEX/*YV#O=-5LWGKY MNKIJ)C/EO>]!Y7S0>/\';DEF[U..";I)B[)^Y7*T+4O[Y

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end